2004 SCIENTIFIC PROGRAM COMMITTEE

Seated (left to right): Drs. Muskin, Goldfinger, Taylor, ]zyaram (Chairperson) Judge (V^G^Bpma^Pandya, Ordorica, McDowell. 2ndstRow Standing (left to right): Drs. Blinder, Pandurangi, D'Alli, Goldstein, Stabinsky, Gabbard, Horton, MacKenzie, Rothschild, Crone, Cheong, LeMelle, Foulks, Worley, Casey. Not Pictured: Drs. Anderson, Baker, Baron, Chou.

May 1,2004

Dear Colleagues and Guests: Welcome to the 157th Annual Meeting of the American Psychiatric Association. The coming week will highlight the best in our profession in the largest psychiatric meeting in the world. Our meeting has become an outstanding international forum to discuss the latest scientific advances and traditional humane values in psychiatry and how we will continue to integrate these bodies of knowledge to provide excellent patient care. This year's Annual Meeting theme is "Psychotherapy and Psychopharmacology: Dissolving the Mind-Brain Barrier." Many sessions throughout the week will highlight important aspects of the theme. In addition, please make a special effort to attend the Presidential Symposia, from 2:00-5:00 p.m., on Monday, Tuesday, and Wednesday. On Tuesday evening, a special Presidential Forum will be presenting with the showing of the extraordinary film, "I Am Sam." An entire track of sessions, presented in collaboration with the National Institute on Drug Abuse have been scheduled throughout the meeting. I join our colleagues from North America in greeting the thousands of colleagues from other parts of the world who have joined us in New York At the Opening Session, from 5:00 p.m.-6:30 p.m., on Sunday, we will officially welcome the leaders from psychiatric societies in the U.S. and around the world. I will present my Presidential Address, and I look forward to seeing you there. Please also make sure to attend the Convocation of Distinguished Fellows on Monday night at 5:30 p.m., where we will honor all those being inducted as fellows and distinguished fellows and many receiving awards from APA. The William C. Menninger Memorial lecture will be presented by the distinguished writer, Tom Wolfe. Organizing a meeting like ours represents the best in collaboration between our members and our staff. Special congratulations go to Dr. Geetha Jayaram and the members of die Scientific Program Committee and to the APA staff who work on the Annual Meeting. Welcome to New York

Sincerely,

Marcia Kraft Goin, M.D. APA President Dissolving the Mind-Brain Barrier American Psychiatric Association

1000 Wilson Boulevard Suite 1825 Arlington, VA 22209-3901 Telephone: 703.907.7822 Fax: 703.907.1090 May 1,2004 E-mail: [email protected]

157th Annual Meeting New York, NY Dear APA Members and Guests: May 1-6, 2004 President Welcome to New York, NY, and the 157th Annual Meeting of the American Psychiatric Association. This Marcia Kraft Goin, M.D. historic city, with its vibrancy, cultural diversity, and excitement, provides a perfect setting for the scientific presentations we have planned. As you read through the Program Bock, you will notice a number of sessions Scientific Program Committee 2003-2004 related to the theme "Psychotherapy and Psychopharmacology: Dissolving the Mind-Brain Barrier," chosen by Geetha Jayaram, M.D., Chairperson our President, Dr. Marcia Kraft Goin. Let me draw your attention to just a few of the many exciting sessions Sheila Judge, M.D. Vice-Chairperson presented this week One Presidential Symposium will be presented each day on Monday-Wednesday from Tanya Anderson, M.D. 2:00 p.m.-5:00 p.m. A Presidential Forum will be held on Tuesday evening where the film, "I Am Sam," will Robert W. Baker, M.D. David A. Baron, D.O. be shown and discussed. David A. Casey, M.D. Josepha A. Cheong, M.D. The Business Meeting will be held on Sunday, from 12:30 p.m. to 1:30 p.m.; all voting members are Catherine C. Crone, M.D. Richard E. D'Alli, M.D. encouraged to attend. The Opening Session will be held on Sunday, from 5:00 p.m. to 6:00 p.m. Exhibits will Leslie A. Horton, M.D. be open 10:00 a.m. to 4:30 p.m. on Sunday, 10:00 a.m. to 5:30 p.m. on Monday, 10:00 a.m.-6:00 p.m. on Stephanie LeMelle, M.D. Tuesday, and from 10:00 a.m. to 3:00 p.m. on Wednesday. Please note that the Convocation of Distinguished Philip R. Muskin, M.D. Patricia I. Ordorica, M.D. Fellows will begin at 5:30 p.m., on Monday, May 3. Award-winning author, Tom Wolfe, will present the William Anand Pandya, M.D. G Menninger Memorial Lecture during the Convocation. Anthony J. Rothschild, M.D. Harvey Stabinsky, M.D. David H. Taylor, M.D. The Advances in Research session will be held on Monday at 10:30 a.m. This session highlights the latest Linda L.M.Worley, M.D. research findings in psychiatry and summarizes their relevance to clinical practice. This session has become an Consultants excellent way to start off the Annual Meeting's research programs, in conjunction with the Young Investigators' Barton J. Blinder, M.D. Poster and Oral/Slide Sessions also on Monday You will find an expanded number of small group sessions, James C. Chou, M.D. including Discussion Groups; Research Consultations with selected experts in the field; and Master Educator Edward Foulks, M.D. Glen O. Gabbard, M.D. Clinical Consultations, a series of clinically-based seminars with outstanding clinician educators, offered to APA Marion Z. Goldstein, M.D. members only A special series of sessions will be presented in collaboration with the National Institute on K. Roy MacKenzie, M.D. David M. McDowell, M.D. Drug Abuse. Please consult the brochure in your registration packet for further information. Ananda K. Pandurangi, M.D. You will note in the Program Book that we are continuing with an expanded series of noon Forums. This Committee on Commercial Support format allows us to schedule sessions that may not fit in the usual formats or that focus on late-breaking topics Stephen M. Goldfinger, M.D. of importance to the field. Chairperson

Annual Meetings Department It is extremely important that you fill out and return the evaluation forms for this meeting. The members Cathy L. Nash, Director of the Scientific Program Committee are interested in your opinion regarding the quality of the content of the (703) 907-7822 Hope Ball-Mann Annual Meeting. The information we obtain will be used to plan next year's Annual Meeting. Registrar (703)907-7810 Once again, welcome to New York I look forward to sharing a week of exciting and professionally Vernetta V. Copeland Associate Director rewarding activities with you. (703)907-7811 Kendra Grant Sincerely, Administrator, Commercially- Supported Activities (703)907-7812 Sharita M. Morse (faft**9*»' Scientific Program Coordinator ^J&fc+s (703) 907-7807 Geetha Jayaram, M.D., M.B.A. Elizabeth Rumsey Chairperson Administrator, CME Courses (703)907-7813 Scientific Program Committee Byron D. Phillips Scientific Program Coordinator (703) 907-7379 Catha Stewart Scientific Program Coordinator (703) 907-7805 Geralyn Trujillo Scientific Program Coordinator (703) 907-7808 APA 157th ANNUAL MEETING

New York, NY May1-6, 2004

KEY I OCATIONS -1AMTS CENTER AtVIF RTf" ANT PsVCHJ ATRIP •VS'sOfl VTTON F\rl [BIT A rmnomjaumal cf Psychiatry APPI Bookstore, Halls 1A-Q Levd 1 Located in Halls 1 A-C, Level l,Javits Center, along with the Publishers' Annual Meetings Office Rooms 1A02/3, Level 1 Bookfair. Houis of operation will be: Saturday, 10:00 a.m.-5:00 p.rn^ Sunday, APA Communications Center Rooms 1C02/3/4, Level 1 8:00 un.-4:30 pjn.; Monday, 10:00 a_m.-5:30 pjn.; Tuesday, 10:00 a.m.- APA Exhibit Halls 1A-Q Level 1 6:00 p.m; and Wednesday 10:OC a.m.-3:00 p.m. A few of the many APA A/V Preview Room Room 1B05, Level 1 activities exhibited include: membership, APAs internet-based programs, CME Course Enrollment North Pavilion, Level 1 continuing medical education, quality improvement, psychiatric services, Computerized Evaluation Concourse, Level 2 clinical resources, advocacy cook, career development, and APA Periodicals. DoifyBiitfftm Rooms 1C02/3/4, Level 1 Education Office Room 1C05, Level 1 APA JOB BANK Exhibit Office North Concourse, Level 2 Located in the APA Resource Center and open during the Centers hours Exhibits/Publishers' Bookfair Halls 1A-C Level 1 of operatioa Visit tke APAoc-site JobBankat APA2004! Theonline Information/Locator Center North Concourse, Level 2 APA Job Bank will power the popular on-site Job Bank providing Internet Vilkge Concourse, Level 2 improved tools for both employers and candidates at the APA's Annual Lost & Found Rooms 1A02/3, Level 1 Meeting. Candidates and employers are encouraged to activate their Message Center North Concourse, Level 2 resume and job postings in advance of the meeting for besc results. For On-Site Job Bank and more information on the Job Bank, visit www.psw h.o rg /10bbank, Placement Center • APA Exhibit, Halls 1 A-C, Level 1 PsyhiatricSeriia& APP! Bookstore, Halls 1A-C, Level 1 APA COMMUNICATIONS OFFICE/PRESS OFFICE Registration North Pavilion, Level 1 Located in Rooms 1O02/3/4, Level 1, Javits Center. Hours of operation: Saturday, 12 noon-5:00 pjn.; Sunday-Wednesday 8:00 a.m.- FIRST AID 6:00 p.m.; and Thursday, 8:OC a.ra.-1 IKK ajn.. Located in Hall ID Rear Corridor, Level 1, Javits Center. Hours of The Press Office K for the use of registered press only. operation: Tuesday, April 27, through Thursday, May 6, opens one hour prior to show opening and doses one hour after the last event of the evening. DAILY BULLET IN Information on emergency services may be found on page VII. The Deify Et&Sm accepts -written requests from APA members for publicity of component, committee, and allied group events as space COURTESY SHUTTLE BUS SERVICE allows. Four issues are published. The issue for Saturday/Sunday is printed Service wiH begin oo Saturday, May 1, at approximately 7:30 ajn., and -will in advance. Copy for die Monday; Tuesday, and Wednesday/Thursday operate dairy throughout the meeting commensurate with the scientific program issues can be dropped off in Rooms 1C02/3/4, Level 1, by 12 noon prior schedule, and will conclude on Thursday, May 6, at 6:00 p.m. TLe Javits to the date of publication. Center will serve as the "hub" for all shuttle bus routes. A detailed Shuttle Bus Schedule will be included in each registration packet and posted in the RESIDENTS' RESOURCE CENTER lobbies of participating hotels. Refer to the city map on page VI for the Located in the Versailles Terrace, Second Floor, Sheraton New York. The location of hotels in relation to Javits Center. Residents'Resource Center-will be open from 7:00 a.m. to 6:00 pjn., Sunday, May 2, through Wednesday, May 5. Daily activities are scheduled EXHIBITS for residents (such as the Residents Only Discussion Groups and Resident Commercial and educational exhibits are located in Halls 1 A-C Level 1, Summits) and for medical students as weft. Meet and network with leaders Javits Center, along with the Publishers' Bookfair. As a convenience to in psychiatry and your colleagues. Resources specifically for residents and registrants, the Publishers' Bookfair opens on Saturday 10;OC aJn.-5.OO p.m. medical students available are available here. Hours for commercial and educational exhibits: Sunday, 10rX a.m,-4;30 pjn,; Monday, 10KK a,m.-5:30 p.m., Tuesday, 10:00 a.m-6:OC p.m., and Vtfednesday, WOMEN'S RESOURCE CENTER 10:00 a,m.-3:00 p.m. All exhibits will close on Wednesday at 3:00 p.m. The Center will be open from 7:X a.m. to 5:00 pjn., Sunday, May 2, and Please refer to the APA Exhiixc Gtodetor additional information on Monday,May3. The Center is located in Javhs Center. CtaSunday,in participating companies. APA periodicals -will be located in the APPI Room 1DG6, Level 1, and on Monday in Room Room 2D16, Level 2. Bookstore. This is an inf onnal networking Center with some workshops on topics such as "passing the boards." INFORMATION/LOCATOR CENTER Located on the North Concourse, Javits Center and staffed during CENTER FOR INTERNATIONAL GUESTS registration hours (with the exception of Thursday, May 6, when the Center Due to a lack of funding, we regret we are unable to provide an will be open until 5;QC p.m.). Up-to-date general information about the International Visitor Center this year, program, component meetings, the local area, and the locations of various activities and events can be obtained there. Meeting participants can also find BUSINE SS CE NTE RS out where colleagues who are registered for the meeting are staying. Javits Center Location- Mail Boxes, Etc., Crystal Palace (202-244-3744) Times of operation; Open during show hours MESSAGE CENTER Located on the North Concourse, Javits Center and staffed during Marriott Location: $<*> Floor (to the far left of the hotel check-in counters) registration hours. Messages can be left and picked up at the Message Center. Tunes of operation: Saturday: 8:15 i.m.-6:X p.m.; Sunday: 9:15 a.m.-7:00 Message monitors will be strategical)' located in the Exhibit Hall and p.m.; Monday-Friday: 6:30 aja-10:30 pjn. elsewhere in Javits Center. Registrants whose names appear on these monitors should pick up dieir messages at the Message Center. Hilton: Location: 2nd Floor (behind the elevators) Times of operation: Saturday-Sunday: 7:00 ajn.-7:00 pjn,; Monday-Friday: 7:00a.m.-9:00p.m.;

II REGISTRATION CME COURSE ENROLLMENT ADMISSION TO ALL SESSIONS BY REGISTRATION BADGE TICKET PURCHASE REQUIRE D Located in the North Pavilion, Level 1, Javks Center. Hours of operation: FOR CME COURSES Saturday, 10:00 a.m.-5:00 p.m.; Sunday, 7:30 Jim-5:00 p.m.; Monday. 7:30 Located in the North Pavilion, Level 1, Javits Center. Hours of operation ajn,-5:3C pm; Tuesday 7:30 ajn.-6:CO p.m.; ^Wednesday, 7:30 a.m.-5:00 p.m.; ^ ^ same M registration. Tickets for CME Courses not sold by April 3 and Thursday, 7:30 a.m.-2:OQ p.m. will be on sale to all registrants beginning at 10:OC a.m. on Saturday, May 1. You must show your registration badge before you can enroll in courses. On-Site Registration Fee Schedule: APAMEMBERS APA ART ASSOCIATION Full-Time R£gktraaoa Ml) $ 75.00 ^^ done kyApA members and/or their significant others. Please stop D^Re&tiauoafNortiAmwxnMeTbK} S140.00 r^-the exHbit for inforrnation on joining the APA Art Asscciation. Dairy Registration (frserrtaiond Merrixrs) $215.00 Medical Students no charge APA AUXJLIARY BOOTH \rsvMfc\fac-vc Located on the North Concourse, Level 2, Javits Center. HOUR of £SSSSoa I79C CC rTV^ "tl' ^ ^^ f'T !? "*'MO ^ :, r^t^vv^rr^••••• Stop by the boot : h co obtain information on the Auxiliary's program Nonmember Residents,' Students,' Advocac,y' . schedulHu %i ei andA informatio ( n on membership™k^i,' . Group Members, or Mental Health Chaplains 95.00 Daily Registration/^ "Nam^rber" oHegais) 400.30 H nfc , *. I C J L ""•"•'-'• arBe Complimentary'copies of the latest issues of TkeAntriamjaanzlff GUEST REGISTRATION F^yiiig^fifj^s^KSma^AaKle^PffliieOyt TfeArrEiicmlnmtisjGenatni: „ . r n • • inn™ /Vit&^ 7k/twWA^'WC^ One only per full-ume registrant . 100.03 ^^^ ^JB 2J3£J«J be obtained at the APA/APPI Periodicals Only one guest » aUowed to register ^chfuE-urne meetmg ^^ ^ ^ ^ Booblore Co ^ ies of fyk^x*,, The gtst rnei r&&m&exareb&6(hadambeane toressr^rtwi .,., r ., ,. , . c ct regisiiant. ., • ,_, , , „ „ , will be a\ ailabk at stands locate dIL throughouL t /lavit • s jCenter- . Stall wil-nl selnl atthesajTSaddrKi. APA members cannot register as a guest ; they ,. , , . . „ .„. , r° . . , , ,. discounted subscriptions to all APA/ APPnI journals, demonstrate online must register as an APA member. , , .,T • _i- L • • j L access for subscribers, ans^sT qi^soons regarding submissions, aod snow r^- r,o Mm . ...., m^JteAsxi^jMvtJH^^^p^&tfa^,^ Audioupesolmost sessionsve avaJabk shordy after each session nonmemberpH^pankvam (vtffcrfa^) feypree*). ' concludes and may be purchased at the MobJtape Boothlocated on the NONMEMBER PSYCHIATRIC RESIDENTS AND OTHER North Concoune, in Javits Center, FULL-TIME STUDENTS must present documentation to register in their cONTINUING mEDICAL eDUCATION respective category and qualify for the reduced fee. (Examples indude: a valid full-time [12 V hours per semester] student ED; a letter from pur Educational Objectiws: At the conclusion of this meeting, participants instructor or director of training verifying your status as a psychiatric ™1 ™ a"'e ro: resident; or similar documentation.) • Better understand new research findings in the fields of psychiatry and Note: There are no exemptions or reduced fees available for CME ncuroscience; courses. The registration fee covers admission to ill sessions (except • Acquire new knowledge ind skills in clinical psychiatry, which can be courses), shuttle buses, and includes a badge and copy of the/^gtjtw5aofe, utilized to imp rove patient care; APA Exhibits Guide, and Ne&Resexnk fVqgiarKand A bstraas Becks, and for • Identify- and remove barriers to the transfer of new knowledge for their most categories, a copy of the S^labte. practice, including provision of culturally competent care for diverse populations; Z:\BC-OP & Lit\Images\05-04-2008\PP-P_Icon\RGB\Double • Assess a variety of treatment choices, including psychotherapeutic and Badges are required for all sessions including the Opening Session and pharmacological options; and e^dlibit area. Only an APA member badge will admit you to the Business , g^^j- understand mental health service delivery issues, including Meeting- barriers to care. Badge Color Codes: Blue-Members, Yellow-Nonmembers, Silver-Press, f^e ^p^ ^ accredited by the Accreditation Council for Continuing Red-Exhibitors, Green-APA Staff, and White-Temporary Javits Personnel. MedicJ Education (ACCME) to provide continuing medical education for Registered exhibitors will receive red badges, which allow access only to phvsicians, his/her own booth in the exhibit hall and to ride the shutde bus. If an f^e APA designates this educational activity for a maximum of 66 exhibitor wants to attend sessions, he/she must register for die meeting and category 1 credits toward the AMA Physician's Recognition Award and for paythe appropriate fee. ^ CMErequiremen to f the APA Each physician should claim only those credits thai he/she actually spent in the activity. Please note: Most portions of the scientific program, as outlined below, have been approved for CME credit. The scientific sessions on the official Annual Meeting program, with some exceptions, meet the criteria for category 1 CME credit. Sessions in the following program

III formats are designated as category 1: Advances in Psychopharmacolog}$ TAPE RECORDING AND VISUAL Advances in Research, Oinical Case and Continuous Clinical Case REPRODUCTION POLICIES Conferences, CME Courses, Focus Live, Forums, Industry-Supported Audiotape recording is only permitted for personal use and by members Symposia, Lectures, Medical Updates, New Research Oral/Slide Sessions, of the media. Registrants are welcome to use their own small, portable Research Advances in Medicine, Presidential Symposia, Review of Psychiatry, audiotape recorders to record any session except the Master Educator Scientific and Clinical Reports, Symposia, and Workshops. Other program Clinical Consultations, Clinical Case Conferences, and the activities maybe reported as category 2: Debate, Discussion Groups, Master Continuous Clinical Case Conference, or unless prohibited by the Educator Clinical Consultations, New Research Poster Sessions, and Research presenters. Larger professional tape recorders, however, are not permitted Consultations. Scientific sessions are open to all Annual Meeting registrants, other than those utilized by members of the media and personnel except for the Clinical Case and Continuous Clinical Case Conferences and representing the professional taping firm authorized by APA to audiotape the Master Educator Clinical Consultations, which are open to APA members sessions. The badges of personnel representing this firm and members of only. the media will clearly identify them. Non- media registrants are not PLEASE NOTE: APA MEMBERS ARE REQUIRED TO permitted to videotape any session because the intrusive nature of the MAINTAIN THEIR OWN RECORDS OF CME HOURS. recording may disrupt the session. More detailed guidelines for media REPORTING OF CME CREDIT IS ON AN HONOR BASIS. representatives may be obtained in the Press Office. To document CME credit earned at the Annual Meeting, participants should record the sessions they attended on the Certificate of Attendance SMOKING POLICY log sheet found in the front of the 2004 A nruol Meeting CME Syllable & There will be NO SMOKING in scientific sessions Proceeding Summary Book. Credit is earned on an hour-for-hour basis. A or in the exhibit hall Smoking will only be permitted in parchment Certificate of A ttendanae is also available. designated areas. The Certificate of Attendance (or copy) may be forwarded to other organizations requiring verification of participation in the APA Annual Meeting. GUIDE TO THE PROGRAM BOOK The APA requires members to participate in a total of 150 hours of CME On page V, you will find the table of contents for ease in locating activities within a three-year reporting period. At least 60 hours must be in category 1 activities. information about this meeting. A topic index is included to assist you with finding sessions of interest. The individual program for each day's CME report forms may be obtained from the Department of CME at the sessions is listed by start time with the formats listed alphabetically under APA or online at www.psych.org. Staff will be available in the APA Resource those times. NOTE: To make it easier for you to plan your day, we Center to answer any of your questions about CME. have prepared a separate " Days-at-a-Glance," which is included in .ANNUAL MEETING I- 'VALUATION your registration packet If you have any questions about this book or the scientific sessions, The Annual Meeting Scientific Program Committee needs your please feel free to stop by the Annual Meetings Office in Javits Center, recommendations and evaluations to plan next year's Annual Meeting. A and we will be gkd to help you. Also, all central office APA staff members participant evaluation form is enclosed with your registration packet and will be wearing green badges. Please feel free to direct your questions to them. includes instructions for completing the form. BEFORE YOU LEAVE THE MEETING, PLEASE COMPLETE YOUR FORM AND DROP IT IN ONE OF THE EVALUATION BOXES LOCATED FUTUiRF APA MEETINGS THROUGHOUT THE MEETING SITES. You can receive a parchment Certificate of Attendance at the Annual Meeting by returning your completed form (to the Annual Meetings Office, Information/Locator APA ANNUAL MEETINGS Center, or APA Exhibit, all located in Javits Center) or by completing the 2005 May 21-26 Atlanta, GA computerized general evaluation on the Concourse, Level 1, in Javits Center.. 2006 May 20-25 Toronto, Ont., Canada SESSION CAPACITY So that all in attendance may benefit, we ask your assistance when INSTITUTES ON PSYCHIATRIC SERVICES overcrowding occurs: 2004 October 6-10 Atlanta, GA * Please find seating as far forward as possible. 2005 October 5-9 San Diego, CA * Move to the center of the row and fill all seats so that chairs are available 2006 October 6-10 New York, NY on aisles for additional attendees. * Overcrowding of meeting rooms may subject the session to shutdown by Tentative program schedules and hotel information for the 2004 Institute the Fire Marshal; therefore, we urge all attendees to locate seating rather on Psychiatric Services are available at the Information/Locator Center, than stand in aisles or against walls. located on the North Concourse, Javits Center. * If space does not permit you to attend a session, an audiotape of that session may be available. Please check the order form included in your registration packet.

IV TABLE OF CONTENTS

Floor Plans for Javits Center, New York Hilton, and Marriott Marquis VI-XV City Map XVI Local Information XVII Special Acknowledgments XVIII-XX Audiotape Sales Information XXI Format Descriptions XXII-XXIII Disclosure Information XXIV-XXXIX Saturday Sessions 1-4 Sunday Sessions 5-12 Monday Sessions 13-40 Tuesday Sessions 41-67 Call for 2005 Annual Meeting Papers 68 Wednesday Sessions 69-92 Thursday Sessions 93-106 Topic Index 107-121 Participant Index 122-134 Call for 2005 Annual Meeting Papers 135 Audiotape Sales Information 136 2004 Institute on Psychiatric Service 137 American Psychiatric Publishing Inc 138-139 Industry-Supported Symposia 140-166 APAExhibit Back Cover

Refer to the APA Exhibits Guide for information on: Exhibits, Publishers' Bookfair, and Dining Facilities in Javits Center.

The information provided and views expressed by presenters on this program are not necessarily those of the American Psychiatric Association, nor does the American Psychiatric Association warrant the accuracy of any information reported.

® American Psychiatric Assocktion.

VV 5

t

Level 4

24 The 4E Terrace Lounge 25 Cocktail Lounge toWBsntei* Leve/3 1« Food Court:

fjiitiHt Cite co. {Men famlL fSJMjw&UfcrfftMMy' ciiifCT'mrLSi l£il yMUMlfa-my . 19 CoocfergeOesk *m»ttr*«rt9»n.«kM», totom*^*H**u»tmt* ^^Umtiv^m^on^t iroiiN«y5l»w»TW««»» Tnwtl«irt(»ir»l»«. p(V*MOT«M«Ji»lMN»t) 20 Chase ATM 21 Mall Boxes Etc 22 Hudson News 23"Wn^igCar" ^^sr«fmMiMy-iMith, <**, Mtery^,

Lcve/2 7« MxNewYorttOffke (Pma«eofBk»i«*it«U 9 Pu Wk Buses, MM ft M42 10 Shoeshine 11 Hudson News 12 Gourmet Coffee 13 Conderge Desk, 14 Show Shuttle Bus Stop 15 NlTfcrstZfcif 16 Taxi Stand 17 Hudson News Lev**! 1 First AW 2 Food Court fe'ffwMirt*Vm*Mm.ta*>tHm*tD4tt GouMMttGnflMtCMmrt I^C»*iMrv Ctfi««M» Gib Cut. OH*« focufl, SlNfmrnofv wrth Matitwc, vm»€M«in» (»»l»nj, »«ej FtMl «f«ht DinftmfAJiKii 3Coatchec* 4Cottch«ck 5 Ows« ATM 6 Vending Machines

VI itjJavits Convention Center

LEVEL

VII Javitss Convention Center

.4, *, J,, ? JA,. A-L-LAAjl A \,A,.'^-f .-1 IL.,U> A "^/fppfinpV^' Rnnt^ix D Meeting Romms

c B Meetinog Roorn

E Meeting Rooms

C Meeting Rooms

VIII IX

Level 2

Level 3

Javits Convention Center Hilton New York 13.? 5 Avenue ot the Americas,, New York, NY iCGl.9 ,2.;.2oS6-*"000

; Concourse/"' Level_/'; / ",-_,.- v..' ,' ».,-»„ v-- '1.-C ^. ..*. t_- .-_^',l»,,- J.«- '„,• J s,,.-

2nsJX/7/7 Floor7 T I -

X Hilton New York 3rd Floor

4th Floor

XI Marriott Marquis 1535 Broadway New York, NY 10036 212-398-1900 Fourth Floor

5 Vtarriort Marqu& e ""ts/'idr BJH-'.-i *

xni ADC

Broadway Ballroom, Sixth Floor Marriott Marquis Marriott Marquis Seventh Floor

^?* tHJSf f ^ f ' *jf ' I ,> "*t Ji* ^»i• i- * *« ;««*.

7 J~*

V^»

'*

^

XV New York City Map

AQ Algonquin IB Inter-Continental The Barclay RR Rihga Royal BV Belvedere LP Le Parker Meridien RO Roosevelt BW Best Western Convention ME Marriott East Side RY Royalton Center MQ Marriott Marquis SH Sheraton Manhattan CE Courtyard by Marriott East Side MF Mayflower on the Park ST Sheraton NY Hotel CY Courtyard by Marriott Times MI Milford Plaza SG Southgate Tower Square MB Millennium Broadway TI The Time CP Crowne Plaza Times Square MU The Muse TR Travel Inn DB Doubletree Guest Suites NH New York Helmsley WNW New York GH Grand Hyatt NP New York Palace WT W Times Square HI Hilton New York NR New York Renaissance Times WA Warwick Hotel HB Holiday Inn Martinique on Bway Square WE Wellington HM Holiday Inn Midtown 57th NY New Yorker Hotel WS Westin Times Square HP Hotel Pennsylvania NO Novotel New York XVI HU Hudson PC Park Central LOCAL INFORMATION

New York Qty is the Capital of the World. It's a magnet for meetings, because there's something for everyone: for high-rollers and the budget-conscious, art aficionados and sports fans, lovers of show tunes and lovers of Wagner. It's a city of architectural treasures and gorgeous parks, and it's easy to get to. New York is a city of over nine million people covering 301 square miles. New York Qty is made up of five distinct boroughs: Manhattan (where the vast majority of sights are located), the Bronx, Queens, Brooklyn, and Staten Island. Many of New York's oldest and newest buildings rub shoulders in Lower Manhattan. It is from here, too, that you can take the Staten Island ferry for breathtaking views of the famous skyline and the Statue of Liberty. The Theater District and Midtown offer Fifth Avenue's glittering shops as well as museums, entertainment, and such landmark skyscrapers as the glorious Chrysler Building. Museum Mile on the Upper East Side is a cultural paradise, and since it runs alongside Central Park, you can rest en-route and watch New Yorkers at play.

ACCESSIBILITY FOREIGN CURRENCY EXCHANGE TOP TEN NY RESTUARANTS (212-) th Buses and trains have individual travel passes American Express at Bloomingdales, 59 Street Cafe des Artistes, 1 W67th St., 877-3500 there is no joint travel pass. Avoid buses, taxis, and Lexington Avenue (10:00 a.nx-6:00 p.m.). Florent, 69 Gansevoort St., 989-5779 and the subway during rush hour, walk instead. The Four Seasons, 99 E. 52^ St., 754-9494 Chequepoint USA, 1568 Broadway, 8:00 a.m.- Golden Unicorn, 18 E. Broadway, 941-0911 Taxi stands are scarce: Hotels, Perm Station, 11:30 p.m. Hatsuhana, 17 E. 489* St., 355-3345 and Grand Central Terminal are the best places th to find one, or hail one in the street. All licensed Harold Reuter & Co.; Grand Central Station, Lespinasse, St. Regis Hotel, 2 E. 55 St., taxi cabs are yellow, available when roof 7:00 a.m.-7:00 p.m., Monday-Friday, 8:00 a.ra- 339-6719 numbers are lit up. 3:00 p.nx, Saturday and Sunday. Oyster Bar, Grand Central Terminal, Grand Kara International, 12225 Broadway, Suite 813, Central Station, Lower Level, 490-6650 The subway is open 24 hours a day, full service 9:00 a.m.-6:00 p.m., Monday-Friday, 9:00 a.ra- The Rainbow Room, 65th Floor, GE Building, between 6:00 a.m. and midnight. 3:30 p.m., Saturday. 30 Rockefeller Plaza, 632-5000 Union Square Cafe, 21 E. 16th St., 243-4020 AIRPORT TRANSPORTATION Thomas Cook, 1590 Broadway, 9:00 a.ra-7:00 Zen Palate, 663 9* Ave., 582-1669 From JFK, Queens, NY p.m., Monday-Saturday. Distance to midtown = 25 miles BROADYWAY THEATERS (212-) Means of transportation: MEDICAL EMERGENCIES Ambassador, 215 W. 49* St., 239-6200 Yellow medallion taxi = $35 NY Hotel Urgent Medical Services/Travelers Barrymore, 243 W. 47* St., 239-6200 Private car service = $25 - $150 Medical Center Belasco, 111 W. 44* St., 239-6200 Public bus (MTA) = $2.00 952 Fifth Avenue (76* - 77 Streets), # ID, NYC Booth, 222 W. 45* St., 239-6200 Subway (MTA) =$2.00 10021. Telephone: (212) 737-1212. Contact Broadhurst, 235 W. 44* St., 239-6200 Shuttle services = $13 - $19 Sheik Martinez. Medical/dental services 24 Broadway, 1681 Broadway, 239-6200 hours for house calls or at urgent/care center, Brooks Atkinson, 256 W. 47* St., 307-4100 From LaGuardia, Queens, NY provided by caring, board-certified doctors. Cort, 138 W. 48* St., 239-6200 Distance to midtown = 8 miles Eugene O'Neill, 230 W. 49* St., 239-6200 Means of transportation: APA GOLF TOURNAMENT Gershwin, 222 W. 51" St., 307-4100 Yellow medallion taxi = $16 - $26 The Golfers of the APA (GAPA) invite you to John Golden, 252 W. 45* St., 239-6200 Private car service = $25 - $130 participate in their 2004 golf tournament to Helen Hayes, 240 W. 44* St., 307-4100 Public bus (MTA) = $2.00 benefit the American Psychiatric Foundation. Imperial, 249 W. 45* St., 239-6200 Subway (MTA) =$2.00 The tournament is scheduled for Monday, May Longacre, 220 W. 48* St., 239-6200 Shuttle services = $10 - $15 3,2004, at Cherry Qeek Golf Links. This is a Lunt-Fontanne, 205 W. 46* St., 307-4100 scenic links-style course with rolling fairways and Lyceum, 149 W. 45* St., 239-6200 TAXI COMPANIES Majestic, 245 W. 44* St., 239-6200 New York Qty Taxi & Limousine Commission elevated tees and greens situated in Riverhead on the eastern end of Long Island. The course, Marquis, 211 W. 45* St., 307-4100 regulates the city's famous yellow fleet of 12,187 Martin Beck, 302 W. 45* St., 239-6200 licensed medallion taxis. Within the city, taxis designed by Charles Jurgens can stretch to 7,187 yards with a par of 73 and the fairways are Minskoff, 200 W. 45* St., 307-4100 cruise the streets looking for passengers. Taxi Music Box, 239 W. 45* St., 239-6200 stands are at many hotels and transportation generous and long with water coming into play Nedelander, 208 W. 41« St., 307-4100 terminals. Yellow medallion taxis are the only on four of the holes. If you are interested in Neil Simon, 250 W. 52^ St., 307-4100 vehicles authorized to pick up street hails. One registering for this event, please contact W. Palace, 1564 Broadway, 307-4100 fare covers all passengers: cabs need not be Stanley Jennings, Jr., MD., at 804-320-7881, by Plymouth, 236 W. 45* St., 239-6200 shared. Fare begins at $2.00, and then increases email at wsjennings@ tuckerpsychiatric.com or Richard Rodgers, 226 W.46* St., 307-4100 30

XVII SPECIAL ACKNOWLEDGMENTS

The American Psychiatric Association expresses its deep appreciation for the following:

Abbott Laboratories: support of the Industry-Supported Bristol-Myers Squibb Sweden: support of the Luncheon for Symposia, "Combination Therapy: New Strategies in the U.S. and International Residents, "Patients Who Want to Die: Are Management of Severe Mental Disorders," Sunday, May 2,1:30 they Suicidal and Where Do They Fit Into DSM?" Sunday, May 2, p.m.; and "Challenges in Treating Bipolar Illness and Comorbid 12 noon. Disorders," Tuesday, May 4,7:00 p.m.; Center for Mental Health Services: support of the APIRE American Academy of Psychiatry and the Law: co-support of Practice Research Network (PRN); and the APA's HIV-related the Manfred S. Guttmacher Award Lecture, Sunday, May 2, 2:30 education programs and materials. p.m. Center for Substance Abuse Treatment: support of the APIRE American Association of Psychiatric Administrators: co- Practice Research Network (PRN). support of the Administrative Psychiatry Award Lecture, Wednesday, May 5,11:00 a.m. Cephalon, Inc.: support of the Industry-Supported Symposia, "Towards DSM-V: Phenomenology, Neurobiology, and Treatment American Psychiatric Foundation: support of the Disaster Response in Depression," Saturday, May 1, 12:30 p.m.; "Targeting Psychiatry Fellowship; and the APIRE Practice Research Network Executive Dysfunctions for Treatment," Sunday, May 2, 8:00 a.m.; (PRN). and "Back to the Future: The Role of Gamma-Aminobutyric Acid in Psychiatric Disorders and Treatment," Wednesday, May 5, 7:00 Association of Mental Health Clergy: co-support of the Oskar p.m.; and the Industry-Supported Breakfast Symposium, "PTSD: Pfister Award Lecture, Tuesday, May 4,11:00 a.m. Searching for Answers in Traumatic Times," Wednesday, May 5, and Thursday, May 6, 7:00 a.m. Association of Women Psychiatrists: support of the joint AWP/APA Women's Career reception and meeting. Cyberonics, Inc.: support of the American Psychiatric Foundation "A Toast to New York" benefit event, Monday, May 3, 7:00 p.m. AstraZeneca Pharmaceuticals: support of the Industry- Supported Symposia, "The Role of Dopamine in Health and Eisai, Inc., Pfizer Inc.: support of the Industry-Supported Symposium, Illness: Science to Practice," Saturday, May 1, 6:00 p.m.; "Novel Intervention Strategies Across the Spectrum of Dementia: Real "Broadening the Horizon of Atypical Antipsychotic Applications," Patients and Real Outcomes," Sunday, May 2,7:00 p.m. Sunday, May 2, 8:00 a.m.; and "Choosing the Right Dose of Atypical Antipsychotics: Art or Science?," Sunday, May 2, 7:00 Eli Lilly and Company: support of the Industry-Supported Symposia, p.m.; the Industry-Supported Breakfast Symposium, "Transcending "Adult ADHD: Clinical Utility and Validity," Saturday, May 1, 1230 Efficacy: Effective Treatment of Psychosis Across Disorders" p.m.; "Bipolar Disorder: Improving Outcomes When Theory, Science, Monday, May 3, and Tuesday, May 4, 7:00 a.m.; the and Clinical Practice Converge," Saturday, May 1, 6:00 p.m.; and APA/AstraZeneca Minority Fellowship and reception, Monday, "Recovering From Schizophrenia: How Treatment Can Improve May 3, 8:00 p.m.; the American Psychiatric Foundation Outcomes and Prevent Chronicity," Sunday, May 2, 7:00 p.m; the "Conversations" event, Tuesday, May 4, 5:30 p.m.; the Industry-Supported Breakfast Symposium, "Recognizing the Many Faces APIRE/AstraZeneca Young Minds in Psychiatry Award; and the of Bipolar Disorder," Monday, May 3, and Tuesday, May 4, 7:00 a.m.; AstraZeneca Young Minds and Minority Fellows Poster Session, partial support of the Simon Bolivar Award Lecture, Wednesday, May 5, Monday, May 3, 7:00 p.m. 9:00 am; and support of the APA/Lilry Resident Research Awards.

Aventis: support of the Travel Fellowship for Women Resident Eli Lilly and Company, Boehringerlngelheim Pharmaceuticals, Inc: Leaders in Psychiatry and Leadership Luncheon, Sunday, May 2,12 support of the Industry Supported Symposium, "Plotting a Course to noon. Remission- Navigating the Intersection of Mind, Brain, and Body," Monday, May 3,7:00 p.m. Bristol-Myers Squibb Company: support of the Industry- Supported Symposia, "Effective Long-Term Management of Estate of Agnes Purcell McGavin: support of the Agnes Purcell Schizophrenia: Real-World Considerations," Sunday, May 2, 7:00 McGavin Award for Distinguished Career Achievement in Child p.m.; "BPD: Regulation of Affect and Impulse Control," Monday, and Adolescent psychiatry. May 3, 7:00 p.m.; and "Optimizing Antipsychotic Treatment in Patients With Schizophrenia and Bipolar Disorder," Wednesday, Forest Laboratories, Inc.: support of the Industry-Supported May 5, 7:00 p.m.; the Industry-Supported Breakfast Symposium, Symposia, "From Pathology to Practice: Evolving Therapeutic "New Advances in the Treatment of Psychosis," Monday, May 3, Strategies for Alzheimer's Disease," Sunday, May 2, 8:00 a.m.; and Tuesday, May 4, 7:00 a.m.; the APA's Solomon Carter Fuller "Moderators and Mediators of Antidepressant Response," Sunday, Award Lecture, Monday, May 3, 2:00 p.m.; and the Reception for May 2, 7:00 p.m.; and "Panic Anxiety: Understanding Its Nature the Solomon Carter Fuller Award Recipient. and Nurturing Recovery," Tuesday, May 4, 7:00 p.m.; the Industry- Supported Breakfast Symposium, "Current Alzheimer's Disease Treatments and Beyond: Advances Impacting Qinical Practice," XVIII SPECIAL ACKNOWLEDGMENTS

Monday, May 3, and Tuesday, May 4, 7:00 a.m.; the American National Institute on Drug Abuse: support of the special Annual Psychiatric Foundation "A Toast to New York" benefit event, Meeting series, "Integrating the Science of Addiction into Psychiatric Monday, May 3, 7:00 p.m.; and the registration portfolios. Practice"; the American Ps)chiatric Institute for Research and Education/Research Training activities; and the Drug Abuse Research GlaxoSmithKline: support of the Industry-Supported Symposia, Scholars in Psychiatry Program (DARSPP). "Preventive Ps)chiatry in Mood Disorders: A New Frontier," Saturday, May 1,12:30 p.m: "Sex, Sexuality, and 5HT", Saturday, May 1,650 pm; Neurocrine Biosciences Inc.: support of the Industry-Supported "The Hidden Faces of Anxiety," Sunday, May 2, 8:00 am; Symposium, "Exploring the True Morbidity of Insomnia," "Ps)fchopharmacology and Reproductive Transitions: Impact of Tuesday, May 4, 7:00 p.m. Psychotropic Medications and Sex Hormones on Brain Functioning, Weight, and Reproductive Safety," Sunday, May 2, 7:00 pm; and "Does Novartis Pharmaceuticals Corporation: support of the Industry- the Pharmacology of Antidepressant Drugs Matter?" Tuesday, May 4,700 Supported Symposium, "Reaching Beyond Alzheimer's Disease pm; the Industry-Supported Breakfast Symposium, "Bipolar Disorder in With Cholinergic Therapy," Monday, May 3,7:00 p.m. Women: Reproductive Implications of Treatment," Wednesday, May 5, and Thursday, May 6, 750 am; the APA/GlaxoSmithKline Fellowship Organon Inc.: support of the Industry-Supported Symposium, Program and reception; the annual oontribution to the APA Presidential "Antidepressant Treatments You May Not Know About, But Fund; the APA/GlaxoSmithKline Young Faculty Award for Research Should...," Sunday, May 2, 8:00 am. Development in Biological Psychiatry, the APIRE/GlaxoSmithKline Severe Mental Illness Fellowship; and the American Psychiatric Ortho-McNeil Pharmaceuticals: support of the Industry- Foundation "AToast to New York" benefit event, Monday, May 3. Supported Symposia, "Bipolar Disorder and Alcoholism: Diagnostic Challenges and Therapeutic Interventions," Saturday, Gralnick Foundation: support of the Alexander Gralnick, MD., May 1, 12:30 p.m.; "Impulsivity: Emerging Clinical Perspectives," Award for Research in Schizophrenia. Saturday, May 1, 6:00 p.m.; and "Binge-Eating Disorder: Genes, Treatments, and Consequences," Tuesday, May 4, 7:00 p.m. Harding Foundation: co-support of the Oskar Pfister Award Lecture, Tuesday, May 4,11:00 am. Otsuka America Pharmaceutical, Inc.: support of the International Medical Graduates (IMG) Caucus Reception; the Ittleson Foundation: support of the Blanche F. Ittleson Award Minority Mental Health Awards; and the American Psychiatric for Research in Child Psychiatry. Foundation "A Toast to New York" benefit event, Monday, May 3, 7:00 pm. Janssen Pharmaceutica and Research Foundation: support of the Industry-Supported Symposia, "Treatment Resistance: Pfizer Inc.: support of the Industry-Supported Symposia, "GAD: Concepts and Management in Mood and Anxiety Disorders," Evidence-Based Considerations From Pathophysiology to Long- Saturday, May 1, 12:30 p.m.; and "Unmasking Bipolar Disorder: Term Management," Saturday, May 1, 6:00 p.m., "The Many Faces Overcoming the Barriers to Treatment Success," Sunday, May 2, of Anxiety: Origins, Pathogenesis, and Management," Sunday, May 1:30 p.m.; the Committee of Asian-American Psychiatrists 2, 8:00 am.; and "Are All Atypical Antipsychotics Equal for recruitment reception; and the American Psychiatric Institute for Treatment of Cognitive and Affective Symptoms in Research and Education/Janssen Research Scholars on Severe Schizophrenia?" Sunday, May 2, 1:30 p.m.; partial support of the Mental Illness Program. Simon Bolivar Award Lecture, Wednesday, May 5, 9:00 am.; support of the Residents' Session, "Meet the Experts: Sunny-Side Johnson & Johnson: support of an unrestricted educational grant Up," Monday, May 3, 7:00 am.; the "Abstracts-On-Disk" Program; to support international activities. and the APA Daily Bulletin newspaper.

Lilly Research Laboratories, a Division of Eli Lilly & Company: Professional Risk Management Services, Inc.: co-support of support of the APA/Lffly Psychiatric Research Fellowship. the Manfred S. Guttmacher Award Lecture, Sunday, May 2, 2:30 p.m. and the American Psychiatric Foundation "A Toast to New Merck & Co., Inc.: support of the Industry-Supported York" benefit event, Monday, May 3, 7:00 p.m. Symposium, "Beyond 5HT: New Treatments for Depression," Sunday, May 2, 1:30 p.m.; and the William C Menninger Memorial Reckitt Benckiser Pharmaceuticals: support of the Industry- Convocation Lecture, Monday, May 3, 5:30 p.m.; and the Supported Symposium, "Pharmacotherapy of Addictions: From APA/Merck & Co., Inc., Early Academic Career Research Award. Clinics Into Office Practice," Monday, May 3, 7:00 p.m.

National Institute of Mental Health: co-support of the APA/NIMH Vestermark Psychiatry Educator Award Lecture, Wednesday, May 5, 2:00 p.m.; support of the American Psychiatric Institute for Research in Education (APIRE) Annual Meeting activities for research trainees; the Program for Minority Research Training in Psychiatry (PMRTP); and the Research Colloquium for Junior Investigators.

XIX SPECIAL ACKNOWLEDGMENTS

Roche Laboratories: support of the Industry-Supported Symposium, UCB Pharma, Inc.: support of the Industry-Supported "Interferon-Induced Depression: Consequences of Treating Chronic Symposium, "Broadening Horizons: Advances in Understanding Hepatitis C," Monday, May 3, 7:00 p.m.; and the Benjamin Rush the Etiology, Effects, and Treatment of Anxiety Disorders," Award Lecture, Monday, May 3,9:00 a.m. Sunday, May 2, 8:00 a.m.

Sanofi-Synthelabo, Inc.: support of the Residents, Medical University of California-Davis, Department of Psychiatry: Students, and Training Directors Luncheon, Sunday, May 2, 12 support of the Residents, Fellows, and Medical Student's noon and the American Psychiatric Foundation "A Toast to New Reception, Monday, May 3, 5:00 p.m. York" benefit event, Monday, May 3,7:00 p.m. Wyeth Pharmaceuticals: support of the Industry-Supported Sepracor, Inc.: support of the Industry-Supported Symposium, Symposia, "Interface Between Depression and Medical Illness," "Beyond Sleep Onset: New Perspectives on the Treatment of Saturday, May 1, 6:00 p.m.; "The Treacherous Triad for Insomnia," Sunday, May 2, 7:00 p.m.; and shuttle bus system. Depression," Sunday, May 2, 1:30 p.m.; "Hormones, Mood, and Cognition: Treatment Considerations in Older Women," Monday, Shire US, Inc.: support of the Industry Supported Symposia, May 3, 7:00 p.m.; "Emotion Regulation and Plasicity of Underlying "Conceptualizing and Treating ADHD Adults," Monday, May 3, Circuitry: Implications for Depression, Anxiety, and Long-Term 7:00 p.m.; and "Adult ADHD Diagnosis and Treatment," Tuesday, Brain Function," Tuesday, May 4, 7:00 p.m.; and "Core Symptom May 4, 7:00 p.m.; and the nine APA/Shire Child and Adolescent Domains in the Anxiety Disorders," Wednesday, May 5, 7:00 p.m.; Psychiatry Fellowships. the Industry-Supported Breakfast Symposium, "Evidence-Based Medicine: The Next Generation," Monday, May 3, and Tuesday, Substance Abuse and Mental Health Services Administration May 4, 7:00 a.m.; the APA/Wyeth Pharmaceuticals MD., Ph.D., (CMHS, CSAP, CSAT): sponsorship of the APA/SAMHSA Research Fellowship; support of the Jeanne Spurlock, MD. Minority Fellowship Program. Congressional Fellowship; and the daily in-house TV program, "APA News Network" The Psychiatrist's Program, The APA-Endorsed Professional Liability Insurance Program: support of the ECP luncheon, Tuesday, May 4,12 noon.

XX American Psychiatric ASSOGMM Audiotapes Recorded Live!

High Quality Continues for the 2004 Annual Meeting...

Live recordings will be available for most of the following: • Lectures • Advances in Research • Advances in Psychopharmacology ' Presidential Symposia • Medical Updates Scientific and Clinical Reports • Symposia • Debate • Roundtable Discussion • Research Advances in Medicine

Tapes may be purchased on site at Mobiltape's booth at the Javits Convention Center.

Mobiltape Company, Incorporated 24730 Avenue Tibbitts, Suite 170 Valencia, CA 91355 Phone: (661) 295-0504 4 (800) 369-5718 Fax: (661)295-8474 Website: www.mobiltape.com XXI FORMAT DESCRIPTIONS

ADVANCES IN PSYCHOPHARMACOLOGY based discussions, and the audience will enter their answers with This three-and-one-half hour session will summarize important new hand-held devices. Results are instantly tallied and projected on clinical and research findings in the treatment of selected psychiatric the screen. disorders, with an emphasis on psychopharmacologic interventions. The session will be based in part, on material contained in The A nerican FORUMS Psychiatric Publishing Textbook ofPsydxpharmunlqiy, ThndEdition, edited by These are flexible presentations that afford an opportunity to highlight Drs. Alan F. Schatzberg and Charles B. Nemeroff. Authors of selected and select topics that are of timely interest to psychiatrists. Speakers chapters from the textbook will present material from their chapters. and panel members are chosen for their expertise and leadership in the The topics were selected by the editor to represent disorders of particu- field. lar current interest to psychiatrists and to focus on aspects of psy- chopharmacology that may be of greatest importance to APA mem- LECTURES bers. Lectures feature a small number of distinguished speakers discussing scientific and cultural topics, many of which will extend our understand- ADVANCES IN RESEARCH ing beyond the usual limits of clinical psychiatry. The Scientific Pro- During this two-hour session, a brief overview of major advances in gram Committee invites the lecturers. research in psychiatry and a preview of selected research presentations scheduled at the Annual Meeting, leading clinical researchers present MASTER EDUCATOR CLINICAL CONSULTATIONS the ktest developments in four different, clinically-relevant areas of These 90-minute, clinically-based seminars are presented by outstanding research. educators. Formats and subject matter will vary, but all will utilize clini- cal material offered by participants. These sessions are limited to 25 CLINICAL CASE CONFERENCES participants on a first-come, first-served basis. THESE SESSIONS During these 90-minute sessions, clinical material is presented by video- ARE OPEN TO APA MEMBERS ONLY. BLUE tape or the treating therapist. One or more experts then discuss the REGISTRATION BADGE OR APA MEMBERSHIP CARD case. THESE SESSIONS ARE OPEN TO APA MEMBERS REQUIRED FOR ADMITTANCE. ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE. MEDICAL UPDATES These 90-minute sessions are designed to provide psychiatrists with the CONTINUOUS CLINICAL CASE CONFERENCES ktest clinical developments in other areas of medicine. Topics may The presenters will review the progress of psychotherapy in two suc- range from subspecialty areas of adult or pediatric medicine (infectious cessive three-hour sessions on consecutive days (Monday-Tuesday and disease, cardiology, gastroenterology, etc.) to new techniques or proce- Wednesday-Thursday, beginning at 9:00 a.m.). Audience participation dures in surgery or radiology. The interface between psychiatry and is encouraged throughout. Participants are requested to attend both these areas is not necessarily emphasized. The intent is to give partici- sessions in their entirety. THESE SESSIONS ARE OPEN TO pants an update from a physician in a particular specialty. APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR NEW RESEARCH ADMITTANCE. This format allows for presentation of the very recent findings. The three types of presentations include: Posters, which are visual, self- COURSES explanatory presentations; Young Investigators' Posters, with presenta- Courses are designed to emphasize learning experiences that actively tions from young investigators, residents, medical students, and research involve participants and include the opportunity for informal exchange or clinical fellows; and Young Investigators' Oral/Slide which are fif- with the faculty. Offered in four-hour (half-day), six-hour (full-day), teen-minute presentations with three minutes for discussion. and eight-hour (full-day) sessions, courses either review basic concepts in a special subject area or present advanced material on a circum- RESEARCH ADVANCES IN MEDICINE scribed topic. Participants must purchase tickets to attend. This two-hour format presents an overview of cutting-edge research in various aspects of medicine. In contrast to the Medical Update series, DEBATE which is more clinically focused, this session will help participants keep Experts in the field, including psychiatrists and nonpsychiatrists, will pace with the rapidly expanding knowledge base and technology in vari- debate a controversial topic in psychiatry. The debate format allows for ous branches of medicine. Several speakers, authorities in their fields, members to hear both pro and con views about important, interesting will present on their topics. and timely concerns for our members. Someone who has expertise in the topic area moderates the debate. A portion of the time is allocated RESEARCH CONSULTATIONS WITH for questions from the audience to the presenters with active participa- This 90-minute format provides an opportunity, in a small group set- tion by participants. ting, for participants to obtain consultations around problems in re- search from outstanding senior researchers. Participants should come DISCUSSION GROUPS prepared to present a specific problem in research, whether it's one of This 90-minute format allows small groups to meet informally with research design, methodology, subject selection or data analysis, etc., selected experts in psychiatry to discuss topics chosen by the which could be presented briefly to the consultant. These sessions are expert. Some of these are reserved for residents only. These sessions limited to 25 participants on a first-come, first-served basis. are limited to 25 participants on a first-come, first-served basis. RE VIEW OF PSYCHIATRY FOCUS LIVE There will be four, three-and-one-half hour sessions presented, based on These 90-minute sessions allow participants to test their knowl- the annual American Psychiatric Publishing Review of Psychiatry Series. edge using an interactive Audience Response System (ARS), Each session includes an abridged presentation by the senior author offering a new and entertaining way to learn. ARS sessions can from each of the chapters in each volume. The topics were selected by make a group of 300 feel like they are having a small group con- the overall editors of the series to represent current areas of new re sultation with an expert clinician. Experts, who served as guest search, new developments in clinical care, and special issues of impor- editors of FOCUS, will lead lively multiple choice question- tance to APA members. XXII FORMAT DESCRIPTIONS

SCIENTIFIC AND CLINICAL REPORT SESSIONS WORKSHOPS Scientific and Clinical Reports are oral presentations of papers prepared Workshops are 90-minute sessions (either Issue or Component), which for submission before publication. In this 90-minute format, reports typically involve brief presentations from individual panel members, are grouped by topic, with floor discussion from the audience following followed by the opportunity for lively and informative discussion. This the presentation of each paper. There is no formal discussant. format provides for substantial audience participation and should be highly interactive. SYMPOSIA Symposia are three-hour sessions consisting of four to six presentations Media Workshops are three-hour sessions held Monday-Thursday, in that are thematically linked and focus on a specific topic relevant to which a feature-length film is shown and discussed. clinical psychiatry. They are designed to provide comprehensive treat- ment of a topic or discussion of the topic from several points of view by the participants and stimulate discussion with the audience. Some symposia are supported by industry and are designated as "Industry- Supported Symposia" in this PragamBook.

XXIII AMERICAN PSYCHIATRIC ASSOCIATION CONTINUING MEDICAL EDUCATION POLICY ON FULL DISCLOSURE

The American Psychiatric Association requires disclosure by presenters at CME activities of any significant financial or other affiliation with commercial goods/organization(s) regulated by the Food and Drug Administration, which may have a direct or indirect interest in the subject matter of the scientific program. A "financial interest" may include, but is not limited to, being a shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization. An "affiliation" may include, holding a position on an advisory committee or some other role or benefit to a supporting organization. The existence of such relationships does not necessarily constitute a conflict of interest, but the prospective audience must be informed of the presenter's affiliation with every commercial supporter by an acknowledgement in the printed program and verbal or visual disclosure to participants at the session (disclosure by slide or overhead is required if AV equipment is used for the presentation). This policy is intended to openly identify any potential conflicts) so that members of the audience in an educational activity are able to form their own judgments about the presentation. The APA also requires verbal disclosure of discussion of unlabeled uses of a commercial product or investigational use of a product not yet approved for this purpose.

The following presenters have indicated that either they or an immediate family member has a significant interest or other affiliation with a commercial supporter of this meeting and/or with the manufacturer(s) of a commercial produces) and/or provider of commercial services (s). The presenter's name and the company's name are listed below, along with the page # the presenter appears on in this Program Bock. The nature of the presenter's relationship with the disclosed company is indicated by the following code: consultant or advisory board1, full-time employment2' research/grant support3, speakers' bureau4, stock or other financial options5, other financial or business relationships6. If a number has not been assigned, the presenter has not disclosed the relationship to the company.

Presenter Manufacture r(s) Program Page # Susan E. Abbey, M.D. Lilly Research Laboratories, a division of Eli Lilly and Company1; Lundbeck1-4; GlaxoSmhhKline1'4; 87 US. Pharmaceuticals, Pfizer Inc.4; Qrganon Pharmaceuticals Inc.4 Anissa Abi-Dargham, M.D. Bristol-Myers Squibb6 11 Lenard A. Adler, M.D. Novartis Pharmaceuticals Corporation6; U.S. Pharmaceuticals, Pfizer Inc.6; 2, 67 Eli Lilly and Company6; Shire Ridgewood Pharmaceuticals6; McNeil Pharmaceuticals6; Johnson and Johnson PRD6 Nassima Ait-Daoud, M.D. Johnson and Johns on PRDl 64 Hagop S. Akiskal, M.D. Lilly Research Laboratories, a division of Eli Lilly and Company1'4; GlaxoSmithKline4; 65 Bristol-Myers Squibb5; Janssen Pharmaceutica Inc.4; Abbott Laboratories, Inc.4 George S. Alexopoulos, M.D. Forest Laboratories, Inc.3'4; Cephalon Inc.3'4; U.S. Pharmaceuticals, Pfizer Inc.4; 7 Lilly Research Laboratories, a division of Eli Lilly and Company4; GlaxoSmithKline4; Janssen Pharmaceutica Inc.4; Wyeth-Ayerst Laboratories4; SmithKline Beecham Pharmaceuticals4 Jonathan E. Alpert, M.D. Pharmavite1'3; Organon Pharmaceuticals Inc.3-4; Forest Laboratories, Inc.3 34, 78 Gustavo Alva, M.D. Corcept Therapeutics, Inc.3; Novartis Pharmaceuticals Corporation3'4; 40 Wyeth-Ayerst Laboratories3'4; Parke-Davis, Division of Warner-Lambert Company3; U.S. Pharmaceuticals, Pfizer Inc.3-4; Otsuka Pharmaceuticals4; Forest Laboratories, Inc.4; Janssen Pharmaceutica Inc.4; Bristol-Myers Squibb4 Andrew F. Angelino, MD. US. Pharmaceuticals, Pfizer Inc.4; GlaxoSmithKline4; AstraZeneca Pharmaceuticals4; 47, 56, 70 Lilly Research Laboratories, a division of Eli Lilly and Company4; Boehringer Ingelheim4; Roche Laboratories, a member of the Roche Group4; Abbott Laboratories, Inc.4; Schering Corporation4; Wyeth-Ayerst Laboratories4 Raymond F. Anton, Jr., M.D. Johnson and Johnson PRD1'4; Ortho McNeil Pharmaceuticals1'4; Bristol-Myers Squibb1-4; 64 U.S. Pharmaceuticals, Pfizer Inc. l>4 Michael R. Arambula, M.D. U.S. Pharmaceuticals, Pfizer Inc.4 46 David B. Arciniegas, M.D. Novartis Pharmaceuticals Corporation1'4; U.S. Pharmaceuticals, Pfizer Inc.4; 87, 93 Janssen Pharmaceutica Inc.4 Scott G Armstrong, M.D. U.S. Pharmaceuticals, Pfizer Inc.4; Novartis Pharmaceuticals Corporation4 71 Bruce A, Arnow, Ph.D. Eli Lilly and Company6 39 Louis J. Aronne, M.D. SanofhSynthelabo Pharmaceuticals, Inc.3; Regeneron1; Amgen1; TAP Pharmaceuticals1; 67 Bristol-Myers Squibb1; Abbott Laboratories, Inc.3-4; Ortho McNeil Pharmaceuticals1'3; Roche Laboratories, a member of the Roche Group3-4 Gregory M Asnis, M.D. Roche Laboratories, a member of the Roche Group6 38 Claudia F. Baldassano, M.D. AstraZeneca Pharmaceuticals6 12 Russell A. Barkley, Ph.D. Eli Lilly and Company1; Shire Ridgewood Pharmaceuticals1; Novartis Pharmaceuticals Corporation1 39 Ernest S. Barratt, M.D. Ortho McNeil Pharmaceuticals1 3 Barbara D. Bartli, M.D. U.S. Pharmaceuticals, Pfizer Inc.3; GlaxoSmithKline3; Sensaquest, Inc.4 60 Andrius Baskys, M.D. AstraZeneca Pharmaceuticals1'3>4 ; Novartis Pharmaceuticals Corporation1'4; Janssen Pharmaceutica Inc.3 13 Elizabeth A. Baxter, M.D. Eli Lilly and Company1 80 Joseph H. Beitchman, M.D. Eli Lilly and Company4 100 XXIV DISCLOSURE INDEX

Bernard D. Beitman, M.D. GlaxoSmithKline4 45,58, 82 Aysenil Belger, Ph.D. Eli Lilly and Company6 10 Ruth M Benca, M.D. Neurocrine1'4; US. Pharmaceuticals, Pfizer Inc. ^j Takeda Pharmaceuticals1'3'4; Sepracor Inc. l>4; 67 Wyeth-Ayerst Laboratories1'4; Merck & Co., Inc.3; Sanofi-Synthelabo Pharmaceuticals, Inc. ^4 Joseph Biederman, M.D. Shire Ridgewood Pharmaceuticals1'3'4; Eli Lilly and Company1-3.4; Cephalon Inc. W; MCHD3; 2,45,85,98, Wyeth-Ayerst Laboratories3'4; US. Pharmaceuticals, Pfizer Inc.3-4; GlaxcSmithKline4; 106 Stanley Foundation3; Alza/McNeil Pharmaceuticals1'4; National Institute on Drug Abuse3' Noven Pharmaceutical1'3 Jed E. Black, M.D. Sepracor Inc.6 11 MaryBlehar,Ph.D. GlaxoSmithKline6 12 Martin Bohus, M.D. Bristol-Myers Squibb6 38, 85 Abba E. Borowich, M.D. AstraZeneca Pharmaceuticals4 89 Kathleen T. Brady, M.D. Abbott Laboratories, Inc.1; U.S. Pharmaceuticals, Pfizer Inc.1' Forest Laboratories, Inc.1; 48, 65, 76 Lilly Research Laboratories, a division of Eli Lilly and Company1; Bristol-Myers Squibb4; 90 SmithKline Beecham Pharmaceuticals1 William Breitbart, M.D. Cephalon Inc.1-4; Janssen Pharmaceutica Inc. *>4; Purdue Pharma1-4; Eli Lilly and Company1; 82 Bristol-Myers Squibb4 Ronald Brenner, M.D. Janssen Pharmaceutica Inc.3; Wyeth-Ayerst Laboratories3; GlaxoSmithKline3; 100 Lilly Research Laboratories, a division of Eli Lilly and Company E. Sherwood Brown, M.D. AstraZeneca Pharmaceuticals3; Eli Lilly and Company3; Bristol-Myers Squibb3 5 Richard Brown, MD. Janssen Pharmaceutica Inc.4; PurduePharma4 30 Richard A. Brown, Ph.D. U.S. Pharmaceuticals, Pfizer Inc.1-5 62 Thomas E. Brown, Ph.D. Cephalon Inc.3; Eli Lilly and Company1'4; GlaxoSmithKline Beecham Hieathcare3; 1, 5,14 McNeil Consumer Healthcare1-4; Novartis Pharmaceuticals Corporation1; U.S. Pharmaceuticals, Pfizer Inc.1; Shire Ridgewood Pharmaceuticals1 Robert S. Brown, Jr.., MD. Schering Corporation3-4; Roche Laboratories, a member of the Roche Group3; 50 Ortno Biotech3-4; Glead3; Amgen3 Peter F. Buckley, M.D. Abbott Laboratories, Inc.1; AstraZeneca Pharmaceuticals1; Bristol-Myers Squibb1; 12,76 Janssen Pharmaceutica Inc.1; Novartis Pharmaceuticals Corporation1; Eli Lilly and Company1 Cathy L. Budman, M.D. Eli Lilly and Company3'4 48 AlanJ.Budney,Ph.D. Sanofi-Synthelabo Pharmaceuticals, Inc.3 89 John W. Burruss, MX). U.S. Pharmaceuticals, Pfizer Inc.1-3-4; Eli Lilly and Company3-4; Wyeth-Ayerst Laboratories4; 81, 94 AstraZeneca Pharmaceuticals1-4; Bristol-Myers Squibb1-4 Vivien K. Burt, M.D. Eli Lilly and Company1-3-4; Wyeth-Ayerst Laboratories4; 8, 39 Lilly Research Laboratories, a division of Eli Lilly and Company1-3-4 Marian I. Butterfield, M.D. Bristol-Myers Squibb1-3; Lilly Research Laboratories, a division of Eli Lilly and Company4 34,35,55, 74,86,105 Daniel J. Buysse, M.D. Sanofi-Synthelabo Pharmaceuticals, Inc.1; Cephalon Inc.1; Sepracor Inc.1; Neurocrine1 67 Alexander Bystritsky, M.D. Wyeth-Ayerst Laboratories3; Lilly Research Laboratories, a division of Eli Lilly and Company3-4; 86 Merck & Co., Inc.3; U.S. Pharmaceuticals, Pfizer Inc.; Forest Laboratories, Inc.4 Joseph R. Calabrese, M.D. National Institute of Mental Health6; Abbott Laboratories, Inc.1-6; GlaxoSmithKline1'6; 26,75 Qba Geigy Corporation, Pharmaceutical Division6; Merck & Co., Inc.6; Teva Pharmaceuticals1; Janssen Pharmaceutica Inc.6; Lilly Research Laboratories, a division of Eli Lilly and Company5; MacArthur Foundation6; National Alliance for Research in Schizophrenia and AffectiveDisorders6; Parke-Davis, Division of Warner-Lambert Company1'6; Robert Wood Johnson Pharmaceutical Research Institute1'6; Sandoz Pharmaceuticals Corporation6; SmithKline Beecham Pharmaceuticals1'6; Stanley Foundation6; Tap Holdings, Inc.1-6; UCB Pharma, Inc.1-6; Wjeth-Aysrst Laboratories6; AstraZeneca Pharmaceuticals1; Bristol-Myers Squibb1; Eli UUy and Company1; Janssen Qlag1; Novartis Pharmaceuticals Corporation1; Shire Ridgewood Pharmaceuticals1 Lucile Capuron, Ph.D. Roche Laboratories, a member of the Roche Group6 38 Gabrielle Carlson, MD. Janssen Pharmaceutica Inc.1-3-4; Eli Lilly and Company1'3-4; Abbott Laboratories, Inc.3-4; 13 Novartis Pharmaceuticals Corporation1'3'4; Johnson and Johnson PRD1-3; Bristol-Myers Squibb1 T .inrla L. Carpenter, MD. Qrganon Pharmaceuticals, Inc.1 •4; Gephalon Inc.1 -3; Cyberonics Inc.3-4; Merck & Co., Inc.3; 6,9 Corcept Therapeutics, Inc.3; Abbott Laboratories, Inc.4; Somerset Pharmaceuticals4; W)tth- A)«rst Laboratories4; US. Pharmaceuticals, Pfizer Inc.3-4; Medtronics3 David A. Casey, M.D. U.S. Pharmaceuticals, Pfizer Inc.4; Forest Laboratories, Inc.4 24 Giovanni B. Cassano, M.D. U.S. Pharmaceuticals, Pfizer Inc.3 65 F. Xavier Castellanos, M.D. McNeil Pharmaceuticals3; Johnson and Johnson PRD3'4; Shire Ridgewood Pharmaceuticals1'3'4 39,47, 65 RubyC. Castilla-Puentes, M.D. GlaxoSmithKline R&D2 58, 77,105 Wilma I. Castilla-Puentes, M.D. GlaxoSmithKline2 105 XXV DISCLOSURE INDEX

Presenter Manufacturers) Program Page # KikiD. Chang, M.D. Lilly Research Laboratories, a division of Eli Lilly and Company1; GlaxoSmithKline1'3'4; 66 Abbott Laboratories, Inc.1'3'4; Shire Ridgewood Pharmaceuticals1'4; Janssen Pharmaceutica Inc.1 Qrtho McNeil Pharmaceuticals3; AstraZeneca Pharmaceuticals1'4 Dennis S. Chamey, MD. AstraZeneca Pharmaceuticals1; Aventis Phannaceuticals1; Bristol-Mjyers Squibb1; 4,6 U.S. Pharmaceuticals, Pfizer Inc.1; Somerset Pharmaceuticals1; Vela Pharmaceuticals1; Wyeth-Ayerst Laboratories1; Qrganon Pharmaceuticals1, Inc.; Otsuka Pharmaceuticals1 KJST. RoyChengappa, MD. EU Lilly and Company3-4; Janssen Pharrnace^ Qrtho McNeflPhamiaceuticals3'4; 12 AstraZeneca Pharmaceuticals3'4; Nbvartis Pharmaceuticals Corporation3; Abbott Laboratories, Inc.3 Josepha A Cheong, MD. Janssen Pharmaceutica Inc.4; GlaxoSmithKline4; Qrtho McNefl Pharmaceuticals4; 28,73 AstraZeneca Pharmaceuticals4; Forest Laboratories, Inc.4; US. Pharmaceuticals, Pfizer Inc.4 John A Chiles, MX). Janssen Pharmaceutica Inc.1'4; Lilly Research Laboratories, a division of Eli Lilly and Company1'4; 99 Bristol-Myers Squibb1'4; AstraZeneca Pharmaceuticals1'4 James CY. Chou, MD. Abbott Laboratories, Inc.1 • 3>4 43 Daniel D. Christensen, MD. Bayer Corporation, Pharmaceutical Division1'4; Bristol-Myers Squibb1-3'4; GlaxoSmithKline1'3'4; 11 Janssen Pharmaceutica Inc.1|3'4; Designer Genes Inc.1-3; LP; Eli LiDyand Company1; Eisai America Inc.4; NPS Pharmaceuticals1'3; US. Pharmaceuticals, Pfizer Inc.1'3-4; SolvayPharmaceuticals, Inc.1-3'4; Wyeth-Ayerst Laboratories1'3'4; Abbott Laboratories, Inc.3'4; Novartis Pharmaceuticals Corporation4; Upjohn, Inc.4; Eccles Institute of Human Genetics3; Myriad Genetics, Inc.1'3; Qrganon USA3 Leslie L Qtrome, MX). Abbott Laboratories, Inc.1-3'4; Lilly Research Laboratories, a division of Eli Lilly and Company1'3; 22,73 Bristol-Myers Squibb1'3'4; US. Pharmaceuticals, Pfizer Inc.1'3-4; Eli Lilly and Company1'3'4; Novartis Pharmaceuticals Corporation1'3> 4; AstraZeneca Pharmaceuticals1'3> 4; Janssen Pharmaceutica Inc.1 •3 Stephan Qaes, MD. GlaxoSmithKline4 2 H.Westleydark,MD. Reckitt Benckiser Pharmaceuticals6 39 Anita L.H. Qayton, MD. Bayer Corporation, Pharmaceutical Division1-3; Boehringer-Ingelheim Pharmaceuticals1>3; 4,66,105 Eli Lilly and Company1'3; US. Pharmaceuticals, Pfizer Inc.4; GlaxoSmithKline1'3; Merck&Go., Inc.3; Organon Pharmaceuticals, Inc. l<3-4; Pherin Pharmaceuticals3 Eml F. Goccaro, MD. Eli Lilly and Company1'3'4'6; Abbott Laboratories, Inc.1-3'6; SmithKline Beecham Pharmaceuticals6; 33, 38, 87 Forest Laboratories, Inc.6 Bruce M. Cohen, MD. Eli Lilly and Company1; Merck & Co.4, Inc.; Variagenics1 13,41, 61 Lee S. Cohen, MD. Forest Laboratories, Inc.3-4; Janssen Pharmaceutica Inc.1- 3>4; 39, 69, 93 Wyeth-Ayerst Laboratories1' 3>4; GlaxoSmithKline1' 3>4; AstraZeneca Pharmaceuticals4; U.S. Pharmaceuticals, Pfizer Inc.4; Eli Lilly and Company1-3-4; Berlex Laboratories3 Michael Cohen EEG Spectrum International2 1 Robert R. Conley, MD. AstraZenecaPharmaceuticals1'3'4;JamsenPharmaceuticaInc.3'4^ Company1'3'4; 15,73 Novartis Pharmaceuticals Corporation1'3'4; Aventis1'4; Pharmaceuticals; Otsuka Pharmaceuticals1'4; Bristol-Myers Squibb1-4; Zenith-Goldline1-3'4 Kathryn M. Connor, MD. Eli Lilly and Company3; U.S. Pharmaceuticals, Pfizer Inc.1-3-4; 34 Pure World Botanicals, Inc.3; Forest Laboratories, Inc.3'4; Ortho McNeil Pharmaceuticals1-4; Cephalon Inc.4-6; Wyeth-Ayerst Pharmaceutical Company1-4; SolvayPharmaceuticals, Inc.4; Ancile Pharmaceuticals1; Nutrition 216 Jeremy D. Coplan, MD. U.S. Pharmaceuticals, Pfizer Inc.4; GlaxoSmithKline3'4; Eli Lilly and Company1 6 Sara A Corya, MD. Eli Lilly and Company3 78 Daniel J. Cox, PhD. McNeil Pharmaceuticals3 106 Joseph T. Coyle, Jr., MD. Abbott Laboratories, Inc.1 •5; Merck & Co., Inc.1 -5; Proctor & Gamble5; Applied Biosystems5; Aventis1; 71 Johnson and Johnson PRD1; Pharmaceuticals; Gephalon Inc.1; Avera Pharm1'5; PrestwickPharm5 Kelly L. Cozza,MD. U.S. Pharmaceuticals, Pfizer Inc.1 71 Catherine C Crone, MD. U.S. Pharmaceuticals, Pfizer Inc.4 15, 56, 98 Jeffrey L. Cummings, MD. Novartis Pharmaceuticals Corporation1-3; Eisai America Inc.1; US. Pharmaceuticals, Pfizer Inc.1-3; 7,13,65 Lilly Research Laboratories, a division of Eli Lilly and Company1; Forest Laboratories, Inc.1; Janssen Pharmaceutica Inc.1; AstraZeneca Pharmaceuticals1; Qrganon Pharmaceuticals, Inc.1; Ono Pharmaceuticals1; SynXPharma1; Bristol-Myers Squibb1; Gephalon Inc.1; Abbott Laboratories, Inc.1-3 Jonathan RT. Davidson, MD. SolvayPharmaceuticals, Inc. *>3-4; US. Pharmaceuticals, Pfizer Inc.l-3-4; GlaxoSmithKline1'3-4; 21,35,67, Wyeth-Ayerst Laboratories3'4; Forest Laboratories, Inc. 1>3-4; Eli Lilly and Company1'3; 69,93 Lilly Research Laboratories, a division of Eli Lilly and Company4; Pure World Botanicals, Inc.3; Ancile Pharmaceuticals1; Roche Laboratories, a member of the Roche Group1; UCB Pharma, Inc.1; Novartis Pharmaceuticals Corporation1; Organon Pharmaceuticals, Inc.1-3; Nutrition 213; Boehringer-Ingelheim Pharmaceuticals ^Johnson and Johnson PRD1; Allergan3; Schwabe3; Pharmacia & Upjohn Company, Inc.;*; Boots Pharmaceuticals1; Guilford Publications5; Bristol-Myers Squibb1; MultiHsalth Systems Inc.5; Penguin Putnam5 XXVI DISCLOSURE INDEX

Lori L. Davis, MD. Abbott Laboratories, Inc.3'4; Bristol-Mjers Squibb3'4; GkxoSrnithKline3'4; Forest Laboratories, Inc.3; 66,104 Lilly Research Laboratories, a division of Eli Lilly and Company3; Janssen Pharmaceutica Inc.3; Qrtho McNeil Pharmaceuticals3'4 MaryH. Davis, M.D. Cephalon Inc.4; Wyeth-Ayerst Laboratories4; Forest Laboratories, Inc.4 18 Charles DeBattista, MD. Abbott Laboratories, Inc.4; Bristol-Myers Squibb1 • 3>4; Cephalon Inc.3'4; GlaxoSmithKline1 •3-4; 2,7 Forest Laboratories, Inc.4; Organon Pharmaceuticals, Inc.4; Corcept Therapeutics, Inc.1'5; 70 Eli Lilly and Company1-3'4; Wyeth-Ayerst Laboratories1' 3-4; Nancy Pritzker Network3; Pharmacia & Upjohn Company, Inc.3'4; U.S. Pharmaceuticals, Pfizer Inc.4; NARSAD3; National Institute of Mental Health3 Melissa P. DelBello, M.D. Abbott Laboratories, Inc.3-4; AstraZeneca Pharmaceuticals; l>3- 4; Eli Lilly and Company3-4; 5, 92 Ortho McNeil Pharmaceuticals1' 3>4; Janssen Pharmaceutica Inc.1-3> 4; GlaxoSmithKline4 Pedro L. Delgado, M.D. Bristol-M)*rs Squibb3-4; Eli Lilly and Company3'4; Glaxo-Wellcome1'3'4; Organon, Inc.3-4; 39,43 Pharmacia & Upjohn Company, Inc.3'4; SolvayPharmaceuticals, Inc.3'4; Forest Laboratories, Inc.3; Janssen Pharmaceutica Inc.1-3; Boehringer Ingelheim1; AstraZeneca Pharmaceuticals3; Parke-Davis, Division of Warner-Lambert Company3; W)eth-A)erst Laboratories1'4; Novartis Pharmaceuticals Corporation3; US. Pharmaceuticals, Pfizer Inc.3; SmithKline Beecham Pharmaceuticals3 AbhflashK.Desai,MD. Forest Laboratories, Inc.4; Novartis Pharmaceuticals Corporation4; Janssen Pharmaceutica Inc.4; 69 AstraZeneca Pharmaceuticals4; Lilly Research Laboratories, a division of Eli Lilly and Company4 Michael]. Detke, M.D. Eli Lilly and Company2'5 24 Daniel A. Deutschman, M.D. UGBPharma,Inc.3'4 18 Mantosh J. Dewan, MD. U.S. Pharmaceuticals, Pfizer Inc.4; AstraZeneca Pharmaceuticals4; GlaxoSmithKline4; 18,42, 64 Janssen Pharmaceutica Inc.3; Lilly Research Laboratories, a division of Eli Lilly and Company3 Karl Doghramji, M.D. Cephalon Inc.3; GlaxoSmithKline3; Merck & Co., Inc.3 55,69,97 P. Murali Doraiswamy, M.D. Pfizer Inc.1'3'4; Eisai America Inc.1-3'4; Merck & Co., Inc.1'3-4; GlaxoSmithKline1-3-4; 11,41 Novartis Pharmaceuticals Corporation1-3'4; Forest Laboratories, Inc.1-3-4; Janssen Pharmaceutica Inc.1-3-4 Martin Dossenbach, M.D. Eli Lilly and Company2 79 Robert E. Drake, MD. Eli Lilly and Company6 10, 43 Roxanne C. Dryden-Edwards, M.D. Lilly Research Laboratories, a division of Eli Lilly and Company4 47,100 Eduardo Dunayevich, M.D. Eli Lilly and Company2 43 Boadie W. Dunlop, MD. Cephalon Inc.3-4; UCB Pharma, Inc.3; Janssen Pharmaceutica Inc.3; Wyeth- A)erst Laboratories3 2 James M Ellison, M.D. Forest Laboratories, Inc.4; Wyeth-Ayerst Laboratories4; GlaxoSmithKline3-4; 27 U.S. Pharmaceuticals, Pfizer Inc.4 Abdelouahed Elmouchtari, M.D. AstraZeneca Pharmaceuticals3 3 Milton K. Erman, M.D. Cephalon Inc.1'3'4-5; Mallinckrodt Pharmaceuticals1'3'4'; Neurocrine Biosciences Inc. Ii3>4>5; Elan1-3'4; 97 Sepracor Inc.3'5; Sanofi Pharmaceuticals, Inc. 1>3>4>; Forest Laboratories, Inc. *«4>5; Takeda Pharniaceuticals3; Aventis Pharmaceuticals3; Janssen Pharmaceutica Inc.1-3; King Pharmaceuticals1'4; US. Pharmaceuticals, Pfizer Inc.;3>5 Javier I. Escobar, MD. US. Pharmaceuticals, Pfizer Inc.1-4; Orphan1-3-4; Bristol-Mjers Squibb1-4 20,43 Dwight L. Evans, MD. GlaxoSmithKline1-3'4; Abbott Laboratories1'4, Inc.1'4; AstraZeneca Pharmaceuticals1-4; 4 Bristol-Mj^rs Squibb1-4; Eli Lilly and Company1'4; US. Pharmaceuticals, Pfizer Inc.1'4; Novartis Pharmaceuticals Corporation1'4; Organon Pharmaceuticals, Inc.1-4; Wyeth-Ayerst Laboratories1'4; Somerset Pharmaceuticals1'4; Janssen Pharmaceutica Inc.1'4; Forest Laboratories, Inc.1'4 Warachal E. Faison, MD. Glaxc&rnithKline2; Forest Laboratories4, Inc.; Bristol-Mjcrs Squibb1-4; OtsukaPharmaceuticals1'4 6,17,62 Stephen V. Faraone, PhJD. Shire Pharmaceutical Development, Inc.1-3'4; Novartis Pharmaceuticals Corporation1'4; Noven1 39,85,98 McNeil Pharmaceuticals1'3'4; Lilly Research Laboratories, a division of Eli Lilly and Company1' 3>4 Martin K. Farlow, M.D. Novartis Pharmaceuticals Corporation1 •3 40 Maurizio Fava, MD. GlaxoSmithKline3'4; Glaxo-Wellcome3-4; SmithKline Beecham Pharmaceuticals3'4; 2,66 Pharmavite3'4; Eli Lilly and Company3'4; U.S. Pharmaceuticals, Pfizer Inc. 3>4; Pharmacia & Upjohn Company, Inc. 3>4; Wyeth-Ayerst Laboratories3'4; Bristol-Myers Squibb3'4; Novartis Pharmaceuticals Corporation3'4; Organon Pharmaceuticals, Inc. 3>4; SanofiXSynthelabo Pharmaceuticals, Inc.3>4; Solvay Pharmaceuticals, Inc.3-4; Forest Laboratories, Inc.3>4; Cephalon Inc.3; Bayer AG Corporation, Pharmaceutical Division4; Janssen Pharmaceutica Inc.4; Lundbeck4; Knoll Pharmaceuticals4; Abbott Laboratories, Inc.3; Parke-Davis, Division of Warner-Lambert Company4; Somerset Pharmaceuticals4; Aspect Medical Systems3; Roche Laboratories, a member of the Roche Group3; Lorex Pharaceuticals3; Lichtwer Pharma GmbH3

XXVII DISCLOSURE INDEX

Presenter Manufacturers) Program Page # Robert L. Finding, M.D. Bristol-Myers Squibb1'3-4; Janssen Pharmaceutica Inc.1-3-4; AstraZeneca Pharmaceuticals1-3-4; 13,26 U.S. Pharmaceuticals, Pfizer Inc.1-3; Novartis Pharmaceuticals Corporation1-3; Lilly Research Laboratories, a division of Eli Lilly and Company1'3 Helen E. Fisher, Ph.D. GlaxoSmithKline4 4,82 AlastairJ. Flint, M.B. Janssen Pharmaceutica Inc.4; Pfizer Canada4; Lundbeck Canada4; Forest Laboratories, Inc.4 85 Edna B. Foa, Ph.D. Cephalon Inc.6 1, 64,93 Ellen Frank, Ph.D. US. Pharmaceuticals, Pfizer Inc.1; Pfizer Italia1; Eli Lilly and Company1; 1, 59,102 Forest Laboratories, Inc.3; Merck & Co., Inc.3; Janssen Pharmaceutica Inc.3 Jean A. Frazier, MD. AstraZeneca Pharmaceuticals4; Bristol-Myers Squibb4; Janssen Pharmaceutica Inc.4; 61 U.S. Pharmaceuticals, Pfizer Inc.1-3i 4; Eli Lilly and Company1'4 NickFreemantle, Ph.D. Wyeth- Ayerst Laboratories6; US. Pharmaceuticals, Pfizer Inc.3 13 Edward S. Friedman, MD. Wyeth-Ayerst Laboratories1'3'4; Cyberonics Inc.3; Bristol-Myers Squibb1'3; Eli Lilly and Company1'3'4; 26 US. Pharmaceuticals, Pfizer Inc.3'4; Qrganon Pharmaceuticals, Inc.3; Forest Laboratories, Inc.3'4; Merck&Go., Inc.3; Pharmacia & Upjohn Company, Inc.3-4; Cephalon Inc.1-3; GlaxoSmithKline1'4; Abbott Laboratories, Inc.4'6, Upjohn (Kalamazoo, MI)3 Matthew J. Friedman, MD. US. Pharmaceuticals, Pfizer Inc.1; GlaxoSmithKline1; Johnson and Johnson PRO1 18,25,60 Mark A Fry*, MD. Abbott Laboratories, Inc.1'3'4; AstraZeneca Pharmaceuticals1'4; Bristol-Myers Squibb1'4; 2,66,70 Gephalon Inc.1; Elan Pharmaceuticals1; Eli Lilly and Company1'4; GlaxoSmithKline1'3'4; Janssen-Glag Pharmaceutica Inc.1-4; Johnson and Johnson PRD1; Novartis Pharmaceuticals Corporation1'4; Qrtho McNeil Pharmaceuticals1'4; Otsuka Pharmaceuticals1'4; UCB Pharma, Inc.1; King Pharmaceuticals3; National Institute of Mental Health3; Solvay Pharmaceuticals, Inc.3; Stanley Medical Research Institute3 GlenO.Gabbard,MD. Bristol-Myers Squibb6 22,29, 38,45 Joel Gallant, MD. Abbott Laboratories Inc.1-4; Boehringer Ingelheim1'3; Bristol-Myers Squibb1-3'4; GlaxoSmithKline1'4; 45 Roche Laboratories, a member of the Roche Group3-4; Gflead Sciences1-3'4; Vertex1; Tanox1; Tibotec-Virco1-3; ViroLogic1; Ortho Biotech, Inc.1-3-4 David R. Gastfriend, MD. Alkermes1 •3-4; Eli Lilly and Company4; Bristol-Myers Squibb4; CMHC Systems1; TeleSage1; 100 Drug Abuse Sciences3; Purdue Pharma4 F. Moises Gaviria, MD. GlaxoSmithKline3; Novartis Pharmaceuticals Corporation3; Janssen Pharmaceutica Inc.3 74 David Geldmacher, MD. Pfizer Inc.1 •3i 4; Eisai America Inc.1 -3-4; Janssen Pharmaceutica Inc.3; Takeda Pharmaceuticals3; 11 Joel Gelernter, MD. Forest Laboratories, Inc.6 67 Mark S. George, MD. Janssen Pharmaceutica Inc.3; Lilly Research Laboratories, a division of Eli Lilly and Company3; 7,30 GlaxoSmithKline3'4; Parke-Davis, Division of Warner-Lambert Company3'4; Medtronic3; Amersham3-4; Cyberonics Inc.1'3-4; Philips3'4; Dunphar3; Dupont Pharma3; Solvay Pharmaceuticals, Inc.3; Mediphysics3-4 S. Nassir Ghaemi, MD. Janssen Pharmaceutica Inc.1-3-4; AstraZeneca Pharmaceuticals1'3'4; Glaxc&mithKline1-4; 1,9, Abbott Laboratories, Inc3-4; Elan Pharmaceuticals3; Forest Laboratories, Inc.4; Eli Lffly and Company4; 46,66 Novartis Pharmaceuticals Corporation3 Walter Ginter Reckitt-Benckiser Pharmaceuticals6 39 Leslie H. Gise, MD. Medco Health1 87,100 Michael J. Gitlin, M.D. Lilly Research Laboratories, a division of Eli Lilly and Company4; Wyeth- Ayerst Laboratories4 88 GlaxoSmithKline4; Bristol-Myers Squibb4; AstraZeneca Pharmaceuticals4; Janssen Pharmaceutica Inc.4; US. Pharmaceuticals, Pfizer Inc.4 Ira D. Click, M.D. AstraZeneca Pharmaceuticals1 •3 -4; Janssen Pharmaceutica Inc.1 •3-4; Bristol-Myers Squibb1 •3-4; 24,50, Lilly Research Laboratories, a division of Eli Lilly and Company1-3'4; US. Pharniaceuticals, Pfizer Inc.1>3-4 63,99 Marcia Kraft Coin, MD. Bristol-Myers Squibb4 7,10,14,22,29,37, 55,67, 83,102 Robert M Goisman, MD. AstraZeneca Pharmaceuticals4; Bristol-Myers Squibb1 71 Joseph F. Goldberg, MD. Abbott Laboratories, Inc.1-3-4; AstraZeneca Pharmaceuticals1'3'4; Bristol-Myers Squibb1'3'4; 2,4,63,88 Eli Lilly and Company1'3; Forest Laboratories, Inc.1'3'4; GlaxoSmithKline1'3'4; UCB Pharma, Inc.1'3; Novartis Pharmaceuticals Corporation1-3; Qrtho McNeil Pharmaceuticals1'3; Pfizer Inc.1'3 Pablo Goldberg, MD. Bristol-Myers Squibb6 38 Robert N. Golden, MD. Bristol-Myers Squibb1; Forest Laboratories, Inc3; GlaxoSmithKline1'4; Janssen Pharmaceutica Inc.1; 4 Qrganon Pharmaceuticals, Inc.3-4; US. Pharmaceuticals, Pfizer Inc.3'4; Wyeth- Ayerst Laboratories1'4 Stephen M Goldfinger, MD. BristotMyers Squibb1'3'4; Janssen Pharmaceutica Inc.1'3-4; AstraZeneca Pharmaceuticals1'3-4; 27,54,77,99 US. Pharmaceuticals, Pfizer Inc.1'4; Mallinckrodt Pharmaceuticals1'4; WAX1-3-4 Marion Z. Goldstein, MD. Eli Lilly and Company1 86 Gerado Gonzalez, M.D. Reckitt-Benckiser Pharmaceuticals6 39 XXVIII DISCLOSURE INDEX

Jack M Gorman, MD. National Institute of Mental Health1;NARS AD1 ; US. Pharmaceuticals, Pfizer Inc.1; 9,19,50, Merck & Go., Inc.1; GlaxoSmithKline1 ;AstraZeneraPhamiare^ 77,92 Janssen Pharmaceutica Inc.1; Forest Laboratories, Inc.1 Elizabeth Gould, Ph.D. Wyeth-Ayerst Laboratories6 66 Barbara L. Gracious, MD. GlaxoSmithKline6 12 Tana A. Grady-Weliky, M.D. US. Pharmaceuticals, Pfizer Inc.1'4; GlaxoSmithKline1-4; Eli Lilly and Company4 18, 96 John F. Greden, M.D. Lilly Research Laboratories, a division of Eli Lilly and Company1; Mallinckrodt Pharmaceuticals1 8,20,47,61 Wyeth- Ayerst Laboratories; Cyberonics Inc.; Pfizer Inc.; Neuronetics Inc.1; Merck & Co., Inc.1 Benjamin D. Greenberg, M.D. Medtronic, Inc.3 83 Laurence L. Greenhill, MD. McNeil Pharmaceuticals1; Lilly Research Laboratories, a division of Eli Lilly and Company1 •3; 106 Shire Ridgewood Pharmaceuticals3 John H. Greist, MD. Abbott Laboratories, Inc.3'6; Forest Laboratories, Inc.3'4'6; Qrganon Pharmaceuticals, Inc.1-3'4; 4 Janssen Pharmaceutica Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company'3'4; Pfizer Inc.1'3'4; SanoftSynthelabo Pharmaceuticals, Inc.1'3; Solvay Pharmaceuticals, Inc.1'3-4; Wyeth-Ayerst Laboratories1'3'4; Bristol-Mjers Squibb1'4; Hbffman-LaRoche Pharmaceuticals4; Healthcare Technology Systems, Inc.6; Glaxc>SmithKline1'3'4; Novartis Pharmaceuticals Corporation4 George T. Grossberg, MD. Forest Laboratories, Inc.1 -3; Novartis Pharmaceuticals Corporation1-3;Ja^ 69 AstraZeneca Pharmaceuticals1; Lilly Research Laboratories, a division of Eli Lilly and Company1'3; Abbott Laboratories, Inc.1-3; Bristol-Myers Squibb3; Organon Pharmaceuticals, Inc.3; U.S. Pharmaceuticals, Pfizer Inc.3; SmithKline Beecham Pharmaceuticals3; Eunoe1 Silvia Hafliger,MD. Roche Laboratories, a member of the Roche Group6 37, 50 Robert E. Hales, M.D. Bristol-Myers Squibb1'4; GlaxoSmithKline4; Forest Laboratories, Inc.4 13,41 Faiq Hameedi, MD. Eli Lilly and Company1 -4; Bristol-Myers Squibb1 •4; Janssen Pharmaceutica Inc.1 •4 53 MarkB.Hamner,M.D. AstraZeneca Pharmaceuticals3'4; Bristol-Myers Squibb3'4; Otsuka Pharmaceuticals4; 5 Forest Laboratories, Inc.3'4; Lilly Research Laboratories, a division of Eli Lilly and Company3; U.S. Pharmaceuticals, Pfizer Inc.5; Merck & Co., Inc.5; Johnson and Johnson PRD1-4-5 William Harlan,M.D. GlaxoSmithKline6 12 Phyllis Harrison-Ross, MD. Eli Lilly and Company5; Caraco Pharmaceutical, LTD5 29 Philip D. Harvey, PhD. Janssen Pharmaceutica Inc.1'3-4; Lilly Research Laboratories, a division of Eli Lilly and Company'3-4; 25 US. Pharmaceuticals, Pfizer Inc.1-3-4; AstraZeneca Pharmaceuticals1'3'4; Bristol-Myers Squibb1'3-4; Novartis Pharmaceuticals Corporation1'3-4 Stephan H. Heckers, MD. Eli Lilly and Company5 13,41, 61 David G Henderson, MD. Janssen Pharmaceutica Inc. ^3> 4; Bristol-Myers Squibb1- 3>4; AstraZeneca Pharmaceuticals1'3>4; 88 Eli Lilly and Company-3-4; US. Pharmaceuticals, Pfizer Inc. 1>3>4 Michael E. Henry GlaxoSmithKline1'3| 4; Eli Lilly and Company' 3>4; Janssen Pharmaceutica Inc.1- 3>4; 61 Bristol-Myers Squibb1'3'4; U.S. Pharmaceuticals, Pfizer Inc. 1> 3>4 J. Paul Hieble, PhD. GlaxoSmithKline2 42 AlanR.Hrsch,M.D. GlaxoSmithKline1 -3; Eli Lilly and Company -3; Pharmacia & Upjohn Company, Inc.1 •3; 95 Ciba Geigy Corporation, Pharmaceutical Division; Johnson and Johnson PRD; Johnson and Johnson PRD1-3; Warner Lambert1-3; Ayerst1-3 Robert MA. Hrschfeld, M.D. Abbott Laboratories, Inc. J>3; Bristol-Myers Squibb1-3; GlaxoSmithKline1'3; 9 Oganon Pharmaceuticals, Inc. ^3; UCB Pharma, Inc.1; Eli Lilly and Company1'4; Wyeth-Ayerst Laboratories1-3; Forest Laboratories, Inc.1-4; Janssen Pharmaceutica Inc.1; U.S. Pharmaceuticals, Pfizer Inc.1; Novartis Pharmaceuticals Corporation1 Eric Hollander, MD. Qrtho McNeil Pharmaceuticals1; Solvay Pharmaceuticals, Inc.1-3; UCB Pharma, Inc.3; 3,63,75, Abbott Laboratories, Inc.1-3; US. Pharmaceuticals, Pfizer Inc.3; Wyeth-Ayerst Laboratories1-3; 92,103 Lilly Research Laboratories, a division of Eli Lilly and Company3 Rona Hu, MD. Cephalon Inc.6 7 James I. Hudson, MD. Eli Lilly and Company'3; US. Pharmaceuticals, Pfizer Inc.3; Qrtho McNeil Pharmaceuticals1-3 67 John R Hughes, MD. U.S. Pharmaceuticals, Pfizer Inc.1-3-4; Sanofi-Synthelabo Pharmaceuticals, Inc.1- 3>4; 61 Pharmacia & Upjohn Company, Inc.1-3-4 Michael Y. Hwang, MD. Janssen Pharmaceutica Inc.1-4; Eli Lilly and Company3-4; US. Pharmaceuticals, Pfizer Inc.4 53 Dan V. losifescu, MD. GlaxoSmithKline4; Qrganon Pharmaceuticals, Inc.4; Eli Lilly and Company; NARSAD3; 50,66 Janssen Pharmaceutica Inc.3; National Institute of Mental Health3; Aspect Medical Systems, Inc.3 WaguihW.Ishak,MD. Eli Lilly and Company; AstraZeneca Pharmaceuticals1; BristolrMjcrs Squibb1; 1,95 Ba}er Corporation, Pharmaceutical Division1; US. Pharmaceuticals, Pfizer Inc.1

XXIX DISCLOSURE INDEX

Presenter Manufacturers) Program Page # Jeanne Jackson-Siegel, MD. US. Pharmaceuticals, Pfizer Inc.1-4; Abbott Laboratories, Inc.4; Eli Lilly and Company1'4; 41 Qrganon Pharmaceuticals, Inc.4; AstraZeneca Pharmaceuticals1'4; Forest Laboratories, Inc.1-4 Philip G. Janicak, MD. Ablx>ttLalx>ratories,Inc.3'4JarnsenPh Squibb1'4; Pfizer Inc.1'4; 14 Lilly Research Laboratories, a division of Eli Lilly and Company3; AstraZeneca Pharmaceuticals4 Geetha Jayaram, MD. GlaxoSmithKline4 6,10,20,45, 71, 80,94,99 Richard T. Jermyn, D.O. Merck & Co., Inc.4; Cephalon Inc.4; Parke-Davis, Division of Warner-Lambert Company4; 95 Ortho McNeil Pharmaceuticals4 DilipV.Jeste,MD. AstraZeneca Pharmaceuticals1'3; Bristol-Myers Squibb1-3; Eli Lilly and Company1'3; 13, 74 Janssen Pharmaceutica Inc.1-3; U.S. Pharmaceuticals, Pfizer Inc.1-3 Michael D. Jibson, MD. AstraZeneca Pharmaceuticals4; U.S. Pharmaceuticals, Pfizer Inc.4; Janssen Pharmaceutica Inc.4 73 HadineJoffe,MD. Eli Lilly and Company4; GlaxoSmithKline4; U.S. Pharmaceuticals, Pfizer Inc.3-4; 39, 40, 93 Wyeth-Ayerst Laboratories4; Abbott Laboratories, Inc.3 Bankole A. Johnson, MD. Johnson and Johnson PRD1; Ortho McNeil Pharmaceuticals6 2,64,77 Lewis L. Judd, MD. Roche Biosciences1-3 21,65 Rajinder A. Judge, M.D. Novartis Pharmaceuticals Corporation2; Organon Priarmaceuticals, Inc.6; Merck & Co., Inc.5; 5 US. Pharmaceuticals, Pfizer Inc.5; Lilly Research Laboratories, a division of Eli Lilly and Company5 NedHKalin,MD. National Institutes of Health3; Dana Foundation3; Janssen Pharmaceutica Inc.1 •4; GlaxoSmithKline1; 66 Forest Laboratories, Inc.1; Wyeth-Ayerst Laboratories1'4; Novartis Pharmaceuticals Corporation1; Bristol-Myers Squibb1; Somerset Pharmaceuticals1; Corcept Therapeutics1; Neurocrine Biosciences Inc.1; SanofhSynthelabo Pharmaceuticals, Inc.1; Otsuka Pharmaceuticals1; Cypress1 Peter W. Kalivas, Ph.D. Janssen Pharmaceutica Inc.3 90 John M Kane, MD. Abbott Laboratories, Inc.1>4; AstraZeneca Pharmaceuticals1'4; BristolrMyers Squibb1-4; 11 Novartis Pharmaceuticals Corporation1'4; Aventis Pharmaceuticals1'4; Organon Pharmaceuticals, Inc. 1>4; US. Pharmaceuticals, Pfizer Inc. ^j Lilly Research Laboratories, a division of Eli Lilly and Company1'4; Janssen Pharmaceutica Inc.1>4 Sandra J. Kaplan, MD. US. Pharmaceuticals, Pfizer Inc.3 54 Shitij Kapur, MD. Eli Lilly and Company-3'4; Janssen Pharmaceutica Inc.1'3'4; US. Pharmaceuticals, Pfizer Inc.1'3-4; 3,12 Wyeth-Ayerst Laboratories1'3'4; AstraZeneca Pharmaceuticals1'3'4; Bristol-Myers Squibb1'4; SolvayKingswood1; Neuromolecular, Inc.1-3; GlaxoSmithKline4 Wayne J.Katon,MD. Lilly Research Laboratories, a division of Eli Lilly and Company1-4; US. Pharmaceuticals, Pfizer Inc.4; 32 SmithKline Beecham Pharmaceuticals1'4; Wyeth-Ayerst Laboratories1-4; Venlafaxine1; Paxfl; Duloexetine1; Forest Laboratories, Inc.4; Pharmacia & Upjohn Company, Inc.3 Walter HKaye,MD. Lilly Research Laboratories, a division of Eli Lilly and Company3; AstraZeneca Pharmaceuticals3 6, 60 Paul E. Keck, Jr., MD. Abbott Laboratories, Inc.1( 3; AstraZeneca Pharmaceuticals1'3; Bristol-Myers Squibb1'3; 6, 31 Corcept Therapeutics1; GlaxoSmithKline1'3; Janssen Pharmaceutica Inc. l>3; Eli Lilly and Company1-3; Novartis Pharmaceuticals Corporation1'3; UCB Pharma, Inc. *>3; Ortho McNeil Pharmaceuticals1-3; U.S. Pharmaceuticals, Pfizer Inc. *•3; Wyeth-Ayerst Laboratories1; Shire Ridgewood Pharmaceuticals1; Elan Pharmaceuticals3; Merck & Co., Inc.3; National Institute of Mental Health3; National Institute on Drug Abuse3; Organon Pharmaceuticals, Inc.3; the Stanley Medical Research Institute3 Richard S.E. Keefe, Ph.D. AstraZeneca Pharmaceuticals1 -3; Janssen Pharmaceutica Inc.1 -3; Aventis Pharmaceuticals1; 10 U.S. Pharmaceuticals, Pfizer Inc.1; Abbott Laboratories, Inc.1, GlaxoSmithKline1; Pharmacia & Upjohn Company, Inc.1; Organon Pharmaceuticals, Inc.1; Lilly Research Laboratories, a division of Eli Lilly and Company1'3 Martin B. Keller, MD. Bristol-Myers Squibb1-4; Cyberonics Inc.1-4; Eli Lilly and Company1'4; Forest Laboratories, Inc.1-3-4; 6,84 Janssen Pharmaceutica Inc.1-4; Merck & Co., Inc.1-3-4; Organon Pharmaceuticals, Inc.1-3'4; Pharmastar1'4; US. Pharmaceuticals, Pfizer Inc.1-3-4; Pharmacia & Upjohn Company, Inc.1'4; Sepracor Inc.1'4; Vek Pharmaceuticals1'4; Mitsubishi Pharma Corporation1; Scirex1; Cypress Bioscience1'4; Collegium1'4; Wyeth-Ayerst Laboratories1'3'4; Cephalon Inc.1; GlaxoSmithKline1; Novartis Pharmaceuticals Corporation1; SanofrSynthelabo Pharmaceuticals, Inc.1; Somerset Pharmaceuticals1; Otsuka Pharmaceuticals1-4 SidneyH Kennedy, MD. AstraZeneca Pharmaceuticals3'4; Boehringer Ingelheim3-4; Eli Lilly and Company3-4; GlaxoSmithKline3'4; 88 Janssen- Ortho Pharmaceutica Inc.3'4; Lundbeck3'4; Wyeth-Ayerst Laboratories3-4; Servier3-4 Justine M Kent, MD. U.S. Pharmaceuticals, Pfizer Inc.1; Cephalon Inc.1 34, 92 Ronald C Kessler, PLD. GlaxoSmithKline; U.S. Pharmaceuticals, Pfizer Inc.1; Eli Lilly and Company1 2,4

XXX DISCLOSURE INDEX

Terence A. Ketter, M.D. Abbott Laboratories, Inc.1'3-4; AstraZenecaPharmaceuticals1'3'4; Bristol-Myers Squibb1'3'4; 51 Elan Pharmaceuticals1'3; Eli Lilly and Company1'3'4; Janssen Pharmaceutica Inc.1-3-4; GlaxoSmithKline1-3'4; Gephalon Inc.1; Novartis Pharmaceuticals Corporation1'4; Shire Ridgewood Pharmaceuticals1 •3 PaulAKetd,MD. Abbott Laboratories, Inc.1'3'4; Lilly Research Laboratories, a division of Eli Lilly and Company1'3'4; 81 AstraZeneca Pharmaceuticals1'3'4; Qrganon Pharmaceuticals, Inc.1 -3'4; Bristol-Myers Squibb1-3'4; Janssen Pharmaceutica Inc. 1>3-4; Wyeth-Ayerst Laboratories1'3'4; Novartis Pharmaceuticals Corporation1'3'4 U.S. Pharmaceuticals, Pfizer Inc.; 1>3'4 AliKhadivi,Ph.D. Lilly Research Laboratories, a division of Eli Lilly and Company1 46 Arifulla Khan, MD. Wyeth- Ayerst Laboratories6 13 Edward Kim, M.D. Lilly Research Laboratories, a division of Eli Lilly and Company3'4; Janssen Pharmaceutica Inc.4; 53,75 AstraZeneca Pharmaceuticals3'4; Forest Laboratories, Inc.3; Novartis Pharmaceuticals Corporation3-4 Bryan H King, MD. Janssen Pharmaceutica Inc.4 18,100 David G. Kingdon, MD. Eli Lilly and Company4-6; Janssen Pharmaceutica Inc.4'6; Bristol-Myers Squibb4'6; Pfizer Inc3-4-6 8,46 Herbert D.Kleber,MD. Reckitt Benckizer Pharmaceuticals1 48,81,84,97 James H Kocsis, MD. Wyeth- Ayerst Laboratories3-4; Forest Laboratories, Inc.3-4; US. Pharmaceuticals, Pfizer Inc.3-4 60 LiliKopala,MD. AstraZeneca Pharmaceuticals1 •3; Eli Lilly and Company1 •3; Janssen Pharmaceutica Inc.1 •3; 9 Novartis Pharmaceuticals Corporation1'3; US. Pharmaceuticals, Pfizer Inc.1-3; Bristol-Myers Squibb1-3 Amos Korczyn, MD. Novartis Pharmaceuticals Corporation6 40 Susan G. Kornstein, M.D. U.S. Pharmaceuticals, Pfizer Inc. l>3; Bristol-Myers Squibb1-3; Eli Lilly and Company1'3; 11 Wyeth-Ayerst Laboratories1-3; Forest Laboratories, Inc.3; GlaxoSmithKline3; Merck & Co., Inc.3; Mitsubishi-Tokyo, Inc.3; Biovail Laboratories, Inc.3; Pharmacia & Upjohn Company, Inc.3; Berlex Laboratories, Inc.3; Novartis Pharmaceuticals Corporation3 Thomas R Kosten, M.D. Reckitt Benckiser Pharmaceuticals6 19, 39, 70 Renu Kotwal, M.D. Ortho McNeil Pharmaceuticals6 3 K. Ranga K Krishnan, M.D. Novartis Pharmaceuticals Corporation3; US. Pharmaceuticals, Pfizer Inc.1; UQB Pharma, Inc.1; 9,13, Somerset Pharmaceuticals1; Lilly Research Laboratories, a division of Eli Lilly and Company1; Synaptic1; 28,41 Glaxc6mithKline1; Merck & Co., Inc.; Qrganon Pharmaceuticals, Inc.; Wyeth- Ayerst Laboratories1; Vela1 Kurt Kroenke, MX). US. Pharmaceuticals, Pfizer Inc.4; Wyeth-Ayerst Laboratories1-3; Eli Lilly and Company1'3 8 Andrew D. Krystal, MX). Sepracor Inc.1'3; Wyeth-Ayerst Laboratories3'4; Sanofi-Synthelabo Pharmaceuticals, Inc.1'3 11 David J.Kupfer, MX). US. Pharmaceuticals, Pfizer Inc.1; Eli Lilly and Company1; Forest Laboratories, Inc.1 11 Sandra L. Kweder, MD. GlaxoSmithKline6 12 Justine K. Lalonde, M.D. Eli Lilly and Company3; US. Pharmaceuticals, Pfizer Inc.3; Ortho McNeil Pharmaceuticals3 67 Raymond W. Lam, MD. Cyberonics Inc.1-4; Eli Lilly Canada1-3'4; GlaxoSmithKline Canada1'3'4; Lundbeck Canada1'4; 88,99 Pfizer Canada1'4; Wyeth- Ayerst Canada1'3-4; Merck & Co., Canada1-3; Litebook Company, Inc.1'4; Roche Canada, a member of the Roche Group1'3; Qrganon Canada1'4; Servier Canada1'3 John Lauriello, MX). US. Pharmaceuticals, Pfizer Inc.1'; AstraZeneca Pharmaceuticals1'3'4; Eli Lilly and Company1'3; 28 Bristol-Myers Squibb1 -3-4; Janssen Pharmaceutica Inc.1 • 3>4 Philip Lavori, PhD. Cyberonics Inc.1; Forest Laboratories, Inc.6; Neuronetics Inc.1 11 Helen Lavretsky, MD. Eisai America Inc.6 11 B any Levin Merck & Co., Inc.3-5; Proctor & Gamble1; U.S. Pharmaceuticals, Pfizer Inc.1 -5 35 Frances R Levin, MD. Eli Lilly and Company1; PharmaNet, Inc.1 47, 51, 84 JeffreyM. Levine, MD. U.S. Pharmaceuticals, Pfizer Inc.4; Wyeth-Ayerst Laboratories4; GlaxoSmithKline4 99 Lydia J. Lewis, B.A. Wyeth-Ayerst Laboratories6 4 Roberto Lewis-Fernandez, MD. U.S. Pharmaceuticals, Pfizer Inc.4 5, 91 Jeffrey A. Lieberman, MD. Eli Lilly and Company6 10, 28, 38 Michael R Liebowitz, MD. Wyeth-Ayerst Laboratories1'4; U.S. Pharmaceuticals, Pfizer Inc.1|4; GlaxoSmithKline1-4 92 Russell F. Lim, MD. Bristol-Myers Squibb1; Eli Lilly and Company1 5 Jean-Pierre Lindenmayer, MD. Novartis Pharmaceuticals Corporation4; Lilly Research Laboratories, a division 73 of Eli Lilly and Company4'6; Janssen Pharmaceutica Inc.6; Bristol-Myers Squibb6; Abbott Laboratories, Inc.4 Marsha M. Linehan, PhD. Lilly Research Laboratories, a division of Eli Lilly and Company3 19,27, 58 Walter Ling, MD. Reckitt Benckiser Pharmaceuticals4 30, 39,70 Sarah H. Lisanby, MD. Neuronetics Inc.1 30, 83, 93 James F. List, MD. Ortho McNeil Pharmaceuticals6 67 Donna L. Londino, MD. Janssen Pharmaceutica Inc.1 •3; Eli Lilly and Company1; Abbott Laboratories, Inc.3 80 Susan Lucak, MD. SolvayPharmaceuticals, Inc.1; GlaxoSmithKline1'4; Novartis Pharmaceuticals Corporation1'4; 22 Forest Laboratories, Inc.1

XXXI DISCLOSURE INDEX

Presenter Manufacturers) Program Page # Constantine Lyketsos, MD. Forest Laboratories, Inc.1 • 3>4; Lilly Research Laboratories, a division of Eli Lilly and Company, 20,65 JanssenPharmaceutica Inc.1-3-4; US. Phannaceuticals, Pfizer Inc. 1-3>4; NeuroLogic Inc.1-3; DuPont1'4; AstraZeneca Pharmaceuticals1; Organon Pharmaceuticals, Inc.1; Abbott Laboratories, Inc.1 •3| 4; Parke-Davis, Division of Warner-Lambert Company3'4; Bayer Corporation, Pharmaceutical Division3-4; Eisai America Inc.4 Novartis Pharmaceuticals Corporation4; Lundbeck4; Bristol-Myers Squibb1'3'4 Thomas Lynch, M.D. Wyeth-Ayerst Laboratories6 41 Robert J. Malcolm, Jr., MD. Johnson and Johnson PRD1 64 Jose R. Maldonado, M.D. Abbott Laboratories, Inc.3; US. Pharmaceuticals, Pfizer Inc.4; Forest Laboratories, Inc.4 7,15,43,98 AnilK.Malhotra,MD. Pfizer Inc.1 •3; Eli Lilly and Company1 •3; Janssen Pharmaceutica Inc.1; Abbott Laboratories, Inc.1 63 Tlieo G Manschreck, MD. Bristol-Myers Squibb1 -4; Eli Ullyand Company1 -4; Pfizer Inc.1-4; Abbott Laboratories, Inc.1'4 62 Lauren B. Marangell, MD. Cyberonics Inc.1'3'4; Stanley Foundation3; National Institutes of Health3; Eli Lilly and Company1'3'4; 30,70,93 Abbott Laboratories, Inc.3; Bristol-Myers Squibb1-4; Forest Laboratories, Inc.1-4; GlaxoSmithKline1 •4; Janssen Pharmaceutica Inc.1; Novartis Pharmaceuticals Corporation1; U.S. Pharmaceuticals, Pfizer Inc.4; Wjeth- Ayerst Laboratories1'4 Sheik Marcus, MD. U.S. Pharmaceuticals, Pfizer Inc.5; Lilly Research Laboratories, a division of Eli Lilly and Company3 61 Stephen RMarder,MD. Janssen Pharmaceutica Inc.1-3-4; Lilly Research Laboratories, a division of Eli Lilly and Company1'3-4; 11,14 U.S. Pharmaceuticals, Pfizer Inc.1-3'4; Bristol-Myers Squibb1'3'4; AstraZeneca Pharmaceuticals1'3'4 John C Markowitz, MD. National Institute of Mental Health3; Forest Laboratories, Inc.3; NARSAD3 5,59,101 Randall D. Marshall, MD. Pfizer Inc.3-4; GlaxoSmithKline3-4; Bristol-Myers Squibb3; UCB Pharma, Inc.3; Cephalon Inc.6 37,51,69 Humberto Martinez, MD. Eli Lilly and Company1; Janssen Pharmaceutica Inc.; Bristol-Myers Squibb1 36 Prakash S. Masand, MD. AstraZeneca Pharmaceuticals3-4; Janssen Pharmaceutica Inc.1-3-4; GlaxoSmithKline1-3-4; 6,9 Forest Laboratories, Inc.1-3'4; Wyeth- Ayerst Laboratories1'3-4; Organon Pharmaceuticals, Inc.1; Pfizer Inc.1-4; Novartis Pharmaceuticals Corporation4; Eli Lilly and Company4; Bristol-Myers Squibb1'4'5 Helen S. Mayberg, MD. GlaxoSmithKline6 2 W. Vaughn McCaU, MX). Sepracor Inc.1-3; Wyeth-Ayerst Laboratories1-3; Sanofi-Synthelabo Pharmaceuticals, Inc.1-3 14,89 Robin G. McCreadie, D.Sc. Eli Lilly and Company3; U.S. Pharmaceuticals, Pfizer Inc.3 103 Stephen P. McDermott, MD. Shire Ridgewood Pharmaceuticals6 67 William M. McDonald, M.D. Wyeth-Ayerst Laboratories4 4 David M. McDowell, MX). Mallinkrot Pharmaceuticals4; Wyeth- Ayerst Laboratories4; Bristol-Myers Squibb4 27,44,50,81, 84,94,99 Susan L. McElroy, MD. Abbott Laboratories, Inc.1; Bristol-Myers Squibb1; ElanPhamiaceuticals1'3; GlaxoSmithKline1'3; 2,9 Janssen Pharmaceutica Inc.1; Eli Lilly and Company-3; Novartis Pharmaceuticals Corporation1; Qrtho McNeil Pharmaceuticals1'3; Wyeth-Ayerst Laboratories1; Sanofi-Synthelabo Pharmaceuticals, Inc.3; Forest Laboratories, Inc.3; Merck & Co., Inc.3; U.S. Pharmaceuticals, Pfizer Inc.3; UCB Pharma, Inc.1'3 Bruce S.McEwen, PhD. 'Wyeth-Ayerst Laboratories6 8 Roger S. Mclntyre, MD. Wyeth- Ayerst Laboratories1'4; Lundbeck1-4; Janssen Pham^aceutk^ Inc. ^^GlaxcSmimKline1-4; 9 AstraZeneca Pharmaceuticals1'4; Lilly Research Laboratories, a division of Eli Lilly and Company1'4; Organon Pharmaceuticals, Inc.1-4; Oryx1-4 Ian G. McKeith, MD. Novartis Pharmaceuticals Corporation6 40 A. Thomas McLellan, PhD. Perdue Pharmaceuticals1 57 Kris A, McLoughlin, M.S.N. U.S. Pharmaceuticals, Pfizer Inc.5 18 Laura F. McNicholas, MD. Reckitt Benckiser Pharmaceuticals6 39,70 Herbert Y. Meltzer, MD. BristotMyers Squibb1-3; AstraZeneca Pharmaceuticals1-3; Janssen Pharmaceuticalnc.1-3; 9 Novartis Pharmaceuticals Corporation1-3; Lilly Research Laboratories, a division of Eli Lilly and Company1'3; US. Pharmaceuticals, Pfizer Inc.1-3; Sanofi-Synthelabo Pharmaceuticals, Inc.1'3; SolvayPharmaceuticals, Inc.1'3; Alan J. Mendelowitz, MD. Bristol-Myers Squibb1-3-4; AstraZeneca Pharmaceuticals1'3-4; Pfizer Inc.1-3-4; Wyeth-Ayerst Laboratories4 92 Julien Mendlewicz, MD. Lundbeck1; Wyeth-Ayerst Laboratories1 21, 65 Matthew A. Menza, MD. Lilly Research Laboratories, a division of Eli Lilly and Company-3'4; Bristol-Myers Squibb1'3-4; 65,86 Cephalon Inc.1-3'4; US. Pharmaceuticals, Pfizer Inc. 1>3'4; Bayer Corporation, Pharmaceutical Division1; GlaxoSmithKline3; Merck & Co., Inc.3; Forest Laboratories, Inc.3 Jonathan M, Meyer, MD. U.S. Pharmaceuticals, Pfizer Inc.6 9,15 Barnett S. Meyers, MD. Forest Laboratories, Inc.3'4; Pfizer Inc.3'4; Eli Lilly and Company -3; Organon Pharmaceuticals, Inc.1'4 85 David MiWowitz, PhD. Eli Lilly and Company4 88 Roumen V. Milev, MD. Eli Lilly and Company Canada1-3-4; GlaxoSmithKline Canada1-4; Lundbeck Canada1-3-4; 88 Janssen Pharmaceutica Inc. Canada1-4; AstraZeneca Pharmaceuticals Canada3 Alexander L. Miller, MD. Abbott Laboratories, Inc.4; AstraZeneca Pharmaceuticals1 -3-4; Bristol-Myers Squibb1 •3'4; 12 Eli Lilly and Company, Janssen Pharmaceutica Inc.1- 3>4; U.S. Pharmaceuticals, Pfizer Inc.3 XXXII DISCLOSURE INDEX

Mark D. Miller, MD. GlaxoSmithKline4; Forest Laboratories, Inc.4 24 Rachel Miller, MS.W. Bristol-Myers Squibb1 99 Jacobo E. Mintzer, MD. Abbott Laboratories1'3'4, AstraZeneca Pharmaceuticals1'3'4; Bristol-Myers Squibb1-3; 6,43 Fujisawa Institute of America3; Janssen Research Foundation3'4; Eli Lilly and Company1'4; Johnson and Johnson PRD3; Lilly Research Laboratories, a division of Eli Lilly and Company3; Novards Pharmaceuticals Corporation; Parke-Davis, Division of Warner-Lambert Company3; US. Pharmaceuticals, Pfizer Inc.1'4; Forest Laboratories, Inc.3; Eisai America Inc.1'3-4; Sanof i-Synthelabo Pharmaceuticals, Inc.3; Somerset Pharmaceuticals3; UCB Pharma, Inc.1; SmithKline Beecham Corporation3; Wyeth- Ayerst Research, Inc.3 ShailaMisri,MD. GlaxcSmithKline3; Lundbecls5; ^eth- Ayerst Laboratories4; AstraZeneca Pharmaceuticals4; 3 US. Pharmaceuticals, Pfizer Inc.4 James E. Mitchell, MD. Eli Lilly and Company, Lilly Research Laboratories, a divisbn of EULiDy and Company3 7,60 Abbott Laboratories, Inc.3 Martha J. Morrell, M.D. GlaxoSmithKline1'3; Novartis Pharmaceuticals Corporation1'3; Qttho McNeil Pharmaceuticals1; 93 John C Morris, MX). Eli Lilly and Company3; Forest Laboratories, Inc.3; Janssen Pharmaceutica Inc.1-3; Ono Pharma1; 6 AstraZeneca Pharmaceuticals1; Bayer Corporation, Pharmaceutical Divisbn1; Bristol-Myers Squibb1; Pfizer Inc.1; GlaxoSmithKline1; Merck& Co., Inc.1; NeuroDX, LLO; Aventis Pharmaceuticals1; Eisai Inc.1; Neurochem1 Bench H Mulsant, MD. AstraZeneca Pharmaceuticals1-3'4'5; Bristol-Myers Squibb1; Gorcept Therapeutics3; Alkermes5; 85 Elan Pharmaceuticals5; Eli Lilly and Company1-3; Forest Laboratories, Inc.1'3-4; GlaxoSmithKline1'3-4; Immune Response5; Janssen Pharmaceutica Inc.1>3-4; Lundbeck; National Institutes of Health3; US. Pharmaceuticals, Pfizer Inc.1-3-4; Eisai Inc.1-3-4; BbgerfjCelsion5; Akzo-Nobel5 Philip R. Muskin, MD. Bristol-Myers Squibb1 •3-4; Cephalon Inc.1 •4; Forest Laboratories, Inc.1 •4; 4,22,73, GlaxoSmithKline1-4; Janssen Pharmaceutica Inc.1-4; US. Pharmaceuticals, Pfizer Inc.1-4; 77, 82 Lilly Research Laboratories, a division of Eli Lilly and Company1-4 Hugh Myrick, MD. Ortho McNeil Pharmaceuticals4; Pfizer Inc.3-4; UCB Pharma, Inc.3-4^bbott Laboratories, Inc.3-4 2 ZiadHNahas,MD. Neuronetics Inc.3; Cyberonics Inc.1-3; Medtronics3 93 Joseph C Napoli, MD. GlaxcSmithKline3'4; US. Pharmaceuticals, Pfizer Inc.3-4; AstraZeneca Pharmaceuticals3; 42 Bristol-Myers Squibb3; Eli Lilly and Company3; Forest Laboratories, Inc.3; Janssen Pharmaceutica Inc.3; Organon Pharmaceuticals, Inc.3; Solvay Pharmaceuticals, Inc.3; Wyeth- Ayerst Laboratories3 Jeffrey A. Naser, MX). Wyeth-Ayerst Laboratories4; Novartis Pharmaceuticals Corporation4 23,72 Henry A. Nasrallah, MD. AstraZeneca Pharmaceuticals1'3> 4; Janssen Pharmaceutica Inc.l-3> 4; 9,24,92 U.S. Pharmaceuticals, Pfizer Inc. 1>3>4; Bristol-Myers Squibb1'4; Abbott Laboratories, Inc.1-4 J.Craig Nelson, MD. Abbott Laboratories, Inc.1-4; Eli UDy and Company1'3-4; Forest Laboratories, Inc.3-4; Glaxo-Wellcome1; 66 Janssen Pharmaceutica Inc.3-4; Organon Pharmaceuticals, Inc.1-3-4; US. Pharmaceuticals, Pfizer Inc.1-3-4; Wyeth- Ayerst Laboratories4; GlaxcSmithKline3-4 Charles B. Nemeroff, MD. Abbott Laboratories, Inc.1-3-4; AFSP3; AstraZer^Pharnraceuticals1-3-4; NAMI3; NARSAD3 1,2,4,29, Eli Lilly and Company4-3-4; Forest Laboratories, Ire.1-3-4;; Janssen Phannaceutica Inc.1-3'4; 58,84 Merck&Go., Inc.1-3; National Institute of Mental Health3; US. Pharmaceuticals, Pfizer Inc.3-4; Stanley Foundation3; Wyeth-Ayerst Laboratories1-3'4; Otsuka Pharmaceuticals1'4; GlaxoSmithKline1'3'4 Organon Pharmaceuticals, Inc.1'4; Acadia Pharmaceuticals1; Corcept Therapeutics1'5; Cypress Bbsciences1; Cyberonics Inc.1; Neurocrine Biosciences Inc.1'5; Novartis Pharmaceuticals Corporation1; Sanoft-Synthelabo Pharmaceuticals, Inc.1; Scirex1; Somerset Pharmaceuticals1; Bristol-Myers Squibb1-3-4 John W. Newcomer, MD. Eli Lilly and Company1-3; Janssen Pharmaceutica Inc.1-3-4; AstraZeneca Pharmaceuticals113-4; 13,41 US. Pharmaceuticals, Pfizer Inc.1-3-4 Michelle G. Newman, Ph.D. U.S. Pharmaceuticals, Pfizer Inc.6 4 Andrew A. Nierenberg, MD. Lilly Research Laboratories, a division of Eli Lilly and Company1'3'4; GlaxoSmithKline1'3'4; 5,86 Wyeth- Ayerst Laboratories1'3'4; Innapharma1; Janssen Pharmaceutica Inc.1; Cyberonics Inc.3'4; Pfizer Inc.3-4; Bristol-Myers Squibb3; Lichtwer Pharma3; Organon Pharmaceuticals, Inc.4; Gederroth3 Philip T.Ninan,MD. Eli Lilly and Company1-3; Gephalon Inc.1-3; US. Pharmaceuticals, Pfizer Inc.1-3; Cyberonics Inc.3; 2,92 Solvay Pharrnaceuticals, Inc.1-3; Wyeth-Ayerst Laboratories1-3-4; Forest Laboratories, Inc.3-4; GlaxoSmithKline3'4; Janssen Pharmaceutica Inc.3-4; Bristol-Myers Squibb4 Ruta M Nonacs, MD. GlaxoSmithKline4 39 Douglas Noordsy, M.D. Eli Lilly and Company3'4 43 Carol S. North, MD. GlaxoSmithKline1 •4; U.S. Pharmaceuticals, Pfizer Inc.4 8,17, 82 Andrei Novae, MX). GlaxoSmithKline4; Forest Laboratories, Inc.4; US. Pharmaceuticals, Pfizer Inc.4; 104,105 Lilly Research Laboratories, a division of Eli Lilly and Company4

XXXIII DISCLOSURE INDEX

Presenter Manufacturers) Program Page # H. George Nurnberg, MD. U.S. Pharmaceuticals, Pfizer Inc. l> 3>4; Eli Lilly and Company1' 3>4; Bristol-Myers Squibb1- 3>4; 86 SmithKline Beecham Pharmaceuticals1' 3>4; Abbott Laboratories, Inc.3-4; Glaxo-Wellcome1'4; Wyeth-Ayerst Laboratories3'4; Parke-Davis, Division of Warner-Lambert Company3; Robert Wood Johnson Pharmaceutical Research Institute3; LJPHA Pharmaceuticals3 David J.Nutt,MD. Cephalon Inc.6 69 Charles P. O'Brien, M.D. Alkermes1; Drug Abuse Sciences1; Schering-Plough, France1 48,49 Maurice M. Ohayon, MD. Eli Lilly and Company5 39 John M. Oldham, MD. Bristol-Myers Squibb6 23,38,59,91 MaryB-OMalleyMD. Cephalon Inc.4; Neurocrine Biosciences Inc.4 67 Maria A. Oquendo, MD. Bristol-Myers Squibb6 47, 63,94 Patricia I. Ordorica, MD. Eli Lilly and Company1; Bristol-Myers Squibb1; U.S. Pharmaceuticals, Pfizer Inc.1 18,26,44,46, 73,81 Michael J. Ostacher, M.D. AstraZeneca Pharmaceuticals4 78 Michael W. Otto, Ph.D. GlaxoSmithKline3; US. Pharmaceuticals, Pfizer Inc.1-3; Janssen Pharmaceutica Inc.1; UCB Pharma, Inc.6; 6,9 Lilly Research Laboratories, a division of Eli Lilly and Company3; Wyeth-Ayerst Laboratories1 4 4 4 MicheleT.Pato5MD. Organon Pharmaceuticals, Inc. ; Solvay Pharmaceuticals, Inc. ; Forest Laboratories, Inc. ; 42,73 Lilly Research Laboratories, a division of Eli Lilly and Company1 Diana O. Perkins, MD. Lilly Research Laboratories, a division of Eli Lilly and Company3-4; US. Pharmaceuticals, Pfizer Inc.3-4; 92 AstraZeneca Pharmaceuticals3; Otsuka Pharmaceuticals3; Bristol-Myers Squibb1-3 RoyHPerlis,MD. Eli Lilly and Company1 -4; GlaxoSmithKline4; Bristol-Myers Squibb1 -4; Elan Pharmaceuticals3; 4 AstraZeneca Pharmaceuticals4 Ethel S. Person, M.D. GlaxoSmithKline6 4 Eric D. Peselow, MD. U.S. Pharmaceuticals, Pfizer Inc.4; GlaxoSmithKline4 47, 50 Timothy J. Petersen, Ph.D. Organon Pharmaceuticals, Inc.6 5 Debra A. Pinals, MD. Pfizer Inc.4; Eli Lilly and Company4; AstraZeneca Phaniiaceuticals4; Janssen Pharmaceutica Inc.4 81 MarkH Pollack, MD. Bristol-Myers Squibb1; Cephalon Inc.1-3; Novartis Pharmaceuticals Corporation1; 6,92 Otsuka Pharmaceuticals1; Roche Laboratories, a member of the Roche Group1; Solvay Pharmaceuticals, Inc.4; Forest Laboratories, Inc.1>3'4; Wyeth-Ayerst Laboratories1'3'4; Janssen Pharmaceutica Inc.1>3'4; US. Pharmaceuticals, Pfizer Inc.1>3'4; UCB Pharma, Inc.1'3; Lilly Research Laboratories, a division of Eli Lilly and Company1'3'4 GlaxoSmithKline1'3'4 Teodor T. Postolache, MD. AstraZeneca Pharmaceuticals4; Gephalon Inc.1 -4; Sanofi-Synthelabo Pharmaceuticals, Inc.4; 78 Abbott Laboratories, Inc.1 Marc N. Potenza, MD. GlaxoSmithKline3; Forest Laboratories, Inc.3 54 Steven G. Potkin, M.D. Novartis Pharmaceuticals Corporation1-3-4 40 Konasale MK Prasad, M.D. GlaxoSmithKline6; Janssen Pharmaceutica Inc.6 52 Jefferson B. Prince, MD. Forest Laboratories, Inc.4 1, 5,14,39 Maria A Pugliese, MD. GlaxoSmithKline2 42 Andres J. Pumariega, M.D. Forest Laboratories, Inc.3-4 71,79 David C Purselle, MD. Forest Laboratories, Inc.6 67 Cameron D. Quanbeck, MD. Ortho McNeil Pharmaceuticals6 2 Charles Raison, MD. Schering Corporation; Roche Laboratories, a member of the Roche Group4; Wyeth-Ayerst Laboratories4 39 Luis F. Ramirez, MD. Bristol-Myers Squibb1-4; Novartis Pharmaceuticals Corporation1-4; Otsuka Pharmaceuticals1-4; 8,27 Abbott Laboratories, Inc.1-4; GlaxoSmithKline1'4; QrganonPharmaceuticals, Inc.1-4 MarkH Rapaport, MD. Eli Lilly and Company1'3'4; US. Pharmaceuticals, Pfizer Inc.3-4; Eli Lilly and Company1-3-4; 1,16,21,28 Novartis Pharmaceuticals Corporation3-4; Forest Laboratories, Inc.1-3-4; GlaxoSmithKline3'4; Pharmacia & Upjohn Company, Inc.3-4; SarKjfi-Synthelabo Pharmaceuticals, Inc.1-3-4; Bristol-Myers Squibb3-4; Wyeth-Ayerst Laboratories4; Janssen Pharmaceutica Inc.1-4; SmithKline Beecham Pharmaceuticals4 Natalie L Rasgon, MD. Forest Laboratories, Inc. 1>3'4; Abbott Laboratories, Inc. ^j Eli Lilly and Company, *>4; 66,70 US. Pharmaceuticals, Pfizer Inc.1-4; Glaxc6mithKline1'4; Wyeth-Ayerst Laboratories1'4 John F. Reinus, MD. Roche Laboratories, a member of the Roche Group6 3 8 John A Renner, Jr., MD. Eli Lilly and Company4 80 Perry F. Renshaw, MD. GlaxoSmithKline1; Eli Lilly and Company1 61 RoyO.Resnikoff,MD. AstraZeneca Pharmaceuticals6; Forest Laboratories, Inc.6; GlaxoSmithKline6; Bristol-Myers Squibb6; 5 Lilly Research Laboratories, a division of Eli Lilly and Company5; Pfizer Inc.6; Wyeth-Ayerst Laboratories6 Kerry J. Ressler, MD. Cephalon Inc.6 2 Charles F. Reynolds III, MD. Forest Laboratories, Inc.3-4; GlaxoSmithKline3'4 91 XXXIV DISCLOSURE INDEX

Richard K. Ries, M.D. Lilly Research Laboratories, a division of Eli Lilly and Company4; Bristol-Myers Squibb4; 19, 65 Janssen Pharmaceutica Inc.4; U.S. Pharmaceuticals, Pfizer Inc.4; Forest Laboratories, Inc.4 Gerald Rogan, MD. Ortho Biotech, Inc.1 80 Steven P. Roose, M.D. Forest Laboratories, Inc.1'3; Organon Pharmaceuticals, Inc.1; Wyeth-Ayerst Laboratories1'3; 5,11 Eli Lilly and Company1'3 Jerrold F. Rosenbaum, M.D. Bristol-Myers Squibb1; Cyberonics Inc.1; Eli Lilly and Company1; Forest Laboratories, Inc.1-4; 5, 30, GlaxoSmithKline1; Wyeth-Ayerst Laboratories1 •4 88 Richard N. Rosenthal, M.D. Alkermes (Cambridge, MA)1 18,101 Erik J. Roskes, MD. Eli Lilly and Company4; U.S. Pharmaceuticals, Pfizer Inc.5 55 Thomas Roth, Ph.D. Takeda Phamiaceuticals1'3'4; SanofrSynthelabo Pharmaceuticals, Inc.1'3-4 Gephalon Inc.1'3-4; 11 Sepracor Inc.1-3'4; Merck& Co., Inc.1-3-4; US. Pharmaceuticals, Pfizer Inc.1-3'4; Lundbeck1'3-4; Novartis Pharmaceuticals Corporation1'3'4; Aventis Pharmaceuticals1'3'4; Neurocrine Biosciences, Inc.1'3'4 Eugenio M Rothe, MD. Shire Ridge-wood Pharmaceuticals1; McNeil Pharmaceuticals1; AstraZeneca Pharmaceuticals1 72 Anthony]. Rothschild, MD. Bristol-Myers Squibb3'4; Lilly Research Laboratories, a division of Eli Lilly and Company3'4; 85,97 Merck & Co., Inc.3'4; Wyeth-Ayerst Laboratories3; Abbott Laboratories, Inc.4, Forest Laboratories, Inc.4; US. Pharmaceuticals, Pfizer Inc.4 Peter P. Roy-Byrne, MD. Glaxc>SmithKline1'3'4; Gephalon Inc.1; Forest Laboratories, Inc.1'3-4; Janssen Pharmaceutica Inc.1; 32,67 US. Pharmaceuticals, Pfizer Inc.1-3'4; Pharmacia &Upjohn Company, Inc.1-4; Wyeth-Ayerst Laboratories1'4; Roche Laboratories, a member of the Roche Group; Novartis Pharmaceuticals Corporation4; Alza1 Michael N. Rubenstein, MD. Janssen Pharmaceutica Inc.6 42 A John Rush, MD. Robert Wood Johnson Pharmaceutical Research Institute3; National Institute of Mental Hsalth3; 5,27,30, Stanley Foundation3; Eli Lilly and Company1; Forest Laboratories, Inc.1|4; Cyberonics Inc.1'4; 84 GlaxoSmithKline1 •4; Merck & Co., Inc.1 •4; Wyeth- Ayerst Laboratories4; Bristol-Myers Squibb4 J. Michael R)on,MD. National Institute of Mental Health3; Janssen Research Foundation3-4; Eisai Inc.4; 13,41 Novartis Pharmaceuticals Corporation1; Bristol-Myers Squibb1'4; US. Pharmaceuticals, Pfizer Inc.4; Abbott Laboratories, Inc.4; AstraZeneca Pharmaceuticals4; Mitsubishi Pharma Corporation3 GaiyS. Sachs, MD. Abbott Laboratories, Inc.1-3'4; Janssen Pharmaceutica Inc.1'3-4; GlaxcjSmithKline1'4; 9 Eli Lilly and Company1'4; BristolrMyers Squibb1-4; Novartis Pharrnaceuticals Corporation1'4; SanofiXSynthelabo Pharmaceuticals, Inc.^ AstraZeneca Pharmaceuticals1'4; Sigma-Tau1; Elan Pharmaceuticals1; Solvay Pharmaceuticals, Inc.4; US. Phamiaceuticals, Pfizer Inc.4 Harold A Sackeim, PhD. Cyberonics Inc.1 •3; Neuronetics, Inc.1; Forest Laboratories, Inc.6 11,30,83 Martha Sajatovic, MD. Eli Lilly and Company1' 3>4; Bristol-Myers Squibb3'4; AstraZeneca Pharmaceuticals1'4; 27 Abbott Laboratories, Inc.3; Janssen Pharmaceutica Inc.1; US. Pharmaceuticals, Pfizer Inc. ^4 Kenneth M Sakauye, MD. Bristol-Myers Squibb4; Lilly Research Laboratories, a division of Eli Lilly and Company1 17 Stephen P. Salloway, MD. Pfizer Inc.1'3'4; Eisai Inc.1'3'4; Johnson and Johnson PRD1'3'4; Novartis Pharmaceutk^ Corporation1-3'4 11 Carl Salzrnan, MD. Otsuka Pharmaceuticals1'3; Bristol-Myers Squibb1-3; US. Pharmaceuticals, Pfizer Inc.1'3; 4 Lilly Research Laboratories, a division of Eli Lilly and Company1'3; GlaxoSmithKline1'3 Mary Sano, PhD. Novartis Pharmaceuticals Corporation1; Janssen Pharrnaceutica Inc.1; Forest Laboratories, Inc.1 6 Seddon R Savage, MD. Ortho McNeil Pharmaceuticals1 •4; Janssen Pharmaceutica Inc.4; Purdue Pharma1 • 3 0 Mary Ann Schaepper, MD. AstraZeneca Pharmaceuticals1; Bristol-Myers Squibb1 72 Martin B. Scharf, PhD. Sepracor Inc.1 •3 >4; Neurocrine Biosciences Inc.1 •3i 4 99 Alan F. Schatzberg, MD. Abbott Laboratories, Inc.1'4; Aventis Pharmaceuticals1'4; Bristol-Myers Squibb1'3-4; 28,39,44, Organon Pharmaceuticals, Inc.1>4; Gorcept Therapeutics1'4'5; Eli Lilly and Company1'3-4; 56,66 Forest Laboratories, Inc.1>4; GlaxoSmithKline1'4; Innapharma1'4; Janssen Pharmaceutica Inc. *>4; Merck & Co., Inc. l<4> 5; Novartis Pharrnaceuticals Corporation1'4; Somerset Pharmaceuticals1'4; Pharmacia &Upjohn Company, Inc.1>4; W)eth-A)erst Laboratories1'4'5; US. Pharrnaceuticals, Pfizer Inc.5 Solvay Priarrnaceuticals, Inc. ^4; Cypress Biosciences5; Elan Pharmaceuticals5; S. Charles Schulz,MD. Abbott Laboratories, Inc.3; Janssen Pharmaceutica Inc.3; AsttaZeneraPharrrnceuticals1'3'4; 5,6 Lilly Research Laboratories, a division of Eli LiUy and Company1'3'4 Larry J. Seidman, PhD. Shire Ridgewood Pharmaceuticals6 39 Stuart N. Seidman, MD. Bayer Corporation, Pharmaceutical Division1; GlaxoSmithKline1; ICOS1; 12 Lilly Research Laboratories, a division of Eli Lilly and Company1

XXXV DISCLOSURE INDEX

Presenter Manufacturers) Program Page # David V. Sheehan, MD. Abbott Laboratories, Inc.1'3-4;AstraZeneca Pharmaceuticals4; Boots Pharrnac^^ 6,22 Boehringer Ingelheim Pharmaceuticals; Bristol-Myers Squibb3-4; GlaxcSmithKline1'4; IQ4; Burroughs-Wellcome Pharmaceutical Company3'4; Eli Lilly and Company4; Gephalon Inc.1; Qba Geigy Corporation, Pharmaceutical Division4; Dista Products Company4; Quintfles3; Excerpta Medica Asia4; Glaxo Pharmaceuticals4; Humana4; McNeil Pharmaceuticals4; Kali-Duphar Laboratories, Inc.3'4; Glaxo-Wellcome3; MerckSharp &Dohme4; Organonlnc.4; Parke-Davis, Division of Warner-Lambert Company3'4; US. Pharmaceuticals, Pfizer Inc.3'4; Pharmacia & Upjohn Company, Inc.1-4; Rhone-Poulenc Rorer Pharmaceuticals4; Roerig4; Roche Laboratories, a member of the Roche Group1-4; SandozPharmaceuticals3-4; Faxmed, Inc1; Schering Corporation4; SmithKline Beecham Pharmaceuticals3'4; Solvay Pharmaceuticals, Inc.4; Tap Holdings, Inc.3>4; TTie Upjohn Company4; ^Jifyeth- Ayerst LaboratDries1-4; Eisai America, Inc.3; National Institutes of Health4; Forest Laboratories, Inc.3; International Clinical Research3; Janssen Pharmaceutica Inc.3; Novartis Pharmaceuticals Corporation3; Marion-Merrell Dow4; SanofiXSynthelabo Recherche (LE H.S.)3; SanofiXSynthelabo Research; Cortex Pharmaceutical1 Yvette I. Sheline, MD. Wyeth-Ayerst Laboratories1 20 Hong Shen, MD. U.S. Pharmaceuticals, Pfizer Inc.5 72 Kenneth I. Shulman, MD. Eli Lilly and Company3 13 Sally A. Shumaker, Ph.D. Eli Lilly and Company1; Wyeth-Ayerst Laboratories1; GlaxoSmithKline6 12,40 Larry J. Siever, MX). Lilly Research Laboratories, a division of Eli Lilly and Company5 85 Jonathan M Silver, MD. Novartis Pharmaceuticals Corporation1-3 87, 88,93 Naomi M. Simon, MD. Gephalon Inc.3; Forest Laboratories, Inc.3-4; GlaxoSmithKline3'4; UCB Pharma, Inc.1'3; 6,92 Lilly Research Laboratories, a division of Eli Lilly and Company3; Janssen Pharmaceutica Inc.3; Novartis Pharmaceuticals Corporation1; U.S. Pharmaceuticals, Pfizer Inc.3'4; Wyeth-Ayerst Laboratories3; Pharmacia & Upjohn Company, Inc.3 Samuel G. Siris, MD. Bristol-Myers Squibb1; U.S. Pharmaceuticals, Pfizer Inc.1; Abbott Laboratories, Inc.1 53 Elizabeth Sirota, MD. Janssen Pharmaceutica Inc.3 80 Andrew E. Skodol II, M.D. U.S. Pharmaceuticals, Pfizer Inc.5; Bristol-Myers Squibb6 38,101 Christine E. Skotzko, M.D. U.S. Pharmaceuticals, Pfizer Inc.4; AstraZeneca Pharmaceuticals4 42 Gary W. Small, MD. US. Pharmaceuticals, Pfizer Inc.1 •4; Eisai Inc.1 -4; Janssen Pharmaceutica Inc.1 •4; Amersham1 •4; 11 Qrganon Pharmaceuticals, Inc.1-4; AstraZeneca Pharmaceuticals1'4; Abbott Laboratories, Inc.1-4; Forest Laboratories, Inc.1-4; Novartis Pharmaceuticals Corporation1'4; Lilly Research Laboratories, a division of Eli Lilly and Company1'4 Michael W. Smith, MD. Janssen Pharmaceutica Inc.3-4; Lilly Research Laboratories, a division of Eli Lilly and Company4; 5 AstraZeneca Pharmaceuticals4; Pfizer Inc.4; Bristol-Myers Squibb3'4; Stanley Foundation3 Oaudio N. Scares, MD. Wyeth-Ayerst Laboratories1-4; Forest Laboratories, Inc.1-3-4; GlaxoSmithKline1-4 12,39,88 Thomas J. Spencer, MD. Shire Pharmaceuticals Development, Inc.1-3; Abbott Laboratories, Inc.3; Bristol-Myers Squibb3; 2,67 Gephalon Inc.3; Eli Lilly and Company1'3'4; GlaxoSmithKline1'3-4; McNeil Pharmaceuticals1'3'4; Janssen Pharmaceutica Inc. !>3- 4; Gelltech Pharmaceuticals, Ltd.3-4; Wyeth-Ayerst Laboratories3'4; Novartis Pharmaceuticals Corporation1'3-4; US. Pharmaceuticals, Pfizer Inc.1-3; Shire US Inc.3-4 David Spiegel, MD. Wyeth-Ayerst Laboratories6 4, 7,15, 51, 56,87 Margaret G. Spinelli, MD. US. Pharmaceuticals, Pfizer Inc.; GlaxoSmithKline4 10, 70,100 Stephen M Stahl, MD. AstraZeneca Pharmaceuticals1'3'4; Bayer Corporation, Pharmaceutical Division113; Asahi1'3; 7,9 Boehringer Ingelheim1'3; Bristol-Myers Squibb1-3-4; Gephalon Inc.1-3-4; Cypress Bbsdence1-3; Forest laboratories, Inc.1-3-4; GlaxcSmkhKline1-3-4; Janssen Pharmaceutica Inc. 1>3>4; Eli Lilly and Company1'3'4; Lundbeck1'3'4; Qtganon Pharmaceuticals, Inc.1>3>4; Watson1'3'4; Parke-Davis, Division of Warner-Lambert Company1'3'4; Solvay Pharmaceuticals, Inc.1-3-4; US. Pharmaceuticals, Pfizer Inc. 1>3-4; Pharmacia & Upjohn Company, Inc.1>3'4; Yamanouchi1'3; Sanofi-Synthelabo Pharmaceuticals, Inc.1)3-4; "Wfyeth-Ayerst Laboratories1-3-4; Abbott Laboratories, Inc.1; Aventis Pharmaceuticals1; Lorex1; Neurocrine Bbsciences, Inc.1; Novartis Pharmaceuticals Corporation; Roche Laboratories, a member of the Roche Group1; Searle1; Sumitomo1; Takeda Abbott Pharmaceuticals1 Dan J. Stein, MD. AstraZeneca Pharmaceuticals6; Eli Lilly and Company6; GlaxcSmithKli^ 3,63 US. Pharmaceuticals, Pfizer Inc.6; Pharmacia & Upjohn Company, Inc.6; Serviei6; Solvay Pharmaceuticals, Inc.6; Roche Laboratories, a member of the Roche Group6; Wyeth- Ayerst Laboratories6; Sumitomo6; Qrtho McNeil Pharmaceuticals6

XXXVI DISCLOSURE INDEX

MurrayB. Stein, MD. Eli Lilly and Company1'314; Forest Laboratories, Inc.1'3; Nbvartis Pharrnaceuticals Corporation3; 6,34,66,67 US. Pharmaceuticals, Pfizer Inc.1-3; GlaxcSmithKline1-3-4; Solvay Phamiaceuticals, Inc.1-3-4; Wyeth-Ayerst Laboratories1'3'4; ADergan1; ALZAGoporaoon1; Alexza Molecular Delivery1; Janssen Research Foundation1; Vela Pharmaceuticals1; Hoffman-LaRoche Pharmaceuticals1; Johnson and Johnson PRD1; UCB Pharma, Inc.1-3; Cephalon Inc.1; Pfizer Canada1'3-4 MeirSteiner,MD. US. Pharmaceuticals, Pfizer Inc.1'3-4; Eli Lilly and Company1'3-4; GlaxoSmithKline1'3-4; Lundbeck1-3-4; 39,61 Novartis Pharmaceuticals Corporation1'3'4; Wyeth-Ayerst Laboratories1-3-4;Proctor ScGamble1'3-4; AstraZeneca Pharmaceuticals1'3'4; Qrtho McNeil Pharmaceuticals1'3'4; Merck&Go, Inc.1i3-4; Berlex Laboratories1'3'4; Barr Laboratories1-3'4 Donna E. Stewart, MD. EliLJy and Company'3-4; Roche Laboratories, a member of the Roche Group4; 86,104 Wyeth-Ayerst Laboratories1-4 Frederick J. Stoddard, Jr., M.D. US. Pharmaceuticals, Pfizer Inc.3'4; GlaxoSmithKline3 45 Nada L. Stotland, MD. U.S. Pharmaceuticals, Pfizer Inc.4; GlaxoSmithKline4; Wyeth-Ayerst Laboratories4 7, 53,73, 86 ZacharyN. Stowe, M.D. Pfizer Inc.3'4; GlaxoSmithKline0; Eli Lilly and Company4; Wyeth-Ayerst Laboratories4 2 Eric C Strain, M.D. Reckitt Benckiser Pharmaceuticals6 70 T. Scott Stroup, M.D. Eli Lilly and Company4; Janssen Pharmaceutica Inc.4; Bristol-Myers Squibb4; 10 Lilly Research Laboratories, a division of Eli Lilly and Company1 TreySunderland, MD. Eisai Inc.1; U.S. Pharmaceuticals, Pfizer Inc.1; Lundbeck1; Bristol-Myers Squibb1; 13,41 Janssen Pharmaceutica Inc.1; Forest Laboratories, Inc.1 AlanCSwann,MD. Abbott Laboratories, Inc.1-3-4; Ortho McNeil Pharmaceuticals1'3'4; GlaxoSmithKline1 -3-4; 3,33 Janssen Pharmaceutica Inc.1-4; Novartis Pharmaceuticals Corporation1'4; UCB Pharma, Inc.1-3; Lilly Research Laboratories, a division of Eli Lilly and Company3; Shire Ridgewood Pharmaceuticals1'3 James M Swanson, MD. Janssen Prarmaceutica Inc.1-3; Shire Ridgewood Pharmaceuticals1'3; Nbvartis Pharmaceuticals Corporation1'3 7 Cephalon Inc.1-3; McNeil Pharmaceuticals1'3; LiDyResearch Laboratories, a division of Eli Uyand Company-3 Conrad M Swartz, MD. Abbott Laboratories, Inc.1 33,89 Holly A Swartz, MD. Eli Lilly and Company4; US. Pharmaceuticals, Pfizer Inc.; GlaxcSrnithKline4 59,102 Robert M Swift, MD. Johnson and Johnson PRD1; US. Pharmaceuticals, Pfizer Inc.1; Drug Abuse Sciences3 64 Rajiv Tandon, MD. AstraZeneca Pharmaceuticals1'3'4; Bristol-Myers Squibb1-3'4; US. Pharmaceuticals, Pfizer Inc.1-3'4; 3,14,92 Janssen Pharmaceutica Inc.1>3>4; Ocsuka Pharmaceuticals1'3'4; Abbott Laboratories, Inc.1-4; Eli Lilly and Company1'3'4 Rudolph Tanzi, PhD. Forest Laboratories, Inc.6 13 Pierre N. Tariot, M.D. AstraZeneca Prjarmaceuticals1-3'4; Eli Lilly and Company1'3'4; Pfizer Inc.1-3'4; 13,41 Bristol-Myers Squibb1-3'4; Janssen Pharmaceutica Inc.1)3>4; Nbvartis Pharmaceuticals Corporation1'3'4 Warren D. Taylor, MD. US. Pharmaceuticals, Pfizer Inc.4; Wyeth-Ayerst Laboratories4; Janssen Pharmaceutica Inc.4 6,41 Mugdha E. Thakur, MD. Sepracorlnc.6 11 Michael E.1hase,MD. BristolrMyers Squibb1'4; Gephalon Inc.1; Pharmacia & Upjohn Company, Inc.1>3'4; 3,9,58,66, Forest Laboratories, Inc.1-4; GlaxoSmithKline1'4; Novartis Pharmaceuticals Corporation1; 73,86 Qrganon Pharmaceuticals Inc.J'4; US. Pharmaceuticals, Pfizer Inc.!'4; Cyberonics Inc.1-3; Solvay Pharmaceuticals, Inc.4; Wyeth-Ayerst Laboratories1'3'4; Eli Lilly and Company1'4 Mauricio F. Tohen, MD. Eli Lilly and Company2 79 Anna Marie Toto, MEd. Eli Lilly and Company5 75 Glenn J. Treisman, MD. U.S. Pharmaceuticals, Pfizer Inc.4; Boehringer Ingelheim4; Abbott Laboratories, Inc.4; 19,20,47, AstraZeneca Pharmaceuticals4; Wyeth-Ayerst Laboratories4; 50,70 Roche Laboratories, a member of the Roche Group; Schering Corporation4; Lilly Research Laboratories, a division of Eli Lilly and Company4 Richard N. Trosch, MD. AstraZeneca Pharmaceuticals6 13 Werner Tschan, MD. Eli Lilly and Company3; GlaxoSmithKline3; Lundbeck3 54 John W. Tsuang, MD. Lilly Research Laboratories, a division of Eli Lilly and Company4; 19, 82 Janssen Pharmaceutica Inc.4; Abbott Laboratories, Inc.4 Phebe M Tucker, MD. Pharmacia & Upjohn Company, Inc.3'4; Solvay Pharmaceuticals, Inc.3-4; Cephalon Inc.; 8 Forest Laboratories, Inc.3-4; GlaxoSmithKline3; U.S. Pharmaceuticals, Pfizer Inc.3; Wyeth-Ayerst Laboratories3; Ortho McNeil Pharmaceuticals3'4 LanyE. Tune, MD. US. Pharmaceuticals, Pfizer Inc.1'3-4; Abbott Laboratories, Inc.1'3-4; Bristol-Myers Squibb1'3-4; 15,71 Janssen Pharmaceutica Inc.1 •3-4; AstraZeneca Pharmaceuticals;1 -3-4 Douglas Turkington, M.D. US. Pharmaceuticals, Pfizer Inc.1-3'4; Bristol-Myers Squibb4; Janssen Pharmaceutica Inc.4-6; 8,46 Lilly Research Laboratories, a division of Eli Lilly and Company4-6 T. Bedirhan Ustun, M.D. Eli Lilly and Company6 2

XXXVII DISCLOSURE INDEX

Presenter Manufacturers) Program Page # Michael A. Van Ameringen, M.D. AstraZeneca Pharmaceuticals3; Bristol-Myers Squibb3; Gephalon Inc.1; GlaxoSmithKline1' 3>4; 23 Eli Lilly and Company3; Janssen-Ortho Pharmaceutica Inc.3; Lundbeck3; Novartis Pharmaceuticals Corporation1; U.S. Pharmaceuticals, Pfizer Inc. 1)3>4; Wyeth-Ayerst Laboratories1'3; SolvayPharmaceuticals, Inc.1 Eve Van Cauter, MD. Neurocrine Biosciences, Inc.6 67 George I. Viamontes, M.D. Johnson and Johnson PRD5; Wyeth-Ayerst Laboratories3; GlaxoSmithKline3; Pfizer Inc.3 45, 58 Adele G Viguera, MD. Eli Lilly and Company3; GlaxoSmithKline6 4, 69, 93 Nora D. Volkow, M.D. AstraZeneca Pharmaceuticals6 3,20, 35,44 Serena Y. Volpp, MD. GlaxoSmithKline6 4 Elizabeth Vreeland, MS.N. Eli Lilly and Company1 • 3>4-6; Johnson and Johnson PRD5 75 Karen D. Wagner, MD. Abbott Laboratories, Inc. 1'3>4; Bristol-Myers Squibb1'3; Wyeth-Ayerst Laboratories1'3; Cyberonks Inc.1; 9 Forest Laboratories, Inc. 1'3>4; GlaxoSmithKline1'3'4; Janssen Pharmaceutica Inc. *>*; UCB Pharma, Inc.1; Novartis Pharmaceuticals Corporation; *»4; OtsukaPharmaceuticals1; Eli LiDyand Company1-3.4; US. Pharmaceuticals, Pfizer Inc. 1>3>4; Organon Inc.3; Natbnal Institute of Mental Ffeakh3 B.Timothy Walsh, MD. Eli Lilly and Company3; Ortho McNeil Pharmaceuticals3 62, 67 James K. Walsh, Ph.D. Cephalonlnc.1'3 97 James G. Waxmonsky, MD. Cephalon Inc.1; McNeil Pharmaceuticals4; AstraZeneca Pharmaceuticals; Eli Lilly and Company3; 67 Janssen Pharmaceutica Inc.4 Allison M.Wehr,M.D. Bristol-Myers Squibb6 45, 57 Peter J. Weiden, M.D. AstraZeneca Pharmaceuticals1'3> 4; Bristol-Myers Squibb1' 3>4; 3,11 Janssen Pharmaceutica Inc. *• 3>4; U.S. Pharmaceuticals, Pfizer Inc. !> 3>4 RisaB.Weisberg,Ph.D. U.S. Pharmaceuticals, Pfizer Inc.3 6 Jeffrey Weiss, Ph.D. Bristol-Myers Squibb5 19 Margaret D. Weiss, MD. Eli Lilly and Company1; Novartis Pharmaceuticals Corporation1; Purdue Pharma1; 2 Janssen-Ortho Pharmaceutica Inc.1'4; GlaxoSmithKline1'4; Circa Dia1-4; Johnson and Johnson PRD1'4; Shire Ridgewood Pharmaceuticals1'4; Pharmacia & Upjohn Company, Inc. ^4 Gary L.Wenk, PhD. Forest Laboratories, Inc.6 6 Paul Whalen, Ph.D. Wyeth-Ayerst Laboratories6 66 Timothy E. Wilens, M.D. Abbott Laboratories, Inc. l>3>4; Celltech Medieva1'3-4; McNeil Pharmaceuticals1' 3>4; 39, 65, 67, Lilly Research Laboratories, a division of Eli Lilly and Company1'3> 4; GlaxoSmithKline1'3> 4; 106 National Institute of Mental Health1- 3>4; National Institute on Drug Abuse1'3> 4; Novartis Pharmaceuticals Corporation1' 3>4; U.S. Pharmaceuticals, Pfizer Inc. l>3-4; SmithKline Beecham Pharmaceuticals1' 3>4; Shire Ridgewood Pharmaceuticals1'3> 4 John W. Winkelman, MD. U.S. Pharmaceuticals, Pfizer Inc. l> 3>4; GlaxoSmithKline1' 3>4; UCB Pharma, Inc. *•4; 55,67,92 Ortho McNeil Pharmaceuticals1'4; Cephalon Inc. *•4; Sepracor Inc. l>4; Elan Pharmaceuticals1'4; Eli Lilly and Company1'4; Wyeth-Ayerst Laboratories1'4 Daniel K. Winstead, MD. Abbott Laboratories, Inc.3 >4; AstraZeneca Pharmaceuticals4; Bristol-Myers Squibb4; 27 CoCensys4; Dista Products, A Division of Eli Lilly Gomapany4; Eli LiDy and Company1'3; Forest Laboratories, Inc.1; Janssen Pharmaceutica Inc.3>4; US. Pharmaceuticals, Pfizer Inc.3; Roerig Division, Pfizer, Inc.3>4 ; SmithKline Beecham Pharmaceuticals3'4; Wyeth-Ayerst Laboratories3'4; The Upjohn Company (with Solvay)3>4; Pharmacia & Upjohn Company, Inc.3 Katherine L. Wisner, MD. Pfizer Inc. ^jGlaxc^mimKline4; Lilly Research I^rx)ratories, a divisbn of EU Lilly and Company1'4 70,100 Tom Wolfe Wyeth-Ayerst Laboratories6 38 Janet Wozniak, MD. Eli Lilly and Company1'3; Janssen Pharmaceutica Inc.4; GlaxoSmithKline6 69,85 Joel Yager, MD. Ortho McNeil Pharmaceuticals1 7,15,47,60,93 Rachel Yehuda, PhD. Johnson and Johnson PRD1'3-4; US. Pharmaceuticals, Pfizer Inc. i-3-4; GlaxoSmithKline1.3.4; 75,92,105 Wyeth-Ayerst Laboratories6; Novartis Pharmaceuticals Corporation1 Kimberly A Yonkers, MD. Berlex Laboratories3; GlaxoSmithKline Beechum Pharmaceuticals1.3> 4; Eli Lilly and Company4; 6,61,100 US. Pharmaceuticals, Pfizer Inc.4; Wyeth-Ayerst Laboratories4 Stuart CYudofsky,MD. Bristol-Myers Squibb6 13,41,45,70,93 Deborah A Yurgelun-Todd, PhD. Eli Lilly and Company3 4,41,61 Mary C Zanarini, EdD. Eli Lilly and Company1'3 23,38,64,102 Wei Zhang, MD. Gephalon Inc.6; US. Pharmaceuticals, Pfizer Inc.6 4,93 Douglas M Ziedonis, MD. Janssen Pharmaceutica Inc.1'3-4; AstraZeneca Pharmaceuticals1.3'4; Bristol-Myers Squibb1-3'4; 48,62,84,100 Lilly Research Laboratories, a division of Eli Lilly and Company1'3'4 Joseph Zohar, MD. Novartis Pharmaceuticals Corporation1; Wyeth-Ayerst Laboratories1'3; Solvay Pharmaceuticals, Inc.1-4; 92 Lundbeck1 •3; Pfizer Inc.1 •3; Lilly Research Laboratories, a division of Eli Lilly and Company3 Jon-Kar Zubieta, MD. Wyeth-Ayerst Laboratories6 8,30 XXXVIII DISCLOSURE INDEX

Voting members of the Board of Trustees, Assembly officers, and members of the Scientific Program Committee cannot receive honoraria or travel reimbursement for participation in Industry-Supported Symposia. In accordance with this policy, the following members are participating in an Industry-Supported Symposium and will not receive any compensation:

Presenter Program Page # Glen O. Gabbard, M.D. 38 Geetha Jayaram, M.D. 6 Philip R. Muskin, M.D. 4

The following presenters on this year's scientific program had not, at the time of this book's printing, returned the APA Disclosure Form. In accordance with APA policy, these presenters are required to submit a Disclosure Form and also provide oral or visual disclosure to participants at the session.

Margo S. Adams 53 RoyM Gulick, M.D 63 Alessandro Nicolo 46 Critstiano Adiutori 46 Erik W. Gunderson, M.D 81 Stefania Papirio 46 Jeffreys. Akman, MD 15,43 Charles J. Hynes, J.D 27 Trevor K P. Price, MD 99 JackD. Barchas, M.D 44 Samuel C. Klagsbrun, M.D 27 Ricardo Secin, MD 58 Gregory Brown, Ph.D 19 Norwood Knight-Richardson, MX). 83 Anne J. Swern, J.D 27 Bill Burmester, MA 82 Lynn Lavendar, Esq 99 Rozaliya Vernikov, M.D 74 BJ. Casey, Ph.D 72 Kenneth Linn, Esq 27 Gabriel Weimann, Ph.D 31 Lisa Colosimo 46 David B. Mallott, MD 99 Francine Weiss, Esq 73 David W. Garland, Esq 73 Michael L. Melamed, MD 74 Robert A. Wise, MD 45 Harvey R. Greenberg, M.D 90 Melodic Morgan-Minott, M.D 72

XXXIX This page intentionally left blank SATURDAY, MAY 1, 2004 157TH ANNUAL MEETING 8:00 a.m. Sessions COURSES 9:00 a.tn.-4;00 p.m. Rooms 2D10/11, Level 2, Javits Center

COURSES i-3 THE BIOPSYCHOSOdAL FORMULATION: AN Course descriptions are available in the CME APPROACH TO ORAL BOARD PRESENTATIONS Course Brochure included in your registration packet Admission by ticket only. Co-Directors: William H Campbell, M.D., Robert M. Rohrbaugh, M.D. Faculty: Catherine Chiles, M.D., Paul D. Kirwin, MD. COURSE 1 8:00 a.m.-12 noon Room IE 06, Level 1, Javits Center COURSE 6 9:00 a.m.-4:00 p.m. Rooms 2D14/15, Level 2, Javits Center ASSESSMENT AND TREATMENT OF DRUG- INDUCED MOVEMENT DISORDERS THE CONCEPTUAL BASIS OF PSYCHIATRY

Director Herman M. Van Praag, M.D. Co-Directors: S. Nassir Ghaemi, M.D., David H. Brendel, M.D. Faculty: Anton J.M. Loonen, M.D. COURSE 2 8:00 a.m.-12 noon Room 1E09, Level 1, Javits Center 12:30 p.m. Sessions

ADD IN CHILDREN AND ADOLESCENTS INDUSTRY-SUPPORTED SYMPOSIA 1-5 Director. Thomas E. Brown, Ph.D. Faculty: Jefferson B. Prince, M.D. INDUSTRY-SUPPORTED SYMPOSIUM 1 12:30 p.m.-3:30 p.m. COURSE 3 8:00 a.m.-12 noon Special Events Hall ID, Level 1, Javits Center Room 2D02/3, Level 2, Javits Center TREATMENT RESISTANCE: CONCEPTS AND USING NEUROFEEDBACK IN YOUR PRACTICE: MANAGEMENT IN MOOD AND ANXIETY INTRODUCTION WITH HANDS-ON EXPERIENCE DISORDERS Supported byJanssenPhamuceuticn andRes&mh Foundation Co-Directors: Thomas M, Broad, M.D., Michael Cohen Chp.: Mark H Rapaport, M.D. Faculty. Laurence Hirshberg, Ph.D., Henry B. Mann, M.D. A Treatment Resistance in Mood and Anxiety Disorders: Evidence From Clinical Trials 9:00 a.m. Sessions Ellen Frank, Ph.D. B Psychotherapeutic Approaches for Patients With COURSES 4-6 Treatment-Resistant Mood and Anxiety Disorders Course descriptions are available in the CME Edna B, Foa, Ph.D. Course Brochure included in your registration C Clinical Pathways for Mood and Anxiety Disorders packet. Admission by ticket only. WaguihW.Ishak,MX>. D Emerging Treatment Options in Treatment-Resistant COURSE 4 9:00 a.m.-4;00 p.m. Mood and Anxiety Disorders Room IE 17, Level 1, Javits Center Mark H. Rapaport, M.D. INTERPERSONAL PSYCHOTHERAPY INDUSTRY-SUPPORTED SYMPOSIUM 2 12:30 p.m.-3:30 p.m. Director Scott P. Stuart, M.D. Empire Ballroom B/C/D, Ballroom Level, Grand Hyatt Faculty: Paula Ravitz, M.D. PREVENTIVE PSYCHIATRY IN MOOD DISORDERS: A NEW FRONTIER Supported by GktxoSnithKLim

Chp.: Charles B. Nemeroff, M.D. (Continued an nextpag) 1 SATURDAY

A Identification of Risk Factors for Development of B Adult ADHD Diagnostic and Self-Report Symptom Depression: Focus on Early-Life Trauma Scales: Development and Validation in the National Charles B. Nemeroff, M.D. Comorbidity Survey Replication (NCS-R) Cohort Lenard A. Adler, M.D. B Achieving the Optimal Balance Between Treatment of Maternal Depression and Infant Medication Exposure C Current Concepts in the Neurobiology of ADHD ZachaiyN. Stowe, M.D. Joseph Biederman, M.D.

C Functional Brain Imaging: Subtyping Depression D Treatment Options and Response Patterns in Adult Helen S. Mayberg, M.D. ADHD Margaret D. Weiss, M.D. D Genetic Research in Psychiatry: Diagnostic and Therapeutic Implications E Our New Understanding of the Prevalence, Stephan Qaes, M.D. Impairments, Comorbidity, and Treatment of Adults With ADHD INDUSTRY-SUPPORTED SYMPOSIUM 3 Thomas J. Spencer, M.D. 12:30 p.m.-3:30 p.m. Grand Ballroom East, Third Floor, Hilton New York INDUSTRY-SUPPORTED SYMPOSIUM 5 12:30 p.m.-3:30 p.m. BIPOLAR DISORDER AND ALCOHOLISM: Imperial Ballroom A, Second Floor, Sheraton New York DIAGNOSTIC CHALLENGES AND THERAPEUTIC INTERVENTIONS TOWARDS DSM-V: PHENOMENOLOGY, Supported, by Ortho-McNeil Pharmaceuticals NEUROBIOLOGY, AND TREATMENT RESPONSE IN DEPRESSION Chp.: Mark A Frye, M.D. Supported by Gepbalan, Inc.

A Neurobiology of Alcohol Withdrawal Chp.: Philip T. Ninan, M.D. Hugh Myrick, M.D. A Pathophys iology of Major Depres s ion: Monoamines, B Pharmacotherapy for Alcoholism Peptides, and Neurotrophins Bankole A. Johnson, M.D. Kerry J. Ressler, M.D.

C The Impact of Alcoholism on the Presentation and B Homology Between Pathophys iology and Symptoms in Course of Bipolar Disorder Major Depression Susan L. McElroy, M.D. Boadie W. Dunlop, M.D.

D The Role of Mood Stabilizers in Bipolar Disorder With C Enhancing Emergence of Antidepressant Benefit Comorbid Alcohol Dependence Charles DeBattista, M.D. Joseph F. Goldberg, M.D. D Pharmacological Approaches to Management of E Bipolar Illness, Substance Abuse Comorbidity, and the Residual Symptoms in Depression Legal System Maurizio Fava, M.D. Cameron D. Quanbeck, M.D. E MIND: Lessons From the Brain INDUSTRY-SUPPORTED SYMPOSIUM 4 Philip T. Ninan, M.D. 12:30 p.m.-3:30 p.m. Broadway Ballroom, Sixth Floor, Marriott Marquis

ADULT ADHD: CLINICAL UTILITY AND VALIDITY 1:00 p.m. Sessions Supported by Eli L illy and Company COURSES 7-12 Chp.: T. Bedirhan Ustiin, M.D. Course descriptions are available in the CME Course Brochure included in your registration A Prevalence of Adult ADHD in the United States: Results packet Admission by ticket only. From the National Comorbidity Survey Replication (NCS-R) Ronald C Kessler, Ph.D.

2 SATURDAY

COURSE/ l:00p.m.-5:00p.m. 5 Room 1E01/2, Level 1, Javits Center

MANAGEMENT OF PSYCHIATRIC DISORDERS IN INDUSTRY-SUPPORTED SYMPOSIA 6-11 PREGNANT AND POSTPARTUM MOTHERS: OVERVIEW INDUSTRY-SUPPORTED SYMPOSIUM 6 6:00 p.m.-9:00 p.m. Co-Directors: Shaila Misri, MD., Diana Carter, M.B. Empire Ballroom B/C/D, Ballroom Level, Grand Hyatt Faculty: Maria R. Corral, MD., Deirdre M Ryan, M.B. TFffi ROLE OF DOPAMINE IN HEALTH AND ILLNESS: SCIENCE TO PRACTICE COURSES 1:00 p.m.-5:00 p.m. Supported by A straZeneca Phmraasuticah Room IE 06, Level 1, Javits Center Chp.: Peter J. Weiden, MD. BEHAVIORAL NEUROANATOMY: AN INTRODUCTION A The Role of Dopamine as a Mediator of Normal Human Reward Director: Nashaat N. Boutros, MD. Nora D. Volkow, MD. Faculty: David L. dark, Ph.D., Edward C. Lauterbach, MD. B From Dopamine to Salience to Psychosis: Why COURSE 9 1:00 p.m.-5:00 p.m. Antipsychotics Are Antipsychotic Room 1E09, Level 1, Javits Center Shitij Kapur, MD.

PSYCHIATRIC GENOMICS: APPLICATIONS FOR C Dopamine and Neuroleptic Dysphoria in Practice CLINICAL PRACTICE Peter J. Weiden, MD.

Director: David A, Mrazek, M.D. D The Role of Dopaminergic/Cholinergic Interaction in Faculty: John L. Black, MD., Brett A. Koplin, MD. Cognition and Psychosis Rajiv Tandon, MD. COURSE 10 1:00 p.m.-5:00 p.m. Rooms 2D02/3, Level 2, Javits Center E The Role of Dopamine in the Neurobiology of Sexual Dysfunction COGNITIVE THERAPY FOR SEVERE MENTAL Abdelouahed Elmouchtari, MD. DISORDERS INDUSTRY-SUPPORTED SYMPOSIUM 7 Director: Jesse H. Wright, MD. 6:00 p.m.-9:00 p.m. Faculty: Michael E. Thase, MD., Monica A. Basco, PhD. Grand Ballroom East, Third Floor, Hilton New York

COURSE 11 1:00 p.m.-5:00 p.m. IMPULSIVITY: EMERGING CLINICAL Rooms 2D04/5, Level 2, Javits Center PERSPECTIVES Supported by Ortho-McNeil Pharmaceuticals ASSESSING THE RISK OF VIOLENCE IN BOTH FORENSIC AND SEX OFFENDER SETTINGS Chp.: Eric Hollander, MD.

Director: Bradley R. Johnson, MD. A Neurobiology of Impulsive Behavior Faculty: Judith V. Becker, PhD. Alan C. Swann, MD.

COURSE 12 1:00 p.m.-5:00 p.m. B When Does Impulsive Behavior Become Pathologic? Rooms 2D06/7, Level 2, Javits Center Ernest S. Barratt, MD.

SYSTEMIC THERAPIES FOR SUBSTANCE ABUSE C Clinical Issues of Impulsivity in Psychiatry DISORDERS Dan J. Stein, MD.

Co-Directors: Peter J. Steinglass, MD., Marc Galanter, MD. D Addressing Impulsive Behavior in Eating Disorders Renu Kotwal, MD.

E Identifying the Spectrum of Impulse-Control Disorders Eric Hollander, MD.

3 SATURDAY

INDUSTRY-SUPPORTED SYMPOSIUM 8 INDUSTRY-SUPPORTED SYMPOSIUM 10 6:00 p.m.-9:00 p.m. 6:00 p.m.-9:00 p.m. Broadway Ballroom, Sixth Floor, Marriott Marquis Imperial Ballroom A, Second Floor, Sheraton New York

BIPOLAR DISORDER: IMPROVING OUTCOMES SEX, SEXUALITY, AND 5HT WHEN THEORY, SCIENCE, AND CLINICAL Supported by GlaxoSnithKLine PRACTICE CONVERGE Supported by Eli Lilly and Company Chp.: Philip R. Muskin, MX).

Chp.: Joseph F. Goldberg, M.D. A Do Sexual Side Effects of Most Antidepressants Jeopardize Romantic Love and Marriage? A The Convergence of Pharmacotherapy and Helen E. Fisher, PhX>. Psychotherapy in Maintenance Treatment of Bipolar Disorder B Love and Sex Paul E. Keck, Jr., MX). Ethel S. Person, MX).

C Talking to Gay Patients About Sex: What Do You Need B Considerations in the Female Patient During to Know? Childbearing Years Serena Y. Volpp, MX). Adele C Viguera, MX).

C Choosing Treatments in Bipolar Depression: What, D Effects of Psychiatric Illness and Medication on Sexual Function When, and Why? Anita L.H Clayton, MX). Roy H Perils, MX). E Talking About Sexual Dysfunction to Enhance D Cognitive Functioning Outcomes: From First Episode Adherence With Medication to Functional Recovery Philip K Muskin, MX). Deborah A. Yurgelun-Todd, PhX>. INDUSTRY-SUPPORTED SYMPOSIUM 11 E Translating Research Into Clinical Practice: From the Bench to the Trenches 6:00 p.m.-9:00 p.m. Joseph F. Goldberg, MX). Imperial Ballroom B, Second Floor, Sheraton New York

INDUSTRY-SUPPORTED SYMPOSIUM 9 INTERFACE BETWEEN DEPRESSION AND MEDICAL ILLNESS 6:00 p.m.-9:00 p.m. Supported by Wyetb Pharmaceuticals Grand Ballroom, Mezzanine Level, Roosevelt Chp.: Dwight L. Evans, M.D. GAD: EVIDENCE-BASED CONSIDERATIONS FROM Co-Chp.: Dennis S. Charney, MX). PATHOPHYSIOLOGY TO LONG-TERM MANAGEMENT Supported by Pfizer Inc. A Heartache and Heartbreak: Depression and Cardiovascular Disease Chp.: John H Greist, MX). Charles B. Nemeroff, MX).

A Prevalence of GAD in the U.S.: Results From the B The Relationship of Depression to Cancer and HIV National Comorbidity Survey Replication Infection Ronald C Kessler, PhX>. David Spiegel, MX).

B Distinguishing GAD: Unique Characteristics C Comorbidity of Depression in Neurological Disorders Wei Zhang, MX). William M. McDonald, MX).

C The Molecular and Cellular Pathophysiology of GAD D Mood Disorders and Medical Illness: Diabetes, Carl Salzman, MX). Osteoporosis, Obesity, and Pain Robert N. Golden, M.D., Dominique L. Musselman, MX)., D Cognitive-Behavior Therapy for the Treatment of GAD Philip W. Gold, MX)., Albert J. Stunkard, M.D., Frank Keefe Michelle G. Newman, Ph.D. E Mood Disorders in the Medically 111: The Patient's E Pharmacotherapies for GAD: From Rough Empiricism Perspective to Elegant Evidence Lydia J. Lewis , B.A. John H Greist, MX).

4 SUNDAY, MAY 2, 2004 157TH ANNUAL MEETING :00 a.m. SrsM . * COURSE 19 8:00 a.m.-12 noon Rooms 2D14/15, Level 2, Javits Center v CO* KM ^ PERSONALITY DISORDERS: COMBINING Course descriptions are available in the CME RELATIONAL THERAPY AND Course Brochure included in your registration PSYCHOPHARMACOLOGY packet Admission by ticket only. Director Roy O. Resnikoff, MD. COURSE 13 8:00 a.m.-12 noon Rooms 1E01/2, Level 1, Javits Center INDUSTRY-SUPPORTED SYMPOSIA 12-18 RISK ASSESSMENT FOR VIOLENCE INDUSTRY-SUPPORTED SYMPOSIUM 12 Director Phillip J. Resnick, M.D. 8:00 a.m.-11:00 a.m. Special Events Hall ID, Level 1, Javits Center COURSE 14 8:00 a.m.-12 noon Rooms 1E03/4/5, Level 1, Javits Center ANTIDEPRESSANT TREATMENTS YOU MAY NOT KNOW ABOUT, BUT SHOULD... ADD IN ADULTS Supported by Orgcnan Inc. Chp.: Jerrold F. Rosenbaum, M.D. Director Thomas E. Brown, Ph.D. Faculty: Jefferson B. Prince, M.D. A The Next Generation of Antidepressants: What Is in the COURSE 15 8:00 a.m.-12 noon Pipeline? Rajinder A. Judge, M.D. Room IE 06, Level 1, Javits Center B Alternative Medications for Depression ENGAGING RESISTANT AND HOSTILE PATIENTS Andrew A. Nierenberg, M.D. INTO PARTICIPATORY TREATMENT C Evidence-Based Psychotherapy for Depression: Director David Mee-Lee, M.D. Principles and Practice COURSE 16 8:00 a.m.-12 noon Timothy J. Petersen, Ph.D. Rooms 2D06/7, Level 2, Javits Center D Device-Based Treatments for Depression AJohnRush,MJD. DSM-IV-TR CULTURAL FORMULATIONS: DIAGNOSIS AND THERAPY E The Future of Treatment-Matching in Depression Steven P. Roose, M.D. Director: Russell F. Lim, MD. Faculty: Candace M. Fleming, Ph.D., Roberto Lewis- INDUSTRY-SUPPORTED SYMPOSIUM 13 Fernandez, M.D., Francis G. Lu, M.D., J. Charles Ndlela, M.D., 8:00 a.m.-11:00 a.m. Michael W. Smith, M.D. Empire Ballroom B/C/D, Ballroom Level, Grand Hyatt

COURSE 17 8:00 a.m.-12 noon BROADENING THE HORIZON OF ATYPICAL Rooms 2D10/11, Level 2, Javits Center ANTIPSYCHOTIC APPLICATIONS Supported by A straZeneca. Pharmaceuticals INTERPERSONAL PSYCHOTHERAPY Chp.: S. Charles Schulz, M.D. Director John G Markowitz, M.D. A Atypical Antipsychotics in Anxiety and PTSD COURSE 18 8:00 a.m.-12 noon MarkB.Hamner,M.D. Rooms 2D12/13, Level 2, Javits Center B Atypical Antipsychotics Treatment of Substance Abuse E. Sherwood Brown, M.D. TEACHING PSYCHIATRY? LET HOLLYWOOD HELP! C Role of Atypicals in the Treatment of Pediatric Psychotic Disorders and Common Comorbidities Director: Steven E. Hyler, M.D. Melissa P. DelBello, MX). Faculty: Carol A. Bernstein, M.D., Michael B. First, M.D. (Continued an next pose) 5 SUNDAY

D Atypicals in the Treatment of Anorexia Nervosa INDUSTRY-SUPPORTED SYMPOSIUM 16 Walter H.Kaye,MX>. 8:00 a.m.-11:00 a.m. Grand Ballroom, Mezzanine Level, Roosevelt E Atypicals in BPD S. Charles Schulz, M.D., A Adityanjee, M.D. BROADENING HORIZONS: ADVANCES IN UNDERSTANDING THE ETIOLOGY, EFFECTS, INDUSTRY-SUPPORTED SYMPOSIUM 14 AND TREATMENT OF ANXIETY DISORDERS 8:00 a.m.-11:00 a.m. Supported by UCB Phtrrm, Inc. Grand Ballroom East, Third Floor, Hilton New York Chp.: Naomi M. Simon, MX). THE MANY FACES OF ANXIETY: ORIGINS, Co-Chp.: Mark H Pollack, MX). PATHOGENESIS, AND MANAGEMENT Supported by Pfizer Inc. A Anxiety on the Upswing? A Public Health Perspective Murray B. Stein, MX). Chp.: Martin B. Keller, MX>. B The Neurobiology of Anxiety and Stress: The Role of A Generalized Anxiety, Social Anxiety, and Panic Glutamate Disorder: New Views on Validity and Nosology Jeremy D. Coplan, MX). Risa B. Weisberg, Ph.D. C Treating Anxiety. Current Therapies and Beyond B Origins and Pathogenesis of Anxiety Symptoms and Mark H Pollack, MX>. Syndromes Dennis S. Charney, MX). D Gender and Anxiety Disorders: Impact and Treatment Implications C Pharmacologic Approaches for Panic Disorder Naomi M. Simon, MX). David V. Sheehan, MX). E Treatment Works: Now What Do We Do? Strategies to D GAD: Current Opinions and Future Options Enhance Treatment Adherence Linda L. Carpenter, MX). Michael W. Otto, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 15 INDUSTRY-SUPPORTED SYMPOSIUM 17 8:00 a.m.-11:00 a.m. 8:00 a.m.-11:00 a.m. Broadway Ballroom, Sixth Floor, Marriott Marquis Imperial Ballroom A, Second Floor, Sheraton New York

FROM PATHOLOGY TO PRACTICE: EVOLVING THE HIDDEN FACES OF ANXIETY THERAPEUTIC STRATEGIES FOR ALZHEIMER'S Supported by GlaxoSnithKlwe DISEASE Supported by Forest Laboratories, Inc. Chp.: Prakash S. Masand, MX).

Chp.: Jacobo E. Mintzer, M.D. A The Somatic Face of Anxiety Prakash S. Masand, M.D. A Synaptic Dysfunction and Neurodegeneration in Alzheimer's Disease B Anxiety in Men and Women: Two Faces of the Same GaryL.Wenk,Ph.D. Coin Kimberly A Yonkers, M.D. B Alzheimer's Disease Update: New Targets, New Options C The Many Faces of Anxiety. Understanding Cultural Jacobo E. Mintzer, MX). and Ethnic Variation in Psychiatric Illness Geetha Jayaram, MX). C Alzheimer's Disease and Vascular Dementia: Where Is the Overlap? D Facets of Psychiatric Illness in the Elderly John C Morris, MX). Warren D. Taylor, M.D.

D Multicultural Issues in Addressing Barriers to Diagnosis and Treatment Warachal E. Faison, MX).

E A Rational Approach to Combination Treatment MarySano, Ph.D.

6 SUNDASUNDAYY

INDUSTRY-SUPPORTEINDUSTRY-SUPPORTEDD SYMPOSIU SYMPOSIUMM 1 818 COURSCOURSE E2 22 9:09:00 0a.m.-4:0 a.m.-4:000 p.m p.m. . 8:O8:0C 0a.m.-11:0 a.m.-11:00 0a.m a.m. . RoomRooms s2D02/3 2D02/3, ,Leve Level 2l 2, Ja\it, Javits sCente Center r ImperiaImperial lBallroo Ballroomm B B, Secon, Second dFloor Floor, ,Sherato Sheraton nNe Neww Yor Yorkk THERAPEUTITHERAPEUTICC INTERVENTION INTERVENTIONSS ININ FATIN EATINGG TARGETINTARGETINGG EXECUTIV EXECUTIVE EDYSFUNCTION DYSFUNCTIONS SFO FORR DISORDERSDISORDERS: :BASI BASICC PRINCIPLE PRINCIPLESS TREATMENTREATMENTT Siipp(MalSupported ly by Cepf\dori, Cephalan, hx. Inc. DirectoDirectorr :Davit Davi!d CJimerson G Jimerson, M.D, M.D. . FacultyFaculty: :Katherin Katharine eA A, .FLilmi Halmi, ,M.D. M.D., Jame, James sE E. .Mitchell Mitchell, M.I)., M.D., , Chp.Chp.: Charle: Charles sDeBattista DeBattista, ML), M.D, . BarbarBarbara aE E. .Wolfe Wolfe, ,Ph.D. Ph.D.. ,Joe Joel lYager Yager, ,M.D M.D..

AA ExecutivExecutive eFunction Function: :Circuit Circuits san and dSymptom Symptoms s COURSCOURSE E2 233 _9:C9:0:0 a.m.-4:CO_p.rn a.m.-4:00 p.m. . StepheStephen nM M. Stahl. Stahl. M.I), MD. . RoomRooms s2DC4/5 2D04/5, ,Leve Level 2l 2, Javit, Javits sCente Center r

BB AddressinAddressingg th the eNeurobiologica Neurobiological lDysfunction Dysfunctions so fo fDefici Deficit t BASIBASICC HYPNOSIS HYPNOSIS: :PRINCIPLE PRINCIPLESS AN ANDD SyndromSyndrome e APPLICATIONAPPLICATIONSS RonRona aHi; Hu, M.D, MD. . DirectoDirectorr :los Jose eR R. .Maldonado Maldonado, ,M.I) M.D,. CC Late-LifLate-Life eDepressio Depression no fo fExecutiv Executive eDysfunction Dysfunction: Nove: Novel l FacultyFaculty: :Davi David dSpiegel Spiegel, ,M.D. MD.. ,Matthe Mattheww Mav May, M.D., M.D., 1, HerberIcrbert t TreatmenTreatment tDevelopmen Development t SpiegelSpiegel, ,M.D. MD., ,Marci Marcia aGreenleal Greenleaf, Ph.D, Ph.D. . GeorgGeorge eS .S Alexopoulos. Alexopoulos. M.I), M.D. .

D Cognitive and Executive Dysfunction in Major Depression 12: v p.m. Session Charles DeBattisu. M.D.

E Addressing Executive Dysfunctions in ADHD BUSINESS MEETING James M. Swanson, M.I). (Voting Members Only*)

12:30 p.m.-1:30 p.m. 9:00 a.m. Sessions Westside Ballroom, 5* Floor, Marriott Marquis CALL TO ORDER COURSES 20-23 Course descriptions are available in the CME Marcia Kraft Goin, MJD., Presukrt Course Brochure included in your registration packet. Admission by ticket only. MEMORIAL TO DECEASED MEMBERS ANNOUNCEMENT OF ELECTION RESULTS COURSE 20 9:OC_a.m.-4:OC p.m. Liza FL Gold, M.D., Chairperson, Comnttee cf Tellers Room IE 15, Level i,Javits Outer REPORTS TO THE MEMBERSHIP ..\DVANCES IN NEUROPSYCHIATRY Secretary Nada L. Stodand, M.D. A nmcm XamprvJuitnc A 55fxi//«? Treasurer Giro! A. Bernstein, M.D. Speaker, Asserrbfy Prakash N. Desai, MD. Director C Edward Coft'ev, M.D. Speaker-Elect, Asserrtfy James E. Nininger, M.D, Faculty: Jeffrey I.. Ciimmmgs, M.D., Mark S. George, M.D., Chairperson, By-Law Ccmrittee: Derek Puddester, MX). Michael R, Trimble, M.D. Chairperson, Flatters Corrmttee: Yvonne B. Ferguson, M.D. Chacrpersan, Membership Commttec Mary K. Marrocco, MJ3. MediatlDirector: James H. Scully, Jr., MJ3. COURSE 21 9:00 a.m.-4:OC p.m. Room IE 17, Level 1, Javits Center ANNUAL FORUM ADJOURNMENT EVIDENCE-BASED MEDICINE: AN INTRODUCTION FOR PSYCHIATRISTS ^Members-in-Training, General Members, Distinguished Fellows, Fellows, Life Fellows, Distinguished Life Fellows, Director: Gregory E. Gray, MI). and Life Members, Badge or APA membership card Faculty: Gabnelle F. Beaubrun, M.D., Lctitia A. Pinson. M.D. necessary for admission. No cameras or tape recorders will be permitiea.

7 SUNDAY

COURSE 30 1:00 p.m.-5;00 p.m. 1:00 p.m. Sessions Rooms 2D10/11, Level 2, Javits Center

COURSES 24-31 PSYCHIATRIC INTERVENTIONS IN DISASTERS: Course descriptions are available in the CME LESSONS FROM EXPERIENCE Course Brochure included in your registration packet Admission by ticket only. Co-Directors: Carol S. North, MD., Betty Pfefferbaum, MD. Faculty: Anthony T. Ng, M.D., Phebe M Tucker, MD. COURSE 24 1:00 p.m.-5;00 p.m. Rooms 1E01/2, Level 1, Javits Center COURSE 31 1:00 p.m.-5:00 p.m. Rooms 2D14/15, Level 2, Javits Center MELATONIN AND LIGHT TREATMENT OF SAD, SLEEP, AND OTHER BODY CLOCK DISORDERS IMPROVING YOUR PRESENTATION SKILLS: A COACHING APPROACH Director Alfred]. Lewy, MD. Faculty: Michael Terman, Ph.D. Director: Luis F. Ramirez, MD. COURSE 25 1:00 p.m.-5:00 p.m. Rooms 1E03/4/5, Level 1, Javits Center 1:30 p.m. Sessions

COGNITIVE THERAPY FOR SCHIZOPHRENIA INDUSTRY-SUPPORTED SYMPOSIA 19-23 Director: Jesse H. Wright, MD. Faculty: Douglas Turkington, MB., David G. Kingdon, MD. INDUSTRY-SUPPORTED SYMPOSIUM 19 1:30 p.m.-4:30 p.m. COURSE 26 1:00 p.m.-5:00 p.m. Special Events Hall ID, Level 1, Javits Center Room IE 06, Level 1, Javits Center THE TREACHEROUS TRIAD FOR DEPRESSION Supported by Wyeth Phariniceutiads DETERMINING MEDICAL FITNESS TO DRIVE: RELEVANT ISSUES FOR PSYCHIATRISTS Chp.: John F. Greden, MD. Director Ian A. Gillespie, MD. A Underdetection and Inadequate Treatment of Physical Symptoms of Depression: The Real Barriers to COURSE 27 - CANCELLED Remission Kurt Kroenke, MD. COURSE 28 1:00 p.m.-5;00 p.m. B Neurochemical Systems Interfacing Physical and Room IE 12, Level 1, Javits Center Emotional Stressors Jon-Kar Zubieta, MD. CURRENT CONCEPTS IN CHILD AND ADOLESCENT EATING DISORDERS C Stress Effects on the Hippocampus: Relevance to Depression Director: Mae S. Sokol, M.D. Bruce S. McEwen, Ph.D. Faculty: Kristina Hoffman-Rieken, RJD. D Gender Considerations in the Treatment of Physical COURSE 29 1:00 p.m.-5;00 p.m. Symptoms of Depression Rooms 2D06/7, Level 2, Javits Center Vivien K. Burt, MD.

USING BOUNDARY CROSSINGS AS CREATIVE E Best Practices for Achieving Remission in Depression THERAPY INSTEAD OF SLIPPERY SLOPES With Physical Symptoms: Current and Future Trends John F. Greden, MX). Director: Gail E. Robinson, M.D. Faculty: Gary R. Schoener, Psy.D., Howard E. Book, MD., Linda M Jorgenson, J.D.

8 SUNDAY

INDUSTRY-SUPPORTED SYMPOSIUM 20 INDUSTRY-SUPPORTED SYMPOSIUM 22 1:30 p.m.-4:30 p.m. 1:30 p.m.-4:30 p.m. Empire Ballroom B/C/D, Ballroom Level, Grand Hyatt Broadway Ballroom, Sixth Floor, Marriott Marquis

BEYOND 5HT: NEW TREATMENTS FOR COMBINATION TFIERAPY: NEW STRATEGIES IN DEPRESSION THE MANAGEMENT OF SEVERE MENTAL Supported by Merck & Co., Inc. DISORDERS Supported fy A bhtt Laboratories Chp.: Jack M, Gorman, MJD. Chp.: Susan L. McElroy, M.D. A Combining Treatment to Enhance SSRI Response Jack M, Gorman, M.D. A Rational Combination Therapy Versus Irrational Polypharmacy B What to Do for SSRI Nonresponders? Susan L. McElroy, M.D. Michael E. Thase, M.D. B Combination Treatment for Acute Mania C The Relationship Between Substance P, 5HT, and Gary S. Sachs, M.D. Other Neurotransmitter Systems Linda L. Carpenter, M.D. C Management of Bipolar Depression: Combination Therapy Versus Monotherapy D Substance P Antagonists: Mechanism of Action and Robert MA Hrschfeld, M.D. Clinical Implications K. Ranga R. Krishnan, M.D. D Managing Bipolar Disorder in Children and Adolescents Karen D. Wagner, M.D. INDUSTRY-SUPPORTED SYMPOSIUM 21 1:30 p.m.-4:30 p.m. E Evidence for the Mechanisms and Efficacy of Grand Ballroom East, Third Floor, Hilton New York Anticonvulsants in the Treatment of Schizophrenia Henry A. Nasrallah, M.D. ARE ALL ATYPICAL ANTIPSYCHOTICS EQUAL FOR TREATMENT OF COGNITIVE AND AFFECTIVE INDUSTRY-SUPPORTED SYMPOSIUM 23 SYMPTOMS IN SCHIZOPHRENIA? 1:30 p.m.-4:30 p.m. Supported by Pfizer Inc. Imperial Ballroom A, Second Floor, Sheraton New York

Chp.: Stephen M, Stahl, M.D. UNMASKING BIPOLAR DISORDER: OVERCOMING THE BARRIERS TO TREATMENT SUCCESS A Schizophrenia: From Circuits to Symptoms Supported byjanssen Pharmtceutica and Research Foundation Stephen M. Stahl, M.D. Chp.: S. Nassir Ghaemi, M.D. B Effect of Atypical Antipsychotic Drugs on Cognition and Negative Symptoms A Bipolar Disorder: A National Health Concern Herbert Y. Meltzer, M.D. Roger S. Mclntyre, M.D.

C Optimal Health Outcomes in Schizophrenia B Redefining Mood Stabilizing Agents: Improved Jonathan M, Meyer, M.D. Treatment Options for Bipolar Disorder S. Nassir Ghaemi, M.D. D Maximizing Function in Patients With Schizophrenia Lili Kopala, M.D. C Safety Considerations in Treating the Bipolar Disorder Patient Prakash S. Masand, M.D.

D The Essential Role of Psychotherapy in Managing Bipolar Disorder Michael W. Otto, Ph.D.

9 SUNDAY 2:30 p.m. Session INTRODUCTION OF STAGE GUESTS INTRODUCTION OF CHAIRPERSON OF THE SCIENTIFIC PROGRAM COMMITTEE LECTURE 1 Geetha Jayaram, MD. 2:30 p.m.-4:QQ p.m. Chairperson, Armed Meeting SaenaficPKgam Camriaee Rooms 1EQ7/8, Level 1, Javits Center INTRODUCTION OF VISITING AAPL/APA'S MANFRED S. GUTTMACHER DIGNITARIES AWARD LECTURE PRESIDENTIAL ADDRESS Marcia Kraft Goin, MD. Margaret G. Spinelli, M.D. To be Btiviixgd by George M. Simpson, MX). Infanticide: The Hope of Prevention RESPONSE OF THE PRESIDENT-ELECT and the Promise of Saved Lives Michelle B.Riba, MD. TobeatxaiiKBlby Allan Tasman, MD. Chp.: Michael A. Norko, MD. ADJOURNMENT Margaret G. Spinelli, MX)., is Assistant Professor of Clinical Psychiatry, Columbia University College of Physicians and Surgeons; and Director of the Maternal 7:00 p.m. Sessions Mental Health Program, New York State Psychiatric Institute. Dr. Spinelli came to the field of perinatal psychiatry after a 15-year career as a nurse in Obstetrics INDUSTRY- SUP PORTED SYMPOS1A24-30 and Gynecology. She graduated from Cornell University Medical College in New York, and INDUSTRY-SUPPORTED SYMPOSIUM 24 completed her residency training in psychiatry at the 7:00 p.m.- 10:00 p.m. Payne Whitney Clinic/Cornell University/The New Special Events Hall ID, Level 1, Javits Center York Hospital. A clinical clerkship on the Mother- Infant Postpartum Unit of the Royal Maudsley and RECOVERING FROM SCHIZOPHRENIA: HOW Bethlem Hospital in London inspired her clinical TREATMENT CAN IMPROVE OUTCOMES AND philosophy. A career in academic and research PREVENT CHRONIdTY psychiatry followed a Postdoctoral Research Fellowship Supported by eli Lilly and Company at Columbia University College of Physicians and Surgeons and The New York State Psychiatric Chp.: Jeffrey A Lieberman, MD. Institute. Her area of NIMH Clinical Research includes Interpersonal Psychotherapy for Antepartum A Laboratory and Imaging Aids to Diagnosis and Depression. Her field of publications includes Assessment of Schizophrenia Pregnancy and Postpartum Psychiatric disorders, Aysenil Belger, PhD. Postpartum Psychosis, Infanticide, Neonaticide, Neurohormones and Mood. Dr. Spinelli's clinical work B Treating First-Episode Schizophrenia: Differential focuses on the treatment of women with psychiatric Effects of Atypical and Typical Antipsychotics on Brain disorders during pregnancy and posipartum periods. Pathomorphology She has testified in criminal cases of mentally 111 Jeffrey A Lieberman, MD. mothers who have killed dieir infants and works with Project Liberty 9/11 and the New York Police C Approaches to Improved Maintenance Treatment and Department. Relapse Prevention THIS SESSION WILL BE AUDIOTAPED. T. Scott Stroup, M.D.

D Psychiatric Rehabilitation 5:00 p.m. Session Robert E. Drake, MX).

OFFICIAL OPENING SESSION E Cognitive Improvement and Therapeutic Alliance Richard S.Keefe, PhD. 5:00p.m.-6:30p.m. Hal] 3E, Level 3, Javits Center CALL TO ORDER Marcia Kraft Coin, M.D., Pi&idem

10 SUNDAY

INDUSTRY-SUPPORTED SYMPOSIUM 25 INDUSTRY-SUPPORTED SYMPOSIUM 27 7:00 p.m.-10:00 p.m. 7:00 p.m.-10:00 p.m. Empire Ballroom B/C/D, Ballroom Level, Grand Hyatt Broadway Ballroom, Sixth Floor, Marriott Marquis

NOVEL INTERVENTION STRATEGIES ACROSS MODERATORS AND MEDIATORS OF THE SPECTRUM OF DEMENTIA: REAL PATIENTS ANTIDEPRESSANT RESPONSE AND REAL OUTCOMES Supported by Forest Laboratories, Inc. Supported by E isai, Inc. Chp.: Steven P. Roose, M.D. Chp.: Gary W. Small, MX). A Moderators and Mediators of Treatment Effects in A Identifying Early Dementia: Mild Cognitive Impairment Antidepressant Trials and Early-Stage Alzheimer's Disease Philip Lavori, Ph.D. P. Murali Doraiswamy, MX). B Gender as a Moderator of Antidepressant Response Susan G. Kornstein, MX). B Identifying and Treating Early Dementia: Case Studies Daniel D. Christensen, MX). C Moving the Goalposts: Is Response a Mediator of Remission? C Exploring Vascular Dementia: Diagnosis, Treatment, David J. Kupfer, M.D. and Behavior Helen Lavretsky, M.D. D Antidepressant Treatment Duration: The Decision to Continue or Switch Treatment D Exploring Differences Between Vascular Dementia and Harold A. Sackeim, Ph.D. Alzheimer's Disease: Case Studies Stephen P. Salloway, MX). E Placebo, Comparator, or Open Treatment? Design Counts E Defining and Achieving Positive Outcomes in Dementia Steven P. Roose, MX). Pharmacotherapy David Geldmacher, M.D. INDUSTRY-SUPPORTED SYMPOSIUM 28 7:00 p.m.-10:00 p.m. F Alzheimer's Disease Prevention: Strategies for Grand Ballroom, Mezzanine Level, Roosevelt Improving Brain and Memory Fitness Gary W. Small, MX). BEYOND SLEEP ONSET: NEW PERSPECTIVES ON THE TREATMENT OF INSOMNIA INDUSTRY-SUPPORTED SYMPOSIUM 26 Supported by Sepracor, Inc. 7:00 p.m.-10:00 p.m. Grand Ballroom East, Third Floor, Hilton New York Chp.: Andrew D. Krystal, MX).

EFFECTIVE LONG-TERM MANAGEMENT OF A Prevalence and Impact of Insomnia: Treating the Entire SCHIZOPHRENIA: REAL-WORLD Insomnia Syndrome CONSIDERATIONS Mugdha E. Thakur, MX). Supported by Bristol-Myers Squibb Company B Differential Diagnosis of Insomnia and Comorbid Chp.: John M. Kane, M.D. Conditions: Importance of Sleep History Jed E. Black, M.D. A The Evolution of Antipsychotic Agents: A Mechanism- Based Review C Measures of Treatment Efficacy Anissa Abi-Dargham, MX). Thomas Roth, Ph.D.

B Optimizing the Long-Term Effectiveness of D Overview of Insomnia Treatment Antipsychotic Therapy Andrew D. Krystal, MX). Stephen R. Marder, MX).

C Managing Patients With Treatment-Resistant Schizophrenia John M. Kane, M.D.

D What Is Effectiveness With Medications? Peter J. Weiden, M.D.

11 SUNDAY

INDUSTRY-SUPPORTED SYMPOSIUM 29 C Strategies for Maintenance Pharmacotherapy: High, 7:00 p.m.-10:00 p.m. Low, or Switch? Imperial Ballroom A, Second Floor, Sheraton New York Peter F. Buckley, M.D.

PSYCHOPHARMACOLOGY AND REPRODUCTIVE D Administration of Atypicals in Bipolar Disorder TRANSITIONS: IMPACT OF PSYCHOTROPIC Claudia F. Baldassano, M.D. MEDICATIONS AND SEX HORMONES ON BRAIN FUNCTIONING, WEIGHT, AND REPRODUCTIVE E Is Polypharmacy the Result of Confused Dosing SAFETY Strategies for Atypical Antipsychotics? Supported by GlaxoSnithKLine Alexander L. Miller, MX).

Chp.: Claudio N. Scares, M.D. Co-Chp.: Mary Blehar, Ph.D.

A Labeling Products for Use in Pregnancy: Moving Forward Sandra L. Kweder, M.D.

B Weight Gain, Psychotropic Medications, and Gender: Potential Pharmacologic Strategies Barbara L. Gracious, M.D.

C Testosterone Decline in the Aging Male: Does Andropause Exist9 Stuart N. Seidman, M.D.

D Perimenopause-Related Mood Disturbance: An Update on Risk Factors and Novel Treatment Strategies Available Claudio N. Scares, M.D.

E Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study Updates Sally A Shumaker, Ph.D., Qaudine Legault, Ph.D., Stephen K Rapp, Ph.D.

Discussant: William Harlan, MX).

INDUSTRY-SUPPORTED SYMPOSIUM 30 7:00 p.m.-10:00 p.m. Imperial Ballroom B, Second Floor, Sheraton New York

CHOOSING THE RIGHT DOSE OF ATYPICAL ANTIPSYCHOTICS: ART OR SCIENCE? Supported byAstraZeneca Pharmaceuticals

Chp.: Peter F. Buckley, M.D.

A Dosing With Atypicals: Receptor Occupancy as a Guide to Titration and Maintenance Shitij Kapur, M.D.

B Acute Stabilization of Psychosis: Options and Approaches K.N. Roy Chengappa, MX).

12 MONDAY, MAY 3, 2004 157TH ANNUAL MEE TING

A Differential Diagnosis of Bipolar Disorder. Clinical 7:00 a.m. Sessions Findings Stephan H Heckers, M.D. PART ! OF INDUSTRY-SLTl-'OK'i F«: BREAKFAST SYMPOSIA .31 35 B Recognizing Bipolar Disorder in Children and Adolescents INDUSTRY-SUPPORTED BREAKFAST Gabrielle Carlson, M.D. SYMPOSIUM 31, PART 1 7:00 a.m.-8:30 a.m. C Bipolarity in Old Age: Diagnostic and Management Grand Ballroom East, Third Floor, Hilton New York Issues Kenneth I. Shulman, M.D. NEW ADVANCES IN THE TREATMENT OF PSYCHOSIS INDUSTRY-SUPPORTED BREAKFAST Supported by Bristol-Myers Squibb Company SYMPOSIUM 34, PART 1 7:00 a.m.-8:30 a.m. Chp.: Robert E. Hales, M.D. Imperial Ballroom A, Second Floor, Sheraton New York Co-Chp.: Stuart C Yudofsky, M.D. EVIDENCE-BASED MEDICINE: THE NEXT A Psychosis Associated With Dementia: Efficacy of the GENERATION Newer Antipsychotics Supported by Wyeth Pharmaceuticals Dilip V. Jeste, M.D. Chp.: K. Ranga R Krishnan, M.D. B Antipsychotic Therapies in Pediatric Patients: The Importance of Safety and Tolerability A How to Make Judgments Under Uncertainty Robert L. Findling, M.D. K. Ranga R. Krishnan, M.D.

INDUSTRY-SUPPORTED BREAKFAST B Improving Outcomes in Anxiety Disorders SYMPOSIUM 32, PART 1 NickFreemantle, Ph.D. 7:00 a.m.-8:30 a.m. Westside Ballroom 3-4, Fifth Floor, Marriott Marquis C Study Designs and Outcome in Antidepressant Clinical Trials CURRENT ALZHEIMER'S DISEASE TREATMENTS Arifulla Khan, M.D., Shirin R.F. Khan, B.S., AND BEYOND: ADVANCES IMPACTING CLINICAL Russel Korts, Ph.D., Michael E. Thase, M.D., PRACTICE Walter A Brown, M.D. Supported by Forest L aboratories, Inc. INDUSTRY-SUPPORTED BREAKFAST Chp.: Trey Sunderland, M.D. SYMPOSIUM 35, PART 1 7:00 a.m.-8:30 a.m. A The Molecular Genetics of Alzheimer's Disease Imperial Ballroom B, Second Floor, Sheraton New York Rudolph Tanzi, Ph.D. TRANSCENDING EFFICACY: EFFECTIVE B Diversity of Neuropsychiatric Impairment: Cognitive TREATMENT OF PSYCHOSIS ACROSS DISORDERS and Behavioral Implications Supported byAstraZeneca Pharmaceuticals JeffreyL. Cummings, M.D. Chp.: Pierre N. Tariot, M.D. INDUSTRY-SUPPORTED BREAKFAST Co-Chp.: John W. Newcomer, M.D. SYMPOSIUM 33, PART 1 7:00 a.m.-8:30 a.m. A Managing Psychosis and Agitation in Dementia Broadway Ballroom, Sixth Floor, Marriott Marquis J. Michael Ryan, M.D.

RECOGNIZING THE MANY FACES OF BIPOLAR B Movement Disorders in the Elderly: How Safe Are the DISORDER Atypical Neuroleptics? Supported by Eli Lilly and Company Richard N. Trosch, M.D.

Chp.: Bruce M. Cohen, M.D. C Lewy Body Dementia: What the Psychiatrist Needs to Know Andrius Baskys, M.D. 13 MONDAY

RESIDENT'S SESSION COURSE 35 8:00 a.m.-12 noon 7:00 a.m.-8:30 a.m. Gramercy A, Second Floor, Hilton New York Versailles Ballroom, Second Floor, Sheraton New York THE PSYCHIATRIST AS EXPERT WITNESS MEET THE EXPERTS: SUNNY-SIDE UP Director: Phillip J. Resnick, MD. Chp.: Marcia Kraft Coin, MD. Co-Chp.: Michelle B. Riba, MD. COURSE 36 8:00 a.m.-12 noon Gramercy B, Second Floor, Hilton New York At this breakfast, nationally recognized "experts" will sit at tables with small groups of residents and discuss a variety of career CURRENT CPT CODING AND DOCUMENTATION issues and opportunities in psychiatry. Topic areas include: REQUIREMENTS Addiction/Substance Abuse, ATDS/HTV, Child and Adolescent Psychiatry, Consultation-Liaison, Cultural Competence, Forensic, Law Co-Directors: Chester W. Schmidt, Jr., MD., Tracy R and Ethics in Psychiatry, Geriatric, Medical Student Issues, Public and Gordy, MD. Community Mental Health, Professional and Leadership Development, Psychodynamic Psychotherapy, and Research in COURSE 37 8:00 a.m.-12 noon Psychiatry. Nassau Suite A, Second Floor, Hilton New York

FAMILIES COPING WITH MEDICAL ILLNESS: AN 8:00 a.m. Sessions INTEGRATIVE TREATMENT APPROACH Director: John S. Rolland, MD. COURSES 32-40 Course descriptions are available in the CME COURSE 38 8:00 a.m.-12 noon Course Brochure included in your registration Rhinelander Gallery North/Center, Second Floor, Hilton packet Admission by ticket only. New York

ADVANCED ASSESSMENT AND TREATMENT OF COURSE 32 8:00 a.m.-12 noon ADD Concourse B, Concourse Level, Hilton New York Director: Thomas E. Brown, Ph.D. IRRESISTIBLE SLEEP: NARCOLEPSY UPDATE Faculty: Jefferson B. Prince, MD.

Director: Lois E. Krahn, MD. COURSE 39 8:00 a.m.-12 noon Faculty: Steven I. Altchuler, M.D., MarkR Hansen, MD., Sutton North, Second Floor, Hilton New York Jarrett W. Richardson, MD. ECT PRACTICE UPDATE COURSE 33 8:00 a.m.-12 noon Concourse E, Concourse Level, Hilton New York Director Charles H Kellner, MD. Faculty: Richard L. Jaffe, MD., W. Vaughn McCall, MD., RECOVERY FROM MENTAL ILLNESS AND STIGMA: Richard D. Weiner, MD. INTEGRATING MEDICINE AND REHABILITATION COURSE 40 8:00 a.m.-12 noon Co-Directors: Eugene A Oulvey, Ph.D., Karen L. Lee, MA Sutton Center, Second Floor, Hilton New York Faculty: Vivek Jain, MD., Shyam K. Bhat, MD., Denise Sommers, MA., Thomas O. Osinowo, MD. COGNITIVE-BEHAVIOR THERAPY FOR ADULT AND PEDIATRIC OCD: THE BASICS COURSE 34 8:00 a.m.-12 noon Concourse G, Concourse Level, Hilton New York Co-Directors: Jonathan Abramowitz, Ph.D., Stephen Whiteside,Ph.D. DRUG TREATMENT OF SCHIZOPHRENIA

Director: Philip G. Janicak, MD. Faculty: Stephen R. Marder, M.D., Rajiv Tandon, MD., Morris B. Goldman, MD.

14 MONDAY

9:00 a.m. Sessions COURSE 43 9:00 a.m.-4:00 p.m. Murray Hill B, Second Floor, Hilton New York

CLINICAL CASE CONFERENCE i DAVANLOO'S INTENSIVE SHORT-TERM DYNAMIC 9:00 a.m.-10:30 a.m. PSYCHOTHERAPY IN CLINICAL PRACTICE Rooms 3D06/7, Level 3, Javits Center Director. James Q. Schubmehl, MX). BOUNDARY ISSUES AND THE CHALLENGE OF Faculty: Alan R Beeber, MX)., Tewfik Said, MX). THE SOMATIZING PATIENT

COURSE 44 9:00 a.m.-4:00 p.m. Moderator James L. Levenson, MX). Nassau Suite B, Second Floor, Hilton New York Presenter. Catherine C Crone, M.D. ADVANCED HYPNOSIS: APPLICATIONS IN THIS SESSION IS OPEN TO APAMEMBERS ONLY. PSYCHIATRY BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR Director: Jose R Maldonado, MX). ADMITTANCE. Faculty: David Spiegel, MX)., Matthew May, MX)., Herbert Spiegel, M.D., Marcia Greenleaf, Ph.D. CONTINUOUS CLINICAL C^L CONFERENCE 1: PART 1 DEB./VH;: 9:00 a.m.-12 noon 9:00 a.m.-10:30 a.m. Rooms 3D01/12, Level 3, Javits Center Room IE 10, Level 1, Javits Center HELPING PATIENTS COUNTER RESOLVED: THE RRC SHOULD CONTINUE TO DEMORALIZATION WHILE LIVING WITH A REQUIRE THAT PSYCHIATRIC RESIDENCY CHRONIC OR RECURRENT PSYCHIATRIC ILLNESS PROGRAMS MUST DEMONSTRATE THAT THE RESIDENTS HAVE ACHIEVED COMPETENCY IN Moderator: James L. Griffith, M.D. PSYCHODYNAMIC PSYCHOTHERAPY Presenters: Lynne M. Gaby, MX)., Julia B. Frank, MX)., Robert W. Keisling, MX)., Jeffrey S. Akman, MX). Moderator. Sheila Judge, MX). Affirmative: Allan Tasrnan, MX)., Lisa A. Mellman, M.D. THIS SESSION IS OPEN TO APAMEMBERS ONLY. Negative: Joel Yager, MX)., Eugene H. Rubin, MX). BLUE REGISTRATION BADGE OR APA THIS SESSION WILL BE AUDIOTAPED. MEMBERSHIP CARD REQUIRED FOR ADMITTANCE. DISCUSSION GROUPS 1-4

9:00 a.m.-10:30 a.m. COURSES 41-44 Course descriptions are available in the CME These sessions are limited to 25 participants on a first- Course Brochure included in your registration come, first-served basis. packet. Admission by ticket only. 1 Jonathan M. Meyer, M.D., on the Medical Care for the COURSE 41 9:00 a.m.-4:00 p.m. Chronically Mentally 111: The Role of the Psychiatrist Clinton Suite, Second Floor, Hilton New York (Meet the Authors) Rooms 2D02/3, Level 2, Javits Center MONEY MATTERS I: USING THEORY IN CLINICAL PRACTICE 2 Robert Michels, M.D., on Who Should Be Psychoanalyzed? Director: Cecilia M. Mikalac, MX). Rooms 2D04/5, Level 2, Javits Center 9:00 a.m.-4:00 p.m. COURSE 42 3 Robert R. Conley, M.D., on What Is the Best Medication Murray Hill A, Second Floor, Hilton New York for People Suffering From Schizophrenia? Rooms 2D06/7, Level 2, Javits Center TRAUMATIC BRAIN INJURY: NEUROPSYCHIATRIC ASSESSMENT 4 Larry E. Tune, M.D., on Dementia and Delirium Director. Robert P. Granacher, Jr., M.D. Room 2D08, Level 2, Javits Center

15 MONDAY rxx vs i.ivi SFSMC >\ i the Research Foundation for Mental Hygiene, Inc. Dr. Greengard received his doctorate in biophysics at Johns 9:CO a.m.-10:30 a.m. Hopkins University in Baltimore and received Room IE 14, Level 1, Javits Center advanced training in brain biochemistry at the University of London and at the National Institute of Moderator: Deborah]. Miles, M.D., Mark H. Rapaport, M.D. Medical Research in London. Presenters: Laura W. Robens, M.D., Paul S. Appelbaum. M.D., Frontiers of Science Lecture Series on Forensic and Ethical Issues in Psychiatry THIS SESSION WILL BE AUDIOTAPED.

Expert clinicians, who served as the guest editors of the first two issues of f-oae, will lead lively multiple-choice, question-based LECTURE 3 discussions. This session covers Forensic and Ethical Issues in Psychiatry, the second session at 11:00 a.m. covers PTSD and 9:00 a.m.-10:30 a.m. Anxiety Disorders, and the third session at 2:00 p.m. covers Room IE 15, Level 1, Javits Center Schizophrenia and CXher Psychotic Disorders. Presented with multiple-choice questions, participants will test their knowledge with an interactive audience response system, which instantly APA'S BENJAMIN RUSH AWARD LECTURE presents the audience responses as a histogram on the screen. Each participant is able to take a self-assessment exam with David Mechanic, Ph.D. answers and discussion led by the expert faculty. The Changing Face of Mental Health Services

Li-'.', "i'i Hi s ?-4 Chp.: Avram H. Mack, M.D. David Mechanic, Ph.D., examines changing patterns of LECTURE 2 mental health services, with a focus on the contribution of managed behavioral health care to the shaping of 9:00 a.m.-10:30 a.m. professional practice and delivery of services, Rooms 1E07/8, Level 1, Javits Center particularly for persons with senous mental illness and those receiving behavioral health care through Paul Grcengard, PruD. Medicaid. Dr. Mechanic is Rene Dubos University Professor of Behavioral Sciences and Founder and Signal Integration in the Brain Director of the Institute for Health, Health Care Policy, CalLibomttie Session Wub the National Institute and Aging Research at Rutgers University in New an Drug A bice Brunswick, New Jersey. He is the author of more than 400 research articles and book chapters and the author Clip.: Satish C Varma, M.D. or editor of 24 books, including Insatpatte Decisions: Tlx Co-Chp.: Marianne T. Guschwan, M.D. InferattiK cfHeahh R^arm and Mental Health ani Soaal Pdicy The Errergra? cfManzgd Gm. A member of the Paul Greengard, PLD., is the Vincent Astor Professor National Academy of Sciences, the American Academy and Head of the Laboratory of Molecular and Cellular of Arts and Sciences, and the Institute of Medicine, Neuroscience at the Rockefeller University in New Dr. Mechanic has received numerous awards, including York City. In 2000, Dr. Greengard received the Nobel the Distinguished Career Award, the Lifetime Prize in Physiology or Medicine for his discovery of Contributions Award in Mental Health from the how dopamine and other neurotransminers exert their American Sociological Association, the Rema Lapouse action in the nervous system. A member of the U.S. Award, the first Carl Taube Award for Distinguished National Academy of Sciences and the Institute of Contributions to Mental Health Services Research from Medicine, Dr. Greengard is the recipient of numerous the American Public Health Association, and the other honors, including the Metropolitan Life Baxter Health Services Research Pnze. Dr. Mechanic Foundation Award for Medical Research, the Charles received his doctorate in sociology from Stanford A. Dana Award for Pioneering Achievements in University in Stanford, California. Health, the Lieber Prize for Outstanding Achievement THIS SESSION WILL BE AUDIOTAPED. in Schizophrenia Research, and the National Academy of Sciences Award in the Neurosciences. Dr. Greengard is the Founder and Senes Editor of Adu&as in Buxhemcal Psydxpharrrncdcgy and A ckanas m Cyrix Nitdectide and Pmtetn Phxpharylaticn Research. He is a member of the Scientific Council of the National Alliance for Research on Schizophrenia and Depression and a member of the Board of Directors of

16 MONDAY

LECTURE 4 ',: .-'!>:5"-.r ARCH VJl NXi INVESTIGATORS' x. * -/ : \-,or-., ; 9:00 a.m.-10:30 a.m. 9:00 a.m.-10:30 a.m. Hall 3E, Level 3, Javits Center Galleria, Level 4, Javits Center Sri Sri Ravi Shankar For further information on New Research Sessions, please refer to the New Research Program Bock included in your registration Psychiatry and Spirituality: A Holistic Perspective packet. Chp.: Richard P. Brown, MX). Co-Chp.: Geetha Jayaram, M.D. WORKSHOPS Sri Sri Ravi Shankar, a humanitarian teacher, .OM?" v- rvrs} V; philosopher, and spiritual leader, was born in 1956 in Papanasum, a village in south India. He completed COMPONENT WORKSHOP 1 9:00 a.m.-10:30 a.m. advanced degrees in modern science and Vedic studies by age 17 years. In 1982 he began to teach Sudarshan Room 1D06, Level 1, Javits Center Kriya, a yogic breath technique that reduces stress, anxiety, and depression and promotes health. HOW TO TEACH AND LEARN CULTURAL Sudarshan Kriya is now taught in more than 100 COMPETENCE IN GERIATRIC PSYCHIATRY countries as part of the Art of Living Course. In the APA Committee on Ethnic Minority Elderly late 1990s, the Sudarshan Kriya technique gained increased recognition when additional medical studies Chp.: Iqbal Ahmed, M.D. confirming its benefits were published. Sri Sri Ravi Participants: Warachal E. Faison, M.D., Walter P. Bland, MX)., Shankar created the Art of Living Foundation, which Kenneth M. Sakauye, MX)., Angela L. Guerrero, MX). offers programs around the world to eliminate stress, COMPONENT WORKSHOP 2 9:00 a.m.-10:30 a.m. restore human values, and encourage people from all Rooms 1E01/2, Level 1, Javits Center backgrounds to join in service to humanity. He is also a founding member of the International Association CAN'T WORK, SHOULDN'T WORK, MUSTN'T for Human Values. Sri Sri Ravi Shankar has addressed WORK: ASSESSING FUNCTION AND MENTAL large audiences at universities and institutions around IMPAIRMENT IN PSYCHIATRIC ILLNESS the world, including the World Economic Forum, the APA Corresponding Committee on Psychiatry in the Workplace International Conference of Human Values and Spiritual Regeneration, and the United Nations Chp.: Marcia A. Scott, M.D. Millennium World Peace Summit of Religious and Participants: Andrea G. Stolar, MX)., Steven E. Pflanz, MX). Spiritual Leaders. He is the author of several books, including Wisdom for the New Millennium. COMPONENT WORKSHOP 3 9:00 a.m.-10:30 a.m. International Psychiatrist Lecture Series Rooms 1E03/4/5, Level 1, Javits Center

MASTER EDUCATOR CLINICAL PUBLIC HEALTH AND MENTAL HEALTH PARTNERSHIP IN TERRORISM AND DISASTERS CONSULTATIONS 1-2 APA ComnitteemPsydjiatricDinEnsionstf

9:00 a.m.-10:30 a.m. Chp.: Robert). Ursano, MX). Participants: Carol S. North, MX)., Dori B. Reissman, MX). These sessions are limited to 25 participants on a first- come, first-served basis. COMPONENT WORKSHOP 4 9:00 a.m.-10:30 a.m. Room 1E09, Level 1, Javits Center 1 John C Racy, M.D., on Treating One's Students and Colleagues: The Eternal Challenge of Boundaries CHILD SOLDIERS: CHILD VICTIMS OF WAR AND Room 1D04, Level 1, Javits Center TERRORISM: PSYCHOSOdAL AND SPIRITUAL NEEDS 2 Eugene V. Beresin, M.D., on Evaluation and Treatment of APA Alliance Eating Disorders Room 1D05, Level 1, Javits Center Co-Chps.: Mohammad Shafii, MX)., Rosalind Hayes, B.A. Participants: Chet Lowe, M.A., Jon A. Shaw, MX)., Peter Moszynski, M.A. THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE. 17 MONDAY

COMPONENT WORKSHOP 5 9;00 a.m.-10;30 a.m. COMPONENT WORKSHOP 10 9:00 a.m.-10:30 a.m. Rooms 2D10/11, Level 2, Javits Center Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis

CAREER CHOICES IN PSYCHIATRY: EXPLORING BRIDGING ACROSS CULTURE AND GENERATIONS: FELLOWSHIP TRAINING AN ASIAN-AMERICAN PERSPECTIVE A PA A ssemtty Committee of A rea Member-in- Training Representatives APA ComnitteeofAsianrAnericanPsychiatrists

Chp.: Thor J. Cornelius, M.D. Chp.: Eric G Li, M.D. Participants: David M. Gellerman, M.D., Richard A Participants: Yujuan Choy, M.D., John S. Luo, M.D., Montgomery, MD., Charles V. Panadero, MD., Shauna P. Salman Akhtar, M.D., Surinder S. Nand, M.D. Reinblatt, M.D. COMPONENT WORKSHOP 11 9:00 a.m.-10:30 a.m. COMPONENT WORKSHOP 6 9:00 a.m.-10:30 a.m. Marquis Ballroom Salons A/B, Ninth Floor, Marriott Rooms 2D12/13, Level 2, Javits Center Marquis

FACILITATING RESEARCH ON MINORITY VAMENTAL HEALTH'S RESPONSE TO TERRORISM POPULATIONS BY MINORITY RESEARCHERS APA Caucus afVA Psychiatrists A PA Assembly Committee cfRepresentatiiES cf Minority/ Uriderrepreserited Groups Co-Chps.: Albert G Gaw, M.D., Patricia L Ordorica, M.D. Participants: Laurent S. Lehmann, M.D., Matthew J. Chp.: Jagannathan Srinivasaraghavan, M.D. Friedman, M.D., Harold S. Kudler, M.D., Mara Kushner, GS.W. Participants: Renato D. Alarcon, M.D., Mantosh J. Dewan, M.D., Roger D. Walker, M.D., Tana A Grady-Weliky,MD. ISSUES 1-18

COMPONENT WORKSHOP 7 9:00 a.m.-10:30 a.m. ISSUE WORKSHOP 1 9:00 a.m.-10:30 a.m. Odets Room, Fourth Floor, Marriott Marquis Room IE 11, Level 1, Javits Center

STATE HOSPITAL PSYCHIATRY: BEEN DOWN SO DISRUPTIVE EMPLOYEES: FEEDBACK-ASSISTED LONG IT LOOKS LIKE UP TO ME COUNSELING AND TREATMENT APA Caucus of'State HospitalPsychiatrists and A nvrican Association cf Psychiatric A dninistratars Co-Chps.: Eva G Ritvo, M.D., Gonzalo F. Quesada, M.D. Participant: Larry Harmon, Ph.D. Co-Chps.: Yad M. Jabbarpour, M.D., Beatrice M. Kovasznay, M.D. ISSUE WORKSHOP 2 9:00 a.m.-10:30 a.m. Participants: JeffreyL. Geller, M.D., Michael F. Hogan, Ph.D., Room IE 12, Level 1, Javits Center Kris A McLoughlin, M.S.N. THE OFFICE OF THE FUTURE: TECHNOLOGY IN COMPONENT WORKSHOP 8 9:00 a.m.-10:30 a.m. PSYCHIATRY O'Neill Room, Fourth Floor, Marriott Marquis A rrericanA sscdationfor Technology in Psychiatry

LEADERSHIP SKILLS FOR PUBLIC ADVOCACY Co-Chps.: Robert C Hsiung, M.D., Ronnie S. Stangler, M.D. APA Committee on Public Affairs Participants: Seth M. Powsner, M.D., Daniel A Deutschman, M.D., Michael Bauer, M.D. Chp.: MaryH Davis, M.D. Participants: Nicholas Myers, B.S.G, Ericka L. Goodwin, M.D. ISSUE WORKSHOP 3 9:00 a.m.-10:30 a.m. Room IE 13, Level 1, Javits Center COMPONENT WORKSHOP 9 9:00 a.m.-10:30 a.m. Ziegfeld Room, Fourth Floor, Marriott Marquis E, K, AND GHB: THE NEW ABCS OF SUBSTANCE ABUSE MISSION POSSIBLE: THE SCIENCE OF CcttaboratiiE Session With the National Institute on Drug A buse PSYCHIATRY AND THE ART OF ADVOCACY APA Committee onDevdopmental Disabilities Chp.: Richard N. Rosenthal, M.D. Participants: Ramon Solhkhah, M.D., Petros Levounis, M.D. Chp.: Donald J. Mordecai, M.D. Participants: Jeremy Veenstra-VanderWeele, M.D., Bryan H, King, M.D., Lee Combrinck-Graham, M.D., Mark Combrinck- Hertz

18 MONDAY

ISSUE WORKSHOP 4 9:00 a.m.-10:30 a.m. ISSUE WORKSHOP 10 9:00 a.m.-10:30 a.m. Room IE 16, Level 1, Javits Center Wilder Room, Fourth Floor, Marriott Marquis

FUNCTIONAL IMAGING IN COURT: USES AND CAN EARLY INTERVENTION PREVENT CONTROVERSIES PSYCHOSIS? MANAGEMENT OF THE PRODROMAL PHASE Chp.: Daniel G. Amen, M.D. Participants: Joseph C Wu, M.D., Steven E. Rudolph, D.O., Chp.: Clarice J. Kestenbaum, M.D. Harold J. Bursztajn, M.D. Participants: Eric R. Marcus, M.D., Ian E. Alger, M.D., Lewis A. Opler, M.D. ISSUE WORKSHOP 5 9:00 a.m.-10:30 a.m. Rooms 2D14/15, Level 2, Javits Center ISSUE WORKSHOP 11 9:00 a.m.-10:30 a.m. Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis REINVENTING CAREERS: TRANSITIONS AND LATER-LIFE STRATEGIES FOR PSYCHIATRISTS DETOXIFICATION OF THE OPIOID-DEPENDENT CHRONIOPAIN PATIENT Chp.: Carolyn B. Robinowitz, M.D. Participants: Carol G Nadelson, M.D., Edward Hanin, M.D., Chp.: Jon M. Streltzer, M.D. Mary V. Seeman, M.D. Participants: Carl R. Sullivan, M.D., Thomas R. Kosten, M.D., Brian Johnson, M.D. ISSUE WORKSHOP 6 9:00 a.m.-10:30 a.m. Room 3D02/11, Level 3, Javits Center ISSUE WORKSHOP 12 9:00 a.m.-10:30 a.m. Booth/Edison Rooms, Fifth Floor, Marriott Marquis DRUG ABUSE AND SUICIDAL BEHAVIOR Collaborative Session With the National Institute en Drug A buse DEATH BY SUICIDE: THE WORDS OF THOSE LEFT BEHIND Chp.: Eric D. Caine, M.D. Participants: Richard K. Ries, M.D., David B. Goldston, Ph.D., Chp.: Michael F. Myers, M.D. Marsha M. Linehan, Ph.D., Gregory Brown, Ph.D. Participants: James E. Barrett, Carla Fine, M.S., Michelle M. Barwell, M.D. ISSUE WORKSHOP 7 9:00 a.m.-10:30 a.m. Room 3D03/10, Level 3, Javits Center ISSUE WORKSHOP 13 9:00 a.m.-10:30 a.m. Imperial/Julliard Rooms, Fifth Floor, Marriott Marquis THE BENZODIAZEPINE CONTROVERSY REVISITED THE AFTER-DEATH TELEPHONE CALL TO FAMILY MEMBERS: CLINICAL PERSPECTIVES Chp.: Christopher K. Chung, M.D. Participants: Dean M. De Crisce, M.D., John W. Tsuang, M.D., Co-Chps.: Sheila M. Loboprabhu, M.D., James W. Richardo Medoza, M.D., Karl S. Burgoyne, M.D. Lomax II, M.D. Participant: Jennifer E. Pate, M.D. ISSUE WORKSHOP 8 9:00 a.m.-10:30 a.m. Rooms 3D04/9, Level 3, Javits Center ISSUE WORKSHOP 14 9:00 a.m.-10:30 a.m. Plymouth/Uris/Shubert Rooms, Sixth Floor, Marriott ARE THERE LIMITS TO BOUNDARY LIMITS? Marquis

Chp.: Malkah T. Notman, M.D. EARLY TRAUMA, PTSD, AND HIV: ASSOCIATION Participants: Elissa P. Benedek, M.D., Linda M. WITH TRANSMISSION AND NONADHERENCE Jorgenson, J.D., Carl P. Malmquist, M.D., Lawrence B. Inderbitzin, M.D. Co-Chps.: Mary Ann Cohen, M.D., JackM, Gorman, M.D. Participants: Rosalind G. Hoffman, M.D., Heidi E. ISSUE WORKSHOP 9 9:00 a.m.-10:30 a.m. Hutton, Ph.D., Glenn J. Treisman, M.D., Jeffrey Weiss, Ph.D. Rooms 3D05/8, Level 3, Javits Center ISSUE WORKSHOP 15 9:00 a.m.-10:30 a.m. BROOKLYN MENTAL HEALTH COURT: FELONY Columbia/Duffy Rooms, Seventh Floor, Marriott Marquis OFFENDERS WITH MENTAL ILLNESS RESPONDING TO THE IMPACT OF SUICIDE ON Co-Chps.: Nancy J. Needell, M.D., Carol Fisler, J.D. CLINICIANS Participants: Matthew D "Ernie, J.D., Lucille Jackson, M.S.W., Kelly OKeefe, M.P.H., David Kelly, J.D., Mary Beth Chp.: Eric M, Plakun, M.D. Anderson, J.D., Lisa Schreibersdorf, J.D. Participants: Jane G. Tillman, Ph.D., Edward R. Shapiro, M.D. 19 MONDAY

ISSUE WORKSHOP 16 9:00 a.m.-10:30 a.m. Empire/Hudson Rooms, Seventh Floor, Marriott Marquis 10:30 a.m. Session

COCAINE AND TOBACCO USE DURING ADVANCES IN RESEARCH PREGNANCY: ADVERSE OUTCOMES IN 10:30 a.m.-12:30 p.m. OFFSPRING Special Events Hall ID, Level 1, Javits Center Collaboratiw Session With the National Institute on Drug A buse FRONTIERS IN THE TREATMENT OF Chp.: Vincent L. Smeriglio, Ph.D. PSYCHIATRIC DISORDERS Participants: Linda C Mayes, M.D., Barry M. Lester, Ph.D., APA Sderiti/kPro^amComritteeandAPA Council on Research Lauren S. Wakschlag, Ph.D., Daniel Pine, M.D. Chp.: Herbert Pardes, M.D. ISSUE WORKSHOP 17 9:00 a.m.-10:30 a.m. Co-Chps.: John F. Greden, M.D., Geetha Jayaram, M.D. Herald/Soho Rooms, Seventh Floor, Marriott Marquis Participants: Gerald Nestadt, M.D., on Epidemiology and CONTROVERSIES AT THE INTERFACE BETWEEN Treatment Implications of Personality Disorders RELIGION AND PSYCHIATRIC PRACTICE Anthony F. Lehman, M.D., on Evidence-Based Treatment in Schizophrenia Co-Chps.: Allan M. Josephson, M.D., John R, Peteet, M.D. John S. March, M.D., on Treatment of Child Adolescent Participants: Yousef Abou-AUaban, M.D., Irving S. Anxiety and Depression: What Have We Learned? Wiesner, M.D., Nalini V. Juthani, M.D. Yvette I. Sheline, M.D., on Hippocampal Volume in Major Depression: Effect of Antidepressant Treatment ISSUE WORKSHOP 18 9:00 a.m.-10:30 a.m. THIS SESSION WILL BE AUDIOTAPED. Cantor/Jolson Rooms, Ninth Floor, Marriott Marquis

PSYCHIATRIC RESEARCH PERSPECTIVES IN LATIN AMERICA 11:00 a,m. Sessions

Co-Chps.: Rodrigo A. Munoz, M.D., Pedro Ruiz, M.D. DISCUSSION GROUPS 5-9 Participants: Javier I. Escobar, M.D., Nora D. Volkow, M.D., Rodolfo D. Fahrer, M.D., Gerardo Heinze, M.D., Jose M. 11:00 a.m.-12:30 p.m. Caldas de Almeida, M.D. These sessions are limited to 25 participants on a first- come, first-served basis.

MEDIA 1-2 5 Gregory E. Gray, M.D., on Evidence-Based Psychiatry (Meet the Authors) MEDIA WORKSHOP 1 9:00 a.m.-12 noon Rooms 2D02/3, Level 2, Javits Center 1E06, Level 1, Javits Center 6 Paul R. McHugh, M.D., on the Future Structure of Drummer Boy Psychiatric Classification and Its Role in Enhancing Therapy, Teaching, and Research Chp.: David L. Dawson, M.D. Rooms 2D04/5, Level 2, Javits Center

MEDIA WORKSHOP 2 9:00 a.m.-12 noon 7 Eric R. Marcus, M.D., on Untying the Gordian Knot: Room IE 17, Level 1, Javits Center Comorbid Bipolar II Illness and Personality Disorders Rooms 2D06/7, Level 2, Javits Center The Movie Traffic Hollywood, Teen Substance Abuse, and U.S. Drug Policy 8 Constantine Lyketsos, M.D., on Depression in Alzheimer's and Other Neurologic Conditions: Evaluation Co-Chps.: Steven E. Hyler, M.D., Isabel Burk, M.S. and Treatment Room 2D08, Level 2, Javits Center

9 Glenn J. Treisman, M.D., on HIV (ForResidents Only) Versailles Terrace, Second Floor, Sheraton New York

20 MONDAY

1 (,X"i.:s MM si ^it >x LECTURE 6

11:00 a.m.-12:30 p.m. 11:00 a.m.-12:30 p.m. Room IE 14, Level 1, javits Center Room IE 15, Level 1, Javits Center

Moderators: Deborah]. Hales, M.D., MarkH. Rapaport, M.D. Julien Mendlewicz, M.D. Prcsenten Jonathan R.T. Davidson, M.D., on PTSD and Anxiety Disorders: Test Your Knowledge The Search for Genes of Bipolar Disorder From Classical Genetics to Novel Molecular Targets Expert clinicians, who served as the guest editors of the first two issues of Focus, will lead lively multiple-choice, question-based Chp.: Lewis L. Judd, MD. discussions. This session covers PTSD and Amety Disorders, Co-Chp: K. RoyMacKenzie, MD. the first session at 9:00 a.m. covers Forensic and Ethical Isues in Psychiatry, and the third session at 2:00 p.m. covers Julien Mendlewicz, MX)., is Professor of Psychiatry on Schizophrienia and Other Psychotic Disorders. Presented with the Faculties of Medicine, Psychology, and Law at the multiple-choice questions, participants will test their knowledge University of Brussels in Brussels, Belgium; Chairman with an interactive audience response system, winch instantly of the Department of Psychiatry at Erasme Hospital in presents the audience responses as a histogram on the screen. Brussels; and Director of the Laboratory of Psychiatric Each participant is able to take a self-assessment exam with Research of the Faculty of Medicine at the Free Uni- answers and discussion led by the expert faculty. versity of Brussels. Professor Mendkwiez's research interests include molecular neurobiology and behav- ioral genetics, particularly of affective disorders; chro- l.l:("\ ! '{ >~ nobiology and sleep; and neuropharmacology. The author of more than 600 scientific articles, Professor LECTURES Mendlewicz is the Founding and Principal Editor of Neuropsydxtbtoicgy and former Editor of the international 11:00 a.m." 12:30 p.m. series A ckttnas in Bide/gad Psychiatry. An active member Rooms IE 07/8, Level 1, Javits Center of many international scientific societies, Professor Mendlewicz is President-Elect of the European College Robert Lipsyte of Neuropsychopharmacology. The numerous honors he has received include the AJE. Bennett Research Surviving Jock Culture Award from the Society of Biological Psychiatry, the Anna Monika International Foundation Prize for Chp.: Ronald L. Kamm, M.D. Research in Depression, the Lieber Prize from the Co-Chp.: David A. Baron, D.O. National Alliance for Research on Schizophrenia and Depression, the Emil Kraepelin Award from the Max- Planck-Institut fur Psychiatric, the APA Special Robert Lipsyte, a longtime city and sports columnist for The New York Ttrres, is the author of 16 books, Presidential Commendation 2003, and the International including In the Country cfllhiss: Carrfart ardAdiiaejar the Forum Award on Mood and Anxiety Disorders 2003. Jaarey, and such best-selling young adult novels as The Professor Mendlewicz received his medical and Contender, One Fat Sunmnr, and Worrier A ngd. A former psychiatric degree from the Free University of Brussels network correspondent at CBS and NBC, Mr. Lipsyte and his doctorate in human genetics and development won an Emmy Award in 1990 for on-camera from Columbia University m New York Gty. achievement as host of die WNET nightly public International Psychiatrist Lecture Series affairs broadcast, "The Eleventh Hour." He was also THIS SESSION WILL BE AUDIOTAPED. host of "The Heahh Show," a weekly, live half-hour program of medical and heahh- related reportage. He contnbutes to the USA Today op-ed page and ESPN.com. In 1966 and in 1996, he won Columbia University's Meyer Berger Award for distinguished reporting. In 2001, he won the American Library Association's Margaret A Edwards Award for lifetime achievement in young adult literature.

21 MONDAY

LECTURE 7 MEDICAL UPDATE ! 11:00 a.m.-12:30 p.m. 11:00 a.m.-12:30 p.m. Room IE 13, Level 1, Javits Center Hall 3E, Level 3, Javits Center IRRITABLE BOWEL SYNDROME APA'S ADOLF MEYER AWARD LECTURE Chp.: Philip R. Muskin, MX). Glen O. Gabbard, M.D. Presenter: Susan Lucak, M.D. THIS SESSION WILL BE AUDIOTAPED. Mind, Brain, and Personality Disorders

Chp.: Marcia Kraft Coin, MD. RESEARCH CONSULTATION WITH

Glen O. Gabbard, MD., is Brown Foundation Chair 11:00 a.m.-12:30 p.m. of Psychoanalysis and Professor in the Department of This session is limited to 25 participants on a first-come, Psychiatry at Baylor College of Medicine in Houston. first-served basis. He is also Training and Supervising Analyst in the Houston-Galveston Psychoanalytic Institute, Joint 1 David V. Sheehan, M.D., on Evaluating Evidence in Editor-in-Chief of the IrtemationdJournal cfPsydxandy- Clinical Trials and Research Papers sis, and Associate Editor of the Arrericstnjwmtl(fPsy- Room 1D03, Level 1, Javits Center driatry. He is the author of more than 240 scientific papers and book chapters and the author or editor of 17 books, including Psyhodynamc Psydriatoy in Conical SCIENTIFIC AND CLINICAL REPORT Practice, Psychiatry and the Gnerm, andLorg-Term SESSIONS 1-8 PsydxxfywTK Psydxjtberapy: A Basic Text A Distinguished Fellow of APA, Dr. Gabbard has SCIENTIFIC AND CLINICAL REPORT SESSION 1 received numerous awards and honors, including the 11:00 a.m.-12:30 p.m. APA Distinguished Service Award, the Edward A Room 1E01/2, Level 1, Javits Center Strecker,-MD. Award from the Institute of Pennsylvania Hospital, and the Mary S. Sigourney ISSUES IN SCHIZOPHRENIA Award for Outstanding Contributions to Psychoanalysis. Dr. Gabbard graduated from Rush Chp.: David L. Garver, M.D. Medical College in Chicago, completed his residency in Co-Chp.: Jamie Mullen, M.D. psychiatry at the Karl Menninger School of Psychiatry in Topeka, Kansas; and received his psychoanalytic 11:00 a.m. training at the Topeka Institute for Psychoanalysis. 2 Rivastigmine and Glantamine Treatment of THIS SESSION WILL BE AUDIOTAPED. Schizophrenic Cognitive Impairment Mohammad Z. Hussain, M.D., Zubaida A Chaudhry, MD.

MASTER EDUCATOR CLINICAL 11:30 a.m. CONSULTATION 3-4 3 Dosing of Second-Generation Antipsychotics in a Large State Hospital System 11:00 a.m.-12:30 p.m. Leslie L. Gtrome, M.D., Ari B. Jaffe, M.D., Jerome Levine, M. D. These sessions are limited to 25 participants on a first- come, first-served basis. 12 noon 4 The Meaning of Response in Acute Schizophrenia 3 Robert G. Robinson, M.D., on Neuropsychiatry of Mary Anne Pressman, M.D., Eric D. Peselow, M.D., Scott Stroke: Recent Advances Solloway, M.D. THIS SESSION WILL BE AUDIOTAPED. Room 1D04, Level 1, Javits Center

4 Elizabeth Auchincloss, M.D., on Finding the Hidden Self: Engaging Difficult Patients in Exploratory Psychotherapy Room 1D05, Level 1, Javits Center

THESE SESSIONS ARE OPEN TO APAMEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE. 22 MONDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 2 SCIENTIFIC AND CLINICAL REPORT SESSION 4 11:00 a.m.-12:30 p.m. 11:00 a.m.-12:30 p.m. Room IE 11, Level 1, Javits Center Room 3D03/10, Level 3, Javits Center

ANIEXTY DISORDERS RECOVERY ISSUES WITH SCHIZOPHRENIA

Chp.: Gregory B. Sullivan, MD. Chp.: Francine Cournos, MD. Co-Chp.: Jeffrey A. Naser, MD. Co-Chp.: Vital N. Shah, MD.

11:00 a.m. 11:00 a.m. 5 Carbon Dioxide Test in Respiratory Panic Disorder: A 11 Do Patients With Schizophrenia Show Periods of Clonazepam Trial Complete Recovery? A 20-Year Follow-Up Antonio E. Nardi, MD., Alexandre M Valenca, M.D., Martin Harrow, Ph.D., Linda S. Grossman, Ph.D., Thomas Fabiana L. Lopes, M.D., Walter A Zin, MD., Isabella H. Jobe, MD., Joseph F. Goldberg, M.D., Robert Faull, B.S. Nascimento, M.D., Marco A Mazzasalma, M.D. 11:30 a.m. 11:30 a.m. 12 Twenty-Year Outcome in Schizophrenia: What's Sex 6 Child Abuse and the Development of PTSD in a Got to Do With It? Canadian Epidemiological Sample Linda S. Grossman, Ph.D., Martin Harrow, Ph.D., Cherise Michael A Van Ameringen, M.D., Catherine L. Rosen, MA, Ellen S. Herbener, Ph.D., Christopher G. Mancini, MD., Beth Pipe, B.S.G, Jonathan Oakman, Ph.D., Fichtner, MD. Michael Boyle, Ph.D. 12 noon 12 noon 13 Recovery From Schizophrenic Psychoses Until Age 35 7 Tiagabine Treatment of Social Anxiety Disorder Erika Lauronen, Johanna Koskinen, Juha M Veijola, Ph.D., Laszlo A Papp, MX)., Philip T. Ninan, MD. Jouko Miettunen, MS.C, Peter B. Jones, MD., Wayne S. THIS SESSION WILL BE AUDIOTAPED. Fenton, MD., Matti K. Isohanni, Ph.D. THIS SESSION WILL BE AUDIOTAPED. SCIENTIFIC AND CLINICAL REPORT SESSION 3 11:00 a.m.-12:30 p.m. SCIENTIFIC AND CLINICAL REPORT SESSION 5 Room IE 12, Level 1, Javits Center 11:00 a.m.-12:30 p.m. Room 3D04/9, Level 3, Javits Center SPECTRUM OF PERSONALITY DISORDERS COMPLICATIONS WITH ATYPICAL Chp.: John M. Oldham, M.D. ANTIPSYCHOTICS Co-Chp.: Robert Kelly, M.D. Chp.: Evaristo O. Akerele, MD. 11:00 a.m. Co-Chp.: Anton C. Trinidad, M.D. 8 Childhood Prevalence of BPD Mary G Zanarini, Ed.D., Dieter Wolke, Ph.D., Jeremy 11:00 a.m. Horwood, M.S.G, Andrea Waylen, Ph.D. 14 A Program for Treating Weight Gain Induced by Atypical Antipsychotics 11:30 a.m. Yael Nehama, MD., Faina Tsodikov, MS.G, Yaacov 9 Apparent Versus Reported Sadness: Correlation With Ashkenazy, M.D., Henry Szor, M.D. Personality Traits Anand Pandya, MD., Eric D. Peselow, M.D. 11:30 a.m. 15 Increased Lipid Levels and Antipsychotic Medication 12 noon Hannu J. Koponen, M.D., Kaisa Saari, MD., Sari 10 High-Lethality Suicide Attempts in BPD Lindeman, MD., Markku J. Savolainen, MD., Matti K. Paul fi Soloff, M.D., Anthony Fabio, Ph.D., Thomas M Isohanni, Ph.D. Kelly, Ph.D., Kevin M. Malone, MD., John J. Mann, M.D. THIS SESSION WILL BE AUDIOTAPED. 12 noon 16 QTc Prolongation Associated With Ziprasidone John W. Goethe, MD., Bonnie L. Szarek, R.N., Charles F. Caley, Pharm.D., Deborah A Piez, MS. THIS SESSION WILL BE AUDIOTAPED.

23 MONDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 6 SCIENTIFIC AND CLINICAL REPORT SESSION 8 11:00 a.m.-12:30 p.m. 11:00 a.m.-12:30 p.m. 3D05/8, Level 3, Javits Center Wilder Room, Fourth Floor, Marriott Marquis

PSYCHOTHERAPY AND PSYCHOPHARMACOLOGY: HEALTH SERVICES DISSOLVING THE MIND-BRAIN BARRIER Chp.: Mary Jane England, M.D. Chp.: David A. Casey, M.D. Co-Chp.: Steven A. Epstein, M.D. Co-Chp.: Andrew O. Skinner, MX). 11:00 a.m. 11:00 a.m. 23 Treatment Effectiveness and Functional Recovery in 17 Interpersonal Psychotherapy for Depressed Elders With Schizophrenia Cognitive Dysfunction Henry A. Nasrallah, MX). Mark D. Miller, MX). 11:30 a.m. 11:30 a.m. 24 Ethnic-Matched, Culturally-Competent, Model-Based 18 Integrating Psychotherapy With Medication to Improve ACT Team: Early Outcome Report Outcome Samuel F. Law, MX)., Jian Yang, MX)., Rosalie Ira D. Click, M.D. Steinberg, M.S.C, Wendy Chow, M.S.W., Joel Sadavoy, M.D. 12 noon 19 Review of Psychotherapy Research Involving a Pill- 12 noon Placebo Control 25 Work Disability and Treatment Access in Psychiatry Arthur Rifkin,MX>. Farifteh F. Duffy, Ph.D., Joyce C West, Ph.D., Ilze THIS SESSION WILL BE AUDIOTAPED. Ruditis, M.S.W., William E. Narrow, M.D., Darrel A Regier, MX). SCIENTIFIC AND CLINICAL REPORT SESSION 7 THIS SESSION WILL BE AUDIOTAPED. 11:00 a.m.-12:30 p.m. Room 3D06/7, Level 3, Javits Center WORKSHOPS TREATMENT OF DEPRESSION COMPONENTS 12-20 Chp.: Thomas L. Schwartz, M.D. Co-Chp.: Marketa M. Wills, MX). COMPONENT WORKSHOP 12 11:00 a.m.-12:30 p.m 11:00 a.m. Rooms 1E03/4/5, Level 1, Javits Center 20 Duloxetine Versus Placebo in the Prevention of Relapse ofMDD WHITHER OUR OWN HISTORY? DEBATING THE Michael J. Detke, MX)., Inmaculada Gilaberte, MX)., VALUE OF THE STUDY OF PSYCHIATRYS PAST David G. Perahia, MX)., Fujun Wang, Ph.D., Thomas C APA Corresponding Committee on History and Library Lee, M.S., Pierre V. Tran, MX). Chp.: Avram H Mack, MX). 11:30 a.m. 21 Response to Antidepressants Is Independent of Gender COMPONENT WORKSHOP 13 11:00 a.m.-12:30 p.ir Tamar D. Wohlfarth, Ph.D., Jitschak G. Storosum, MX)., Room 1E09, Level 1, Javits Center Andre J. A. Elferink, MX)., Barbara J. van Zwieten, Ph.D., Annernarie Fouwels, MX)., Wim Van Den Brink, M.D. WHAT'S NEW IN PSYCHIATRY AND THE LAW AT APA> 12 noon APA Gaundlon Psychiatry and Lawand APA Corrmttee on Judicial 22 Depression and BPD During the Immediate Prepartum Action Period Gisele Apter-Danon, MX)., Rozenn Graignic-Phillippe, Chp.: Renee L. Binder, MX). Marina Gianoli-Valente, Emmanuel Devouche, Ph.D., Participants: Jeffrey L. Metzner, M.D., Alan A, Stone, M.D., Annick Le Nestour, MX). Richard G. Taranto, J.D., Howard V. Zonana, MX). THIS SESSION WILL BE AUDIOTAPED.

24 MONDAY

COMPONENT WORKSHOP 14 11;00 a.m.-12:30 p.m. COMPONENT WORKSHOP 19 11:00 a.m.-12:30 p.m. Rooms 2D10/11, Level 2, Javits Center Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis

NOVEL CAREERS IN PSYCHIATRY: WOMEN WHO APPROACHES TO ASSESSMENT AND DIAGNOSIS HAVE MADE THEIR OWN WAY OF INFANTS AND SMALL CHILDREN APA Gamrittee on Women APA Council on Children, Addescerts, and Their Families

Co-Chps.: Melva I. Green, MD., Madelaine M. Chp.: William C Wood, MD. Wohlreich, MX). Participants: Joan L. Luby, MD., Jean M Thomas, MD., Brian K. Wise, MD., Harry H Wright, M.D. COMPONENT WORKSHOP 15 11:00 a.m.-12:30 p.m. Rooms 2D12/13, Level 2, Javits Center COMPONENT WORKSHOP 20 11:00 a.m.-12:30 p.m. Majestic/Music Box/Winter Garden, Sixth Floor, Marriott UPDATE ON PRACTICE GUIDELINES: PTSD AND Marquis ACUTE STRESS DISORDER APA Steering Committee on Practice Guidelines HELPING OLDER PERSONS WITH SCHIZOPHRENIA: TREATMENT, RESEARCH, AND Chp.: John S. Mclntyre, MX). POLICY Participants: Robert J. Ursano, MX)., Matthew J. APA GoundlanAgng Friedman, MD., Douglas F. Zatzick, M.D., David M. Benedek, MD. Chp.: Carl I. Cohen, MD. Participants: Susan K. Schultz, MD., Harriet P. Lefley, Ph.D., COMPONENT WORKSHOP 16 11:00 a.m.-12:30 p.m. Philip D. Harvey, Ph.D., Stephen J. Bartels, MD. Rooms 2D14/15, Level 2, Javits Center

PUBLIC PSYCHIATRY: LEADING THE WAY IN ISSUES 19-32 TRANSFORMING SERVICE DELIVERY IN THE 21ST CENTURY ISSUE WORKSHOP 19 11:00 a.m.-12:30 p.m. APA Council en Scdal Issues and PuUic Psychiatry Room 1D06, Level 1, Javits Center

Co-Chps.: Altha J. Stewart, MD., JeffreyL. Geller, MD. PSYCHIATRY IN THE PRIMARY CARE SETTING: Participants: Stephen M Thielke, MD., Kenneth S. MAKING IT WORK FOR THE PSYCHIATRIST Thompson, MD., Joy D. McQuery, MD. Chp.: John C Urbaitis, MD. COMPONENT WORKSHOP 17 11:00 a.m.-12:30 p.m. Participants: Ian M Pullen, Joseph M. Schwartz, M.D., Odets Room, Fourth Floor, Marriott Marquis Shauna P. Reinblatt, MD.

FITNESS TO PRACTICE MEDICINE: THE ROLES OF ISSUE WORKSHOP 20 11:00 a.m.-12:30 p.m. THE EVALUATING PSYCHIATRIST Room 3D02/11, Level 3, Javits Center A PA Corresponding Committee on Physician Health, Illness, and Irnpairment NO-SUICIDE DECISIONS, CONTRACTS, AND ASSESSMENT OF RISK: VALUES AND CAUTIONS Chp.: John A. Fromson, MD. Participants: Richard F. Limoges, MD., Stuart A. Chp.: Robert C Drye, MD. Anfang, MD., Linda Logsdon, MD., Michael H. Gendel, M.D., Participants: Cynthia R. Pfeffer, MD., Robert I. Simon, MD. Suzanne E. Vogel-Scibilia, MD. ISSUE WORKSHOP 21 11:00 a.m.-12:30 p.m. COMPONENT WORKSHOP 18 11:00 a.m.-12:30 p.m. O'Neill Room, Fourth Floor, Marriott Marquis Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis CHRONIC FATIGUE SYNDROME: DISEASE OR TERROR AT HOME: ADDRESSING DOMESTIC ABNORMAL ILLNESS BEHAVIOR? VIOLENCE IN YOUR PRACTICE APA Garmittee on Family Violence and Abuse Chp.: Peter Manu, M.D. Chp.: Carole L. Warshaw, MD. Participants: Graeme Hanson, M.D., Sandra L. Bloom, M.D.

25 MONDAY

ISSUE WORKSHOP 22 11:00 a.m.-12:30 p.m. ISSUE WORKSHOP 28 11:00 a.m.-12:30 p.m. Ziegfeld Room, Fourth Floor, Marriott Marquis Gramercy Room, Seventh Floor, Marriott Marquis

CAREER DEVELOPMENT FOR MINORITY WOMEN THE TRANSITIONAL OBJECT IN DEMENTIA PSYCHIATRISTS Co-Chps.: Sheila M. Loboprabhu, M.D., James W. Chp.: Surinder S. Nand, M.D. Lomax II, M.D. Participants: Nalini V. Juthani, M.D., Tanya R. Participant: Pamela J. Petersen-Crair, M.D. Anderson, M.D., Patricia I. Ordorica, M.D., Kathleen M. Kim, M.D., Nutan A Vaidya, M.D. ISSUE WORKSHOP 29 11:00 a.m.-12:30 p.m. Herald/Soho Rooms, Seventh Floor, Marriott Marquis ISSUE WORKSHOP 23 11:00 a.m.-12:30 p.m. Booth/Edison Rooms, Fifth Floor, Marriott Marquis BOUNDARY VIOLATION: HISTORY, TYPOLOGY, AND PREVENTION WHAT PSYCHIATRY RESIDENTS CAN EXPECT FROM NIMH-SPONSORED RESEARCH TRAINING Chp.: Albert G Gaw, M.D. Participants: Axel Hoffer, M.D., Thomas G. Gutheil, M.D., Co-Chps.: Joseph R. Calabrese, M.D., Delia M. Hann, Ph.D. Andrea Celenza, Ph.D. Participants: Robert L. Findling, M.D., Omar Elhaj, M.D. ISSUE WORKSHOP 30 11:00 a.m.-12:30 p.m. ISSUE WORKSHOP 24 11:00 a.m.-12:30 p.m. Cantor/Jolson Rooms, Ninth Floor, Marriott Marquis Imperial/Julliard Rooms, Fifth Floor, Marriott Marquis COGNITIVE THERAPY AND PHARMACOTHERAPY: TREATING PHYSICIANS: ISSUES IN DIVERSITY TEACHING RESIDENTS INTEGRATED TREATMENT METHODS Chp.: Michael F. Myers, M.D. Participants: Daniel P. Chapman, Ph.D., Donna M. Chp.: Donna M. Sudak, M.D. Norris, M.D., David W. Hodo, M.D. Participants: Judith S. Beck, Ph.D., Jesse H Wright, M.D., Edward S. Friedman, M.D. ISSUE WORKSHOP 25 11:00 a.m.-12:30 p.m. Columbia/Duffy Rooms, Seventh Floor, Marriott Marquis ISSUE WORKSHOP 31 11:00 a.m.-12:30 p.m. Marquis Ballroom Salons A/B, Ninth Floor, Marriott DRUG ABUSE AND MENTAL HEALTH Marquis TREATMENT IN LIEU OF IMPRISONMENT TREATING AFRICAN-AMERICAN PATIENTS WITH Chp.: Rodrigo A Munoz, M.D. PSYCHOTHERAPY: A TRAINING DILEMMA Participants: David Deitch, Ph.D., Gretchen Burns, Igor Koutsemok, M.D. Co-Chps.: Anu A Matorin, M.D., Henry L. McCurtis, M.D. Participants: Billy E. Jones, M.D., Pedro Ruiz, M.D., ISSUE WORKSHOP 26 11:00 a.m.-12:30 p.m. Sudhandshu Nene, M.D. Empire/Hudson Rooms, Seventh Floor, Marriott Marquis ISSUE WORKSHOP 32 11:00 a.m.-12:30 p.m. OBTAINING RESEARCH FUNDING FROM NIH: Marquis Ballroom Salon C, Ninth Floor, Marriott Marquis KEYS TO SUCCESSFUL GRANT WRITING Collaborative Session With the National Institute on Drug A buse RISK-MANAGEMENT ISSUES IN PSYCHIATRIC PRACTICE Chp.: Lucinda L. Miner, PhJD. Psychiatrists 'Purchasing Group, Inc. Participant Marina Volkov, Ph.D. Chp.: Alan L Levenson, M.D. ISSUE WORKSHOP 27 11:00 a.m.-12:30 p.m. Participants: Ellen R. Fischbein, M.D., Martin G. Tracy, J.D., Gotham Room, Seventh Floor, Marriott Marquis Jacqueline M. Melonas, J.D., Charles D. Cash, J.D.

TO SMOKE OR NOT TO SMOKE: THE DILEMMAS OF TOBACCO-FREE ADDICTION TREATMENTS Collaborative Session With the National Institute on Drug A buse

Co-Chps.: Petros Levounis, M.D., Edward V. Nunes, M.D. Participants: Paul J. Rinaldi, Ph.D., Ronald B. Lonesome, M.D., Lisa Koen, M.A

26 MONDAY

12 noon Sessions 1:00 p.m. Sessions

FORUMS 1-5 COURSES 45-52 FORUM 1 12 noon-1:30 p.m. Course descriptions are available in the CME Room IE 10, Level 1, Javits Center Course Brochure included in your registration packet Admission by ticket only. EVIDENCE-BASED PSYCHOTHERAPY

Chp.: Darrel A. Regier, MD. COURSE 45 1:00 p.m.-5;00 p.m. Co-Chp.: John S. Mclntyre, M.D. Concourse A, Concourse Level, Hilton New York Participants: A. John Rush, M.D., David Barlow, Ph.D., Joshua E. Wilk, Ph.D., Lisa A Mellman, M.D., Marsha M. DEPRESSION IN LATER LIFE: AN Linehan, Ph.D., Anthony F. Lehman, M.D. INTERDISCIPLINARY APPROACH Discussants: Myrna M. Weissman, Ph.D., Robert Michels, MD. Co-Directors: James M Ellison, MD., Yusuf Sivrioglu, M.D. Faculty: Francesca Cannavo Antognini, Ph.D., Donald A FORUM 2 12 noon-1:30 p.m. Davidoff, Ph.D. Room IE 16, Level 1, Javits Center COURSE 46 1:00 p.m.-5;00 p.m. ETHICAL DILEMMAS IN PRACTICE AND Concourse B, Concourse Level, Hilton New York RESEARCH DREAM TRANSLATION: ONE EMPIRICALLY-BASED Chp.: David M. McDowell, MD. APPROACH Participants: David J. Hellerstein, MD., David A Lowenthal, M.D., Samuel C. Klagsbrun, M.D. Director Milton Kramer, M.D.

FORUM 3 12 noon-1:30 p.m. COURSE 47 1:00 p.m.-5;00 p.m. Petit Trianon, Third Floor, Hilton New York Concourse E, Concourse Level, Hilton New York

ABPN UPDATE: REQUIREMENTS FOR ABPN DIMENSIONS OF PSYCHOTHERAPY SUPERVISION: EXAMINATION A CASE-BASED APPROACH

Chp.: Stephen C. Scheiber, MD. Director. Paul Rodenhauser, M.D. Participants: Michael H. Ebert, MD., Larry R. Faulkner, M.D., Faculty: Ramona Dvorak, MD., Albert F. Painter, Psy.D., David A Mrazek, M.D., Burton V. Reifler, MD., Victor I. John R. Rudisill, Ph.D. Reus, MD., James H. Scully, Jr., M.D., Elizabeth B. Weller, MD., Daniel K. Winstead, MD. COURSE 48 1:00 p.m.-5;00 p.m. Concourse G, Concourse Level, Hilton New York FORUM 4 12 noon-1:30 p.m. Rendezvous Trianon, Third Floor, Hilton New York GAY MEN AND THE PROBLEM OF ROMANTIC LOVE JAILS OR TREATMENT? ALTERNATIVES TO INCARCERATION Director: Richard A Isay, MD.

Chp.: Stephen M Goldfinger, MD. COURSE 49 1:00 p.m.-5:00 p.m. Participants: Charles J. Hynes, J.D., Anne J. Swern, J.D., Gibson Suite, Second Floor, Hilton New York Matthew D'Emic, J.D., Lisa Schreibersdorf, J.D., Kenneth Linn, Esq. THE ADVANCED PRACTICE OF PSYCHOTHERAPY

FORUMS 12 noon-1:30p.m. Director: T. Byram Karasu, MD. Aster Ballroom, Seventh Floor, Marriott Marquis COURSE 50 l:00p.m.-5:00p.m. MUSIC AND THE MIND: BEETHOVEN Gramercy B, Second Floor, Hilton New York

Chp.: Richard Kogan, M.D. RATING SCALES: A BASIC OVERVIEW

Co-Directors: Luis F. Ramirez, M.D., Martha Sajatovic, M.D.

27 MONDAY

COURSE 51 1:00 p.m.-5:00 p.m. 4 MAOIs Madison Suite, Second Floor, Hilton New York K. Ranga K Krishnan, M.D.

TEMPORAL LOBE AND LIMBIC SYSTEM ANATOMY 5 Principles of Pharmacokinetics AND THE RELATION TO PSYCHIATRIC ILLNESS G Lindsay DeVane, Pharm.D.

Co-Directors: Andrew L. Lautin, M.D., Jack Davis, M.S. Faculty: Adam Wolkin, M.D., Ronald A Jones, M.D., FOCUS LIVE SESSION 3 Hamada Hamld, MD. 2:00 p.m.-3:30 p.m.

COURSE 52 1:00 p.m.-5;00 p.m. Room IE 14, Level 1, Javits Center Nassau Suite A, Second Floor, Hilton New York Moderator: Deborah J. Hales, M.D., Mark H Rapaport, M.D. CHILD MURDER BY PARENTS Presenters: John Lauriello, M.D., on Schizophrenia and Other Psychotic Disorders Director Phillip J. Resnick, M.D. Expert clinicians, who served as the guest editors of the first two issues of Focus, will lead lively multiple-choice, question-based discussions. This session covers Schizophrenia and Other NEW RESEARCH YOUNG INVESTIGATORS' Psychotic Disorders, the first session at 9:00 a.m. covers ORAL/SLIDE SESSIONS 2-4 Forensic and Ethical Issues in Psychiatry, and the second session at 11:00 a.m. covers PTSD and Anxiety Disorders. Presented 1:00 p.m.-2:30 p.m. with multiple-choice questions, participants will test their 2 Evidence-Based Medicine knowledge with an interactive audience response system, which Rooms 3D01/12, Level 3, Javits Center instantly presents the audience responses as a histogram on the screen. Each participant is able to take a self-assessment exam 3 Genetics and Brain Imaging: Recent Findings with answers and discussion led by the expert faculty. Rooms 3D03/10, Level 3, Javits Center

4 Addictions, Alcoholism, and College Students LECTURES 8-10 Rooms 3D06/7, Level 3, Javits Center LECTURES For further information on New Research Sessions, please refer to the New Research Program Bock included in your registration packet. 2:00 p.m.-3:30 p.m. Rooms 1E07/8, Level 1, Javits Center

2:00 p.m. Sessions Thomas R. Insel, M.D. Social Neuroscience: A New Basic Science ADVANCES IN PSYCHOPHARMACOLOGY for Psychiatry 2:00 p.m.-5:30 p.m. Special Events Hall ID, Level 1, Javits Center dip.: Josepha A Cheong, M.D. Co-Chp.: Barton J. Blinder, M.D. AN UPDATE FOR CLINICIANS Thomas K Insel, M.D., is Director of the National In- Chp.: Alan F. Schatzberg, M.D. stitute of Mental Health in Bethesda, Maryland. He Co-Chp.: Jeffrey A. Lieberman, M.D. formerly was W.E. Timmie Professor of Psychiatry and Behavioral Sciences and Director of the Center for Be- 1 Introduction to Neurotransmitters, Receptors, Signal havioral Neuroscience at Emory University. In his re- Transduction, and Second Messengers search, Dr. Insel has used molecular, cellular, and Husseini K. Manji, M.D. pharmacological approaches to explore the neurobiol- ogy of complex social behaviors, including maternal 2 Immune System Pathology in Psychiatric Disease behavior, pairbond formation, and aggression. Andrew H Miller, M.D. Dr. Insel has served on over 10 editorial boards for both neuroscience and psychiatric journals. A Fellow 3 Second Generation Antipsychotics of the American College of Neuropsychopharmacol- Jeffrey A Lieberman, M.D. ogy, Dr. Insel has received the Distinguished Investigator Award from the National Alliance for Re- search on Schizophrenia and Depression, the AJE. Bennett Award from the Society of Biological Psychia- 28 MONDAY try, and the Outstanding Service Award from the U.S. LECTURE 10 Public Health Service. He is the author of more than 200 scientific articles and book chapters and the 2:00 p.m,-3:30 p.m. author or editor of four books, including The /Vy- Trianon Ballroom, Third Floor, Hilton New York (hobicktycfOksessiw-Go^^ The Neurobiology cf Parental Behaua: Dr. Insel received his Timothy]. Crow, M.B, medical degree from Boston University Medical School and completed his residency in psychiatry at Language, Psychosis, and the Speciation Event Langley Porter Neuropsychktric Institute-University of California, San Francisco. Chp.: Ananda K. Pandurangi, MD. Frontiers of Science Lecture Series Co-Chp.: Michael D. Garrett, MD. THIS SESSION WILL BE AUDIOTAPED. Timothy J. Grow, MB., is Professor of Psychiatry at the University of Oxford in Oxford, England, a mem- LECTURE 9 ber of the United Kingdom Medical Research Council (MRQ External Staff, Fellow of the Academy of 2:00 p.m.-3:30 p.m. Medical Sciences, and Honorary Director of the Prince Room IE 15, Level 1, Javits Center of Wales Centre for SANE Research on Schizophrenia and Depression in Oxford. Previously he was Deputy APA'S SOLOMON CARTER FULLER AWARD Director and Head of the Division of Psychiatry at the LECTURE MRC Clinical Sciences Centre and a member of the Scientific Staff of the Division of Neurophysiology and Phyllis Harrison-Ross, M.D. Neuropharmacology at the National Institute for Medi- cal Research in London. Dr. Crow has received nu- I Am a Fact, Not a Fiction merous awards in recognition of his work on brain structure and function in patients with schizophrenia, Chp.: Michelle O. dark, MD. including the Alexander Gralnick Award for Research Phyllis Harrison-Ross, MD., is Emeritus Professor of in Schizophrenia from the American Psychiatric Psychiatry and Behavioral Health Services at the NY Association, the Research Prize of the World Federa- Medical College and Emeritus Attending Psychiatrist tion of Societies of Biological Psychiatry, and the and Chief of Psychiatry at Metropolitan Hospital Lieber Prize for Schizophrenia Research from the Center in New York City. She is also in the private National Alliance for Research on Schizophrenia and practice of child and adult psychiatry. Since 2000 she Depression. Dr. Grow is a Fellow of the Royal College has served as the Founder and Managing Partner of the of Psychiatrists. He received his medical degree from Black Psychiatrists of Greater NY and Associates. Dr. London Hospital Medical College and completed his Harrison-Ross currently is a member of the Medical doctoral work in physiology at the University of Review Board of the NY State Commission of Aberdeen, Aberdeen, Scotland. Corrections, a Board member of the Medical Health Distinguished Psychiatrist Lecture Series and Research Association of NY Qty, the Board of THIS SESSION WILL BE AUDIOTAPED. Directors of Northside Center for Child Development, and the Editorial Board of the NY Amsterdam News. PRESIDENTIAL SYMPOSIUM 1 In the 1970s she was a member of the President's 2:00 p.m.-5:00 p.m. Advisory Council on Drug Abuse Prevention and Room IE 10, Level 1, Javits Center helped form the New York Qty Federation of Mental Health, Mental Retardation, and Alcoholism Services. THE BIOPSYCHOSOdAL MODEL: MYTH OR Her books include The Bleak Child and Getting It Togther. REALITY? She has written articles and book chapters on prison health issues. A Distinguished Life Fellow of the APA, Chp.: J. Pierre Loebel, MD. Dr. Harrison-Ross is Past President of Black Co-Chp.: Marcia Kraft Coin, M.D. Psychiatrists of America. She received her medical A Biopsychosocial Model: History degree from Wayne State University College of JohnD.Wynn,MD. Medicine in Detroit, completed her residency in pediatrics at Cornell Medical College-NY Hospital in B Biopsychosocial Integration in Residency Training New York Gty, and completed her residency in adult Deborah S. Cowley, M.T). psychiatry and a fellowship in child psychiatry at Albert C The Biopsychosocial Model: Contribution of Research Einstein College of Medicine and Bronx Municipal Charles B. Nemeroff, MD. Hospital in the Bronx, NY. Recently, the use of Telepychiatry to reach underserved populations has D Biopsychosocial Psychiatry in Clinical Practice GlenO.Gabbard,MX). captured her interest. THIS SESSION WILL BE AUDIOTAPED. THIS SESSION WILL BE AUDIOTAPED. 29 MONDAY

SYMPOSIA 1-26 F Narcissistic Traits in Substance Abusers: Any Treatment Implications? SYMPOSIUM 1 2:00 p.m.-5:00 p.m. Per Vaglum, MD. Rooms 1E01/2, Level 1, Javits Center Discussant: John Livesley, MD. BRAIN STIMULATION: NEW TREATMENTS FOR THIS SESSION WILL BE AUDIOTAPED. MOOD DISORDERS SYMPOSIUM 3 2:00 p.m.-5:00 p.m. Chp.: A. John Rush, MD. Room IE09, Level 1, Javits Center Co-Chp.: Harold A. Sackeim, Ph.D. FUNCTIONAL BRAIN IMAGING OF ADDICTION Collaborative Session With the National Institute on Drug A buse A ECT: Role in Brain Stimulation Harold A Sackeim, PhD. Chp.: Elliot A Stein, Ph.D. B Magnetic Seizure Therapy: Development of a Novel Convulsive Treatment A Neuropsychiatric Implications of Mapping Sarah H. Lisanby, MD. Reward/Aversion Circuitry Hans C. Breiter, MD., Gregory P. Gasic, Ph.D. C Repeated Prefrontal Repetitive Trans cranial Magnetic Stimulation as an Antidepressant An Update B Endogenous Opioid Neurotrans miss ions: Interfacing Mark S. George, MD., Ziad H Nahas, M.D., AndrewF. Reward and Stress Regulation Kozel, MD., Alexander Mishory, MD., Xingbao Li, M.D., Jon-Kar Zubieta, M.D. Berry Anderson, R.N. C Chronic Effects of Drug Use and HIV D The Use of Vagus Nerve Stimulation (VNS) in the Linda Chang, M.D. Long-Term Treatment of Mood Disorders D Neurobiological Substrates of Stimulant Action and Lauren B. Marangell, M.D. Reward Elliot A Stein, PhD. Discussant: Jerrold F. Rosenbaum, MD. THIS SESSION WILL BE AUDIOTAPED. THIS SESSION WILL BE AUDIOTAPED. SYMPOSIUM 4 2:00 p.m.-5;00 p.m. SYMPOSIUM 2 2:00 p.m.-5:00 p.m. Rooms 1E03/4/5, Level 1, Javits Center Room IE 11, Level 1, Javits Center

TREATMENT OF MALADAPTIVE PERSONALITY TREATMENT OF CHRONIC PAIN IN RECOVERING ADDICTS TRAITS Collaborative Session Wth the National Institute on Drug A buse Chp.: James H Reich, M.D. Chp.:JagKhalsa,Ph.D. A Drug Treatment of Maladaptive Personality Traits A Pain Assessment and Issues in Screening James H. Reich, MD. Russ Portenoy, MD. B Neurobiology, Comorbidity, and Drug Treatment of B Assessing Aberrant Drug-Taking Behaviors in Childhood Abused BPD Patients Medically 111 Patients With Pain Thomas Rinne, MD., Wim Van Den Brink, M.D., Steve Passik, PhD. Jaap G. Goekoop, M.D., Roel H Ryk, Ph.D., Ronald de Kloet, Ph.D. C The Development and Treatment of Opioid-Induced Hyperalgesia Walter Ling, MD. C Development and Treatment of Family Pathology Around Quster-B Traits D Prescribing Pain Medications for Recovering Addicts David M. Allen, M.D. With Chronic Pain Richard Brown, MD. D Cognitive Therapy for Maladaptive Personality Traits David P. Bernstein, Ph.D. E Principles of Pain Treatment in Addictive Disorders Seddon R. Savage, MD. E Affective Deficits in Recurrent Suicidal Behavior THIS SESSION WILL BE AUDIOTAPED. Paul S. Links, MD., Yvonne Bergmans, M.S.W., A Barr, Ph.D.

30 MONDAY

SYMPOSIUM 5 2;00 p.m.-5:00 p.m. E Resource Loss and Impact on Civilian Populations: Room IE 12, Level 1, Javits Center Individuals and System Outcomes Stevan Hobfoll, Ph.D. CHILD SOLDIERS, CHILD AND ADOLESCENT VICTIMS OF WAR AND TERRORISM: Discussant: David Rothstein, MX). BIOPSYCHOSOQAL TREATMENT FOR THIS SESSION WILL BE AUDIOTAPED. REINTEGRATION INTO FAMILY AND SOCIETY SYMPOSIUM 7 2:00 p.m.-5:00 p.m. A PA Alliance Room IE 16, Level 1, Javits Center

Chp.: Frank G. Njenga, M.D. I REST MY CASE Co-Chp.: Rosalind Hayes, B.A. A msrican A ssodation (/Practicing Psychiatrists

A Children's Response to Terrorism in Nairobi: The 1998 Chp.: Janis G. Chester, M.D. U.S. Embassy Bombing in Kenya Frank G. Njenga, MX). A The HIPAA Suit Robert L. Pyles, MX). B The Voices of Girl-Child Soldiers Yvonne Keairns, Ph.D. B Shrager Versus Magellan Daniel Shrager, MX). C Terror and Terrorism: Community Responses and Needs C The RICO Suit Robert J. Ursano, M.D., Carol Fullerton, Ph.D. Janis G. Chester, MX).

D Child Soldiers Reintegration: A Holistic Community- D Eist Versus Maryland BPQA Based Approach Harold I. Eist, M.D. Michael Wessells, Ph.D. Discussants: Deborah G Peel, MX)., Roger Peele, MX). E Survey of Youth, Violence, and Public Health in Bogota, THIS SESSION WILL BE AUDIOTAPED. Colombia Luis Duque, MX)., L.F. Klevins, MX)., C. Ramirez SYMPOSIUM 8 2:00 p.m.-5;00 p.m. Room 3D02/11, Level 3, Javits Center Discussants: Robert J. Ursano, M.D., Yvonne Keairns, Ph.D. THIS SESSION WILL BE AUDIOTAPED. FROM RESPONSE TO RECOVERY: THE CONSUMER AND CLINICIAN COLLABORATION IN SYMPOSIUM 6 2:00 p.m.-5:00 p.m. DEPRESSION AND PSYCHOSIS Room IE 13, Level 1, Javits Center Chp.: Shervert H. Frazier, MX). NEW DIRECTIONS IN TERRORISM AND Co-Chp.: Evelyn Barkin POLITICAL VIOLENCE: CAUSES AND RESPONSES IntemrticmlSodetyfcrPditicalPsychcl^ Council on Global A Sarah's Struggle: Adolescence, Abandonment, and Psychiatry Bipolar Disorder Sarah Duckworth Chp.: Jerrold M. Post, M.D. B To Be or Not To Be? The Hidden Crisis of Adult and A Path to Collective Madness Adolescent Male Depression and Suicide Dipak Gupta, Ph.D. William S. Pollack, Ph.D.

B When Hatred Is Bred in the Bone C From Illness to Wellness: New Strategies for Recovery Jerrold M. Post, M.D. Anne Whitman, Ph.D.

C Terror on the Internet: The New Arena, The New D Bipolar and MDD in Mid-Life Challenges Paul E. Keck, Jr., MX). Gabriel Weimann, Ph.D. E Geriatric Depression, Alcohol Abuse, and Suicidality D Cultural Approaches Linking Terrorism and Traumas Everet Page Stevan M. Weine, M.D. (Continued on nextpag)

31 MONDAY

F Late-Life Depression: Is Getting Well Enough? C Recent Mental Health Team Efforts in the Combat- Sumer Verma, MX). Support Hospital Robert D. Forsten, M.D. Discussant: Christopher M. Palmer, MX). THIS SESSION WILL BE AUDIOTAPED. D Mental Health Intervention in Mortuary Affairs Workers During Combat SYMPOSIUM 9 2:00 p.m.-5;00 p.m. Panakkal David, MX). Rooms 3D04/9, Level 3, Javits Center E Health-Promotion and Preventive-Medicine Efforts in RECENT ADVANCES IN THE TREATMENT OF the Most Recent Gulf Wars PSYCHIATRIC DISORDERS IN PRIMARY CARE: A Robert T. Ruiz, MX). U.S./U.K. PERSPECTIVE F Jealous in Honor, Sudden in Quarrel: Psychiatric Chp.: Wayne J. Katon, M.D. Practice in Iraqi Freedom Co-Chp.: Lawrence Mynors-Wallis, D.M. William F. Haning III, MD.

A The Pathways Study: A Randomized Trial of G Emotional Cycle of Deployment: Family and Military Collaborative Care in Patients With Diabetes and Member Perspective Depression Simon H. Pincus, MX). Wayne J. Katon, MX)., Michael Von Korff, Sc.D., Elizabeth Lin, MX)., Gregory Simon, M.D., Paul Qechanowski, M.D., Discussants: Robert D. Forsten, MX)., Panakkal David, M.D., Evette Ludman, Ph.D., Edward A. Walker, MX). Robert T. Ruiz, MX). THIS SESSION WILL BE AUDIOTAPED. B Cognitive-Behavior Therapy and Medication for Primary Care Panic Disorder Sustained Superiority to SYMPOSIUM 11 2:00 p.m.-5:00 p.m. Usual Care Odets Room, Fourth Floor, Marriott Marquis Peter P. Roy-Byrne, M.D., Michelle G. Gaske, Ph.D., Murray B. Stein, MX)., J. Greer Sullivan, MX)., Alexander PTSD IN PERSONS WITH SERIOUS MENTAL Bystritsky, MX)., Wayne J. Katon, M.D., Cathy D. ILLNESS Sherbourne, Ph.D. Chp.: Kristina H Muenzenmaier, MX). C Problem-Solving Treatment by Nurses for Psychological Co-Chp.: Lewis A. Opler, M.D. Disorders in Primary Care Lawrence Mynors-Wallis, D.M., Anthony Kendrick, MX)., A Prevalence and Patterns of PTSD Among Persons With Christopher Thompson, MX)., Judith Lathlean, M.A., Lucy Severe Mental Illness Simons, B.A., Ruth Pickering, B.S.G David B. Albert, Ph.D., Linda A. Teplin, Ph.D., Karen M. Abram, Ph.D., GaryM. McClelland, Ph.D. D Cost-Effectiveness of Antidepressants in Primary Care Robert G Peveler, MX)., Anthony Kendrick, M.D., B An Exploration of PTSD and MDD Comorbidity Christopher Thompson, MX)., Martin Buxton Patricia Resnick, Ph.D. THIS SESSION WILL BE AUDIOTAPED. C Assessment and Treatment of Trauma in Persons With SYMPOSIUM 10 2:00 p.m.-5:00 p.m. Serious Mental Illness Rooms 3D05/8, Level 3, Javits Center Kristina H. Muenzenmaier, MX)., Lewis A. Opler, MX)., Anne-Marie Shelley, Ph.D., Mary-Jane Alexander, Ph.D., MENTAL HEALTH TEAMS: HEALTH PROMOTION Michelle Fox, B.A. AND PRESERVATION IN WAR AND PEACE D Cognitive-Behavioral Treatment of PTSD in Clients Chp.: James J. Staudenmeier, Jr., MX). With Severe Mental Illness Co-Chp.: William F. Haning III, MX). Kim T. Mueser, Ph.D., Stanley Rosenberg, Ph.D., Kay Jankowski, Ph.D., Jessica Hamblen, Ph.D., Patricia A Mental Health Teams: Background and Recent History Carty,M.S. James J. Staudenmeier, Jr., MX)., Bryan Bacon, D.O., William F. Haning III, MX)., Thomas A. HcMin, M.D. Discussant: Judith Herman, MX). THIS SESSION WILL BE AUDIOTAPED. B Psychology of War Jason L. Engeriser, M.D.

32 MONDAY

SYMPOSIUM 12 2;00 p.m.-5:00 p.m. SYMPOSIUM 14 2;00 p.m.-5;00 p.m. O'Neill Room, Fourth Floor, Marriott Marquis Ziegfeld Room, Fourth Floor, Marriott Marquis

BEHAVIORAL DIMENSIONS OF PSYCHIATRIC CURRENT CONCEPTS OF THE NEUROBIOLOGY DISORDERS OF THE SELF

Chp.: Stephen B. Shanfield, M.D. Chp.: Todd E. Feinberg, M.D. Co-Chp.: Julian P. Keenan, Ph.D. A Impulsivity in Psychiatric Disorders Alan C Swann, M.D. A What Neuropathology Can Teach Us About the Neurobiology of the Self B Aggression in Personality Disorders Todd E. Feinberg, M.D. Emil F. Coccaro, M.D. B Neuroimaging the Self C Mood Reactivity Dimension in Diagnosis Julian P. Keenan, Ph.D. Conrad M. Swartz, M.D. C Self, Memory, and the Brain D The Dimensional Construct in Psychiatric Disorders Joseph LeDoux, Ph.D. Stephen B. Shanfield, M.D. THIS SESSION WILL BE AUDIOTAPED. D Affect Regulation, the Right Hemisphere, and the Self Allan N. Schore, Ph.D. SYMPOSIUM 13 2:00 p.tn.-5;00 p.m. THIS SESSION WILL BE AUDIOTAPED. Wilder Room, Fourth Floor, Marriott Marquis SYMPOSIUM 15 2:00 p.m.-5:00 p.m. NEURODEVELOPMENT AND SCHIZOPHRENIA: Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis CLINICAL AND BASIC SCIENCE PERSPECTIVES THE DEVELOPMENT OF ADAP: THE Chp.: Alan S. Brown, M.D. ADOLESCENT DEPRESSION AWARENESS PROGRAM A In-Utero Exposure to Infection and Schizophrenia in Adult Offspring Chp.: Karen L. Swartz, M.D. Alan S. Brown, M.D., Melissa D. Begg, Sc.D., Catherine A. Co-Chp.: Todd S. Cox, M.D. Schaefer, Ph.D., Stefan Gravenstein, M.D., Richard J. Wyatt, M.D., Michaeline Bresnahan, Ph.D., Ezra S. A Current Status of Depression Education in Schools Susser, M.D. Boglarka Szabo, M.D., Todd S. Cox, M.D., Elizabeth A. Kastelic, M.D., Karen L. Swartz, M.D. B Prenatal Viral Infection, Brain Development, and Schizophrenia B Development of a Model Depression Education S. Hossein Fatemi, M.D., M. Araghiniknam, Ph.D., Curriculum Jessica Laurence, B.S., Robert Sidwell, Ph.D., Karen L. Swartz, M.D., Todd S. Cox, M.D., Elizabeth A. Susanne Lee, Ph.D., Joel Stary, B.S. Kastelic, M.D., Sallie Mink, B.S.N., Sally G. Hess, B.S.N., Lizza C Gonzales, B A, Boglarka Szabo, M.D. C Advanced Paternal Age and Risk for Schizophrenia Dolores Malaspina, M.D., Alan S. Brown, M.D., Ezra S. C Creation of Supplemental Learning Tools for Susser, M.D., Susan Harlap, M.D., Raymond Goetz, Ph.D. Depression Education Sallie Mink, B.S.N., Elizabeth A. Kastelic, M.D., Todd S. D Eariy Gestational Irradiation in the Primate as a Model Cox, M.D., Sally G. Hess, B.S.N., Lizza C Gonzales, BA, of Schizophrenia Sandra Durfee, M.L A, Karen L. Swartz, M.D. Lynn D. Selemon, Ph.D., John G. Csernansky, M.D., Lei Wang, Ph.D., Patricia S. Goldman-Rakic, Ph.D., D Evaluation of the ADAP Teenage Depression Pasko Rakic, M.D. Curriculum Todd S. Cox, M.D., Elizabeth A. Kastelic, M.D., Karen L. Discussant: Ezra S. Susser, M.D. Swartz, M.D. THIS SESSION WILL BE AUDIOTAPED. E Change in Adolescent Attitudes About Depression Treatment Elizabeth A. Kastelic, M.D., Sally G. Hess, B.S.N., Lizza C Gonzales, BA, Todd S. Cox, M.D., Karen L. Swartz, M.D.

(Contained on nextpa$ 33 MONDAY

F Training of ADAP Educators: Bringing the Curriculum D An Attorney's Approach to Cross-Examination of an to Schools Expert in a Custody Dispute Sally G. Hess, B.S.N., Todd S. Cox, MD., Elizabeth A. Harold A. Mayers Kastelic, M.D., Sallie Mink, B.S.N., Lizza C Gonzales, B.A, Boglarka Szabo, MD., Karen L. Swartz, MD. E The Court's Role Regarding Expert Testimony in Child- Custody Proceedings Discussants: J. Raymond DePaulo, Jr., MD., Paramjit Anthony Marano, J.D. Joshi, MD. THIS SESSION WILL BE AUDIOTAPED. THIS SESSION WILL BE AUDIOTAPED. SYMPOSIUM 18 2:00 p.m.-5;00 p.m. SYMPOSIUM 16 2:00 p.m.-5:00 p.m. Imperial/Julliard Rooms, Fifth Floor, Marriott Marquis Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis EVOLUTIONARY AND ETHOLOGICAL THE DEATH PENALTY: LAW AND MEDICAL PERSPECTIVES ON SOCIAL ANXIETY DISORDER ETHICS IN THE FACE OF NEW COURT OPINIONS Chp.: Franklin R. Schneier, MD. Chp.: Alfred M. Freedman, M.D: A What Social Phobia Reveals About Our Evolved Human A Capital Punishment and American Exceptionalism Nature and Vice Versa Carol Steiker, J.D. Randolph M Nesse, MD., James L. Abelson, M.D.

B Human Rights and Medical Ethics: The American B Gene-Environment Interactions and the Development Conflict of Tearfulness in Monkeys Alan A. Stone, MD. Stephen J. Suomi, Ph.D.

C Mental Disabilities and the Death Penalty: Evaluations C Subordinate Status, Social Anxiety Disorder, and and Legal Protections After Atkins Versus Virginia Dopamine Function James W. Ellis, J.D. Franklin R. Schneier, M.D., Richard G. Heimberg, Ph.D., Marc Laruelle, MD., Michael R. Liebowitz, MD. D Competency to Be Executed and Forced Medication: Singleton Versus Norris, Ethical Considerations D Eye Contact as a Threat in Social Anxiety Disorder Howard V. Zonana, MD. Justine M Kent, MD.

E Diagnosis of Diminished Responsibility and the Death Discussant: MurrayB. Stein, MD. Penalty: Implications of Atkins Versus Virginia THIS SESSION WILL BE AUDIOTAPED. Richard Bonnie, J.D. SYMPOSIUM 19 2:00 p.m.-5:00 p.m. Discussants: Paul S. Appelbaum, MD., Ezra E.H Majestic/Music Box/Winter Garden, Sixth Floor, Marriott Griffith, M.D. Marquis THIS SESSION WILL BE AUDIOTAPED. BEYOND B12: AN UPDATE ON NUTRITION AND PSYCHIATRY SYMPOSIUM 17 2:00 p.m.-5;00 p.m. Booth/Edison Rooms, Fifth Floor, Marriott Marquis Chp.: Kathryn M. Connor, MD. Co-Chp.: Marian I. Butterfield, M.D. THE SCIENTIFIC BASIS OF EXPERT TESTIMONY: ITS APPLICATION TO MATRIMONIAL DISPUTES A Nutrition and Psychiatry: A Historical Perspective Chp.: Alex Weintrob, MD. Kathryn M Connor, MD.

A Psychiatric Testimony: Science or Wizardry? B Omega-3, Essential Fatty Acids, and Psychiatric Alex Weintrob, MD. Disorders Jerry MCott,Ph.D. B The Uses and Misuses of Psychological Tests in Child- Custody Evaluations C SAMe, Folate, and B12: One-Carbon Metabolism and Paul Hymowitz, Ph.D. Depression Jonathan E. Alpert, MD., David Mischoulon, MD., C The Expectation for Evidence-Based Testimony Under George I. Papakostas, MD., Timothy J. Petersen, Ph.D., Daubert John J. Worthington III, M.D., Andrew A Nierenberg, MD., Diane H. Schetky, MD. Maurizio Fava, MD.

34 MONDAY

D Psychiatric Applications of Chromium C Good and Bad News for Low-Income Children Whose Jonathan R.T. Davidson, MD. Mothers Are Treated for Depression Anne Riley, Ph.D., Marina Broitmand, Ph.D., E Glyconutritionals: Review and Relevance to Psychiatry Maryjo Coiro, Ph.D., Judith Robertson, B.S. Marian I. Butterfield, MD. THIS SESSION WILL BE AUDIOTAPED. D The Effect on Children of Treating Parents for Depression SYMPOSIUM 20 2;00 p.m.-5;00 p.m. Judy Garber, PhD., Elizabeth McCauley, Ph.D., Plymouth/Uris/Shubert Rooms, Sixth Floor, Marriott Guy Diamond, Ph.D., Kelly Schloredt, Ph.D., Marquis Ginny Burks, Ph.D., Russ Hanford, Ph.D., Cynthia Flynn, M.S. TELLING STORIES: THE PSYCHIATRIST AS NOVELIST E Preventive Intervention for Families With Depression: Lessons From a Three-Year Follow-Up Chp.: Dinah Miller, MX). William R. Beardslee, MX).

A Two Views of Human Nature: Depth Perception or Discussant: Patricia R. Cohen, Ph.D. Diplopia? THIS SESSION WILL BE AUDIOTAPED. Roderick J. Anscombe, MD. SYMPOSIUM 22 2:00 p.m.-5;00 p.m. B Taming Demons: The Novel as a Way of Working Empire/Hudson Rooms, Seventh Floor, Marriott Marquis Through Trauma Alvin A. Rosenfeld, M.D. OBESITY: LESSONS LEARNED FROM ADDICTION Collaborate? Session With the National Institute an Drug A buse C The Novel as Grist for the Mill: Whose Psychotherapy Is It Anyway? Chp.: Joseph Frascella, Ph.D. Paul A Buttenwieser, M.D. A Genetic, Motivational, and Metabolic Factors Modulate D Empathy and the Mystery Novel: Getting to the Truth the Neural Drive to Maintain Body Weight Keith R. Ablow, MD. Barry Levin, MD.

E Narrative Truths: Fiction and Nonfiction B Cortico-Striatal-Hypothalamic Networks and Peter D. Kramer, M.D. Motivation for Food: Integration of Cognition, Reward, and Energy F From the Laptop to the Bookstore: On Getting Your AnnE.Kelley,Ph.D. Creative Writing Published David J. Hellerstein, M.D. C Food and Drug Cravings: Metaphor or Common THIS SESSION WILL BE AUDIOTAPED. Mechanism? Marcia L. Pelchat, Ph.D. SYMPOSIUM 21 2:00 p.m.-5;00 p.m. Columbia/Duffy Rooms, Seventh Floor, Marriott Marquis D Common and Diverging Neurobiological Features of Feeding and Drug Self-Administration in Humans DO CHILDREN BENEFIT WHEN THEIR PARENTS Dana Small, Ph.D. WITH DEPRESSION ARE TREATED SUCCESSFULLY? E Obesity and Addiction: Neuroimaging Studies Gene-Jack Wang, MX)., Nora D. Volkow, M.D., Chp.: Myraa M Weissman, Ph.D. Joanna S. Fowler, Ph.D. Co-Chp.: Daniel J. Pilowsky, MX). Discussant: Nora D. Volkow, MD. A Children at High Risk for Depression: Current THIS SESSION WILL BE AUDIOTAPED. Knowledge and Future Directions Myrna M. Weissman, Ph.D.

B STAR-D Child Study: Background and Preliminary Data Daniel J. Pilowsky, M.D., Jonathan E. Alpert, M.D., Gabrielle M. Cerda, M.D., Judy Garber, Ph.D., Carrol Hughes, Ph.D., Cheryl King, Ph.D., Erin M. Malloy, MD., Bella Sood, M.D., Myrna M. Weissman, Ph.D. 35 MONDAY

SYMPOSIUM 23 2;00 p.m.-5;00 p.m. B Common and Specific Genetic Factors in the Herald/Soho Rooms, Seventh Floor, Marriott Marquis Development of Substance Dependence Laura J. Bierut, MD., Alison Goate, D.Phil., John ALCOHOL, DRUG, AND PSYCHIATRIC DISORDERS Rice, PhD., Anthony Hinrichs, Ph.D., Tatiana IN THE U.S.: CURRENT STATUS AND TRENDS Foroud, Ph.D., Howard Edenberg, PhD., Collaborative Session With the National Institute on Drug A buse Raymond R Crowe, MD.

Chp.: Deborah S. Hasin, Ph.D. C Addiction Molecular Genetics: Remarkably Converging Co-Chp.: Bridget F. Grant, Ph.D. Results George Uhl, M.D. A Prevalence, Disability, and Time Trends in Alcohol Abuse and Dependence in the U.S., 1992 to 2002 D Using the Systems Biology of Motivation for Genetic Frederick S. Stinson, Ph.D., Bridget F. Grant, Ph.D., Studies in Psychiatry Deborah A. Dawson, Ph.D., S. Patricia Chou, Ph.D., Mary C Gregory P. Gasic, PhD., Hans G Breiter, MD. Dufour, MD., Roger P. Pickering, M.S. E Genetic and Environmental Factors Modulate Cocaine B A Second Look at Binge Drinking and Alcohol Use Abuse in Monkey Models Disorders Among College and Noncollege Youth Michael Nader, PhD. Deborah A Dawson, Ph.D., Bridget F. Grant, Ph.D., THIS SESSION WILL BE AUDIOTAPED. Frederick S. Stinson, Ph.D., S. Patricia Chou, Ph.D. SYMPOSIUM 25 2:00 p.m.-5;00 p.m. C Major Depression and Alcohol, and Drug Use Disorders Marquis Ballroom Salons A/B, Ninth Floor, Marriott in the U.S.: Variations in Co-Occurrence Marquis Deborah S. Hasin, Ph.D., Bridget F. Grant, Ph.D. PSYCHIATRIC REHABILITATION: INTEGRATING D Trends in Prevalence of Marijuana Use Disorders in the MIND AND BODY GLOBALLY U.S., 1992 to 2002 World Psychiatric Association's Section on Rehabilitation and World Wilson Compton III, MD., James Colliver, Ph.D., Bridget F. Association for Psychosoaal Rehabilitation Grant, Ph.D., Frederick S. Stinson, Ph.D. Chp.: Zebulon G Taintor, MD. E U.S. Prevalence of Personality Disorders and Co- Co-Chp.: Ida Kosza, MD. Occurrence With Alcohol and Drug Use Disorders Bridget F. Grant, Ph.D., Frederick S. Stinson, PhD., A Brain Responses to the Environment Showing Deborah A. Dawson, Ph.D., S. Patricia Chou, Ph.D., Rehabilitation Works Roger P. Pickering, M.S. Robert Cancro, MD., Zebulon C Taintor, MD.

Discussant: Norman Sartorius, MD. B Schizophrenia and Drug-Abuse Outcomes: Poverty, THIS SESSION WILL BE AUDIOTAPED. Culture, and Community Gregory C Bunt, M.D., Carole Siegel, PhD. SYMPOSIUM 24 2:00 p.m.-5;00 p.m. Cantor/Jolson Rooms, Ninth Floor, Marriott Marquis C Human Rights for Individuals With Mental Illnesses Humberto Martinez, MD. GENETIC AND ENVIRONMENTAL FACTORS CONTRIBUTING TO VULNERABILITY TO D The Worldwide Family Movement ADDICTION Geraldine Marshall CcUaborad'iE Session With the National Institute on Drug A buse E Penetrating Prisons With Rehabilitation Chp.: Jonathan D. Pollock, Ph.D. Zebulon C Taintor, MD.

A Using Twin Data to Identify Alternative Drug Abuse Discussant Naotaka Shinfuku Phenotypes THIS SESSION WILL BE AUDIOTAPED. Ming T. Tsuang, MD., Michael Lyons, Ph.D., Stephen V. Faraone, PhD., William Kremen, Ph.D., Stephen Glatt, Ph.D.

36 MONDAY

SYMPOSIUM 26 2;00 p.m.-5;00 p.m. Marquis Ballroom Salon C, Ninth Floor, Marriott Marquis 5:30 p.in. Session

EFFECTIVE TREATMENT OF PTSD: WHAT WORKS CONVOCATION OF DISTINGUISHED BEST FOR WHOM? FELLOWS

Chp.: Bessel A. Van Der Kolk, MD. 5:30 p.m.-6:30 pan. Co-Chp.: Marylene Goitre, Ph.D. Hall 3E, Level 3, Javits Center

A Exposure Versus Pharmacological Treatment of PTSD: All Distinguished Life Fellows, Distinguished Differential Response and Long-Term Outcome Fellows, Fellows, members, and registered guests Bessel A Van Der Kolk, MD., Joseph F. Spinazzola, Ph.D., are invited. James Hopper, Ph.D., Margaret Blaustein, Ph.D., William Simpson, Ph.D., Elise Hopper, Ph.D. Presiding: Marck Kraft Coin, MX)., Pvesidert

B What Works Best for Whom? Case Studies in Grand Marshals: Ian E. Alger, MD., Sheik B. Combination Treatment Blume,MD. Randall D. Marshall, MD. Marshals: Nalini V. Juthani, MD., J. Richard Qccone, MD. C Emotion Regulation and Interpersonal Skills Training INTRODUCTION OF DISTINGUISHED LIFE for Chronic PTSD Related to Childhood Abuse and FELLOWS Multiple Traumatization Michelle B. Riba, MD., President-Elect Marylene Qoitre, Ph.D. INDUCTION OF DISTINGUISHED FELLOWS Michelle B. Riba, MD. D PTSD Treatment Outcome Research: The Study of Unrepresentative Samples INTRODUCTION OF FIFTY-YEAR Joseph F. Spinazzola, Ph.D., Margaret Blaustein, Ph.D., DISTINGUISHED LIFE FELLOWS, FIFTY- Bessel A Van Der Kolk, MD. YEAR LIFE MEMBERS, AND THIS SESSION WILL BE AUDIOTAPED. INTERNATIONAL FELLOWS Marck Kraft Coin, MD. INTRODUCTION OF FELLOWS 3:00 p.m. Session Marck Kraft Coin, MD. PRESENTATION OF SPECIAL PRESIDENTIAL COMMENDATIONS 'NT.WKIISEARCH POSTER SI. «^fON ; Marck Kraft Coin, MD. 3:00 p.m.-5:00 p.m. PRESENTATION OF DISTINGUISHED Galleria, Level 4, Javits Center SERVICE AWARDS Marck Kraft Coin, MD. ANXIETY, STRESS, ADDICTIONS, AND ALCOHOL DISORDERS INTRODUCTION OF THE MEMBERSHIP COMMITTEE CHAIRPERSON AND AWARD For further information on New Research Sessions, please refer BOARD CHAIRPERSONS to the New Research Pro-am and Abstracts Bock included in your Marck Kraft Coin, MD. registration packet. PRESENTATION OF AWARDS Marck Kraft Coin, MD.

AP A/Lilly Resident Research Awards APIRE/Kempf Fund Awards for Research Development in Psychobiological Psychktry Human Rights Awards Blanche F. Itdeson Award for Research in Child Psychktry Agnes Purcell McGavin Award for Distinguished Queer Achievement in Child and Adolescent Psychktry Jack Weinberg Memorial Award for Geriatric Psychktry

WILLIAM C MENNINGER MEMORIAL CONVOCATION LECTURE Tom Wolfe 37 MONDAY

LECTURE 11 7:00 p.m. Sessions 5:30 p.m.-6:30 p.m. Hall 3E, Level 3, Javits Center INDUSTRY-SUPPORTED SYMPOSIA 36-42

WILLIAM C MENNINGER INDUSTRY-SUPPORTED SYMPOSIUM 36 MEMORIAL LECTURE 7:00 p.m.-10:00 p.m. Grand Ballroom East, Third Floor, Hilton New York Tom Wolfe BPD: REGULATION OF AFFECT AND IMPULSE Body and Soul CONTROL Supported, by Bristol-Myers Squibb Company Tom Wolfe is recognized around the world as the pre- eminent social commentator of our time. For over Chp.: John M. Oldham, MD. three decades he has chronicled and forecast American Co-Crip.: Andrew E. Skodol II, MD. mass culture with a wit and insight that eludes most futurists. His runaway best seller "fix Bonfire of the A New Findings on the Biology of BPD Vanities stands as a brilliant evocation of both the Martin Bonus, M.D., Christian G. Schmahl, M.D. peculiar class structure and politics of New York Qty, and the economic excesses of the 1980s. His most B BPD and Mood Disorder Spectrum recent novel, A Man in Full has received both Pablo Goldberg, M.D., Maria A Oquendo, M.D., Barbara H outstanding, critical, and popular success. Hailed by Stanley, PhD. Tine and The Wall Street Journal as even better than its phenomenally successful predecessor, it had an C BPD and the Impulse-Control Spectrum unprecedented first-run printing of 1.2 million copies Emil F. Coccaro, M.D. and was nominated for the National Book Award four weeks prior to publication. As Newwxk states, "no D Evidence-Based Psychotherapy for BPD writer - reporter or novelist - is getting our world on Glen O. Gabbard, M.D. paper better than Tom Wolfe." Called the father of "New Journalism," Wolfe is the author of twelve E Pharmacological Treatment of BPD: Current and Future books, including the national best sellers TheRqftt Stuff, Strategies The Electric Kod-A id A dd Test, Radical OncandMau- Jeffrey A Lieberman, M.D. Mauwg the Flak Catchers, and The Bonfire cftbe Vanities. In 1979, Wolfe won the American Book Award for Discussant: Mary C Zanarini, Ed.D. general nonfiction for TheRiqjtt Stiff, In 1980, he was named recipient of the Harold D. Vursell Memorial INDUSTRY-SUPPORTED SYMPOSIUM 37 Award by The American Academy and Institute of Arts 7:00 p.m.-10:00 p.m. and Letters and received the Columbia Journalism Westside Ballroom 1-2, Fifth Floor, Marriott Marquis Award for distinguished service in the field of journalism that same year. Raised in Richmond, INTERFERON-INDUCED DEPRESSION: Virginia, Wolfe received his bachelor's degree from CONSEQUENCES OF TREATING CHRONIC Washington and Lee University and his doctorate in HEPATITIS C American Studies from Yale University. Afterward, he Supported by Roche Laboratories went to work as a reporter for The Springfield Union (in Massachusetts), The WashingonPost, and TheNewYork Chp.: Gregory M. Asnis, M.D. Herald Tribune, where he first began to push the envelope of conventional journalistic license. Since A Interferon-Induced Depression: An Overview and then, his writing has appeared in New York Magazine, Analysis Rdliy% Stone, .Esquire, and Horpers's. Gregory M. Asnis, M.D.

B Pathophysiological Mechanisms of Interferon Alpha- Induced Neuropsychiatric Symptoms Lucile Capuron, Ph.D.

C Pegylated Interferon: Therapy of Hepatitis C With Fewer Depressive Effects John F. Reinus, M.D.

38 MONDAY

D Diagnosis and Treatment of Interferon Alpha- D Plotting the Course to Remission: Balanced Strategies Psychiatric Side Effects in Patients With Hepatitis C to Improve Outcomes Virus Vivien K. Burt, MX). Charles Raison, M.D. E Looking Beyond the Symptoms of Depression: Discussant: Silvia Hafliger, MX). Considerations for Special Populations Ruta M. Nonacs, M.D. INDUSTRY-SUPPORTED SYMPOSIUM 38 7:00 p.m.-10:00 p.m. INDUSTRY-SUPPORTED SYMPOSIUM 40 Westside Ballroom 3-4, Fifth Floor, Marriott Marquis 7:00 p.m.-10:00 p.m. Grand Ballroom, Mezzanine Level, Roosevelt CONCEPTUALIZING AND TREATING ADHD ADULTS PHARMACOTHERAPY OF ADDICTIONS: FROM Supported by Shire US, Inc. CLINICS INTO OFFICE PRACTICE Supported by Reckitt Benckiser Pharmaceuticals Chp.: TimothyE. Wilens, M.D. Chp.: Thomas R. Kosten, MX). A ADHD Adult Case Jefferson B. Prince, MX). A A Patient's Perspective on Office-Based Opiate Treatment B Adult ADHD: A Conceptual Model Walter Ginter Russell A. Barkley, Ph.D. B Prescription Drug Abuse and Psychiatric Comorbidity C Neurobiology of Adult ADHD HWestleyClark,MX>. Francisco Castellanos, MX). C Opiate Pharmacotherapy and the Neurobiology of D Adult ADHD: A Family-Genetic Perspective Opiate Abuse and Dependence Stephen V. Faraone, Ph.D. Thomas R. Kosten, MX).

E Adult ADHD: What Does Neuropsychology Tell Us? D Pain and Depression: Gateway to Addiction and Larry J. Seidman, Ph.D. Opportunity for Treatment Walter Ling, MX). F Pharmacologic Treatment of Adult ADHD TimothyE. Wilens, M.D. E Buprenorphine for Opiate Addiction Treatment: Pharmacology and Ginical Use INDUSTRY-SUPPORTED SYMPOSIUM 39 Laura F. McNicholas, MX). 7:00 p.m.-10:00 p.m. Broadway Ballroom, Sixth Floor, Marriott Marquis F Cultural Sensitivity in Addictions Treatment Gerado Gonzalez, M.D. PLOTTING A COURSE TO REMISSION: NAVIGATING THE INTERSECTION OF MIND, INDUSTRY-SUPPORTED SYMPOSIUM 41 BRAIN, AND BODY 7:00 p.m.-10:00 p.m. Supported by Eli Lilly and Company and Bcehringer Inglheim Imperial Ballroom A, Second Floor, Sheraton New York Pharmaceuticals, Inc. HORMONES, MOOD, AND COGNITION: Chp.: Alan F. Schatzberg, M.D. TREATMENT CONSIDERATIONS IN OLDER Co-Chp.: Ruta M. Nonacs, M.D. WOMEN Supported by Wyeth Pharmaceuticals A Does Everybody Hurt? Epidemiology of Physical Symptoms and Depression Chp.: Lee S. Cohen, MX). Maurice M. Ohayon, M.D. Co-Chp.: Hadine Joffe, MX).

B Comorbidity With Painful Physical Symptoms: A Gonadal Steroids and the Brain: Implications in Aging Understanding the Intersection of Brain and Body Women Bruce A Arnow, Ph.D. Meir Steiner, MX).

C 5HT and Norepinephrine: Navigating the Broad Range B Depression in Perimenopausal Women: Women at Risk of Symptoms and Response to Antidepressants Pedro L. Delgado, M.D. Lee S. Cohen, MX). (CartinHed on nextpag) 39 MONDAY

C Menopause and Mood Disturbances: From Theory to INDUSTRY-SUPPORTED SYMPOSIUM 42 Novel Treatment Strategies 7:00 p.m.-10:00 p.m. Qaudio N. Scares, M.D. Imperial Ballroom B, Second Floor, Sheraton New York

D Assessment and Treatment of Hot Flashes in REACHING BEYOND ALZHEIMER'S DISEASE WITH Menopausal Women CHOLINERGIC THERAPY HadineJoffe,MD. Supported by Nautrtis Pharmtceuticals Cooperation

E The Women's Health Institute Memory Study. Updates Chp.: Steven G. Potkin, M.D. on the Effect of Estrogen Plus Progestin on die Incidence of Dementia and Cognitive Impairment in A Dementia With Lewy Bodies Within Our Grasp Menopausal Women Ian G. McKeith, MX). Sally A. Shumaker, PhJD., Claudine Legault, PhD. B Parkinson's Disease Beyond Dopaminergic Therapy Amos Korczyn, M.D.

C Exploring and Managing Vascular Features of Dementia Martin K. Farlow, M.D.

D Extending Treatment Options and Not Letting Go Gustavo Alva, M.D.

40 TUESDAY, MAY 4, 2004

157TH ANNL >A1. MEE TING

A Optimizing Functional Outcome in Bipolar Disorder 7:00 a.m. Sessions Deborah A, Yurgelun-Todd, Ph.D.

PART 2 OF INDUSTRY-SUPPORTED BREAKFAST B Neuroimaging Findings in Bipolar Disorder SYMPOSIA 31-35 Stephan H. Heckers, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 31, C New Directions in Medication Development for Bipolar PART 2 Disorder 7:00 a.m.-8:30 a.m. Bruce M. Cohen, M.D., William Carlezon, Ph.D., Perry F. Grand Ballroom East, Third Floor, Hilton New York Renshaw, M.D., Andrew L. Stoll, M.D.

NEW ADVANCES IN THE TREATMENT OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 34, PSYCHOSIS, PART 2 PART 2 Supported by Bristd-Myers Squibb Company 7:00 a.m.-8:30 a.m. Imperial Ballroom A, Second Floor, Sheraton New York Chp.: Robert E. Hales, M.D. Co-Chp.: Stuart C Yudofsky, M.D. EVIDENCE-BASED MEDICINE: THE NEXT GENERATION, PART 2 A Antipsychotic Therapies in Geriatric Patients: The Supported by Wyeth Pharmaceuticals Importance of Safety and Tolerability J. Michael Ryan, M.D. Chp.: K. Ranga R. Krishnan, M.D.

B Unique Challenges in the Pharmacotherapy of First- A Psychotherapy for Treatment of Depression: Recent Episode Schizophrenia Developments Diana O. Perkins, M.D. Thomas Lynch, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 32, B Pharmacological Treatment of Agitation in Dementia: PART 2 Evidence-Based Recommendations 7:00 a.m.-8:30 a.m. Warren D. Taylor, M.D. Westside Ballroom 3-4, Fifth Floor, Marriott Marquis INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 35, CURRENT ALZHEIMER'S DISEASE TREATMENTS PART 2 AND BEYOND: ADVANCES IMPACTING CLINICAL 7:00 a.m.-8:30 a.m. PRACTICE, PART 2 Imperial Ballroom B, Second Floor, Sheraton New York Supported by Forest Laboratories, Inc. TRANSCENDING EFFICACY: EFFECTIVE TREATMENT OF PSYCHOSIS ACROSS DISORDERS, Chp.: Trey Sunderland, M.D. PART 2 Supported byAstraZenxa Pbarmaceutxak A Neuroimaging in Alzheimer's Disease: Diagnosis, Treatment and Prevention Chp.: Pierre N. Tariot, M.D. P. Murali Doraiswamy, M.D. Co-Chp.: John W. Newcomer, M.D. A Avoiding Comorbidities in Treatment B New Treatment Strategies for Alzheimer's Disease: The John W. Newcomer, M.D. Role of Early Diagnosis Trey Sunderland, M.D. B Transcending Efficacy in Psychosis: Where the Rubber Meets the Road INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 33, Jeanne Jackson-Siegel, M.D. PART 2 7:00 a.m.-8:30 a.m. Broadway Ballroom, Sixth Floor, Marriott Marquis

RECOGNIZING THE MANY FACES OF BIPOLAR DISORDER, PART 2 Supported by Eli Lilly and Company

Chp.: Bruce M. Cohen, M.D. 41 TUESDAY

a,o>. Sessions COURSE 58 8:00 a.m.-12 noon Gramercy A, Second Floor, Hilton New York

COURSES 53-61 THE DETECTION OF MALINGERED MENTAL Course descriptions are available in the CME ILLNESS Course Brochure included in your registration packet Admission by ticket only. Director: Phillip J. Resnick, MD.

COURSE 59 8:00 a.m.-12 noon COURSE 53 8:00 a.m.-12 noon Nassau Suite A, Second Floor, Hilton New York Concourse B, Concourse Level, Hilton New York TREATING MEDICAL STUDENTS AND PHYSICIANS DOING RESEARCH ON A SHOESTRING BUDGET Co-Directors: Michael F. Myers, M.D., Leah J. Dickstein, MD. Director. Mantosh J. Dewan, MD. Faculty: Michele T. Pato, MD., Edward K. Silberman, M.D. COURSE 60 8:00 a.m.-12 noon COURSE 54 8:00 a.m.-12 noon Nassau Suite B, Second Floor, Hilton New York Concourse E, Concourse Level, Hilton New York DISASTER PSYCHIATRY: TERRORISM, TRAUMA, AND THINGS TO DO EXPANDING HEALTH CARE DELIVERY? LET A PA Carmittee on Psychiatric Dimensions rfDisaster TELEPSYCHIATRY HELP! Director: Joseph C Napoli, MD. Director: Steven E. Hyler, MD. Faculty: Michael Blumenfield, MD., V. Alex Kehayan, Ed.D. Faculty. Clarice J. Kestenbaum, MD., Namita Rajouria, MD., Gerald Segal, MS., William M Tucker, M.D. COURSE 61 8:00 a.m.-12 noon COURSE 55 8:00 a.m.-12 noon Sutton North, Second Floor, Hilton New York Concourse G, Concourse Level, Hilton New York PAIN MANAGEMENT FOR PSYCHIATRISTS: AN OVERVIEW OF TREATMENT APPROACHES THE WAY OF YOGA AND HERBS IN THE TREATMENT OF STRESS, DEPRESSION, AND AGGRESSION Director Raphael J. Leo, M.D.

Co-Directors: Richard P. Brown, M.D., Patricia L. Gerbarg, MX). **:UU a.m. Sessions COURSE 56 8:00 a.m.-12 noon Beekman Parlor, Second Floor, Hilton New York CLINICAL .CASH CONFERENCE 2 9:00 a.m.-10:30 a.m. HOW TO USE YOUR PALM OS PDA IN PSYCHIATRIC Rooms 3D06/7, Level 3, Javits Center PRACTICE: BASIC ASSESSING AND TREATING PSYCHIATRIC Co-Directors: John S. Luo, MD., Richard A. Montgomery, M.D. SYMPTOMS IN INDIVIDUALS WITH Faculty: Robert J. Boland, MD., Carlyle H. Chan, M.D., CARDIOVASCULAR DISEASE Robert C Hsiung, MD., Christopher R. Thomas, M.D. Moderator: Christine E. Skotzko, MD. COURSES/ 8:00 a.m.-12 noon Presenters: Lynnette Krueger, M.S.N., Maria A. Bryant Suite, Second Floor, Hilton New York Rueda-Lara, MD.

THE MISSING PIECE OF THE PUZZLE: TIC THIS SESSION IS OPEN TO APAMEMBERS ONLY. DISORDERS IN ADULTS WITH OCD OR ADD BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE. Director: Maria A. Pugliese, M.D. Faculty. J. Paul Heble, Ph.D., Michael N. Rubenstein, MD., Orrin Palmer, MD., Paul F. Kriger, B.S., Laura J. Umbrell, L.P.N.

42 TUESDAY

CONTINUOUS CLINICAL CASE CONFERENCE 1: COURSE 65 9:00 a.m.-4:00 p.m. • *At< i ;•• Madison Suite, Second Floor, Hilton New York 9:00 a.m.-12 noon Rooms 3D01/12, Level 3, Javits Center A PSYCHODYNAMIC APPROACH TO TREATMENT- REFRACTORY MOOD DISORDERS HELPING PATIENTS COUNTER DEMORALIZATION WHILE LIVING WITH A CHRONIC OR RECURRENT Director: Eric M. Plakun, M.D. PSYCHIATRIC ILLNESS Faculty: David L. Mintz, M.D., Edward R. Shapiro, M.D.

Moderator James L. Griffith, M.D. COURSE 66 9:00 a.m.-4:00 p.m. Presenters: Lynne M. Gaby, M.D., Julia B. Frank, M.D., Murray Hill A, Second Floor, Hilton New York Robert W. Keisling, M.D., Jeffrey S. Akman, M.D. UPDATES IN NEUROPSYCHIATRY: DELIRIUM, TRAUMATIC BRAIN INJURY, AND POST-STROKE THIS SESSION IS OPEN TO APAMEMBERS ONLY. DEPRESSION BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE. Director: Jose R. Maldonado, M.D.

COURSE 67 9:00 a.m.-4;00 p.m. COURSES 62-68 Murray Hill B, Second Floor, Hilton New York Course descriptions are available in the CME Course Brochure included in your registration PERSONALITY AND POLITICAL BEHAVIOR packet Admission by ticket only. International Society for Pditical Psychology and A PA Council on Global Psychiatry

COURSE 62 9:00 a.m.-4:00 p.m. Director: Jerrold M. Post, M.D. Concourse A, Concourse Level, Hilton New York COURSE 68 9:00 a.m.-4;00 p.m. TREATING THE SELF AND INTERPERSONAL Rhinelander Gallery North/Center, Second Floor, Hilton PROBLEMS OF PERSONALITY DISORDER New York HOW TO PASS THE BOARDS! THE PART II ORAL Director John Livesley, M.D. EXAM

COURSE 63 9:00 a.m.-4;00 p.m. Co-Directors: James GY. Chou,, M.D., Gregory C Bunt, M.D. Clinton Suite, Second Floor, Hilton New York

PSYCHIATRY UPDATE: IN SPANISH DISCUSSION GROUPS 10-13 A mzrican Society of Hispanic Psychiatry 9:00 a.m.-10:30 a.m. Co-Directors: Gabriel Kaplan, M.D., Javier I. Escobar, M.D. Faculty: Pedro L. Delgado, M.D., Eduardo Dunayevich, M.D., These sessions are limited to 25 participants on a first-come, Jacobo E. Mintzer, M.D., Humberto Marin, M.D., first-served has is. Ana Kaplan, M.D. 10 Robert I. Simon, M.D., on Assessing and Managing Suicide COURSE 64 9:00 a.m.-4:00 p.m. Risk; Clinically-Based Guidelines for Risk Management (Meet Gramercy B, Second Floor, Hilton New York the Authors) Rooms 2D02/3, Level 2, Javits Center INTEGRATED DUAL DISORDER TREATMENT: EVIDENCE-BASED PRACTICE 11 Peter V. Rabins, M.D., on What Can Brain Diseases Teach Us About the Mind-Brain Interface? Co-Directors: MaryF. Brunette, M.D., Robert E. Drake, M.D. Rooms 2D04/5, Level 2, Javits Center Faculty: LindyFox, MA, Kim T. Mueser, Ph.D., Douglas Noordsy, M.D. 12 Salman Akhtar, M.D., on Qoss-Cultural Psychotherapy Rooms 2D06/7, Level 2, Javits Center 13 Altha J. Stewart, M.D., on Public Psychiatry: Leading the Way in Transforming Service Delivery in the 21st Century Room 2D08, Level 2, Javits Center

43 TUESDAY

LLCTLRFS 12-15 LECTURE 13

9:00 a.m.-10:30 a.m. LECTURE 12 Room IE 15, Level 1, Javits Center

9:00 a.m.-10:30 a.m. Nora D. Volkow, M.D. Rooms 1E07/8, Level 1, Javits Center Why Docs the Human Brain Become Addicted? APA'S RESEARCH IN PSYCHIATRY Collaborative Session With the Natural Institute AWARD LECTURE an Drug Abuse

JackD. Bare has, M.D. Chp.: David M. McDowell, MD. Co-Chp.: Patricia I. Ordorica, M.D. Adventures in Psychiatric Research: Neurobiology to Public Policy Nora D. Volkow, M.D., is Director of the National Institute on Drug Abuse (NIDA) in Bethesda, Maryland. Chp.: Alan F. Schatzberg, MD. Before assuming this position in May 2003, she was Associate Director of Life Sciences, Director of Nuclear Co-Chp.: Barrel A. Regier, M.D. Medicine, and Director of the NIDA-Department of Jack D, Barchas, MD., is Barklie McKee Henry Energy Regional Neuroimaging Center at Brookhaven Professor and Chair of the Department of Psychiatry at National Laboratory in Upton, New York She was also We ill Medical College of Cornell University and Psychia- Professor of Psychiatry and Associate Dean of the trist-in-Chief at New York Hospital in New York Gty. School of Medicine at the State University of New York He is also Executive Director of the Pntzker Depression at Stony Brook. Her research has focused on the Network, Chair of the Board of Trustees of the New mechanisms underlying the reinforcing, addictive, and York Academy of Medicine and of the Board of Trustees toxic properties of drugs of abuse in the human brain. of the Association for Research in Nervous and Mental She has also investigated the rewarding and therapeutic Disease, and President and Chair of the Board of actions of stimulant drugs and the changes that occur in Directors of the Robert j. and Claire Pasarow Founda- dopamine brain activity with aging. Dr. Volkow is the tion. Dr. Barchas formerly was Editor of A nhnes cf author or coauthor of more than 280 peer-reviewed General I-tydnatry. HLs scholarly activities have centered publications and more than 50 book chapters and other on the study of neuroregulators and have included re- manuscripts and is the editor of three books. She has search projects in the areas of molecular regulation, bio- received numerous awards for her research and has been chemical neuroanatomy, analytical neurochemistry, be- elected to the Institute of Medicine of the National havioral neurochemistry, and clinical biochemistry and Academy of Sciences. Dr. Volkow received her medical pharmacology. A Distinguished Life Fellow of the degree from the National University of Mexico in Mexico American Psychiatric Association and a member of the Qty and completed her residency in psychiatry at New Institute of Medicine of the National Academy of York University. Sciences, Dr. Barchas is a recipient of the A.E. Bennett Distinguished Psychiatrist Series Award and the Lifetime Achievement Award from the THIS SESSION WILL BE AUDIOTAPED. Society of Biological Psychiatry. Dr. Barchas received his medical degree from Yale University School of Medicine in New Haven, Connecticut, and completed his residency MASTIi K HI >l "GATOR (XJMCAL in psychiatry at Stanford University in Stanford, California. roxsLi TvnoNs THIS SESSION WILL BE AUDIOTAPED. 9:00 a.m.-10:30 a.m.

This session is limited to 25 participants on a first-come, first-served basis.

Francisco Fernandez, M.D., on Neurupsvchiatric Complications of f 1IV-1 Infection Room 1DC5, Level 1, Javits Outer

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP C\RD REQUIRED FOR ADMITTANCE.

44 TUESDAY

RESEARCH ADVANCES IN MEDICINE WORKSHOPS 9:00 a.m.-11:00 a.m. Room 1E09, Level 1, Javits Center COMPONENTS 21-26 THE EPIDEMIOLOGY AND TREATMENT OF PSYCHIATRIC COMORBIDITIES COMPONENT WORKSHOP 21 9:00 a.m.-10:30 a.m. Collaborative Session With the National Institute an Drug A buse Room IE 11, Level 1, Javits Center

Chp.: Joel J.Wallack,M.D. THE NEUROBIOLOGYOF SELF-AWARENESS: Co-Chp.: Geetha Jayaram, M.D. LEARNING FROM AUTISM AND BPD ABOUT HOW WE KNOW OURSELVES Participants: Kathleen Merikangas, Ph.D., on Epidemiology of APA Committee on Psychotherapy by Psychiatrists Comorbid Psychiatric and Addictive Disorders Joseph Biederman, M.D., on Comorbidity of Psychiatric and Chp.: Bernard D. Beitman, M.D. Addictive Disorders in Children Participants: George I. Viamontes, M.D., Jyotsna Nair, M.D., Paul Thuluvath, M.D., on Depression in Hepatitis C Patients Glen O. Gabbard, M.D., Eva M. Szigethy, M.D. and Interferon Treatment Joel Gallant, M.D., on Research Advances in HIV Care COMPONENT WORKSHOP 22 9:00 a.m.-10:30 a.m. THIS SESSION WILL BE AUDIOTAPED. Rooms 2D10/11, Level 2, Javits Center

BLOOD ON THE FLOOR: RESPONDING TO RE VIEW OF PSYCHIATRY; SECTION 1 CATASTROPHIC EVENTS AND HIGH RISKS 9:00 a.m.-12:30 p.m. APA Committee on Standards and Survey Procedures Special Events Hall ID, Level 1, Javits Center Chp.: Steven I. Altchuler, M.D. NEUROPSYCHIATRIC ASSESSMENT Participants: Marlin RA Mattson, M.D., Robert A. Wise, M.D.

Chp.: Stuart C. Yudofsky, M.D. COMPONENT WORKSHOP 23 9:00 a.m.-10:30 a.m. Co-Chp.: Florence Kim, M.D. Rooms 2D12/13, Level 2, Javits Center 1 Withdrawn THE TIES THAT BIND: CONSIDERATIONS OF CULTURE AND FAMILY IN MENTAL HEALTH 2 Neurological and Neuropsychological Exam of the TREATMENT Psychiatric Patient APA/SAMHSA Minority Felloisship Selectionarid Program Mark Lovell, Ph.D., Glen Getz, MA Comespondirg Committee

3 Electrophysiological Testing Chp.: Timothy G. Benson, M.D. Nashaat N. Boutros, M.D., Struve Frederick, Ph.D. Participants: Marketa M. Wills, M.D., Shanta P. Henderson, M.D., Osvaldo Gaytan, Jr., M.D., Denise M. 4 Neuropsychiatric Lab Testing Richardson, M.D. Florence Kim, M.D., Stuart C Yudofsky, M.D. COMPONENT WORKSHOP 24 9:00 a.m.-10:30 a.m. 5 Selected Neuroimaging Topics in Psychiatric Disorders O'Neill Room, Fourth Floor, Marriott Marquis Thomas E. Nordahl, M.D., Ruth E. Salo, Ph.D. UNIVERSAL HEALTH CARE AND OTHER MODELS APA Council on Healthcare Systems and Fintndrg ROUND TABLE DISCUSSION 9:00 a.m.-10:30 a.m. Chp.: Barry F. Chaitin, MD. Room IE 10, Level 1, Javits Center Participants: Anita S. Everett, M.D., Bruce J. Schwartz, M.D., Paul H Wick, M.D., Frederick J. Stoddard, Jr., M.D., Allison M. COERCION AND TREATMENT: MEDICAL, LEGAL, Wehr, M.D., Manoj R. Shah, M.D., Carrie L. Ernst, M.D., AND ETHICAL ISSUES Rodrigo A. Munoz, MD., Captane P. Thomson, M.D. Moderator: Carol Fisler, J.D. Participants: A. Sasha Bardey, M.D., Mary Zdanowicz, J.D., Heather Barr, J.D., Thomasetta Harper

45 TUESDAY

COMPONENT WORKSHOP 25 9;00 a.m.-10:30 a.m. ISSUE WORKSHOP 36 9:00 a.m.-10:30 a.m. Palace Room, Sixth Floor, Marriott Marquis Room IE 13, Level 1, Javits Center

REVISION OF THE APA ETHICS ANNOTATIONS: USING COGNITIVE THERAPY FOR PSYCHOSIS IN FOSTERING DIALOGUE PSYCHIATRIC PRACTICE APA Task Faroe to Update theEthics A rmotatians Chp.: David G. Kingdon, M.D. Chp.: Laura W. Roberts, M.D. Participants: Douglas Turkington, MX)., Shanaya Rathod, MX). Participants: Michael R Arambula, M.D., Richard D. Milone, M.D., Philip Candilis, M.D., S. Nassir Ghaemi, MD., ISSUE WORKSHOP 37 9:00 a.m.-10:30 a.m. Scott Y. Kim, MX)., Jennifer Radden, Ph.D. Room IE 14, Level 1, Javits Center

COMPONENT WORKSHOP 26 9:00 a.m.-10:30 a.m. THE THEATER OF EMOTIONS Columbia/Duffy Rooms, Seventh Floor, Marriott Marquis Chp.:IanE.Alger,MX>. THE JUVENILE JUSTICE SYSTEM: ASSESSMENT, Participants: Ferruccio A di Cori, M.D., Ferruccio SERVICES, AND DATA USE Marotti, MD., Stefania Papirio, Alessandro Nicolo, APA Corresponding Committee on Juvenile Justice Issues Lisa Colosimo, Critstiano Adiutori

Co-Chps.: R Gregg Dwyer, M.D., Carl C Bell, MX). ISSUE WORKSHOP 38 9:00 a.m.-10:30 a.m. Participants: Johnny L. Williamson, MX)., Richard L. Room IE 16, Level 1, Javits Center Frierson, MX). INITIAL PSYCHIATRIC INTERVIEW: A PSYCHODYNAMIC APPROACH TO 90801 ISSUES 53-58 A msriamA caderry afPsydxarialysis and Dynamic Psychiatry

Chp.: Gopalakrishna K. Upadhya, MX). ISSUE WORKSHOP 33 9:00 a.m.-10:30 a.m. Participant Moitri N. Datta, MX). Rooms 1E01/2, Level 1, Javits Center ISSUE WORKSHOP 39 9:00 a.m.-10:30 a.m. MENTAL HEALTH NEEDS OF OUR SOLDIERS AND Room 3D02/11, Level 3, Javits Center THEIR FAMILIES HOW TO LAUNCH A SUCCESSFUL PRIVATE Chp.: Howard J. Osofsky, M.D. PRACTICE, PART 1 Participants: Neal Mazer, MX)., Robert J. Ursano, M.D., Marleen Wong, Ph.D. Co-Chps.: William E. Callahan, Jr., MX)., Keith W. Young, MX). Participants: Jacqueline M. Melonas, J.D., Donna ISSUE WORKSHOP 34 9:00 a.m.-10:30 a.m. Vanderpool, J.D., Martin G. Tracy, J.D., Tracy R Gordy, M.D., Rooms 1E03/4/5, Level 1, Javits Center Chester W. Schmidt, Jr., M.D.

THE IMPACT OF MIGRATION ON ADDICTIVE ISSUE WORKSHOP 40 9:00 a.m.-10:30 a.m. DISORDERS: A CHALLENGE FOR THE AMERICAS Room 3D03/10, Level 3, Javits Center Collaboratne Session With the National Institute on Drug A buse MY NAME IS WALTER JAMES CROSS Chp.: Amelia Musacchio de Zan, MX). Participants: Pedro Ruiz, M.D., Patricia I. Ordorica, MX). Chp.: David L. Dawson, MX).

ISSUE WORKSHOP 35 9:00 a.m.-10:30 a.m. ISSUE WORKSHOP 41 9:00 a.m.-10:30 a.m. Room IE 12, Level 1, Javits Center Rooms 3D04/9, Level 3, Javits Center

THE CLINICAL IMPACT OF TREATING CIVIL AND ONLINE VIDEO GAMES: PSYCHOPATHOLOGICAL CRIMINALLY-MANDATED PSYCHIATRIC PATIENTS OR PSYCHOTHERAPEUTIC?

Co-Chps.: Merrill R Rotter, M.D., Ali Khadivi, Ph.D. Co-Chps.: JeffreyN. Wilkins, M.D., Jack Kuo, M.D. Participants: Scott D. Rogge, M.D., Patrica Mourilhe, M.D. Participants: William Huang, M.D., Kimberly S. Young, Ph.D., Kurt Squire, Ph.D., Stephanie M. Stewart, M.D., Maressa H. Orzack, Ph.D., Constance Steinkuehler, Ph.D. 46 TUESDAY

ISSUE WORKSHOP 42 9:00 a.m.-10:30 a.m. ISSUE WORKSHOP 48 9:00 a.m.-10:30 a.m. Odets Room, Fourth Floor, Marriott Marquis Imperial/Julliard Rooms, Fifth Floor, Marriott Marquis

INFERTILITY: A CHRONIC ILLNESS WITH CHRONIC EMERGING PHARMACOTHERAPIES FOR CHALLENGES TREATMENT OF STIMULANT DEPENDENCE Collaborative Session With the National Institute on Drug A buse Chp.: Roxanne G Dryden-Edwards, M.D. Chp.: Francis J. Vocci, Ph.D. ISSUE WORKSHOP 43 9:00 a.m.-10:30 a.m. Participants: Steven Shoptaw, Ph.D., Kyle M. Kampman, M.D., Wilder Room, Fourth Floor, Marriott Marquis Frances R. Levin, M.D., Stephen L. Dewey, Ph.D.

VALUES-BASED TREATMENT OF RELATIONAL ISSUE WORKSHOP 49 9:00 a.m.-10:30 a.m. DISORDERS Lyceum Room, Fifth Floor, Marriott Marquis

Co-Chps.: Glenn N. Siegel, M.D., Mary Pittman, M.S. UPDATE ON HEPATITIS C AND PSYCHIATRIC ISSUES ISSUE WORKSHOP 44 9:00 a.m.-10:30 a.m. Ziegfeld Room, Fourth Floor, Marriott Marquis Co-Chps.: Andrew F. Angelino, M.D., Glenn J. Treisman, M.D. ISSUE WORKSHOP 50 9:00 a.m.-10:30 a.m. ORAL BOARDS BOOT CAMP Majestic/Music Box/Winter Garden, Sixth Floor, Marriott Marquis Co-Chps.: Elyse D. Weiner, M.D., Eric D. Peselow, M.D. FIBROMYALAGIA: CURRENT UNDERSTANDING ISSUE WORKSHOP 45 9:00 a.m.-10:30 a.m. AND FUTURE DIRECTIONS Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis Chp.: Alan Z.A. Manevitz, M.D. STEROID ABUSE: GROWING PROBLEM FOR Participant: James P. Halper, M.D. ADOLESCENTS AND A HIDDEN PROBLEM FOR ADULTS ISSUE WORKSHOP 51 9:00 a.m.-10:30 a.m. Collaboratiw Session With the National Institute on Drug A buse Plymouth/Uris/Shubert Rooms, Sixth Floor, Marriott Marquis Chp.: Donald R. Vereen, Jr., M.D. Participants: Gary I. Wadler, M.D., Harrison G. Pope, Jr., M.D., THE ART OF THE UNCONSCIOUS: SHAKESPEARE, Linn Goldberg, M.D., Diane L. Elliot, M.D. POETRY, FILM, AND PSYCHIATRY

ISSUE WORKSHOP 46 9:00 a.m.-10:30 a.m. Co-Chps.: Steven E. Pflanz, M.D., Charles R. Joy, M.D. Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis ISSUE WORKSHOP 52 9:00 a.m.-10:30 a.m. ENGAGING THE HOMELESS IN TREATMENT Royale Room, Sixth Floor, Marriott Marquis STRATEGIES AND RESULTS THE IMPACT OF 9/11 ON PSYCHIATRIC RESIDENTS Chp.: John S. Mclntyre, M.D. AND TRAINING PROGRAMS Participants: Kevin Mclntyre, M.D., Linda Morgan, Ph.D., Odysseus Adamides, Jr., M.D. Chp.: Renato D. Alarcon, M.D. Participants: Nyapati R. Rao, M.D., Maria A. Oquendo, M.D., ISSUE WORKSHOP 47 9:00 a.m.-10:30 a.m. Milton Kramer, M.D., Anne O'Connell, M.D. Booth/Edison Rooms, Fifth Floor, Marriott Marquis ISSUE WORKSHOP 53 9:00 a.m.-10:30 a.m. NEW TECHNOLOGIES FOR THE ASSESSMENT OF Empire/Hudson Rooms, Seventh Floor, Marriott Marquis ADHD IMPLEMENTING THE INSTITUTE OF MEDICINE Co-Chps.: Martin H Teicher, M.D., Gianni L. Faedda, M.D. REPORT: FOSTERING RESEARCH CAREERS VIA Participants: Carl M. Anderson, Ph.D., F. Xavier RESIDENCIES Castellanos, M.D. Chp.: Joel Yager, M.D. Participants: Wayne S. Fenton, M.D., Regina S. James, M.D., John F. Greden, M.D., Joel J. Silverman, M.D. 47 TUESDAY

ISSUE WORKSHOP 54 9:00 a.m.-10:30 a.m. MLD1A3-4 Gotham Room, Seventh Floor, Marriott Marquis MEDIA WORKSHOP 3 9:00 a.m.-12 noon A SHARED-CARE MODEL FOR TREATING THE Room 1D06, Level 1, Javits Center HOMELESS MENTALLY ILL Cultural Assessment in Clinical Psychiatry: Two Training Ohp.: Samuel Packer, MX). Videotapes Participants: Carol Zoulalian, M.A., Sharon Gazely, MX). Co-Chps.: Francis G. Lu, MX)., Harriett Koskoff ISSUE WORKSHOP 55 9:00 a.m.-10:30 a.m. Gramercy Room, Seventh Floor, Marriott Marquis MEDIA WORKSHOP 4 9:00 a.m.-12 noon Room IE 06, Level 1, Javits Center GROUP INTERVENTIONS WITH ADOLESCENTS IN OUTPATIENT, INPATIENT, AND SCHOOL SETTINGS When Boys Fly: Club Drugs in the Gay Male Community

Chp.:FadyHajal,M£>. Chp.: Petros Levounis, MX). Participant: Saul Scheidlinger, Ph.D. Participant: Steven J. Lee, MX).

ISSUE WORKSHOP 56 9:00 a.m.-10:30 a.m. Herald/Soho Rooms, Seventh Floor, Marriott Marquis 11:00 a.m. Sessions ADDICTION RESEARCH AS A CAREER CHOICE IN PSYCHIATRY DISCUSSION GROUPS 14-17 Collaborative Session With the National Institute anDrugA buse 11:00 a.m.-12:30 p.m. Chp.: Ivan D. Montoya, MX). Participants: Herbert D. Kleber, MX)., Douglas M. These sessions are limited to 25 participants on a first-come, Ziedonis, MX)., Ronald L. Cowan, MX)., Nathalie Maullin, MX)., first-served basis. Kathleen T. Brady, MX)., Charles P. O'Brien, MX). 14 Joel F. Paris, M.D., on Personality Disorders Over Time ISSUE WORKSHOP 57 9:00 a.m.-10:30 a.m. (Meet the Authors) Cantor/Jolson Rooms, Ninth Floor, Marriott Marquis Rooms 2D02/3, Level 2, Javits Center

IT DOESN'T HAPPEN TO US: EXPLORING TRAUMA 15 Barton J. Blinder, M.D., on Psychiatric Comorbidity in the AND RESILIENCY IN MINORITIES Eating Disorders: Diagnosis, Treatment, and Research Rooms 2D04/5, Level 2, Javits Center Co-Chps.: Napoleon B. Higgins, Jr., M.D., Lacresha L. Hall, MX). Participants: Jean-Marie E. Alves-Bradford, M.D., Eric R. 16 Paul S. Appelbaum, M.D., on Ethics in Psychiatric Practice Williams, MX)., Aruna S. Rao, M.D. Room 2D08, Level 2, Javits Center ISSUE WORKSHOP 58 9:00 a.m.-10:30 a.m. Marquis Ballroom Salons A/B, Ninth Floor, Marriott 17 Nancy C Andreasen, M.D., on Publishing and Grant (For Residents Onty) Marquis Writing Versailles Terrace, Second Floor, Sheraton New York CUTTING-EDGE MANAGEMENT OF TOURETTE'S SYNDROME AND ITS COMORBIDITIES

Co-Chps.: Cathy L. Budman, MX)., John T. Walkup, M.D. Participants: Anthony L. Rostain, MX)., Fred Penzel, Ph.D.

48 TUESDAY

Lectures 14-15 LECTURE 15

11:00 a.m.-12:30 p.m. LECTURE 14 Room IE 15, Level 1, Javits Center

11:00 a.m.-12:30 p.m. Charles P. O'Brien, M.D. Rooms 1E07/8, Level 1, Javits Center Anticraving Medication: A New Class of APA'S OSKAR PFISTER AWARD LECTURE Psychoactive Medication? Collaborative Session With the Naticnd Institute Elizabeth S. Bowman, M.D. an Dn^> A bi&e

Dialogue From the Rims of the Grand Canyon: On Chp.: Erie D. Collins, MD. Bridging the Post-Freudian Chasm Between Co-Chp.: David A, Baron, M.D. Religion and Psychiatry Charles P. O'Brien, M.D., is Kenneth Appel Professor Chp.: George T. Harding IV, M.D. and Vice-Chairman of the Department of Psychiatry at the University of Pennsylvania and Director of Research Freud's theories on religion advanced psychiatric at the Mental Illness Research, Education and Clinical understanding of religion, but his dismissive Center at the Veterans Affairs Medical Center in Phila- reductionism created a wide gap of eroded trust between delphia. He established and directs a clinical research psychiatrists and clergy. Elizabeth S. Bowman, M.D., program that has elucidated the basic nature of addiction discusses the nature of this gap and proposes a bridge for and improved the treatment of addictive disorders discussion between science and religion that ac- through investigation of new medications, behavioral in- knowledges the differences in language and methods terventions, and instruments for measuring the seventy between these disciplines. Dr. Bowman is Qinical of addiction. The findings of Dr. O'Brien's research Professor of Neurology at Indiana University School of group have been described in more than 400 publica- Medicine in Indianapolis where she formerly was tions. A Distinguished Life Fellow of the American Psy- Professor of Psychiatry. She is also in the private chiatric Association (APA), Dr. O'Brien is Past President practice of psychiatry and is Attending Psychiatrist in the of the American College of Neuropsychopharmacology epilepsy clinic at Indiana University Hospitals in Indian- and the Association for Research in Nervous and Mental apolis. Her religion and psychiatry curriculum taught at Disease. He is a member of the Institute of Medicine of the Indiana University School of Medicine served as the ) the National Academy of Sciences and a recipient of sev- core of the \9%Madd Gl (,AT( >K (:i.l M( :AI. CiiNsl ITATIONS6--

11:00 a.m.-12:30 p.m.

Thesfirst-servee sessionds arbasise limite. d to 25 participants on a first-come, first-served basis.

6 MarRook Em. Servis 1D04,, M.D.Leve,l 1o,n Javit Personalits Centey Disorderr s Room 11)0-4, Level 1, Javits Ck'nter

••/f.V2*t* i/i rjt.\/ r»l'^V

49 TUESDAY

7 Ira D. Click, M.D., on Combining and Integrating 12 noon Medication and Psychotherapy for Schizophrenia and Other 28 Buprenorphine: An Effective Treatment for Heroin Axis 1 Disorders Addicts Room 1D05, Level 1, Javits Center Paolo Marzorati, MD., Livia Guglielmino, MD., Rosella Silenzio, Pierluig Vigezzi, MD., Filomena Corrado, MD., THESE SESSIONS ARE OPEN TO APAMEMBERS Margherita De Chiara, MD., Edoardo Cozzolino, MD. ONLY. BLUE REGISTRATION BADGE OR APA THIS SESSION WILL BE AUDIOTAPED. MEMBERSHIP CARD REQUIRED FOR ADMITTANCE. SCIENTIFIC AND CLINICAL REPORT SESSION 10 11:00 a.m.-12:30 p.m. MEDICAL UPDATE 2 Room IE 11, Level 1, Javits Center 11:00 a.m.-12:30 p.m. Room IE 13, Level 1, Javits Center PANIC DISORDER

HEPATITIS B AND C: WHAT'S NEW? Chp.: David A Casey, MD. Co-Chp.: Andrew O. Skinner, MD. Chp.: Silvia Hafliger, MD. Presenter: Robert S. Brown, Jr., M.D. 11:00 a.m. THIS SESSION WILL BE AUDIOTAPED. 29 Early Detection of Relapse in Patients with Panic Disorder With Agoraphobia RESEARCH CONSULTATION WITH Matig R. Mavissakalian, MD., Shenyang Gou, Ph.D. 11:30 a.m. 11:00 a.m.-12:30 p.m. 30 Three-Year Prophylaxis in Panic Disorder: To Continue or Discontinue? This session is limited to 25 participants on a first-come, Yujuan Choy, MD., Eric D. Peselow, MD., Mary first-served basis. Paizis, M.D., Jamie A. Luff, MD., Gonzalo Laje, MD., Mary T. Guardino, B.A., Mary Anne Pressman, M.D. 2 Matcheri S. Keshavan, M.D., on Brain Imaging Studies in Schizophrenia 12 noon Room 1D03, Level 1, Javits Center 31 Discontinuation of Medications in Panic Patients Eric D. Peselow, MD., Mary Anne Pressman, MD., Jamie A SCIENTIFIC AND CLINICAL REPORT Luff, MD., Mary Paizis, M.D., Gonzalo Laje, M.D., MaryT. SESSIONS 9-18 Guardino, B.A. THIS SESSION WILL BE AUDIOTAPED. SCIENTIFIC AND CLINICAL REPORT SESSION 9 11:00 a.m.-12:30 p.m. SCIENTIFIC AND CLINICAL REPORT SESSION 11 Rooms 1E01/2, Level 1, Javits Center 11:00 a.m.-12:30 p.m. Room IE 12, Level 1, Javits Center BUPRENORPHINE THERAPY ISSUES IN DEPRESSION Chp.: David M McDowell, MD. Co-Chp.: Daniel W. Hicks, MD. Chp.: Glenn J. Treisman, MD. Co-Chp.: Christine J. Truman, MD. 11:00 a.m. 26 ^Challenges in Increasing Access to Buprenorphine 11:00 a.m. Treatment 32 Brain Bioenergetics and Thyroid Hormone Treatment in Joyce C West, Ph.D., Thomas R. Kosten, MD., Joshua E. MDD Wilk, Ph.D., Dace Svikis, Ph.D., Elisa G. Triffleman, M.D., Dan V. losifescu, M.D., Nicholas R. Bolo, Ph.D., John E. Donald S. Rae, MA., William E. Narrow, MD. Jensen, Ph.D., Andrew A Nierenberg, MD., Julie L. Ryan, B.A, Perry F. Renshaw, MD., Maurizio Fava, M.D. 11:30 a.m. 27 *A Double-Blind, Double-Dummy, Randomized, Prospective, Efficacy Study of the Partial Mu Opiate 11:30 a.m. Agonist Buprenorphine for Acute Detoxification of 33 Depressed Outpatients From Primary Care Versus Heroin Addicts Specialty Care Settings Michael R. Oreskovich, MD., Andrew J. Saxon, M.D., Bradley N. Gaynes, M.D., A. John Rush, MD., Madhukar H. Meiling K. Ellis, B.S., Carol A. Make, MS.W., Joseph P. Trivedi, MD., Donald Spencer, MD., Timothy J. Reoux, MD., Patricia C Knox, Ph.D. Petersen, Ph.D., Michael Klinkman, M.D., Robert N. Golden, M.D. * Collaborative Session With the National Institute on Drug Abuse 50 TUESDAY

12 noon SCIENTIFIC AND CLINICAL REPORT SESSION 14 34 Limits to the Treatment of Major Depression 11:00 a.m.-12:30 p.m. Gabor I. Keitner, MD. Rooms 3D05/8, Level 3, Javits Center THIS SESSION WILL BE AUDIOTAPED. PSYCHOPHARMACOLOGY SCIENTIFIC AND CLINICAL REPORT SESSION 12 11:00 a.m.-12:30 p.m. Chp.: David A Gutman, MD. Room 3D03/10, Level 3, Javits Center Co-Chp.: Jeffrey M Friend, MD.

ADHD 11:00 a.m. 41 Antipsychotic Treatment and Sexual Adverse Events: Chp.: Frances R. Levin, MD. The Role of Prolactin Co-Chp.: Rebecca W. Brendel, MD. Rikus Knegtering, MD.

11:00 a.m. 11:30 a.m. 35 ADHD Comorbidity in Preschool Children 42 Three-Bead Extended-Release Carbamazepine Capsule Atilla Turgay, M.D., Rubaba Ansari, MA., David Ng, M.D., (SPD417) Continuation: Maintenance Therapy in Bipolar Michael Schwartz, Ph.D., Aruz Mesci Disorder Terence A Ketter, M.D., Amir H Kalali, MD., Richard H. 11:30 a.m. Weisler,M.D. 36 Atomoxetine for Comorbid ADHD and Affective Symptoms 12 noon JeffreyH. Newcorn, M.D. 43 Parkinsonism in a Nursing Home: Underrecognition Hubert H. Fernandez, MD., Joseph Friedman, M.D., Martha 12 noon Trieschmann, MD. 37 Abuse Liability Assessment of Atomoxetine in a Drug- THIS SESSION WILL BE AUDIOTAPED. Abusing Population Donald K Jasinsky, M.D., Douglas E. Faries, Ph.D., Albert J. SCIENTIFIC AND CLINICAL REPORT SESSION 15 Men, M.D. 11:00 a.m.-12:30 p.m. THIS SESSION WILL BE AUDIOTAPED. Rooms 3D06/7, Level 3, Javits Center

SCIENTIFIC AND CLINICAL REPORT SESSION 13 ISSUES IN PSYCHIATRIC RESEARCH AND 11:00 a.m.-12:30 p.m. PSYCHOPHARMACOLOGY Rooms 3D04/9, Level 3, Javits Center Chp.: Nikhil D. Nihalani, MD. UNDERSTANDING THE EFFECTS OF TERRORISM Co-Chp.: Robert Kelly, MD. Chp.: Randall D. Marshall, M.D. Co-Chp.: Elspeth C Ritchie, M.D. 11:00 a.m. 44 Concurrent Use of Multiple Antipsychotics in Psychiatric 11:00 a.m. Inpatients 38 Effects of 9/11 and Chronic Stress on Female Drinking Bonnie L. Szarek, R.N., John W. Goethe, M.D., Theodore F. and Anxiety Mucha,MD. Judith A. Richman, Ph.D., Joseph A. Flaherty, MD., Joseph S. Wislar, M.S., Michael Fendrich, Ph.D., Kathleen M. 11:30 a.m. Rospenda, Ph.D. 45 How Do Psychiatric Patients Perceive Research Participation? 11:30 a.m. Cherise Rosen, MA., Linda S. Grossman, Ph.D. 39 Psychosocial Predictors of Long-Term Resilience Following the 9/11 Attacks 12 noon David Spiegel, MD., Lisa D. Butler, Ph.D., Cheryl 46 Polypharmacy and Its Ramifications in a Chronic Koopman, Ph.D., Jay Azarow, Ph.D., Juliette G Psychiatric Hospital Desjardins, M.D., Xin- Hua Chen, B.A, Helena G Jambur V. Ananth, MD., Sarath Gunatilake , M.D., Sharat Kraemer, Ph.D. Parameswaran, B.S., Chris E. Marshall, B.S., Steven Brown, Ph.D. 12 noon THIS SESSION WILL BE AUDIOTAPED. 40 The Terrorist as a Nonpatient Subject of Psychiatric Investigation David Rothstein, MD. THIS SESSION WILL BE AUDIOTAPED. 51 TUESDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 16 SCIENTIFIC AND CLINICAL REPORT SESSION 18 11:00 a.m.-12:30 p.m. 11:00 a.m.-12:30 p.m. Wilder Room, Fourth Floor, Marriott Marquis Majestic/Music Box/Winter Garden, Sixth Floor, Marriott Marquis CHILD AND ADOLESCENT PSYCHIATRY VIOLENCE, TRAUMA, AND VICTIMIZATION Chp.: Cynthia K Pfeffer, M.D. Co-Chp.: Arun R. Kunwar, M.D. Chp.: Paula G. Panzer, M.D. Co-Chp.: Leslie L. Buckley, M.D. 11:00 a.m. 47 Externalizing Behaviors in Preadolescent Children: A 11:00 a.m. National Panel Study 53 Evaluation of a Therapeutic Interagency Preschool for David J. Pevalin, Ph.D., John Cairney, Ph.D., Terrance J. Traumatized Children Wade,Ph.D. Terrance J. Wade, Ph.D., Jane Sites, Ed.D., Frank W. Putnam, Jr., M.D. 11:30 a.m. 48 Gender and the Prediction of Drug and Alcohol Abuse in 11:30 a.m. Adolescent Inpatients 54 Mental Health in Postwar Afghanistan Daniel F. Becker, M.D., Carlos M. Grilo, Ph.D. Barbara Lopes-Cardozo, M.D., Oleg Biluuma, M.D., Carol Gotway- Crawford, Ph.D., Maru Anderson 12 noon 49 Prevalence and Outcomes of Childhood Adversity in an 12 noon Australian Population 55 A Three-Dimensional Model of Violence in Stephen J. Rosenman, M.D., Bryan Rodgers, Ph.D. Schizophrenia THIS SESSION WILL BE AUDIOTAPED. Menahem I. Krakowski, M.D., Pal Czobor, Ph.D. THIS SESSION WILL BE AUDIOTAPED. SCIENTIFIC AND CLINICAL REPORT SESSION 17 11:00 a.m.-12:30 p.m. Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis WORKSHOPS

SCOAL AND COMMUNITY PSYCHIATRY a:>MPONE .NTS 27-32

Chp.: Susan Stabinsky, M.D. COMPONENT WORKSHOP 27 11:00 a.m.-12:30 p.m. Co-Chp.: William A. James, M.D. Rooms 2D10/11, Level 2, Javits Center

11:00 a.m. WHEREFORE NEUROSdENCE: HOW MUCH DOES 50 Evaluation of an HIV Intervention for Psychiatric Care THE PSYCHIATRIST NEED TO KNOW? Providers in South Africa A PA /OdxoSmithKlirK Fellow Pamela Y. Collins, M.D., Kezziah Mestry, LL.B., Graham Lindegger, Ph.D., Thobile Nzama, Francine Cournos, M.D., Co-Chps.: Joshua L. Roffman, M.D., Carrie L. Ernst, MD. Milton L. Wainberg, M.D. Participants: Asher B. Simon, M.D., Jason M. Morrison, M.D., Konasale M.R, Prasad, M.D. 11:30 a.m. 51 Developing Capacity Within CBOs for Health Education COMPONENT WORKSHOP 28 11:00 a.m.-12:30 p.m. and Outreach Rooms 2D12/13, Level 2, Javits Center Mary Jane Massie, M.D., David Lounsbury, Ph.D., Bruce Rapkin, Ph.D. WHAT DO EMPLOYERS WANT? EMPLOYEE MENTAL HEALTH BENEFITS 12 noon APA Committee on A PA /Business Relationships 52 Inter-European Countries Comparison on Treatment Use for Mental Health Disorders Viviane Kovess, M.D., Jordi Alonso, M.D., Mathias G Co-Chps.: Norman A Clemens, M.D., Jeffrey P. Kahn, MX). Angermeyer, TeryBrugha Participants: Michael J. Thompson, Liisa Chider, MA THIS SESSION WILL BE AUDIOTAPED.

52 TUESDAY

COMPONENT WORKSHOP 29 11:00 a.m.-12;30 p.m. ISSUE WORKSHOP 60 11:00 a.m.-12:30 p.m. Rooms 2D14/15, Level 2, Javits Center Room IE 14, Level 1, Javits Center

HELPING DISTRICT BRANCHES RELATE TO APA THE PORTRAYAL OF PSYCHIATRY IN RECENT AND TO THEIR MEMBERS AMERICAN FILM APA Corresponding Committee on District Branch/State Association Relations Chp.: Steven E. Pflanz, MX).

Chp.: Donald G. Langsley, MX). ISSUE WORKSHOP 61 11:00 a.m.-12:30 p.m. Participants: Nada L. Stotland, MX)., Ann Marie T. Room 3D02/11, Level 3, Javits Center Sullivan, M.D., Margo S. Adams HOW TO LAUNCH A SUCCESSFUL PRIVATE COMPONENT WORKSHOP 30 11:00 a.m.-12;30 p.m. PRACTICE, PART 2 Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis Co-Chps.: William E. Callahan, Jr., MX)., Keith W. Young, M.D. THE TEACHING OF GAY, LESBIAN, BISEXUAL, AND Participants: Tracy R Gordy, MX)., Chester W. TRANSGENDER ISSUES Schmidt, Jr., M.D. A PA New York County District Branch's Comrittee on Gay and L esbian Issues ISSUE WORKSHOP 62 11:00 a.m.-12:30 p.m. Odets Room, Fourth Floor, Marriott Marquis Chp.: Kenneth B. Ashley, MX). Participants: Stewart L. Adelson, M.D., Richard O. Hire, M.D., USING ART AND POETRY: FROM MEDICATION Elizabeth LeQuesne, M.D., Khakasa H, Wapenyi, MX). MANAGEMENT TO COUNTERTRANSFERENCE

COMPONENT WORKSHOP 31 11:00 a.m.-12:30 p.m. Chp.: Charles R. Joy, MX). Plymouth/Uris/Shubert Rooms, Sixth Floor, Marriott Participant Stuart A. Copans, MX). Marquis ISSUE WORKSHOP 63 11:00 a.m.-12:30 p.m. SEX, DRUGS, AND HIV: SYNERGISTIC EPIDEMICS APA NewYork County District Branch's AIDS Committee O'Neill Room, Fourth Floor, Marriott Marquis

Co-Chps.: Kristina L.N. Jones, M.D., John A.R. PSYCHIATRIC REHABILITATION AND Grimaldi, Jr., MX). PSYCHODYNAMICS Participants: Bryan J. McGreal, M.D., Mary Ann Cohen, MX)., Elizabeth V. Getter, M.D. Co-Chps.: Anand Pandya, MX)., Grace Otto, R.N. Participants: Veronica Popoiu, M.S.N., Eric Leventhal, CS.W., COMPONENT WORKSHOP 32 11:00 a.m.-12:30 p.m. Manuel Trujillo, M.D. Cantor/Jolson Rooms, Ninth Floor, Marriott Marquis ISSUE WORKSHOP 64 11:00 a.m.-12:30 p.m. LOOKING BACK, LOOKING FORWARD: PATHWAYS Ziegfeld Room, Fourth Floor, Marriott Marquis FOR BLACKS IN PSYCHIATRY APA Gormittee of Black Psychiatrists MANAGEMENT OF DIFFICULT SCHIZOPHRENIA Co-Chps.: Michelle O. Clark, M.D., N. Kalaya Okereke, MX>. Participants: Carl C Bell, M.D., Hugh Butts, M.D., Marketa M. Chp.: Michael Y. Hwang, MX). Wills, MX). Participants: Edward Kim, MX)., Faiq Hameedi, MX)., David P. Folsom, M.D., Samuel G. Siris, MX).

ISSUES 5^-76 ISSUE WORKSHOP 65 11:00 a.m.-12:30 p.m. Booth/Edison Rooms, Fifth Floor, Marriott Marquis ISSUE WORKSHOP 59 11:00 a.m.-12:30 p.m. Rooms 1E03/4/5, Level 1, Javits Center THE APPLICATION OF BEDSIDE EXECUTIVE- FUNCTION MEASURES APPROACHING MORAL ISSUES IN MENTAL HEALTH TREATMENT Chp.: Jeffrey A Cordes, MX). Participants: Jason E. Schillerstrom, MX)., Kaustubh G. Joshi, M.D. Chp.: John R. Peteet, M.D. Participants: Martha Jurchak, Ph.D., Leigh C Bishop, MX).

53 TUESDAY

ISSUE WORKSHOP 66 11:00 a.m.-12:30 p.m. ISSUE WORKSHOP 72 11:00 a.m.-12:30 p.m. Imperial/Julliard Rooms, Fifth Floor, Marriott Marquis Gotham Room, Seventh Floor, Marriott Marquis

THE PSYCHIATRY RESIDENT AS EDUCATOR: A CLINICAL EFFECTS OF SEXUAL ABUSE BY PROPOSAL FOR CURRICULUM AND SUPERVISION CATHOLIC PRIESTS: A FORENSIC PERSPECTIVE

Co-Chps.: Ruth M. Lamdan, M.D., Autumn Ning, M.D. Chp.: Allan S. Nineberg, M.D. Participants: Karriem L. Salaam, M.D., Diane B. Gottlieb, M.D., Edward A. Volkman, M.D., Roya Lewis, M.D. ISSUE WORKSHOP 73 11:00 a.m.-12:30 p.m. Gramercy Room, Seventh Floor, Marriott Marquis ISSUE WORKSHOP 67 11:00 a.m.-12:30 p.m. Lyceum Room, Fifth Floor, Marriott Marquis PROBLEMS IN THE PSYCHIATRIC EDUCATION OF INTERNATIONAL MEDICAL GRADUATES INTERFACE BETWEEN PSYCHIATRY AND OBSTETRICS: COMPREHENSIVE PERINATAL CARE Chp.: Milton Kramer, M.D. Participants: Nyapati R. Rao, M.D., Brunhild Kring, M.D., Chp.: Johannes Bitzer Jeffrey Goldberg, D.O., Nalini V. Juthani, M.D. Participants: Maria F. Hofecker-Fallahp, M.D., Werner Tschan, M.D. ISSUE WORKSHOP 74 11:00 a.m.-12:30 p.m. Herald/Soho Rooms, Seventh Floor, Marriott Marquis ISSUE WORKSHOP 68 11:00 a.m.-12:30 p.m. Palace Room, Sixth Floor, Marriott Marquis DRUGS AND OTHER ADDICTIONS: DOES ONE SIZE FIT ALL? CLOSING A PSYCHIATRIC PRACTICE: CLINICAL AND Collaborative Session With the Natioml Institute on Drug A buse RISK-MANAGEMENT ISSUES Chp.: Steven J. Grant, Ph.D. Chp.: Robinette N. Bell, M.D. Participants: Linda Cottier, Ph.D., Nathan A. Shapira, M.D., Participants: Donna Vanderpool, J.D., Denny Rodriguez, J.D. Nancy M. Petry, Ph.D., Marc N. Potenza, M.D.

ISSUE WORKSHOP 69 11:00 a.m.-12:30 p.m. ISSU£ WORKSHOP 75 11:00 a.m.-12:30 p.m. Royale Room, Sixth Floor, Marriott Marquis Marquis Ballroom Salons A/B, Ninth Floor, Marriott Marquis REHABILITATING TRAUMATIZED GIRLS IN RESIDENTIAL JUVENILE-JUSTICE SETTINGS STRESS, TRAUMA, AND DRUG ABUSE Collaborative Session With the National Institute on Drug A base Chp.: Cheryl D. Wills, M.D. Chp.: Nancy Pilotte, Ph.D. ISSUE WORKSHOP 70 11:00 a.m.-12:30 p.m. Participants: Paul Plotsky, Ph.D., Martin H. Teicher, M.D., Dean Columbia/Duffy Rooms, Seventh Floor, Marriott Marquis Kilpatrick, Ph.D., Lisa M. Najavits, Ph.D.

THE OUT-OF-THE-SHADOW PROJECT ISSUE WORKSHOP 76 11:00 a.m.-12:30 p.m. Marquis Ballroom Salon C, Ninth Floor, Marriott Marquis G" -Chps.: Edward F. Foulks, M.D., Susan E. Smiley Participants: Suzanne E. Vogel-Scibilia, M.D., Stephen M. CHILDREN AND FAMILIES FACING TERRORISM, Goldfinger, M.D. DISASTERS, AND COMPLEX EMERGENCIES

ISSUE WORKSHOP 71 11:00 a.m.-12:30 p.m. Chp.: Howard J. Osofsky, M.D. Empire/Hudson Rooms, Seventh Floor, Marriott Marquis Participants: Richard F. Mollica, M.D., Sandra J. Kaplan, M.D., Arieh Y. Shalev, M.D., Eric Noji, M.D. PSYCHOGENIC SEIZURES: A PROTOTYPE OF SOMATOFORM DISORDER

Chp.: Selim Benbadis, M.D. Participant Francisco Fernandez, M.D.

54 TUESDAY

12 noon Sessions COURSE 69 1:00 p.m.-5:00 p.m. Concourse B, Concourse Level, Hilton New York FORUMS 6-8 BRIEF PSYCHODYNAMIC PSYCHOTHERAPY: THE CORE CONFLICTUAL RELATIONSHIP THEME FORUM 6 12 noon-1:30 p.m. METHOD Room IE 10, Level 1, Javits Center Director: Howard E. Book, M.D. REVERSING THE CRIMINALIZATION OF THE SERIOUSLY MENTALLY ILL COURSE 70 1:00 p.m.-5:00 p.m. A PA Corresponding Canvritteean Jails and Prisons Concourse E, Concourse Level, Hilton New York Co-Chps.: Marcia Kraft Coin, M.D., Hemy C Weinstein, M.D. BASIC FAMILY SKILLS FOR AN INPATIENT Participants: H. Richard Lamb, M.D., Tom Hamilton, Ph.D., PSYCHIATRIST ErikJ.Roskes,M.D. Director: Alison M. Hem, M.D. FORUM 7 12 noon-1:30 p.m. Faculty: Laura Drury, M.S.W. Room IE 16, Level 1, Javits Center COURSE 71 1:00 p.m.-5:00 p.m. UNCONSCIOUS PREDICTION, CONSCIOUS Beekman Parlor, Second Floor, Hilton New York MONITORING, AND THERAPEUTIC CHANGE: IS THERE A MIND-BRAIN BARRIER? OVERVIEW AND UPDATE OF SLEEP DISORDERS MEDICINE Chp.: Mirian I. Butterfield, M.D. Participant Regina Pally, M.D. Director Karl Doghramji, M.D. Faculty: John W. Winkelman, M.D., Thomas D. Hurwitz, M.D. FORUMS 12 noon-1:30 p.m. Astor Ballroom, Seventh Floor, Marriott Marquis COURSE 72 1:00 p.m.-5:00 p.m. Bryant Suite, Second Floor, Hilton New York SHOULD SEX BE PREVENTED IN PSYCHIATRIC UNITS? ARGUMENTS AND NEW DIRECTIONS MEDITATION FOR PSYCHOTHERAPISTS AND THE PARADIGM OF HEALTH Chp.: Milton L. Wainberg, M.D. Participants: Elizabeth B. Ford, M.D., Carol A. Bernstein, M.D., Director: James T. Sacamano, M.D. Marshall Forstein, M.D., Paulo E. Mattos, M.D. COURSE 73 1:00 p.m.-5:00 p.m. Gibson Suite, Second Floor, Hilton New York NEW RESEARCH POSTER SESSION 6 12 noon - 2:00 p.m. WRITING ABOUT CLINICAL EXPERIENCES Galleria, Level 4, Javits Center

BIOLOGICAL PSYCHIATRY AND Director John S. Strauss, M.D. PSYCHOPHARMACOLOGY COURSE 74 1:00 p.m.-5:00 p.m. For further information on New Research Sessions, please refer to Gramercy A, Second Floor, Hilton New York the NewResmnhPmgramBook included in your registration packet. THE EVALUATION AND IDENTIFICATION OF THE MAJOR DEMENTIAS 1:00 p.m. Sessions Director: Raymond A Faber, M.D. Faculty: Kevin F. Gray, M.D., Randolph B. Schiffer, M.D. COURSES 69-76 Course descriptions are available in the CME Course Brochure included in your registration packet Admission by ticket only.

55 TUESDAY

COURSE 75 1:00 p.m.-5:00 p.m. of numerous awards, including the American Academy Nassau Suite A, Second Floor, Hilton New York of Child and Adolescent Psychiatry Leadership Award for Best Chairman of a Department of Psychiatry. A HOW TO USE YOUR PALM OS PDA IN PSYCHIATRIC graduate of Tulane University School of Medicine in PRACTICE: ADVANCED New Orleans, Dr. Scully completed his residency training in psychiatry at the University of Colorado Medical Center in Denver. Director: John S. Luo, MD. Distinguished Psychiatrist Lecture Series Faculty: Richard A. Montgomery, M.D., Charles J. Rainey, M.D., THIS SESSION WILL BE AUDIOTAPED. Raymond J. Kloss, M.D., Hendry Ton, MD.

COURSE 76 1:00 p.m.-5:00 p.m. LECTURE 17 Sutton Center, Second Floor, Hilton New York 2:00 p.m.-3:30 p.m. THE COMPLEXITIES OF CHRONIC PAIN: Room IE 15, Level 1, Javits Center PSYCHIATRIC ISSUES AND TREATMENTS APA'S MARMOR AWARD LECTURE Co-Directors: Allen Lebovits, Ph.D., MatthewB. Smith, MD. Faculty: Andrew F. Angelino, MD., Robert Cancro, MD., David Spiegel, M.D. Michael R. dark, MD., Michel Dubois, M.D. Feeling and Healing: Biopsychosocial Treatments and Their Effects on Medical Illness

2:00 p.m. Sessions Chp.: Alan F. Schatzberg, MD.

LECTURES 16-18 David Spiegel, MD., is the Jack, Lulu & Sam Willson Professor of Medicine and Associate Chair of the Department of Psychiatry and Behavioral Sciences at LECTURE 16 Stanford University School of Medicine in Stanford, California, where he is also Director of die Center on 2:00 p.m.-3:30 p.m. Stress and Health. In addition, he is Medical Director of Rooms 1E07/8, Level 1, Javits Center the Stanford Center for Integrative Medicine at Stanford Medical Center, which provides supportive care for medically ill patients. Dr. Spiegel is Second Vice- James H. Scully, Jr., M.D. President of the American College of Psychiatrists (he will assume the Presidency in 2006) and Past President of How Many Psychiatrists Do We Need? the Society for Clinical and Experimental Hypnosis. A Distinguished Fellow of the American Psychiatric Chp.: Linda L.M. Worley, MD. Association, he has received the Edward A. Strecker, Co-Chp.: Catherine G Crone, MD. MD., Award from the Institute of Pennsylvania Hospital for his contributions to clinical psychiatry, and the James H, Scully, Jr., MD., became Medical Director of Hilgard Award from the International Society of the American Psychiatric Association (APA) in January Hypnosis for his research contributions to the 2003. As Medical Director, Dr. Scully is responsible for development of medical hypnosis. He serves on the overseeing approximately 250 full-time staff in the editorial boards of numerous journals and was Editor of Association and its three corporate subsidiaries, the the American Psychiatric Press' Progress in Psychiatry series. American Psychiatric Institute for Research and Dr. Spiegel received his medical degree from Harvard Education, the American Psychiatric Foundation, and Medical School and completed his residency training in American Psychiatric Publishing, Inc. Among his areas psychiatry at the Massachusetts Mental Health Center of responsibility are legislative advocacy and policy and Cambridge Hospital and a fellowship at the development, continuing medical education and lifelong Laboratory of Community Psychiatry, all at Harvard learning, communications, member services, and health Medical School in Boston. services research. Dr. Scully formerly was the Alexander THIS SESSION WILL BE AUDIOTAPED. Donald Professor and Chair of the Department of Neuropsychiatry and Behavioral Science and President of the Educational Trust at the University of South Carolina School of Medicine in Columbia, South Carolina. He served as interim director of the South Carolina Department of Mental Health from 2000 to 2001. A Distinguished Fellow of APA, Dr. Scully is the recipient 56 TUESDAY

LECTURE 18 B Using Fiscal and Clinical Measures During Times of Limited Resources 2:00 p.m.-3:30 p.m. Theodore C Lutterman, Lucille Schacht, Ph.D. Trianon Ballroom, Third Floor, Hilton New York C State Policy Choices for Children's Mental Health in A. Thomas McLellan, Ph.D. Tough Budget Times Chris Koyanagi Conceptual and Methodological Flaws in the Evaluation of Addiction Treatment D The Impact of Budget Cuts on Rural Mental Health Collaborative Session With the National Institute Dennis Mohatt, M.A. anDrug Abuse E Cuts Cutting Into the Possibility of Recovery Chp.: Renee M Sorrentino, MX). Tom Lane, Laura Lee Hall, Ph.D. Co-Chp.: Shelly F. Greenfield, MD. F After All This, Do You Still Want to Be a Public A. Thomas McLellan, PhD., is Professor of Psychiatry at Psychiatrist? the University of Pennsyivania School of Medicine and Allison M. Wehr, MD., Jennifer K. Coffman, MD. the Director of the Treatment Research Institute in THIS SESSION WILL BE AUDIOTAPED. Philadelphia. He and his colleagues developed some of the most widely used measurement instruments in addiction research, including the Addiction Severity REVIEW OF PSYCHIATRY: SECTION 2 Index (ASI) and the Treatment Services Review (TSR), 2:00 p.m.-5:30 p.m. which have been translated into more than 20 languages. Special Events Hall ID, Level 1, Javits Center In their research, Dr. McLellan and his colleagues have used these instruments to evaluate a variety of therapies, COGNITIVE-BEHAVIOR THERAPY medications, and interventions used in the treatment of alcohol and drug dependence. They are currently investigating the active and inactive ingredients of Chp.: Jesse H Wright, M.D. treatment, the appropriate duration and content of treatment for various types of patients, and methods for 6 Cognitive Therapy for Schizophrenia transferring findings from treatment research into Jan L. Scott, M.D., David G. Kingdon, M.D., Douglas practical applications for the practitioner and provider. Turkington, MD. Dr. McLellan is the author of more than 400 articles and book chapters in addiction research and serves as the 7 Cognitive Therapy for Bipolar Dis order Editor-in-Chief of Journal cfSubstance Abuse Treatment. His Monica A. Basco, Ph.D., A John Rush, M.D., Noelle many honors include the 2003 Innovators Combating McDonald, B.S., Megan Merlock, B.A. Substance Abuse Award from the Robert Wood Johnson Foundation. Dr. McLellan received his doctoral degree 8 Computer-As s isted Cognitive-Behavior Therapy from Bryn Mawr College in Philadelphia and received Jesse H Wright, M.D. postgraduate training in psychology at Oxford University in England. Frontiers of Science Lecture Series 9 Cognitive Therapy "with Medical Patients THIS SESSION WILL BE AUDIOTAPED. Thomas Sensky, M.B. 10 Cognitive Therapy for Children and Adolescents PRESIDENTIAL SYMPOSIUM 2 Anne Marie Albano, Ph.D., Amy L. Krain, Ph.D., Elizabeth 2:00 p.m.-5:00 p.m. Podniesinksi, M.A., Keith Ditkowsky, MD. Astor Ballroom, Seventh Floor, Marriott Marquis

WITHER GO THE STATES: THE IMPACT OF BUDGET SYMPOSIA 27-58 CUTS SYMPOSIUM 27 2:00 p.m.-5:00 p.m. Chp.: David A. Pollack, M.D. Rooms 1E01/2, Level 1, Javits Center

A Overview of the Impact of State Budget Cuts: Problems BEHAVIORAL ACTIVATION, COGNITIVE THERAPY, and Solutions AND MEDICATION FOR MAJOR DEPRESSION Michael F. Hogan, Ph.D. Chp.: Steven D. Hollon, Ph.D.

(Continued on nextpag} 57 TUESDAY

A Methods and Acute-Phase Outcomes A Interpersonal Psychotherapy in Brazil: Similarities and Sona A. Dimidjian, Steven D. Hollon, Ph.D., Keith S. Differences With the U.S. Dobson, Ph.D., Karen B. Schmaling, Ph.D., Robert J. Ana CF. Andrade, MA, Francisco Lotufo-Neto, MD., Beny Kohlenberg, Ph.D., Michael Addis, Ph.D., David L. Lafer, MD., Marcelo Feijo Dunner, MD. B From Practice to Theory: Group Music Therapy and B Prevention of Relapse Medication Compliance in Patients With Bipolar Keith S. Dobson, PhD., Steven D. Hollon, Ph.D., Sona A Disorder Dimidjian, Karen B. Schmaling, Ph.D., Robert J. Ruby C Castilla-Puentes, MD., James M Perel, PhD. Kohlenberg, Ph.D., Shireen Rizvi, David L. Dvinner, MD. C What Is the Role of Psychotherapy in Patients With C Prediction of Treatment Response Bipolar Disorders? Cultural Issues Shireen Rizvi, Sona A Dimidjian, Steven D. Hollon, Ph.D., Carlos Leon-Andrade, MD., Roxana Galeno, MD. Keith S. Dobson, Ph.D., Karen B. Schmaling, PhD., Robert]. Kohlenberg, Ph.D., David L. Dunner, MD. D Treatment of Sleep Problems in Bipolar Patients Franklin Escobar, MD. Discussants: Jan Fawcett, M.D., Marsha M Linehan, Ph.D. THIS SESSION WILL BE AUDIOTAPED. E Some Useful Interventions in the Course of Bipolar Disorders in Argentina SYMPOSIUM 28 2:00 p.m.-5:00 p.m. Jose R. Bozzo, MD. Rooms 1E03/4/5, Level 1, Javits Center Discussants: Ricardo Secin, MD., Alberto Serrano, MD. THIS SESSION WILL BE AUDIOTAPED. NEW PERSPECTIVES IN THE TREATMENT OF COMPLEX PTSD SYMPOSIUM 30 2:00 p.m.-5:00 p.m. Room 1E09, Level 1, Javits Center Chp.: James A Chu, MD. PSYCHOTHERAPY AND PHARMACOTHERAPY: A Update on the Memory Wars: Evaluating and Working DISSOLVING THE MIND-BRAIN BARRIER With Traumatic Memory APA GcmritteemPsydxxheratybyPsydyia^ James A Chu, MD. Chp.: Barton J. Blinder, MD. B Betrayal Trauma Theory: Dimensions of Harm and Co-Chp.: Bernard D. Beitman, MD. Healing Jennifer J. Freyd, Ph.D. A Dynamic Imaging of the Brain: Actions, Dysfunction, Therapeutic Transformation C Significance of Relationship in the Treatment of George I. Viamontes, MD. Complex Trauma Christine Courtois, Ph.D. B Psychotherapy and Pharmacotherapy: Theoretical Basis and Empirical Studies of Combined Treatment D Using EMDR to Resolve Trauma-Based Distortions of Michael E. Thase, MD. the Self in Complex PTSD Denise J. Gelinas, PhD. C Split Treatment- Conflict and Collaboration Michelle B. Riba, MD. E Treatment Outcome Research and Complex PTSD Bessel A Van Der Kolk, MD., Joseph F. Spinazzola, PhD. D Integrating Psychotherapy and Pharmacotherapy: The Clinical Challenge Bernard D. Beitman, MD. Discussant: Judith Herman, MD. THIS SESSION WILL BE AUDIOTAPED. Discussant: Charles B. Nemeroff, MD. THIS SESSION WILL BE AUDIOTAPED. SYMPOSIUM 29 2:00 p.m.-5:00 p.m. Room IE 06, Level 1, Javits Center

BIPOLAR PATIENTS: TREATMENTS AND CULTURAL ISSUES IN LATIN AMERICA

Chp.: Carlos Leon-Andrade, MD. Co-Chp.: Ruby C. Castilla-Puentes, MD.

58 TUESDAY

SYMPOSIUM 31 2:00 p.m.-5:00 p.m. D Impact of SARS on Health Care Professionals Room IE 10, Level 1, Javits Center Sharon Straus, M.D., Wayne L. Gold, MD., Kumanan Wilson, M.D., Moira Kapral, M.D., Gloria Rambaldini, M.D., PRACTICE GUIDELINES, QUALITY INDICATORS, Darlyne Rath, M.S.C. AND A PRACTICE RESEARCH NETWORK: AN INTERNATIONAL VIEW E I Am So Alone: Lessons Learned From Experiences of World Psychiatric A ssodation Quarantined Individuals During the SARS Outbreak in Toronto Chp.: John S. Mclntyre, M.D. Laura Hawryluck, MX)., Wayne L. Gold, MX)., Susan Co-Chp.: Wolfgang Gaebel, M.D. Robinson, R.N., Sandro Galea, MD., Rima Styra, MX). THIS SESSION WILL BE AUDIOTAPED. A Treatment Guidelines in Psychiatry: Results of an International Survey SYMPOSIUM 33 2:00 p.m.-5:00 p.m. Wolfgang Gaebel, M.D., S. Weinmann, M.D. Room IE 12, Level 1, Javits Center INTERPERSONAL PSYCHOTHERAPY: RESEARCH B Clinically-Based Quality Indicators UPDATE John M. Oldham, M.D. Chp.: John C. Markowitz, M.D. C APA Practice Guideline Project Status and Challenges John S. Mclntyre, M.D. A Group Interpersonal Psychotherapy for Depression in Uganda D Assessing Evidence-Based Practice Guidelines in Myrna M. Weissman, Ph.D., Paul Bolton, M.B., Helena Routine Psychiatric Practice Verdeli, Ph.D., Richard Neugebauer, Ph.D., Judith Barrel A. Regier, MX)., Joyce C. West, Ph.D., William E. Bass, M.P.H., Kathleen Qougherty, M.S.W., Priya Narrow, M.D., Farifteh F. Duffy, Ph.D., Joshua E. Wickramaratne, Ph.D. Wilk,Ph.D.

Discussants: Rodrigo A. Munoz, MD., George B Combination of IPT and Medication in Outpatients With Christodoulou, M.D. Depression: Is It the Best We Can Do? THIS SESSION WILL BE AUDIOTAPED. Marc B.J. Blom, MX)., Kosse Jonker, Erik Hoencamp, MX)., Philip Spinhovem, Ph.D., Judith Haffmans, Ph.D., Richard Van Dyck, M.D. SYMPOSIUM 32 2:00 p.m.-5:00 p.m. Room IE 11, Level 1, Javits Center C IPT for Anxiety and Depression in Primary Care in Scotland THE SCARS OF SARS: ITS IMPACTS ON PATIENTS, Roslyn Law, Psy.D. HEALTH CARE WORKERS, AND THE COMMUNITY D Brief Interpersonal Psychotherapy for Depression in Chp.: Rima Styra, M.D. Women Co-Chp.: Francis G. Lu, M.D. Holly A. Swartz, M.D., Ellen Frank, Ph.D., M Katherine Shear, M.D., Michael E. Thase, MX)., John Scott, M.A, A PTSD and Depression in Patients Diagnosed With SARS Rima Styra, M.D., Wayne L. Gold, M.D., Susan E Long-Term Prophylaxis and Other Benefits of Robinson, R.N., Laura Hawryluck, M.D., Gerald Maintenance Interpersonal Psychotherapy Devins, M.D., Kenneth Mah, Ph.D. Ellen Frank, Ph.D., Jill M. Cyranowski, Ph.D., Holly A. Swartz, M.D., David J. Kupfer, M.D. B The Psychological Impact of SARS on the Uninfected Health Care Worker Discussant: Myrna M. Weissman, Ph.D. Wayne L. Gold, M.D., Rima Styra, M.D., Laura THIS SESSION WILL BE AUDIOTAPED. Hawryluck, MX)., Susan Robinson, R.N., Allison McGeer, MX)., Sidney H. Kennedy, M.D., Calvin Fones, MX).

C Stress in the Time of SARS: Health Care Workers' Reactions to the Singapore SARS Outbreak Calvin Fones, MX)., David Koh, M.D., M. K. Lim, MX)., S.E. Chia, F. Qian, N. Chew, S.M. Ko

59 TUESDAY

SYMPOSIUM 34 2:00 p.m.-5:00 p.m. B Osteoporosis and Anorexia Nervosa: An Update Room IE 13, Level 1, Javits Center David B. Herzog, MX)., Anne Klibanski, MX)., Karen K. Miller, Madhu Misra, MX)., Mary P. Manzo, AB., Safia C WOMEN'S SEXUALITY UPDATE: OVERCOMING Abidi, B.S. OBSTACLES TO PLEASURE C Predictors of Treatment Acceptance in Anorexia Nervosa Chp.: Barbara D. Bartlik, M.D. Katherine A. Halmi, MX)., W. Stewart Agras, MX)., Scott J. Crow, M.D., James E. Mitchell, MX)., G. Terrence A How Sexual Attractiveness, Pheromones, Fertility, and Wilson, Ph.D., Susan Bryson, Ph.D., Helena C Hysterectomy Are Related Kraemer, Ph.D. Winnifred B. Older, PhD. D Eating Problems and Disorders in Bariatric Surgery B Changes in Sexual Functioning Across the Menstrual Patients Cycle and During and After Pregnancy James E. Mitchell, MX)., Martina deZwaan, MX)., Ross D. Catherine A. Birndorf, MX). Crosby, PhX>., Stephen A. Wonderlich, Ph.D.

C New Treatment Options for Women With Sexual E Body Image: Evolutionary Neurobiology Meets Dysfunction Psychodynamic Psychiatry in the Agora Barbara D. Bardik, MX)., Amy Kossoy, B.A., Marina Arnold E. Andersen, MX). Rozenberg, Julie Kolzet, B.S., Adriel Gerard THIS SESSION WILL BE AUDIOTAPED.

D The Positive Uses of Adult Movies Catering to Women SYMPOSIUM 37 2:00 p.m.-5;00 p.m. Candida Royalle Rooms 3D01/12, Level 3, Javits Center

E Antidepressants and Sexual Dysfunction: A Women's PSYCHIATRIC INTERVENTIONS WITH MEDICALLY- Issue EVACUATED SOLDIERS James H. Kocsis, MX). THIS SESSION WILL BE AUDIOTAPED. Chp.: Stephen J. Cozza, MX).

SYMPOSIUM 35 2:00 p.m.-5:00 p.m. A A Medical Center Response to Combat Casualties Room IE 14, Level 1, Javits Center Thomas M. Fitzpatrick, MX).

CONTEMPORARY ISSUES IN SPORT PSYCHIATRY B A Psychiatry Consultation Service Response to Trauma International Society for Sport Psychiatry Victims: Program to Prevent Psychiatric Comorbidity Harold J. Wain, Ph.D. Chp.: Ronald L. Kamm, MX>. C Global War on Terror: Walter Reed Army Medical Center A FIST: A Unique Program for Boxers at Career End Inpatient Psychiatry's Perspective Ronald L. Kamm, MX). Theodore S. Nam, M.D.

B The Impact of Injury on the Adolescent Athlete and the D A Psychiatric Continuum of Care System in Support of Family the Global War on Terror Thomas S. Newmark, M.D. Douglas A. Waldrep, MX).

C Keeping the Athlete Out of Trouble Discussants: Robert J. Ursano, MX)., Matthew J. Friedman, MX). Eric D. Morse, MX). THIS SESSION WILL BE AUDIOTAPED. THIS SESSION WILL BE AUDIOTAPED. SYMPOSIUM 38 2:00 p.m.-5:00 p.m. SYMPOSIUM 36 2:00 p.m.-5:00 p.m. Room 3D02/11, Level 3, Javits Center Room IE 16, Level 1, Javits Center HOW TO LAUNCH A SUCCESSFUL PRIVATE EATING DISORDERS 2004: FROM PETS TO PSYCHE PRACTICE, PART 3

Chp.: Joel Yager, MX). Chp.: William E. Callahan, Jr., M.D. Co-Chp.: David B. Herzog, M.D. Co-Chp.: Keith W. Young, M.D.

A Effects of Weight Loss on 5HT Activity and Symptoms in A Personal Factors Leading to a Successful Private Practice Anorexia Nervosa William E. Callahan, Jr., M.D. Walter H. Kaye, MX)., Ursula Bailer, MX)., Carolyn Meltzer. MX)., Guido K.W. Frank, MX)., Chet Mathis, Ph.D., Julie Pnce, Ph.D. 60 TUESDAY

B Office Location and Design for Efficiency and Success B Perinatal Depression: Bridging the Gap Between Keith W. Young, M.D. Maternal Distress and Infant Well-Being Sheila Marcus, M.D., Heather A Flynn, PhD., Delia M. C Streamlining Overhead and Managing Your Business in Vazquez, M.D., Juan F. Lopez, M.D., Susan C Private Practice McDonough, Ph.D. Keith W. Young, M.D. C The Undertreatment and Morbidity of Perinatal D Marketing Your Unique Private Practice Depression in Obstetrics Settings William E. Callahan, Jr., M.D. Heather A. Flynn, PhD., Sheila Marcus, M.D. THIS SESSION WILL BE AUDIOTAPED. D Mental Health Treatment Among Pregnant SYMPOSIUM 39 2:00 p.m.-5:00 p.m. Underprivileged Women Room 3D03/10, Level 3, Javits Center Kimberly A. Yonkers, M.D. THIS SESSION WILL BE AUDIOTAPED. USE OF MANDATES AND LEVERAGE IN COMMUNITY-BASED TREATMENT SYMPOSIUM 41 2:00 p.m.-5:00 p.m. Rooms 3D05/8, Level 3, Javits Center Chp.: Paul S. Appelbaum, M.D. NEUROIMAGING SEMINAR A Leverage and Mandated Community Treatment John Monahan, Ph.D. Chp.: Bruce M. Cohen, M.D.

B A Multis ite Study of Mandated Community Treatment: A Tools and Methods of Neuroimaging Research Methods and Prevalence Perry F. Renshaw, M.D. Henry J. Steadman, Ph.D. B Functional Neuroanatomy of Psychiatric Disorders C When Are Mandates and Leverage Applied in Community Deborah A. Yurgelun-Todd, Ph.D. Treatment? Paul S. Appelbaum, M.D. C Neuroimaging in Psychotic Disorders Stephan H. Heckers, M.D. D Patients' Attitudes Toward the Use of Legal Leverage in Community Treatment D Brain Imaging Studies of Depressive Illness Jeffrey W. Swanson, Ph.D., Marvin S. Swartz, M.D., H. Ryan Michael E. Henry Wagner, Ph.D., Eric B. Elbogen, Ph.D. E Neuroimaging in Childhood Disorders E Mandated Treatment: Legal, Ethical, and Policy Jean A. Frazier, M.D. Implications THIS SESSION WILL BE AUDIOTAPED. Marvin S. Swartz, M.D. SYMPOSIUM 42 2:00 p.m.-5:00 p.m. Discussant: Stephanie LeMelle, M.D. Rooms 3D06/7, Level 3, Javits Center THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 40 2:00 p.m.-5;00 p.m. SMOKING AND COMORBID MENTAL DISORDERS Collaborative Session With the National Institute on Drug A buse Rooms 3D04/9, Level 3, Javits Center Chp.: John R Hughes, M.D. PERINATAL DEPRESSION: BURDEN, NEUROBIOLOGY, AND TREATMENT A Psychiatric Comorbidity of Smoking and Nicotine Dependence: An Epidemiologic Perspective Chp.: John F. Greden, M.D. Naomi Breslau, Ph.D. Co-Chp.: Heather A. Flynn, Ph.D. B The Neurobiology of Nicotine Dependence and A The Neuropsychobiology of Perinatal Mood Disorders: Comorbid Psychiatric Disorders Are Hormonal Changes Relevant? George F. Koob, Ph.D., Athina Markou, Ph.D. Meir Steiner, MJD.

(Continued on nettpag)

61 TUESDAY

C Nicotine-Dependence Treatment in Individuals With E An International Perspective on Ethnicity, Culture, and Schizophrenia Psychopharmacology Douglas M. Ziedonis, M.D. TarekA.Okasha,M.D.

D Behavioral and Pharmacological Treatments for Smokers Discussants: Tarek A Okasha, M.D., Warachal E. Faison, M.D. With Depression THIS SESSION WILL BE AUDIOTAPED. Richard A. Brown, Ph.D. THIS SESSION WILL BE AUDIOTAPED. SYMPOSIUM 45 2:00 p.m.-5;00 p.m. Wilder Room, Fourth Floor, Marriott Marquis SYMPOSIUM 43 2;00 p.m.-5;00 p.m. Odets Room, Fourth Floor, Marriott Marquis DELUSIONAL DISORDER: A RE CONSIDERATION OF THE SCIENTIFIC AND CONCEPTUAL BASIS FOR TRAGIC EVENTS IN THE EMERGENCY THE DSM REFORMULATION OF PARANOIA DEPARTMENT: THE ROLE OF PSYCHIATRY AND THE INSTITUTIONAL IMPACT Chp.: Alan A Stone, M.D. Co-Chp.: G Robert Qoninger, M.D. Chp.: John B. Herman, M.D. A The Concept of Delusional Disorder in DSM-IV A Preparation and Organization for Tragedies in the Nancy C. Andreasen, M.D. Emergency Room Maryfran Hughes, R.N. B The Importance of Narcissism in Delusional Disorders C. Robert Qoninger, M.D. B Managing Grief in the Group Setting Jennifer M. Lafayette, M.D. C Delusional Disorder: The Validity of the Diagnosis Theo C Manschreck, M.D. C Staff Support in Responding to Tragedies Lawrence T. Park, M.D. D Delusional Disorder: Does the DSM Diagnosis Make Clinical Sense? D Residency Training and Tragedy in the Emergency Alan A. Stone, M.D. Department Felicia A Smith, M.D. E Involuntary Treatment: The Constitutional Issues THIS SESSION WILL BE AUDIOTAPED. Richard G. Taranto, J.D. THIS SESSION WILL BE AUDIOTAPED. SYMPOSIUM 44 2:00 p.m.-5:00 p.m. O'Neill Room, Fourth Floor, Marriott Marquis SYMPOSIUM 46 2:00 p.m.-5:00 p.m. Ziegfeld Room, Fourth Floor, Marriott Marquis CULTURE, ETHNICITY, RACE, AND PSYCHOPHARMACOLOGY: NEW RESEARCH TRANSLATIONAL RESEARCH ON EATING PERSPECTIVES DISORDERS Chp.: Pedro Ruiz, M.D. Chp.: B. Timothy Walsh, M.D. Co-Chp.: Michael J. Devlin, M.D. A Ethnicity, Pharmacogenetics, and Psychopharmacotherapy A Excitatory and Inhibitory Neurobiological Controls of Keh-Ming Lin, M.D. Eating GaryJ. Schwartz, Ph.D., Nori Geary, Ph.D. B Pharmacotherapy in African Americans William B. Lawson, M.D. B Dieting and Stress Combine Synergistically to Produce an Animal Model of Binge Eating C Ethnicity, Culture, and Psychopharmacology: Asian Mary M. Hagan, Ph.D., Pamela K. Wauford, B.S., Paula C Perspectives Chandler, B.S., Rachel J. Placidi, MA, KimberlyD. EdmondHT.Pi,M.D. Oswald, B.S., Jason B. Viana, B.S.

D Hispanics: Disease, Genes, and Treatment Outcome C An Animal Model of Food Addiction That May Relate to Ricardo P. Mendoza, M.D. Binge Eating or Bulimia Bartley G. Hoebel, Ph.D., Carlo Colantuoni, A.B., Nicole N. Avena, A.B., Pedro Rada 62 TUESDAY

D Symptom Profiles and 5HT Regulation in Bulimia SYMPOSIUM 49 2:00 p.m.-5:00 p.m. Nervosa Booth/Edison Rooms, Fifth Floor, Marriott Marquis David G Jimerson, M.D., Barbara E. Wolfe, Ph.D., Eran D. Metzger, M.D. OBSESSIVE-COMPULSIVE SPECTRUM DISORDERS: UPDATE ON CLINICAL MANAGEMENT E Inhibitory and Excitatory Controls of Eating in Patients With Eating Disorders Chp.: Jon E. Grant, M.D. Michael J. Devlin, M.D., B. Timothy Walsh, M.D., Diane A. Co-Chp.: Katharine A. Phillips, MD. Klein, M.D. THIS SESSION WILL BE AUDIOTAPED. A Neurobiology of the OCD Spectrum Dan J. Stein, M.D. SYMPOSIUM 47 2:00 p.m.-5:00 p.m. Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis B Obsessive-Compulsive Personality Disorder: Its Treatment and Relationship to OCD WHAT EVERY PSYCHIATRIST NEEDS TO KNOW Jane L. Eisen, M.D. ABOUT HIV/AIDS C Update on the Ginical Features and Treatment of BDD Chp.: Francine Cournos, M.D. Katharine A. Phillips, MD. A HIV Treatment Update D Identifying and Treating Hypochondriasis RoyM.Gulick,M.D. Jonathan Abramowitz, Ph.D.

B Ten Things You Need to Know About Brain Dysfunction E Clinical Management of Pathological Gambling and Stephen J. Ferrando, M.D. Kleptomania Jon E. Grant, MD. C Five Things You Need to Know: Drug-Drug Interactions Marshall Forstein, MD. Discussant: Eric Hollander, M.D. THIS SESSION WILL BE AUDIOTAPED. THIS SESSION WILL BE AUDIOTAPED. SYMPOSIUM 48 2:00 p.m.-5:00 p.m. SYMPOSIUM 50 2:00 p.m.-5:00 p.m. Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis Imperial/Julliard Rooms, Fifth Floor, Marriott Marquis PERSONALITY DISORDERS IN THE WORKPLACE GENETIC CORRELATES IN BIPOLAR DISORDERS Chp.: James H. Reich, M.D. Co-Chp.: Per Vaglum, M.D. Chp.: Joseph F. Goldberg, M.D. Co-Chp.: Anil K. Malhotra, MD. A Personality, Job Stress, and Mental Health Among Physicians A Phenotype in Genetic Studies of Bipolar Disorder Per Vaglum, M.D. Martin Alda, M.D.

B Pharmacogenetics of Bipolar Disorder B Avoidant and Dependent Personality Traits in the c Workplace Anil K. Malhotra, MD., Youssef Has. oun, MD., Joseph F. James H. Reich, M.D. Goldberg, M.D.

C The Relationship Between Personality Disorders and C Bipolar Disorder and Alcohol Abuse: Are There Shared Military Service Genetic Contributions? Paul S. Links, M.D., D. Randall Boddam, M.D. Joseph F. Goldberg, M.D.

D Interventions for Personality Disorders in the Workplace D Genetics of Suicidal Behavior in Bipolar Disorder David P. Bernstein, Ph.D. Maria A. Oquendo, MD., J. John Mann, MD.

E Personality Characteristics That Support Resuming of E Genetic Evidence for a Bipolar Spectrum Interrupted Careers J. Raymond DePaulo, Jr., MD. Elsa F. Ronningstam, Ph.D. THIS SESSION WILL BE AUDIOTAPED.

Discussants: Ira D. Click, MD., Jack Maser, Ph.D. THIS SESSION WILL BE AUDIOTAPED. 63 TUESDAY

SYMPOSIUM 51 2:00 p.m.-5:00 p.m. SYMPOSIUM 53 2:00 p.m.-5:00 p.m. Majestic/Music Box/Winter Garden, Sixth Floor, Marriott Columbia/Duffy Rooms, Seventh Floor, Marriott Marquis Marquis THE BOUNDARIES OF BPD CRITICAL PERSPECTIVES ON GENDER IDENTITY DISORDER IN CHILDREN AND ADOLESCENTS Chp.: Joel F. Paris, MD.

Chp.: Richard R Pleak, MD. A A New Examination of the Interface Between BPD and MDD A Diagnosing Gender-Atypical Youth: A History of Gender John G. Gunderson, MD. Identity Disorder in Childhood Karl E. Bryant, MA B Borderline or Bipolar? Donald W. Black, MD. B Historical and Ethical Perspectives on Gender-Atypical and Trans gender Youth C Substance Abuse and Its Relationship to Remission From Richard R Pleak, MD. BPD Mary G Zanarini, EdD., Frances R Frankenburg, M.D., John C Trans gender Teens: Gender Atypicality at Puberty and Hennen, PhD., D. Bradford Reich, MD. Beyond Sarah E. Herbert, MD. D Why Psychiatrists Do Not Diagnose BPD Joel F. Paris, MD. D Gender Variance in Children and Adolescents: A Critical Reinterpretation of Case Studies Discussant: Thomas H McGlashan, MD. Darryl B. Hill, PhD. THIS SESSION WILL BE AUDIOTAPED.

E Childhood Gender Identity Disorder What Should We SYMPOSIUM 54 2:00 p.m.-5:00 p.m. Treat and Why? Empire/Hudson Rooms, Seventh Floor, Marriott Marquis Edgardo J. Menvielle, MD., Catherine Tuerk, RN. THIS SESSION WILL BE AUDIOTAPED. ANTICONVULSANTS FOR TREATING MULTIPLE COMPONENTS OF ALCOHOL-DEPENDENCE SYMPOSIUM 52 2:00 p.m.-5:00 p.m. SYNDROME Plymouth/Uris/Shubert Rooms, Sixth Floor, Marriott Marquis Chp.: Bankole A Johnson, MD. Co-Chp.: Robert M. Swift, MD. THE ART AND SCIENCE OF BRIEF THERAPIES A What Are the Critical Neurobiological Substrates Chp.: Mantosh J. Dewan, M.D. Involved in the Development of Alcohol-Dependence? Raymond F. Anton, Jr., MD. A Solution-Focused Brief Therapy: Doing What Works Brett Steenbarger, PhD. B What Is the Utility of Various Gasses of Pharmacological Agents in Treating Different Components of the Alcohol- B Brief Behavior Therapy Dependence Syndrome? Edna B. Foa, PhD. Robert M. Swift, MD., George Kenna, PhD.

C Cognitive Therapy: Practice and Training C What Is the Effectiveness of Various Classes of Judith S. Beck, PhD. Pharmacological Agents at Reducing Craving for Alcohol? D The Impact of Common Factors on Psychotherapy Nassima Ait-Daoud, MD. Outcomes Roger P. Greenberg, PhD. D How Effective Are Anticonvulsants at Treating Alcohol- THIS SESSION WILL BE AUDIOTAPED. Withdrawal Symptoms? Robert J. Malcolm, Jr., MD., Hugh Myrick, MD., Elizabeth Noll,M.S.W., Brent Taylor

E How Effective Are Anticonvulsants at Improving the Overall Clinical Picture of Alcohol Dependence? Bankole A Johnson, MD. THIS SESSION WILL BE AUDIOTAPED. 64 TUESDAY

SYMPOSIUM 55 2:00 p.m.-5:00 p.m. D Integrating AA and Psychotherapy Herald/Soho Rooms, Seventh Floor, Marriott Marquis Richard K. Ries, M.D.

ADHD SUBTYPES AND SUBGROUPS AT RISK FOR Discussants: Kathleen T. Brady, M.D., Michael H. Gendel, M.D. SUBSTANCE USE DISORDERS THIS SESSION WILL BE AUDIOTAPED. Collaborative Session With the National Institute en Drug A buse SYMPOSIUM 57 2:00 p.m.-5:00 p.m. Chp.: Naimah Z. Weinberg, M.D. Marquis Ballroom Salons A/B, Ninth Floor, Marriott Marquis A Subtypes of ADHD Youth At Risk for Substance Abuse Timothy E. Wilens, M.D. AN UPDATE ON PARKINSON'S DISEASE AND ITS PSYCHIATRIC COMPLICATIONS B Childhood ADHD, Comorbidity, and Risk for Late- Chp.: Matthew A. Menza, M.D. Adolescent Drug Abuse Ken C Winters, Ph.D., Gerald August, PhJD., George M. A Parkinson's Disease: Update on Treatment, Etiology, and Realmuto, M.D. Pathogenesis Margery Mark, M.D. C Developmental Twin Studies of Relations Between Substance Use and ADHD B Depression in Parkinson's Disease James J. Hudziak, M.D., Dorett Boomsma, M.D., Richard D. Jeffrey L. Cummings, M.D. Todd,M.D. C Psychosis in Parkinson's Disease D Variability in Risk for Substance Use and Disorder Laura Marsh, M.D. Among Children Diagnosed With ADHD Brooke S.G. Molina, Ph.D., William E. Pelham, Jr., Ph.D., D Cognitive Impairment, Dementia, and Parkinson's Elizabeth M. Gnagy, B.S. Disease Iracema Leroi, M.D. E Behavioral and Cognitive Predictors of Adolescent Substance Use in Children With ADHD E Anxiety, Fatigue, and Sleep in Patients With Parkinson's JeffreyHalperin, Ph.D., Seth Harty, M.S., Nicole Thorn, B.A., Disease Jeffrey H. Newcorn, M.D. Matthew A. Menza, M.D.

F Long-Term Follow-Up of Childhood ADHD: Discussant: Constantine Lyketsos, M.D. Development of Adult Substance Abuse THIS SESSION WILL BE AUDIOTAPED. F. Xavier Castellanos, M.D., Rachel G. Klein, Ph.D., Sal Mannuzza, Ph.D., John L. Moulton, Ph.D. SYMPOSIUM 58 2:00 p.m.-5:00 p.m. THIS SESSION WILL BE AUDIOTAPED. Marquis Ballroom Salon C, Ninth Floor, Marriott Marquis

SYMPOSIUM 56 2:00 p.m.-5:00 p.m. UNIPOLAR MDD: INTERNATIONAL UPDATE Cantor/Jolson Rooms, Ninth Floor, Marriott Marquis APA Council on Global Psychiatry

ALCOHOLICS ANONYMOUS AND SPIRITUALLY Chp.: Lewis L. Judd, M.D. ORIENTED RECOVERY Co-Chp.: Juan J. Lopez-Ibor, Jr., M.D.

Chp.: Marc Galanter, M.D. A MDD: A New Paradigm of Understanding and Treatment Co-Chp.: Edgar Nace, M.D. Lewis L. Judd, M.D.

A Research on Spirituality's Role in Recovery B A Psychobiological Model of Depression: Implications for Marc Galanter, M.D. Treatment Hagop S. Akiskal, M.D. B The Effectiveness of AA: Empirical Research C Predictive Factors in Resistant Depression: New Perspectives European Data Barbara S. McCrady, Ph.D. Julien Mendlewicz, M.D.

C The Interaction Between AA and Personality Disorder D A New Public Health Agenda for Depression Edgar Nace, M.D. Norman Sartorius, M.D.

Discussants: Giovanni B. Cassano, M.D., Costas Stefanis, M.D. THIS SESSION WILL BE AUDIOTAPED. 65 TUESDAY

A Evidence-Based Utilization of Antiepileptic Drugs 3:00 p.m. Session S. Nassir Ghaemi, M.D.

NEW RESEARCH POSTER SESSION 7 B Integrated Treatment of Bipolar Disorder in Children and 3:00 p.m.-5:00 p.m. Adolescents Galleria, Level 4, Javits Center Kiki D. Chang, M.D.

CHILD AND ADOLESCENT PSYCHIATRY, C Bipolar Disorders in Women: Clinical and Metabolic PSYCHOTHERAPIES, AND OUTCOME STUDIES Correlates Natalie L. Rasgon, M.D. For further information on New Research Sessions, please refer to the NewResearch ProgramBook included in your registration packet. D Recognizing and Treating Comorbid Depression and Anxiety in Bipolar Disorder Lori L. Davis, M.D.

7:00 p.m. Sessions E The Challenge of Treating Bipolar Disorder and Substance Abuse INDUSTRY-SUPPORTED SYMPOSIA43-49 MarkA.Frye,M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 43 INDUSTRY-SUPPORTED SYMPOSIUM 45 7:00 p.m.-10:00 p.m. 7:00 p.m.-10:00 p.m. Grand Ballroom East, Third Floor, Hilton New York Westside Ballroom 3-4, Fifth Floor, Marriott Marquis

EMOTION REGULATION AND PLASIdTY OF DOES THE PHARMACOLOGY OF ANTIDE PRESS ANT UNDERLYING CIRCUITRY: IMPLICATIONS FOR DRUGS MATTER? DEPRESSION, ANXIETY, AND LONG-TERM BRAIN Supported by GlaxoSnithKLine FUNCTION Supported by Wyeth Pharmaceuticals Chp.: Maurizio Fava, M.D.

Chp.:NedHKalin,M.D. A Antidepressant Treatment and the Effect of Medical and Psychiatric Comorbidity A Amygdala and Prefrontal Cortical Interactions in Dan V. losifescu, M.D. Emotion Regulation and Psychopathology NedHKalin,M.D. B Response Versus Remission: Are There Meaningful Differences Among Antidepressants? B Hippocampal Size in Depression: Cause and Effect Michael E. Thase, M.D. Alan F. Schatzberg, M.D. C Short- and Long-Term Tolerability Issues "with C Experience-Dependent Effects on Structural-Plasticity in Antidepressants Limbic and Cortical Structures Involved in Emotion Anita L.H. Clayton, M.D. Regulation Elizabeth Gould, Ph.D. D Augmentation and Combination Strategies in Depression: What Is the Evidence? D The Human Amygdala: Vigilance, Threat Assessment, Maurizio Fava, M.D. and Psychopathology Paul Whalen, Ph.D. E Translating Mechanisms of Action Into Clinical Outcome of Depress ion INDUSTRY-SUPPORTED SYMPOSIUM 44 J. Craig Nelson, M.D. 7:00 p.m.-10:00 p.m. Westside Ballroom 1-2, Fifth Floor, Marriott Marquis INDUSTRY-SUPPORTED SYMPOSIUM 46 7:00 p.m.-10:00 p.m. Broadway Ballroom, Sixth Floor, Marriott Marquis CHALLENGES IN TREATING BIPOLAR ILLNESS AND COMORBID DISORDERS Supported by A bbott Laboratories PANIC ANXIETY: UNDERSTANDING ITS NATURE AND NURTURING RECOVERY Supported by Forest Laboratories, Inc. Chp.: Lori L. Davis, M.D. Chp.: Murray B. Stein, M.D. 66 TUESDAY

A Born or Made Anxious? The Role of Temperament and B Family and Genetic Studies of Binge-Eating Disorder Environment James I. Hudson, M.D. Murray B. Stein, MD. C Treatment of Binge-Eating Disorder B Born or Made Anxious? Anxiety Disorder Gene Mapping B.Timothy Walsh, M.D. and Identification Joel Gelernter, M.D. D Psychiatric Comorbidity Associated With Binge-Eating Disorder C Extreme Anxiety and Suicide Justine K. Lalonde, M.D. David C Purselle, M.D. E Addressing Medical Comorbidity Associated With Binge- D Understanding and Treating Primary Care Panic Eating Disorder Disorder Using a Collaborative Care Approach Louis J. Aronne, M.D. Peter P. Roy-Byrne, M.D. INDUSTRY-SUPPORTED SYMPOSIUM 49 E Choosing Medications for Panic Disorder 7:00 p.m.-10:00 p.m. Jonathan RT. Davidson, M.D. Imperial Ballroom B, Second Floor, Sheraton New York

INDUSTRY-SUPPORTED SYMPOSIUM 47 EXPLORING THE TRUE MORBIDITY OF INSOMNIA 7:00 p.m.-10:00 p.m. Supported by Neunxrine Bicsdenoes Inc. Grand Ballroom, Mezzanine Level, Roosevelt Chp.: John W. Winkelman, M.D. ADULT ADHD DIAGNOSIS AND TREATMENT Supported by Shire US, Inc. A Assessing the Complaint of Insomnia MaryB. OMalley, M.D. Chp.: Thomas J. Spencer, M.D. B Metabolic and Endocrine Effects of Sleep Deprivation A Adult ADHD: Clinical Overview Eve Van Cauter, M.D. Thomas J. Spencer, M.D. C Psychiatric Morbidity of Insomnia B Understanding and Utilization of Diagnostic Rating Ruth M. Benca, M.D. Scales Lenard A. Adler, M.D. D Quality of Life and Health Care Costs in Insomnia C Cognitive-Behavioral Therapies: Treatments and Daniel J. Buysse, M.D. Outcomes Stephen P. McDermott, M.D. E Current and Future Treatments of Insomnia John W. Winkelman, M.D. D Treatment With Stimulants Timothy E. Wilens, M.D. PRESIDENTIAL FORUM 9 E Treatment With Nonstimulants 7:00 p.m.-10:00 p.m. James G. Waxmonsky, M.D. As tor Ballroom, Seventh Floor, Marriott Marquis

INDUSTRY-SUPPORTED SYMPOSIUM 48 IAMSAM 7:00 p.m.-10:00 p.m. Imperial Ballroom A, Second Floor, Sheraton New York Chp.: Marcia Kraft Goin, M.D. Participants: Jessie Nelson, Daniel J. Siegel, M.D. BINGE-EATING DISORDER: GENES, TREATMENTS, AND CONSEQUENCES Supported by Ortho-McNeil Pharrntceuticak

Chp.: James I. Hudson, M.D.

A The Neurobiology of Binge-Eating and Obesity James F. List, M.D.

67 AMERICAN PSYCHIATRIC ASSOCIATION - 158TH ANNUAL MEETING

MAY 21-26,2005 Atlanta, Georgia CALL FOR PAPERS PRESIDENT'S THEME: Psychosomatic Medicine: Integrating Psychiatry & Medicine

Michelle Riba, M.D. President Marian I. Butterfield, M.D., Chairperson Scientific Program Committee THE SUBMISSION SCHEDULE

Format Deadline

Industry-Supported Symposium June 1,2004 Course September 7, 2004 Reports September 7, 2004 Symposium September 7, 2004 Workshops Issue: September 7, 2004 Component: September 20, 2004 New Research December 3, 2004

Incomplete and/or Incorrect Forms Will Not Be Considered. For complete submission forms, you may download the forms at www.psych.org, click on the Annual Meeting logo, then click on submission forms. You may also contact theAPA toll free at 1-888-357-7924, and speak directly with an Answer Center Coordinator. If you want to volunteer to chair a session, please send a letter to the attention of Dr. Butterfield at the American Psychiatric Association. Please indicate your name, address, area of expertise, and the type of session you would like to chair. Please be aware that we receive more requests than available slots. If you are selected as a chairperson, you will be notified by the end of November.

68 WEDNESDAY, MAY 5, 2004

157THANNUAL MEETING

7:00 a.m. Sessions 8:00 a.m. Sessions

PART 1 OF INDUSTRY-SUPPORTED BREAKFAST COURSES 77-85 SYMPOSIA 50-51 Course descriptions are available in the CME Course Brochure included in your registration packet Admission by ticket only. INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 50, PARTI 7:00 a.m.-8:30 a.m. 8:00 a.m.-12 noon Imperial Ballroom A, Second Floor, Sheraton New York COURSE 77 Concourse B, Concourse Level, Hilton New York PTSD: SEARCHING FOR ANSWERS IN TRAUMATIC TIMES ASSESSING POSITIVE AND NEGATIVE SYMPTOMS IN Supported by Qphalon, Inc. PSYCHOSIS WITH THE PANSS

Chp.: Jonathan R.T. Davidson, M.D. Co-Directors: Lewis A. Opler, M.D., Paul M. Ramirez, Ph.D. COURSE 78 8:00 a.m.-12 noon A PTSD: Its Burden and the Toll From Terrorism Concourse E, Concourse Level, Hilton New York Randall D. Marshall, MD. BIOETHICS UPDATE 2004 B Brain Imaging in PTSD: Going Beyond 5HT David J.Nutt,MX>. Director: Edmund G. Howe, M.D. C Sleep in PTSD and Other Anxiety Disorders Karl Doghramji, M.D. COURSE 79 8:00 a.m.-12 noon Bryant Suite, Second Floor, Hilton New York INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 51, PARTI PSYCHIATRIC CONSULTATION IN LONG-TERM 7:00 a.m.-8:30 a.m. CARE Imperial Ballroom B, Second Floor, Sheraton New York Director: George T. Grossberg, M.D. BIPOLAR DISORDER IN WOMEN: REPRODUCTIVE Faculty. Judith H. W. Crossett, M.D., Abhilash K. Desai, M.D. IMPLICATIONS OF TREATMENT Supported by GJaxoSrrithKLine COURSE 80 8:00 a.m.-12 noon Gibson Suite, Second Floor, Hilton New York Chp.: Adele G Viguera, M.D. Co-Chp.: Lee S. Cohen, M.D. INSANITY DEFENSE EVALUATIONS A Treatment of Bipolar Illness During Pregnancy Director: Phillip J. Resnick, M.D. Lee S. Cohen, M.D. COURSE 81 8:00 a.m.-12 noon B Bipolar Illness During the Postpartum Period: Update on Treatment Gramercy B, Second Floor, Hilton New York Adele C Viguera, M.D. CONTEMPORARY MALPRACTICE LIABILITY: A C Treatment of Bipolar Illness in Adolescence: PRACTICAL GUIDE Implications for Younger Women Janet Wozniak, M.D. Co-Directors: Eugene M. Lowenkopf, M.D., Abe M. RychikJ.D. Faculty: Jacqueline M. Melonas, J.D., Richard G. Hersh, MX).

69 WEDNESDAY

COURSE 82 8:00 a.m.-12 noon CONTINUOUS CLINICAL CASE CONFERENCE 2: Murray Hill B, Second Floor, Hilton New York PART 1 9:00 a.m.-12 noon PSYCHIATRY IN JAIL Rooms 3D01/12, Level 3, Javits Center

Director: Ole J. Thienhaus, MD. TWO HOSPITALIZED PATIENTS WITH REFRACTORY Faculty: Melissa P. Piasecki, M.D., Jan Budetti, M.S.W., John N. MOOD DISORDER AND COGNITIVE IMPAIRMENT Chappel, MD., Richard Horton, MD. Moderator: Stuart C Yudofsky, MD. COURSE 83 8:00 a.m.-12 noon Presenters: Richard L. Munich, MD., Efram Bleiberg, M.D., Lauren B. Marangell, MD., Alice Rogan, MD., Florence Nassau Suite A, Second Floor, Hilton New York Kim, MD. HELPING PARENTS FROM THE INSIDE OUT: THIS SESSION IS OPEN TO APAMEMBERS ONLY. ATTACHMENT, MINDSIGHT, AND THE BRAIN BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE. Director Daniel J. Siegel, MD.

COURSE 84 8:00 a.m.-12 noon COURSES 86-90 Sutton North, Second Floor, Hilton New York Course descriptions are available in the CME Course Brochure included in your registration INFANTICIDE: A DIALOGUE BETWEEN THE packet Admission by ticket only. PSYCHIATRIST AND THE ATTORNEY

Co-Directors: Margaret G. Spinelli, MD., Katherine L. COURSE 86 9:00 a.m.-4:00 p.m. Wisner,MD. Concourse A, Concourse Level, Hilton New York Faculty: George Parnham, J.D. PSYCHOTHERAPY OF BORDERLINE PERSONALITY COURSE 85 8:00 a.m.-5:00 p.m. Gramercy A, Second Floor, Hilton New York Co-Directors: Otto F. Kernberg, MD., Frank E. Yeomans, M.D. OFFICE-BASED BUPRENORPHINE TREATMENT OF Faculty: John F. Qarkin, Ph.D., Eve Caligor, MD. OPIOID-DEPENDENT PATIENTS COURSE 87 9:00 a.m.-4:00 p.m. Co-Directors: Thomas R. Kosten, MD., Eric C Strain, MD. Beekman Parlor, Second Floor, Hilton New York Faculty: Walter Ling, MD., Laura F. McMcholas, M.D. THE NEUROENDOCRINOLOGY OF MOOD DISORDERS 9:00 a.m. Sessions Co-Directors: Mark A Frye, MD., Natalie L. Rasgon, MD. Faculty: D. Jeffrey Newport, MD., Michael Bauer, MD., CLINICAL CASE CONFERENCE 3 Catherine A. Roca, M.D., Charles DeBattista, MD. 9:00 a.m.-10:30 a.m. Rooms 3D06/7, Level 3, Javits Center COURSE 88 9:00 a.m.-4:00 p.m. Clinton Suite, Second Floor, Hilton New York PSYCHIATRIC ISSUES IN THE MANAGEMENT OF PATIENTS WITH HIV INFECTION MONEY MATTERS II: ADVANCED CLINICAL PRACTICE Moderator: Glenn J. Treisman, MD. Presenters: Andrew F. Angelino, MD., Heidi E. Hutton, Ph.D. Director: Cecilia M Mikalac, MD.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

70 WEDNESDAY

COURSE 89 9:00 a.m.-4:00 p.m. Following an internship in pediatrics, he spent three years Murray Hill A, Second Floor, Hilton New York at the National Institutes of Health as a research fellow in the laboratory of Nobel Prize winner Julius Axelrod, INTRODUCTION TO COGNITIVE-BEHAVIORAL Ph.D. He returned to Hopkins in 1973 to complete his THERAPY Psychiatric residency, in which he is board certified, and joined the faculty. In 1980, he was promoted to Profes- sor of Neuroscience, Pharmacology and Psychiatry, and Co-Directors: Robert M. Goisman, MD., Philip G. in 1982 he assumed the Directorship of the Division of Levendusky, Ph.D. Child and Adolescent Psychiatry, being named the Distinguished Service Professor in 1985. Dr. Coyle's re- COURSE 90 9:00 a.m.-4:00 p.m. search interests include developmental neurobiology, Sutton Center, Second Floor, Hilton New York mechanisms of neuronal vulnerability, and psychophar- macology. He has published over 500 scientific articles MED-PSYCH DRUG-DRUG INTERACTIONS and has edited seven books. He has received NIH funding for his research for nearly 30 years and is the Co-Directors: Scott C. Armstrong, MD., Kelly L. Cozza, MD. Director of an NIMH Conte Center on the Neurobiol- Faculty: David M. Benedek, MD., Jessica R. Oesterheld, M.D., ogy of Schizophrenia. His research contributions have Neil B. Sandson, MD. been recognized by the reception of the John Jacob Abel Award from the America Society for Pharmacology and Experimental Therapeutics, the Gold Medal Award from DISCUSSION GROUPS 18-19 the Society for Biological Psychiatry, the Efron Award from the American College of Neuropsychopharmacol- 9:00 a.m.-10:30 a.m. ogy, the Foundation Fund Research Award from the American Psychiatric Association (APA), the McAlpin These sessions are limited to 25 participants on a first-come, Award from the National Mental Health Association, the first-served has is. Salmon Award from the New York Academy of Medicine, and the Pasarow Foundation Award for 18 Milton Viederman, M.D., on Psychological Engagement Neuroscience. Dr. Coyle is a Distinguished Fellow of the During the Consultation Process (Meet the Authors) APA He is Past-President of the American College of Rooms 2D02/3, Level 2, Javits Center Neuropsychopharmacology (2001) and Past-President (1991) of the Society for Neuroscience, which has over 19 Geetha Jayaram, M.D., on Patient Safety (Far Residents Onfy) 30,000 members. He sits on over 20 journal editorial JAMA Versailles Terrace, Second Floor, Sheraton New York boards including and is the Editor-in-Chief of the Anhwes (/General Psychiatry, the most highly cited journal in the field. Distinguished Psychiatrist Lecture Series LECTURES 19-20 THIS SESSION WILL BE AUDIOTAPED.

LECTURE 19 LECTURE 20

9:00 a.m.-10:30 a.m. Rooms 1E07/8, Level 1, Javits Center 9:00 a.iru-10:30 a.m. Room IE 15, Level 1, Javits Center Joseph T. Coyle, Jr., M.D. APA'S SIMON BOLIVAR AWARD LECTURE The Role of Glutamate in the Pathophysiology of Schizophrenia Andres J. Pumariega, M.D.

Chp.: Yoram Barak, MD. Latino Youth in the U.S.: Developmental Co-Chp.: Larry E. Tune, MD. and Mental Health Challenges

From 1991 to 2001, Joseph T. Coyle, Jr., MD., served as Chp.: Ana E. Campo, MX). Chairman of the Consolidated Department of Psychiatry at Harvard Medical School, which included the nine hos- Andres J. Pumariega, M.D., is Professor and Director of pital programs of psychiatry affiliated with the Medical Child and Adolescent Psychiatry at East Tennessee State School. He now holds the Eben S. Draper Chair of Psy- University (ETSU) in Johnson City, Tennessee; and chiatry and Neuroscience at Harvard. After graduating Director of the ETSU Center of Excellence for Children from Holy Cross College, he received his medical degree from Johns Hopkins School of Medicine in 1969. (Continued on mxtpag) 71 WEDNESDAY

13 The Developmental Psychobiology of Early Attachment in State Gistody. Dr. Pumariega chairs the Cbmmunity Myron Hofer, M.D. Psychiatry Committee and was the founding Chair of the Work Group on Community-Based Systems of Care of the American Academy of Child and Adolescent Psy- 14 The Developmental Neurobiology of Face Perception chiatry (AACAP); was a member of the National Charleston Nelson, Ph.D., Lisa Scott, B.S. Advisory Council for the Center for Mental Health Services (CMHS'); and chaired the Latino Panel for the 15 Developmental Psychobiology of Tourette's Syndrome CMHS Managed Care Initiative; and is a member of the Kathy A Gallardo, M.D., James E. Swain, M.D., James F. Board of Directors of the American Association of Leckman, M.D. Cbmmunity Psychiatrists (AACP). Hie is the author of more than 100 scientific papers, oook chapters, and monographs, mosdy focusing on community child psychiatry and cross-cultural mental health. Ms books WORKSHOPS include Umcal Assessn&t of'ChfldandAddesoenl'Behawor (co-edited with H. Vance)and Handbook (f Child and Adolescent Systems of Cure: The NewGcmrttnity Psychiatry (co- COMPONENTS 33-41 edited with N. Winters). A Distinguished Fellow of the American Psychiatric Association and a Fellow of COMPONENT WORKSHOP 33 9:00 a.m.-10;30 a.m. AACAP, Dr. Pumariega has received numerous awards, Room 1D06, Level 1, Javits Center including the Outstanding Mentor Award and the Ethics in Managed Care Award from the AACP, and the Exemplary Psychiatrist Award from the National TERRORISM IN AMERICA: THE DISTANT VICTIMS Alliance for the Mentally 111. Dr. Pumariega received his AND THE ROLE OF IMG PSYCHIATRISTS medical degree from the University of Miami and com- APA Committee on International Medical Graduates pleted his residency in psychiatry and a fellowship in child and adolescent psychiatry at Duke University Medi- Co-Chps.: Fructuoso R. Irigoyen-Rascon, M.D., Godehard cal Center in Durham, North Carolina. Oepen, M.D. THIS SESSION WILL BE AUDIOTAPED. Participants: Jose M. Canive, M.D., Chowallur D. Chacko, M.D. MASTER EDUCATOR CLINICAL CONSULTATIONS 8-9 COMPONENT WORKSHOP 34 9:00 a.m.-10:30 a.m. Rooms 2D10/11, Level 2, Javits Center 9:00 a.m.-10:30 a.m. CPT CODING AND DOCUMENTATION UPDATE These sessions are limited to 25 participants on a first-come, APA Committee onRBRVS, Codes, and Reimbursements first-served basis. Chp.: Chester W. Schmidt, Jr., M.D. 8 Susan D. Block, M.D., on Psychiatric Issues and Participants: Tracy R. Gordy, MD., Edward Gordon, MD., Interventions at the End of Life Napoleon B. Higgins, Jr., M.D., Melodic Morgan-Minott, M.D., Room 1D04, Level 1, Javits Center Joseph M Schwartz, M.D.

9 Michael D. Garrett, M.D., on Can the Ordinary Mind COMPONENT WORKSHOP 35 9:00 a.m.-10:30 a.m. Empathize With Psychotic Experiences? Rooms 2D12/13, Level 2, Javits Center Room 1D05, Level 1, Javits Center THE PSYCHIATRIST IN THE SCHOOLS: THESE SESSIONS ARE OPEN TO APAMEMBERS MEDICATION, BOUNDARIES, AND TRANSFERENCE ONLY. BLUE REGISTRATION BADGE OR APA ISSUES MEMBERSHIP CARD REQUIRED FOR ADMITTANCE. APA Gamespondirg Committee mMe^ Chp.: Eugenio M. Rothe, M.D. REVIEW OF PSYCHIATRY: SECTION 3 Participants: Hong Shen, M.D., Mary Ann Schaepper, M.D., 9:00 a.m.-12:30 p.m. TrinaB. Allen, M.D. Special Events Hall ID, Level 1, Javits Center COMPONENT WORKSHOP 36 9:00 a.m.-10:30 a.m. DEVELOPMENTAL PSYCHOBIOLOGY Rooms 2D14/15, Level 2, Javits Center

Chp.: BJ. Casey, Ph.D. TAKING THE FIRST STEP: WHAT ARE MY OPTIONS IN THE TRANSITION TO PRACTICE? 11 Developmental Psychobiology: An Overview APA A ssemUy Committee of Early Career Psychiatrists BJ. Casey, Ph.D. Chp.: Murali Gopal, M.D. 12 Withdrawn Participants: Jeffrey A Naser, MD., Matthew W. Norman, MD., Angelique D. Goodhue, MD., Adam R. Chester, D.O. 72 WEDNESDAY

COMPONENT WORKSHOP 37 9:00 a.m.-10:30 a.m. ISSUES 77-103 O'Neill Room, Fourth Floor, Marriott Marquis ISSUE WORKSHOP 77 9:00 a.m.-10:30 a.m. APA ETHICS PROCEDURES Rooms IE 01/2, Level 1, Javits Center APA Ethics Appeal Board MIRROR, MIRROR ON THE WALL: AMBITION AND Chp.: Wade C Myers, MD. THE TEACHING PSYCHIATRIST Participants: William Arroyo, MD., Harriet C Stern, MD., A ssodationforA caderric Psychiatry Donald G. Langsley, MD., Spencer Eth, MX)., Laura W. Roberts, MD., Nada L. Stotland, MD., Richard D. Milone, MD. Co-Chps.: Susan J. Lieff, MD., Philip R. Muskin, MD. Participant: Josepha A Cheong, MD. COMPONENT WORKSHOP 38 9:00 a.m.-10:30 a.m. Ziegfeld Room, Fourth Floor, Marriott Marquis ISSUE WORKSHOP 78 9:00 a.m.-10:30 a.m. Rooms 1E03/4/5, Level 1, Javits Center DOLLARS: THE PHARMACEUTICAL INDUSTRY IN PSYCHIATRIC TRAINING THE TRAUMA OF MEDICAL MISTAKES: AN APA Committee ofResidents andFettovts EXPERIENTIAL WORKSHOP

Co-Chps.: William C Wood, MD., Geoff reyM. Hopkins, MD. Co-Chps.: Michael F. Myers, MD., Leah J. Dickstein, MD. Participants: David A Goldberg, MD., John B. Herman, MD., Participants: Rabbi Goldie Milgram, Barry Bub, MD. Michael D. Jibson, MD., Michele T. Pato, MD., Michael E. Thase, MD. ISSUE WORKSHOP 79 9:00 a.m.-10:30 a.m. Room 1E09, Level 1, Javits Center COMPONENT WORKSHOP 39 9:00 a.m.-10:30 a.m. Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis THE PORTRAYAL OF ECT ON TELEVISION, FILM, AND THE INTERNET REDUCING DISPARITIES IN ACCESS TO PSYCHIATRIC CARE: APA PERSPECTIVES Chp.: Patrick Ying, MD. APA Steering Committee to Reduce Disparities in A a&s to Psychiatric Care ISSUE WORKSHOP 80 9:00 a.m.-10:30 a.m. Co-Chps.: Altha J. Stewart, MD., Roger D. Walker, MD. Room IE 10, Level 1, Javits Center Participants: Pedro Ruiz, MD., Francis G. Lu, MD., Edward F. Foulks, MD., Carl C Bell, MD., Patrick I. Ordorica, MD., Richard K. Harding, MD. PSYCHODYNAMIC TREATMENT OF DEPRESSION

COMPONENT WORKSHOP 40 9:00 a.m.-10:30 a.m. Chp.: Fredric N. Busch, MD. Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis Participants: Marie G. Rudden, MD., Theodore Shapiro, MD.

NEW CLASSIFICATION OF PSYCHOPATHOLOGY OF ISSUE WORKSHOP 81 9:00 a.m.-10:30 a.m. INFANTS AND YOUNG CHILDREN Room IE 11, Level 1, Javits Center APA CorKspordir%ComritteeGnIrfantyan^ WHEN USUAL TREATMENTS FAIL: ANTIPSYCHOTIC Chp.: Irene Qiatoor, MD. STRATEGIES FOR REFRACTORY SCHIZOPHRENIA Participants: Thomas F. Anders, MD., Daniel J. Siegel, MD., Jean M. Thomas, MD. Chp.: Jean-Pierre Lindenmayer, MD. Participants: John W. Rosenberger, MD., Robert R. Conley, MD., Richard P. Brown, MD., Leslie L. Citrome, MD. COMPONENT WORKSHOP 41 9:00 a.m.-10:30 a.m. Majestic/Music Box/ Winter Garden, Sixth Floor, Marriott Marquis ISSUE WORKSHOP 82 9:00 a.m.-10:30 a.m. Room IE 12, Level 1, Javits Center CONSULTATION AND LEGAL CLARIFICATION IN SEXUAL HARASSMENT TREATMENT OF PATIENTS WITH DRUG APA New Jersey Psychiatric Association DEPENDENCE AND PSYCHIATRIC ILLNESS Collaborative Session With the National Irstitute on Drug A buse Co-Chps.: Rita R. Newman, MD., Annette J. Hollander, MD. Participants: Maria T. Lymberis, MD., David W. Co-Chps.: Wilson Compton III, MD., Roger D. Weiss, MD. Garland, Esq., Francine Weiss, Esq. Participants: Edward V. Nunes, MD., Alan S. Bellack, PhD, JoyM.Schmitz,Ph.D. 73 WEDNESDAY

ISSUE WORKSHOP 83 9:00 a.m.-10:30 a.m. ISSUE WORKSHOP 89 9:00 a.m.-10:30 a.m. Room IE 13, Level 1, Javits Center Rooms 3D05/8, Level 3, Javits Center

KUNDALINI YOGA MEDITATION TECHNIQUES FOR THE SISSY DUCKLING: THE PERILS OF CHILDHOOD PSYCHIATRIC DISORDERS GENDER VARIANCE

Chp.: David Shannahoff-Khalsa, B.A. Co-Chps.: Edgardo J. Menvielle, MX)., Catherine Tuerk, R.N.

ISSUE WORKSHOP 84 9;00 a.m.-10;30 a.m. ISSUE WORKSHOP 90 9:00 a.m.-10:30 a.m. Room IE 14, Level 1, Javits Center Wilder Room, Fourth Floor, Marriott Marquis PTSD IN THE NEW YORK FIRE DEPARTMENT: BODIES AND MINDS GERIATRIC PSYCHIATRY AROUND THE GLOBE: PRESENT AND FUTURE Chp.: Kevin V. Kelly, MX). Participants: Kristina L.N. Jones, MX)., Claire Chp.: Dilip V. Jeste, MX). Cammarata, C.S.W. Participants: Hugh G Hendrie, MX)., Kirsten Abelskov, MX)., Alvaro Camacho, M.D., Tonmoy Sharma, M.D. ISSUE WORKSHOP 85 9:00 a.m.-10:30 a.m. ISSUE WORKSHOP 91 9:00 a.m.-10:30 a.m. Room IE 16, Level 1, Javits Center Booth/Edison Rooms, Fifth Floor, Marriott Marquis WOMEN'S MENTAL HEALTH IN TIMES OF TURMOIL: AN INTERNATIONAL PERSPECTIVE PREMARITAL COUNSELING: THE FACTS OF LIFE A ssodatian of Wamzn Psychiatrists AND MORE

Chp.: Sylvia W. Olarte, MX). Chp.: Lawrence Bryskin, MX). Participants: Marta B. Rondon, MX)., Unaiza Maz, MX)., Ana E. Participants: Rabbi Yaakov Neuberger, BA, Judy Young, B.A., Campo, MX)., Marian I. Butterfield, M.D. Sophia Simantov, Peshy Neuberger, B.A., Rabbi Shlomo Gissinger, Sori Teitelbaum, B.A. ISSUE WORKSHOP 86 9:00 a.m.-10:30 a.m. Room 3D02/11, Level 3, Javits Center ISSUE WORKSHOP 92 9:00 a.m.-10:30 a.m. Imperial/Julliard Rooms, Fifth Floor, Marriott Marquis MIGRATION AND PROFESSIONAL IDENTITY EXPERIENCE OF ORGANIZING RUSSIAN-AMERICAN PSYCHOTHERAPY ISSUES THROUGHOUT THE LIFE PSYCHIATRY CYCLE IN ASIAN WOMEN

Chp.: Nelly Katsnelson, MX). Chp.: Albert C. Gaw, M.D. Participants: Rozaliya Vernikov, M.D., Michael L. Participants: Alice C Tso, M.D., Nalini V. Juthani, M.D., Melamed, MX). Norma C. Panahon, M.D.

ISSUE WORKSHOP 87 9:00 a.m.-10:30 a.m. ISSUE WORKSHOP 93 9:00 a.m.-10:30 a.m. Room 3D03/10, Level 3, Javits Center Lyceum Room, Fifth Floor, Marriott Marquis

VASCULAR DEMENTIA: ASSESSMENT, IMAGING, PRACTICAL MANAGEMENT OF MOOD DISORDERS AND TREATMENT Co-Chps.: Gary E. Miller, M.D., Richard L. Noel, MX). Chp.: F. Moises Gaviria, MX). Participant: Georgia Gaiser, PA-C Participants: Neil H. Pliskin, Glenn T. Stebbins, Ph.D., Christopher C. Duros, M.D. ISSUE WORKSHOP 94 9:00 a.m.-10:30 a.m. Palace Room, Sixth Floor, Marriott Marquis ISSUE WORKSHOP 88 9:00 a.m.-10:30 a.m. Rooms 3D04/9, Level 3, Javits Center DISSOLVING THERAPEUTIC BARRIERS: SPIRITUALITY GROUP WORK WITH PSYCHIATRIC MEDICAL TRAINING FOR PSYCHIATRISTS: WHAT STAFF DO WE NEED TO KNOW? Chp.: C Paul Yang, M.D. Chp.: Peter Manu, MX). Participants: Hendry Ton, M.D., Heather M. Hall, MX). Participants: Raymond E. Suarez, M.D., James L. Levenson, M.D., Bruce R. Levy, M.D., Roger G. Kathol, M.D. 74 WEDNESDAY

ISSUE WORKSHOP 95 9:00 a.m.-10:30 a.m. ISSUE WORKSHOP 100 9:00 a.m.-10:30 a.m. Plymouth/Uris/Shubert Rooms, Sixth Floor, Marriott Gramercy Room, Seventh Floor, Marriott Marquis Marquis SEXUAL SATISFACTION AND MENTAL HEALTH IN GUIDELINE DEVELOPMENT FOR THE ORTHODOX JEWISH WOMEN ASSESSMENT OF COMPETENCY Co-Chps.: Rachel Yehuda, Ph.D., Michelle E. Friedman, M.D. Chp.: Thomas S. Zaubler, M.D. Participant' Talli Rosenbaum, P.P.T. Participants: Peter M. Bob, M.D., Cynthia N. Hoen, J.D. ISSUE WORKSHOP 101 9:00 a.m.-10:30 a.m. ISSUE WORKSHOP 96 9:00 a.m.-10:30 a.m. Herald/Soho Rooms, Seventh Floor, Marriott Marquis Royale Room, Sixth Floor, Marriott Marquis TREATMENT OF ADULT ADHD: COMBINING INNOVATIONS IN ACADEMIC EMERGENCY COGNITIVE AND MEDICAL APPROACHES PSYCHIATRY Co-Chps.: Anthony L. Rostain, M.D., J. Russell Ramsay, Ph.D. Co-Chps.: William R. Dubin, M.D., Henry W. Weisman, M.D. Participants: Brook E. Zitek, D.O., Mahrukh S. Khan, M.D., ISSUE WORKSHOP 102 9:00 a.m.-10:30 a.m. Robert O'Brien, Harris Strokoff, Margaret A. Minehart, M.D., Cantor/Jolson Rooms, Ninth Floor, Marriott Marquis Carolyn Ulmer, M.S.W., Marcella Maguire, Ph.D. IMPLEMENTING PSYCHOSOdAL TREATMENTS IN ISSUE WORKSHOP 97 9:00 a.m.-10:30 a.m. REAL-WORLD SETTINGS Columbia/Duffy Rooms, Seventh Floor, Marriott Marquis Chp.: Edward Kim, M.D. ADDICTION PSYCHIATRY: SCIENCE, CRAFT, AND Participants: Elizabeth Vreeland, M.S.N., Anna Marie SPIRITUALITY Toto, M.Ed.

Chp.: Richard]. Frances, M.D. ISSUE WORKSHOP 103 9:00 a.m.-10:30 a.m. Participants: Sheila B. Blume, M.D., Avram H, Mack, M.D., Marquis Ballroom Salons A/B, Ninth Floor, Marriott Marc Galanter, M.D., Sheldon I. Miller, M.D., Robert B. Marquis Millman, M.D., Edgar Nace, M.D., Lionel P. Solursh, M.D. CRIMINAL JUSTICE SYSTEM AND SERIOUS MENTAL ISSUE WORKSHOP 98 9:00 a.m.-10:30 a.m. ILLNESS, PROBLEMS, AND SOLUTIONS Empire/Hudson Rooms, Seventh Floor, Marriott Marquis Co-Chps.: Joseph R. Calabrese, M.D., Janet Berry, J.D. Participants: Omar Elhaj, M.D., Sol Wachtler, J.D. UNDERSTANDING AND TREATING COMPULSIVE SEXUAL BEHAVIOR

Chp.: Eric Hollander, M.D. MEDIA 5-6 Participants: Eli Coleman, Ph.D., Jon Morgenstern, Ph.D., Frederick Muench, M.A., Jeffrey Parsons, Ph.D., Milton L. MEDIA WORKSHOP 5 9:00 a.m.-12 noon Wainberg, M.D. Room 1E06, Level 1, Javits Center

ISSUE WORKSHOP 99 9:00 a.m.-10:30 a.m. Postgenocide Psychological Trauma in Film, The Summer of Gotham Room, Seventh Floor, Marriott Marquis Aviya

KENDRA'S LAW BECOMES REALITY: ASSISTED Co-Chps.: Maurice Preter, MD., Harold J. Bursztajn, M.D. OUTPATIENT TREATMENT IN MANHATTAN Participants: Leonti H. Thompson, M.D., Yehuda Nir, M.D., Amira Kohn-Trattner, CS.W., Gila Almagor

Co-Chps.: Andrew M. Kleiman, M.D., GaryR. Collins, M.D. MEDIA WORKSHOP 6 9:00 a.m.-12 noon Participant: Jennifer Correale, J.D. Odets Room, Fourth Floor, Marriott Marquis

The Beginning Stages of Couples' Therapy: Video Case Studies

Chp.: Ian E. Alger,M.D.

75 WEDNESDAY

11:00 a.m. Sessions LECTURE 22

DISCUSSION GROUP 20 11:00 a.m.-12:30 p.m. Room IE 15, Level 1, Javits Center 11:00 a.m.-12:30 p.m. APA'S ADMINISTRATIVE PSYCHIATRY This session is limited to 25 participants on a first-come, AWARD LECTURE first-served basis. Peter F. Buckley, M.D. Larry B. Silver, M.D., on Clinical Management of ADHD With Children, Adolescents, and Adults (Meet the Author?) Public Academic Liaison: Pursuit of Best Practices Rooms 2D02/3, Level 2, Javits Center in a Time of Economic Entrenchment Chp.: Stuart B. Silver, MJD. LECTURES 21-22 Peter F. Buddey, MX)., is Professor and Chairman of the Department of Psychiatry and Health Behavior at the Medical College of Georgia in Augusta, He formerly was LECTURE 21 Professor of Psychiatry and Vice Chairman of the Department of Psychiatry at Case Western Reserve 11:00 a.m.-12:30 p.m. University School of Medicine and Medical Director at Rooms 1E07/8, Level 1, Javits Center Northcoast Behavioral Healthcare System, the state adult psychiatric services provider for Cleveland and Toledo, Kathleen T. Brady, M.D. Ohio. Dr. Buckley conducts research on the neurobiology and treatment of schizophrenia. He is the Stress and Relapse to Substance Use Disorders author of more than 200 scientific articles, abstracts, and QJlabonaae Session With the National Institute book chapters and the author or editor of seven books, on Drug Abuse including The Neunxfajdopnental Basis cf Schizophrenia and Sexuality and Serious Mental Illness, Dr. Buckley is the Clip.: David W. Brook, MD. Editor-in-Chief of the Journal of Dual Diagnosis and serves Co-Dip.: Sheila B. Blume, MD. on the editorial board of Aoidemc Psychiatry, Current Psychiatry, Drug

76 WEDNESDAY

11 Stephen M. Goldfinger, M.D., on Establishing 12 noon Relationships, Enhancing Adherence, and Improving 58 Topiramate Treatment of Alcohol Dependence: Effects Outcomes on Psychosocial Functioning and Its Relationship With Room 1D05, Level 1, Javits Center Heavy Drinking Bankole A. Johnson, MD., Nassima Ait-Daoud, MX)., THESE SESSIONS ARE OPEN TO APA MEMBERS Jennie Z. Ma, PhX)., Fatema Z. Akhtar, M.S., John D. ONLY. BLUE REGISTRATION BADGE OR APA Roache, PhX)., Norman Rosenthal, MD., Charles L. MEMBERSHIP CARD REQUIRED FOR ADMITTANCE. Bowden, MX)., Carlo C DiQemente, Ph.D., Martin A. Javors, Ph.D. THIS SESSION WILL BE AUDIOTAPED. MEDICAL UPDATE 3 11:00 a.m.-12:30 p.m. SCIENTIFIC AND CLINICAL REPORT SESSION 20 11:00 a.m.-12:30 p.m. Room IE 13, Level 1, Javits Center Room IE 11, Level 1, Javits Center BETTER SEX: NATURALLY CROSS-CULTURAL ISSUES

Chp.: Philip R. Muskin, M.D. Chp.: Leslie A. Horton, M.D. Presenter Richard P. Brown, MX). Co-Chp.: CJaudio O. Cabrejos, MX). THIS SESSION WILL BE AUDIOTAPED. 11:00 a.m. 59 Prevalence of Maternal Depression in Honduras RESEARCH CONSULTATION WITH Lawson R. Wulsin, MX)., Eugene C Somoza, MX)., Miguel Coello, MD., Jeffrey Heck, MD., Manuel Sierra 11:00 a.m.-12:30 p.m. 11:30 a.m. This session is limited to 25 participants on a first-come, 60 Screening for Depression Among Chinese Americans first-served basis. in Primary Care Using Two Items Albert Yeung, M.D., Jessica L. Murakami, B.A., Maurizio 3 Jack M. Gorman, M.D., on Designing and Implementing Fava, MD., Wendy M. Guyker, B.S., Melissa E. Studies Contrasting Psychopharmacology and Psychotherapy Abraham, Ph.D. Room 1D03, Level 1, Javits Center 12 noon 61 Suicidal Thinking in Colombian Youth With a History SCIENTIFIC AND CLINICAL REPORT of Attempted Suicide Ruby C Castilla-Puentes, MD., Wilma I. SESSIONS 19-27 Castilla-Puentes, MX)., Sandra R. Castilla-Puentes, MX)., Leo Russo, PhX)., Ivan S. Gomez, MD., Gilma P. SCIENTIFIC AND CLINICAL REPORT SESSION 19 de Contreras, MS.W., Miguel Habeych, MX). 11:00 a.m.-12:30 p.m. THIS SESSION WILL BE AUDIOTAPED. Rooms 1E01/2, Level 1, Javits Center SCIENTIFIC AND CLINICAL REPORT SESSION 21 ALCOHOL ABUSE 11:00 a.m.-12:30 p.m. Room IE 12, Level 1, Javits Center Chp.: Harvey Stabinsky, MD. Co-Chp.: Robert Kelly, MD. SUICIDE

11:00 a.m. Chp.: Douglas G. Jacobs, MX). 56 The Effects of State Income Inequality and Alcohol Co-Chp.: Robert M. Davis, MD. Tax on Alcohol Dependence Qaire Henderson, MD., Xinhua Liu, Ph.D., Ana Diez 11:00 a.m. Roux, Ph.D., Bruce G. Link, Ph.D., Deborah S. 62 Suicidality and Second-Generation Antipsychotics in Hasin, Ph.D. Patients With Schizophrenia Yoram Barak, MX)., Dov Alzenberg, MD., Haim 11:30 a.m. Knobler, MX)., Ilona Mirecki, MD. 57 Effect of Age on Long-Term Outcomes of Inpatient Alcoholism Treatment Neelofar Khan, MX)., Elizabeth). Nickel, MA, Elizabeth C Penick, Ph.D., Barbara]. Powell, Ph.D., Barry I. (Continued on nextpag) Liskow, MX)., Jan L. Campbell, MD., Sandra B. Hall 77 WEDNESDAY

11:30 a.m. 11:00 a.m. 63 Melancholia and Suicide Attempt Probability and 68 fMRI of Spatial Working Memory in Schizotypal Lethality Personality Disorder Michael F. Grunebaum, M.D., Hanga G. Galfalvy, Ph.D., Harold W. Koenigsberg, M.D., Monte S. Buchsbaum, MD., Maria A Oquendo, MD., Ainsley K. Burke, PhD, J. John Bradley Buchsbaum, PhD., Jason Schneiderrnan, Cheuk Mann, MD. Tang, PhD., Antonia S. New, MD., Larry J. Siever, MD.

12 noon 11:30 a.m. 64 Nonviolent Suicides in Women Are Increased During 69 Hypofrontality in Patients With Schizophrenia and and After High Exposure to Tree Pollen Bipolar Disorders: An fMRI Study Teodor T. Postolache, MD., Mark A Goldstein, B.A, Mircea G Polosan, MD., Monica Baciu, PhD., Christoph Richard Herrell, Ph.D., Srirangam S. Shreeram, MD., Segebarth, PhD., Thierry Bougerol, PhD. Courtney M Thrower, MA, John W. Stiller, MD., Hirsh Komarow, MD. THIS SESSION WILL BE AUDIOTAPED. 12 noon 70 Low Levels of Antibodies to Cardiolipin in First- SCIENTIFIC AND CLINICAL REPORT SESSION 22 Episode and Chronic Schizophrenia 11:00 a.m.-12:30 p.m. Pinkhas Sirota, MD., Irene Bogdanov, MD., Aviva Room 3D03/10, Level 3, Javits Center Katzav, M.S.G, Ruth Hershko, MD., Joab Chapman, MD. THIS SESSION WILL BE AUDIOTAPED. BIPOLAR DISORDER SCIENTIFIC AND CLINICAL REPORT SESSION 24 Chp.: Robert M Post, M.D. 11:00 a.m.-12:30 p.m. Co-Chp.: Candace R. Good, MD. Rooms 3D05/8, Level 3, Javits Center

11:00 a.m. PSYCHOPHARMACOLOGY RESEARCH IN 65 Characteristics of Patients Treated With Gabapentin DEPRESSION Referred to a Bipolar Specialty Clinic Michael J. Ostacher, MD., Heather Schloss, B.A, Lori R. Chp.: Susan Stabinsky, MD. Eisner, B.A, Andrew A Nierenberg, M.D. Co-Chp.: Donld W. Hicks, MD.

11:30 a.m. 11:00 a.m. 66 Olanzapine/Fluoxetine Combination: Rapid Onset 71 Prevalence of MTHFR C677T and Mehionine Synthase With Low Risk of Mania A2756G Polymorphisms in Major Depression and Sara A Corya, MD., Paul E. Keck, Jr., MD., Michael E. Impact on Response to Fluoxetine Treatment Thase, MD., Sanjay Dube, MD., Susan D. Briggs, Ph.D., David Mischoulon, MD., Laura Kean Kramer, MD., Michael Case, MS., Mauricio F. Tohen, MD. Stefania Lamon-Fava, MD., Jacob Selhub, PhD., Roy H Perlis, MD., Jonathan E. Alpert, MD., Maurizio Fava, MD. 12 noon 67 Psychotic Features in MDD Are Associated With 11:30 a.m. Mania 72 Oral S-Adensoyl Methionine (SAMe) for Ekkehard Othmer, M.D., Cherilyn DeSouza, M.D., Antidepressant Augmentation: An Open-Label Trial Jonathan E. Alpert, M.D., George I. Papakostas, M.D., Elizabeth J. Nickel, M.A, Edward N. Hunter, PhD., John J. Worthington III, MD., Timothy J. Petersen, PhD., Elizabeth C. Penick, PhD., Sieglinde G Othmer, PhD., David Mischoulon, MD., Alana M Burns, B.A, Teodoro Barbara J. Powell, PhD. Bottiglieri, PhD., Andrew A Nierenberg, MD., Maurizio THIS SESSION WILL BE AUDIOTAPED. Fava, MD.

SCIENTIFIC AND CLINICAL REPORT SESSION 23 12 noon 11:00 a.m.-12:30 p.m. 73 Somatic Symptoms as Predictors of Time to Onset of Rooms 3D04/9, Level 3, Javits Center Response to Fluoxetine in MDD George I. Papakostas, MD., Timothy J. Petersen, PhD., BIOLOGICAL PSYCHIATRY Dan V. losifescu, MD., Katherine Sklarsky, B.A, Andrew A Nierenberg, MD., Jonathan E. Alpert, MD., Chp.: David A Casey, MD. Maurizio Fava, MD. Co-Chp.: Katherine G. Ruiz-Mellott, MD. THIS SESSION WILL BE AUDIOTAPED.

78 WEDNESDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 25 SCIENTIFIC AND CLINICAL REPORT SESSION 27 11:00 a.m.-12:30 p.m. 11:00 a.m.-12:30 p.m. Rooms 3D06/7, Level 3, Javits Center Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis

OUTCOMES IN PSYCHOSIS ISSUES IN PSYCHIATRIC EPIDEMIOLOGY

Chp.: Carol L. Trippitelli, M.D. Chp.: Mkhil D. Nihalani, MD. Co-Chp.: MarkN. Rudolph, MD. Co-Chp.: Mark S. Wright, MD.

11:00 a.m. 11:00 a.m. 74 IOSOHO: Intercontinental Schizophrenia Outpatient 80 Ethnicity, Diagnosis, and Health Care Utilization in Health Outcomes Study Incarcerated Women Martin Dossenbach, MD., Andrew Hodge, M.S.C., Ruth A Catherine F. Lewis, MD. O'Halloran, Ph.D. 11:30 a.m. 11:30 a.m. 81 Psychotropic Drug Utilization in Six European 75 Male Patients With Schizophrenia Have Impairment in Countries the Processing of Spatial Information From Giovanni De Girolamo, M.D., Jordi Alonso, M.D., Isabelle Dissociated Spatial Reference Frames Gasquet, Leo Russo, Ph.D., Gemma Vilagut, Gabriella Miranda H. Chakos, M.D., Yevgeny Gelfand, Andre Polidori, M.D., Heather Bryson Fenton, Ph.D., Peter J. Weiden, MD., Narender Dargani, B.S. 12 noon 82 Onset of DSM-IV Alcohol Abuse and Dependence: A 12 noon 10-Year Prospective Study 76 Predictors of Outcome in 52 Cases of Psychotic Deborah S. Hasin, Ph.D., Xinhua Liu, Ph.D., Jason P. Nonaffective Disorders Herrick, B.A Mauricio F. Tohen, M.D., Carlos A Zarate, Jr., MD., John THIS SESSION WILL BE AUDIOTAPED. Hennen, Ph.D., Hari M. Kaur Khalsa, AB., Paola Salvatore, M.D., Ross J. Baldessarini, M.D. THIS SESSION WILL BE AUDIOTAPED. WORKSHOPS SCIENTIFIC AND CLINICAL REPORT SESSION 26 11:00 a.m.-12:30 p.m. ajMPON}<;NTS42-48 Wilder Room, Fourth Floor, Marriott Marquis COMPONENT WORKSHOP 42 11:00 a.m.-12:30 p.m. SUBSTANCE ABUSE Room 1D06, Level 1, Javits Center CoUahoratiiE Session With the National Institute on Drug A buse ONLINE INTERACTION BETWEEN APA, MEMBERS, Chp.: Daniel P. Chapman, M.D. AND THE PUBLIC Co-Chp.: Vital N. Shah, MD. APA Ad Hoc Wcnk Group on Irfamatian Systems

11:00 a.m. Chp.: Robert C Hsiung, MD. 77 Risk Factors for DSM-IV Cannabis Abuse and Participants: Herbert S. Peyser, MD., William Bruce, B.A Dependence Jason P. Herrick, B.A, Jakob Meydan, Psy.D., Xinhua Liu, Ph.D., Deborah S. Hasin, Ph.D. COMPONENT WORKSHOP 43 11:00 a.m.-12:30 p.m. Room 3D02/11, Level 3, Javits Center 11:30 a.m. 78 Cannabis Use Reduces the Likelihood of Sustained RESPONSE TO THE SIMON BOLIVAR AWARD Remission From Other Drugs LECTURE ON LATINO YOUTH IN THE U.S.: Edward V. Nunes, M.D., Efrat Aharonovich, Ph.D., Xinhua DEVELOPMENTAL AND MENTAL HEALTH Liu, Ph.D., Rivka R. Galchen, M.D., Deborah S. CHALLENGES Hasin, Ph.D. APA Commttee of Hispanic Psychiatrists

12 noon Co-Chps.: Ana E. Campo, MD., Andres J. Pumariega, MD. 79 Substance-Induced Risk for Depression in a Participants: Ian A Canino, M.D., Pedro Ruiz, M.D., Renato D. Substance-Dependent Population Alarcon, M.D. Rivka R. Galchen, M.D., Xinhua Liu, Ph.D., Efrat Aharonovich, Ph.D., Edward V. Nunes, M.D., Deborah S. Hasin, Ph.D. THIS SESSION WILL BE AUDIOTAPED. 79 WEDNESDAY

COMPONENT WORKSHOP 44 11:00 a.m.-12:30 p.m. ISSUES 104-119 O'Neill Room, Fourth Floor, Marriott Marquis ISSUE WORKSHOP 104 11:00 a.m.-12:30 p.m. PSYCHIATRIC ETHICS IN THE U.S. AND Rooms 1E03/4/5, Level 1, Javits Center THROUGHOUT THE WORLD APA Ethics Carrrrittee INNOVATIVE METHODS OF PROMOTING USE OF EVIDENCE-BASED PSYCHOPHARMACOLOGY Co-Chps.: Spencer Eth, MX)., Driss Moussaoui, MD. Participants: Wade C Myers, MX)., Philip T. Merideth, M.D., Chp.: David N. Osser, MD. Ahmed Okasha, MX)., Juan J. Lopez-Ibor, Jr., MD. Participants: Carole C Upshur, Ed.D., Robert D. Patterson, MX)., Kenneth O. Jobson, MD., Richard C COMPONENT WORKSHOP 45 11:00 a.m.-12:30 p.m. Hermann, MD. Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis

THE 2004 MEDICARE UPDATE AND MAKING THE ISSUE WORKSHOP 105 11:00 a.m.-12:30 p.m. MOST OF THE CARRIER ADVISORY COMMITTEE Room 1E09, Level 1, Javits Center APA Medicare Adusory Corresponding Camrittee WHEN PSYCHIATRISTS HAVE SUFFERED A MENTAL Chp.: Edward Gordon, MD. ILLNESS: THEIR STORIES AND INSIGHTS Participants: Gerald Rogan, MD., Ellen Jaffe, Seth P. National A Itianoefor the Mentalfy III Stein, JX). Co-Chps.: Michael F. Myers, MD., Leah J. Dickstein, MX). COMPONENT WORKSHOP 46 11:00 a.m.-12:30 p.m. Participants: Elizabeth A. Baxter, MD., Marian Fireman, MD., Booth/Edison Rooms, Fifth Floor, Marriott Marquis Raymond M Reyes, MD., Suzanne E. Vogel-Scibilia, MD., Francine Cournos, MD., Kay R Jamison, Ph.D. IS THERE A STANDARD OF CARE FOR THE TREATMENT OF DEMENTIA' ISSUE WORKSHOP 106 11:00 a.m.-12:30 p.m. Rooms 2D10/11, Level 2, Javits Center APA CornritteemAcoessard EffectorElderly 2 WILL OUTCOMES EVALUATION AND RESEARCH : Allan A Anderson, MD.Chp. INITIATIVES SAVE THE THERAPEUTIC Participants: Marsden H. McGuire, MD., Julian Off say, MD., COMMUNITY? Douglas A Kalunian, MD.

COMPONENT WORKSHOP 47 11:00 a.m.-12:30 p.m. Chp.: Gregory C Bunt, MD. Plymouth/Uris/Shubert Rooms, Sixth Floor, Marriott Participants: Charles Devlin, George DeLeon, Ph.D., Britta Marquis Muehlbach, MA., Marc Galanter, MX).

BEND IT LIKE BECKHAM: ASIAN WOMEN, ISSUE WORKSHOP 107 11:00 a.m.-12:30 p.m. ACHIEVEMENTS, AND CULTURAL CONFLICTS Rooms 2D12/13, Level 2, Javits Center APA Council an Global Psychiatry NEGATIVE-SYMPTOM SPECTRUM DISORDERS: Co-Chps.: Ramaswamy Viswanathan, MD., Jacquelyn B. RESPONSE TO PHARMACOTHERAPY OF Chang, MD. ASPERGER'S DISORDER Participants: Geetha Jayaram, MX)., Michelle B. Riba, MD., Madelyn H Hicks, MX)., Madhulika S. Khandelwal, Ph.D., Chp.: Elizabeth Sirota, MD. Sudeepta Varma, MD. Participants: Donna L. Londino, MD., Jeffrey L. Rausch, MD.

COMPONENT WORKSHOP 48 11:00 a.m.-12:30 p.m. ISSUE WORKSHOP 108 11:00 a.m.-12:30 p.m. Marquis Ballroom Salon C, Ninth Floor, Marriott Marquis Rooms 2D14/15, Level 2, Javits Center BUPRENORPHINE IN THE TRENCHES: WHAT THE SOMETIMES IT IS ABOUT YOU: THE USE OF SELF IN GENERAL PSYCHIATRIST NEEDS TO KNOW ENGAGING AND TREATING HOMELESS APA GcmespandirgComriate INDIVIDUALS Psychiatry and APA Correspond Comrittee on TreatnttSenias for Patients Tilth Addictive Disorders Chp.: Marvin A. Nierenberg, MX). Co-Chps.: Marianne T. Guschwan, MX)., John A Participants: Amy Cohen, N.P., Dillon C Euler, MD., Renner, Jr., MD. VanYu,MD. Participants: George F. Kolodner, MX)., Samuel M Silverman, MD. 80 WEDNESDAY

ISSUE WORKSHOP 109 11:00 a.m.-12:30 p.m. ISSUE WORKSHOP 115 11:00 a.m.-12:30 p.m. Ziegfeld Room, Fourth Floor, Marriott Marquis Empire/Hudson Rooms, Seventh Floor, Marriott Marquis

MULTIPLE PERSPECTIVES ON THE PATHOLOGICAL SUICIDE AND SCHIZOPHRENIA: A FAMILY FEAR RESPONSE: INTEGRATION OF INTERVIEW PSYCHOTHERAPEUTIC AND PSYCHOPHARMACOLOGIC THERAPIES Chp.: Paul A. Kettl, M.D.

Co-Chps.: David Steinman, MX)., Jennifer M. Bonovitz, Ph.D. ISSUE WORKSHOP 116 11:00 a.m.-12:30 p.m. Gotham Room, Seventh Floor, Marriott Marquis ISSUE WORKSHOP 110 11:00 a.m.-12:30 p.m. Imperial/Julliard Rooms, Fifth Floor, Marriott Marquis ETHICAL AND PRACTICAL CHALLENGES IN EMERGENCY PSYCHIATRIC RESEARCH THE DAY I DIED: A NEAR-DEATH DOCUMENTARY Co-Chps.: Rebecca W. Brendel, MX)., Melissa E. Abraham, Ph.D. AND THE MIND-BRAIN BARRIER Participant: Lawrence T. Park, MX).

Chp.: B. Jason MacLurg, MX). ISSUE WORKSHOP 117 11:00 a.m.-12:30 p.m. Herald/Soho Rooms, Seventh Floor, Marriott Marquis ISSUE WORKSHOP 111 11:00 a.m.-12:30 p.m. Lyceum Room, Fifth Floor, Marriott Marquis DEVELOPING A COMMUNITY MENTAL HEALTH RESPONSE TO DISASTERS AND TERRORISM WHAT LOVE HAS TO DO WITH IT: EXPLORING THE ROLE OF LOVE IN MENTAL ILLNESS Co-Chps.: John W. Burruss, M.D., Jennifer E. Pate, MX). Participant: Meg Crady Co-Chps.: Robert W. Herholzer, M.D., Bita Ghafoori, Ph.D. ISSUE WORKSHOP 118 11:00 a.m.-12:30 p.m. ISSUE WORKSHOP 112 11:00 a.m.-12:30 p.m. Cantor/Jolson Rooms, Ninth Floor, Marriott Marquis Majestic/Music Box/Winter Garden, Sixth Floor, Marriott Marquis JUVENILE-JUSTICE SUCCESS SERIES, CHAPTER 1: MUSICIANSHIP, JAZZ, AND BLUES PSYCHIATRY AND HOMELAND SECURITY: AN EXERCISE IN WEAPONS OF MASS DESTRUCTION Chp.: Cheryl D. Wills, M.D. RESPONSE PLANNING ISSUE WORKSHOP 119 11:00 a.m.-12:30 p.m. Co-Chps.: Larry H. Pastor, MX)., Dickson S. Diamond, MX). Marquis Ballroom Salons A/B, Ninth Floor, Marriott Participant Richard T. Keller, UN. Marquis

ISSUE WORKSHOP 113 11:00 a.m.-12:30 p.m. POLITICS AND PREGNANCY: THE REGINA Royale Room, Sixth Floor, Marriott Marquis MCKNIGHT CASE Chp.: Andrea G. Stolar, M.D. FITNESS-FOR-DUTY EVALUATIONS FOR LAW- Participants: David J. McDowell, PhX)., Lynn M. Paltrow, J.D. ENFORCEMENT OFFICERS

Chp.: Marilyn Price, M.D. Participants: Debra A. Finals, MX)., Bernice Kelly, Psy. 12 noon Sessions

ISSUE WORKSHOP 114 11:00 a.m.-12:30 p.m. FORUMS 10-11 Columbia/Duffy Rooms, Seventh Floor, Marriott Marquis FORUM 10 12 noon-1:30 p.m. EVALUATING TREATMENT WITH FUNCTIONAL Room IE 10, Level 1, Javits Center BRAIN IMAGING BUPRENORPHINE: WHAT THE CLINICIAN SHOULD KNOW Co-Chps.: Daniel G. Amen, M.D., Joseph C Wu, M.D. Participant: Barton J. Blinder, M.D. Chp.: Herbert D. Kleber, M.D. Participants: David M. McDowell, MX)., Roberta Sales, R.N., Erik W. Gunderson, MX)., Patricia I. Ordorica, MX).

81 WEDNESDAY

FORUM 11 12 noon-1:30 p.m. COURSE 94 1:00 p.m.-5:00 p.m. Astor Ballroom, Seventh Floor, Marriott Marquis Gibson Suite, Second Floor, Hilton New York

9/11 RESEARCH: A RE VIE WAND REVIEWS DELIRIUM IN THE GENERAL HOSPITAL

Chp.: Anand Pandya, M.D. Director: Peter J. Manos, M.D. Participants: Carol S. North, M.D., Craig L. Katz, MX)., Sandro Faculty: J. H. Atkinson, Jr., M.D., William Breitbart, M.D., Galea, M.D., Ezra S. Susser, M.D. Edwin H. Cassem, M.D.

NEW RESEARCH POSTER SESSION 8 COURSE 95 1:00 p.m.-5;00 p.m. 12 noon-2:00 p.m. Gramercy B, Second Floor, Hilton New York Galleria, Level 4, Javits Center INTEGRATING PSYCHOTHERAPY AND SCHIZOPHRENIA AND PSYCHOTIC DISORDERS, PHARMACOTHERAPY AND BRAIN IMAGING APA Convrittee on Psychotherapy by Psychiatrists

For further information on New Research Sessions, please refer to Director: Barton J. Blinder, M.D. the NewReseanh Program Book included in your registration packet. Faculty: Bernard D. Beitman, M.D., Jerald Kay, M.D.

COURSE 96 1:00 p.m.-5:00 p.m. 1:00 p.m. Sessions Murray Hill B, Second Floor, Hilton New York

STREET DRUGS AND MENTAL DISORDERS: COURSES 91-97 OVERVIEW AND TREATMENT Course descriptions are available in the CME Course Brochure included in your registration Director John W. Tsuang, M.D. packet. Admission by ticket only. Faculty: Thomas Newton, M.D., Karen A. Miotto, M.D.

COURSE 97 1:00 p.m.-5:00 p.m. COURSE 91 1:00 p.m.-5:00 p.m. Sutton North> Second Floor, Hilton New York Concourse B, Concourse Level, Hilton New York I FOUND IT AT THE MOVIES: USING FILM CLIPS TO PSYCHIATRY AND THE INTERNET UNDERSTAND AND TEACH PSYCHIATRY A rreriam A ssodationfor Technology and Psychiatry Director: Frederick W. Engstrom, M.D. Co-Directors: Robert S. Kennedy, M.A, Thomas AM. Kramer, M.D.

COURSE 92 1:00 p.m.-5:00 p.m. 2:00 p.m. Sessions Concourse E, Concourse Level, Hilton New York LECTURES 23-24 THE CLINICAL APPLICATION OF CULTURAL PSYCHIATRY LECTURE 23 Director Wen-Shing Tseng, M.D. Faculty: J. David Kinzie, M.D., Keh-Ming Lin, M.D., Jon M. 2:00 p.m.-3:30 p.m. Streltzer, M.D., Joseph J. Westermeyer, M.D. Rooms 1E07/8, Level 1 Javits Center

COURSE 93 1:00 p.m.-5:00 p.m. Helen E. Fisher, Ph.D. Bryant Suite, Second Floor, Hilton New York The Brain In Love MEN SEXUALLY ABUSED AS BOYS: MEANINGS, CONSEQUENCES, AND TREATMENT Chp.: Philip K Muskin, M.D.

Director Murray D. Schane, M.D. Helen E. Fisher, Ph.D., is Research Professor and Faculty: Howard Fradkin, Ph.D., Bill Bumester, M.A., Member of the Center for Human Evolutionary Studies William Holmes, MD., Kenneth Singer, M.S.W. in the Department of Anthropology at Rutgers University in New Brunswick, New Jersey. Dr. Fisher

82 WEDNESDAY has lectured widely on the evolution of human sexuality, School of Medicine in Philadelphia, and completed his romance and family life, and gender differences in the residency in psychiatry at Massachusetts General brain and behavior. Her most recent book Why We Lave: Hospital, and his residency in child psychiatry at The Nature aniCherrKtrycfRomtfticLoie^s based in part Children's Hospital Medical Center and Judge Baker on research on brain physiology conducted with Guidance Center in Boston. colleagues at the Albert Einstein College of Medicine and THIS SESSION WILL BE AUDIOTAPED. the State University of New York at Stony Brook Her other books include The First Sex: The Natural Talents of WommardHawTheyAreChat^^^Wc^Anac^of PRESIDENTIAL SYMPOSIUM 3 Low: TheNatundHistory cfManogwy, Adultery, ardDvvonx; 2:00 p.m.-5:00 p.m. and The Sex Cantnut' TTxEwlutiancfHmtm Behavior. Dr. Room IE 11, Level 1, Javits Center Fisher has served as an anthropological commentator and consultant for businesses and the media, including RECONSTRUCTING POSTWAR MENTAL HEALTH the BBC, NBCs "Today Show," WNET-TV (New SERVICES Yorl^, the Canadian Broadcasting Corporation, Reader's A rrencan Psychiatric Association and the World Psychiatric Association Digest, and Time-Life Books. She has been honored with the Distinguished Service Award of the American Chp.: Marcia Kraft Coin, MD. Anthropological Association for her work in Co-Chp.: Rodrigo A Munoz, MD. communicating anthropology to the broad public audience. Dr. Fisher received her doctorate in physical A Wars and Mental Health in Iraq anthropology at the University of Colorado in Boulder. Abdul M Al-Jadiry, MD. THIS SESSION WILL BE AUDIOTAPED. B Mental Health in Iraq and the U.S. Military Elspeth C Ritchie, MD. LECTURE 24 C Strategies for Post-War Rehabilitation of Mental 2:00 p.m.-3:30 p.m. Health Services: Focusing on Iraq Room IE 15, Level 1, Javits Center Ahmed Okasha, MD.

APA/NIMH VESTERMARK PSYCHIATRY Discussants: Norman Sartorius, MD., Norwood Knight- EDUCATOR AWARD LECTURE Richardson, MD. THIS SESSION WILL BE AUDIOTAPED. Eugene V. Beresin, M.D.

Striking Accord: RE VIEW OF PSYCHIATRY: SECOON 4 Tales of Teaching and the Heart 2:00 p.m.-5:30 p.m. Special Events Hall ID, Level 1, Javits Center Chp.: Richard Balon, MD. DEEP BRAIN STIMULATION IN PSYCHIATRIC Eugene V. Beresin, MD., is Associate Professor of TREATMENT Psychiatry at Harvard Medical School and Director of the Consolidated Massachusetts General Hospital and Chp.: Sarah H Lisanby, M.D. McLean Hospital Child and Adolescent Psychiatry Residency Training Program in the Boston area. He is 16 Transcranial Magnetic Stimulation in Depression also Medical Director of the Massachusetts General Thomas E. Schlaepfer, MD., Markus Kosel, MD. Hospital Child and Adolescent Psychiatry Outpatient Clinic, Co-Director of the Harvard Medical School 17 Transcranial Magnetic Stimulation Studies of Center for Mental Health and Media, and Director of the Schizophrenia and Other Disorders Elizabeth Thatcher Acampora Endowment, an outreach Ralph E. Hoffman, MD. program for underserved youth and families. Dr. Beresin is Media Editor for Acaderric Psychiatry, and Editor of the 18 Deep Brain Stimulation in Psychiatry Child Psychiatry Residents In-Training Examination Benjamin D. Greenberg, M.D. (Child PRITE), and has been appointed as the next Editor-in-Chief of PRITE. A former President of the 19 Vagus Nerve Stimulation in Psychiatry American Association of Directors of Psychiatry Harold A Sackeim, Ph.D. Residency Training, Dr. Beresin has won a number of local and national teaching awards, including the Parker J. 20 Magnetic Seizure Therapy: Development of a Novel Palmer "Courage to Teach" Award of the Accreditation Convulsive Technique Council of Graduate Medical Education. He received his Sarah H. Lisanby, MD. medical degree from the University of Pennsylvania 83 WEDNESDAY

!-;>7\n>OS.iA59-8f-» SYMPOSIUM 61 2:00 p.m.-5:00 p.m. Room 1E09, Level 1, Javits Center SYMPOSIUM 59 2:00 p.m.-5:00 p.m. Rooms 1E01/2, Level 1, Javits Center PRACTICAL TECHNIQUES IN THE ASSESSMENT AND TREATMENT OF TOBACCO DEPENDENCE Collaborative Session With the National Institute on Drug A buse WHAT YOU NEED TO KNOW ABOUT TREATMENT OF HIV-RELATED DISORDERS Chp.: Jill Williams, MX). Chp.: Marshall Forstein, MX). A Assessment of Tobacco Dependence A Treating Mood Disorders Jonathan Foulds, Ph.D. Warren M. Liang, MX). B Motivational Assessment and Enhancement Strategies B Treating Anxiety in Tobacco Treatment Antoine B. Douaihy, MX). Jonathan Krejci, Ph.D. C Treating Psychosis Shahrad Rod Amiri, M.D. C Pharmacotherapy Treatments for Tobacco Dependence D Treating Sleep Jill Williams, MX). Marshall Forstein, MX). D Psychosocial Treatment of Tobacco Dependence in E Treating Pain Mental Health Settings Philip Bialer, M.D. Marc L. Steinberg, Ph.D. THIS SESSION WILL BE AUDIOTAPED. E Addressing Tobacco Through Program and System SYMPOSIUM 60 2:00 p.m.-5:00 p.m. Changes Rooms 1E03/4/5, Level 1, Javits Center Douglas M Ziedonis, MX). THIS SESSION WILL BE AUDIOTAPED. CHOOSING THE BEST TREATMENT FOR SUBSTANCE ABUSE SYMPOSIUM 62 2:00 p.m.-5:00 p.m. Collaborative Session With the National Institute on Drug A buse Room IE 10, Level 1, Javits Center

Chp.: Herbert D. Kleber, MX). TREATMENT-RESISTANT DEPRESSION Co-Chp.: David M. McDowell, MX). Chp.: Charles B. Nemeroff, MX). A Choosing the Right Treatment for Opioid Dependence Herbert D. Kleber, M.D. A Introduction to Treatment-Resistant Depression B Choosing the Best Treatment for Cocaine Dependence Charles B. Nemeroff, MX). Adam M. Bisaga, MD. B Long-Term Outcomes in Treatment-Resistant C Choosing the Best Treatment: Marijuana and Cub Depression A John Rush, M.D. Drugs David M. McDowell, MD. C Introduction to a Treatment-Resistant Depression Patient Registry D Treatment of Comorbid Conditions Martin B. Keller, MD. Frances R. Levin, MX)., Suzette M. Evans, Ph.D., Herbert D. Kleber, M.D. D Long-Term Treatment and Outcomes in Treatment- Resistant Depression With Pharmacotherapy, EOT, E Choosing the Best Treatment for Psychosocial Repetitive Trans cranial Magnetic Stimulation, MST, Interventions and VNS Therapy Jami Rothenberg, Ph.D. Thomas E. Schlaepfer, MX). THIS SESSION WILL BE AUDIOTAPED. Discussant Edward V. Nunes, MX). THIS SESSION WILL BE AUDIOTAPED.

84 WEDNESDAY

SYMPOSIUM 63 2:00 p.m.-5:00 p.m. SYMPOSIUM 65 2:00 p.m.-5:00 p.m. Room IE 12, Level 1, Javits Center Room IE 14, Level 1, Javits Center

PSYCHOTIC DEPRESSION IN 2004: THE NIMH NEUROIMAGING AND EMOTIONAL COLLABORATIVE SEVERE DEPRESSION STUDY DEREGULATION IN BPD

Chp.: Barnett S. Meyers, MD. Chp.: Kenneth R, Silk, M.D. Co-Chp.: Martin Bohus, MD. A Challenges in the Diagnosis of Psychotic Depression: Assessment, Epidemiology, and Biology A Brain Imaging of Impulsivity and Affective Instability Anthony]. Rothschild, MD., Michael A. Bell, M.D., in BPD Jayendra K. Patel, MD., David P. Morin, MD., Dorothy Larry J. Siever, MD., Antonia S. New, MD., Monte S. Sit, MD., Colby Calkins, B.S., Denette Guerin, MS. Buchsbaum, MD., W. Gordon Frankle, MD., Harold W. Koenigsberg, MD., Isak Prohovnik, Ph.D., Marc B Pharmacotherapy of Unipolar Major Depression: What Laruelle, MD. Is the Evidence? Benoit H. Mulsant, MD., Robert H, Howland, M.D., B Affect Regulation and BPD: fMRI and Daily Michael E. Thase, M.D., Mary C McShea, MS., Taafoi S. Experience of Mood Kamara, B A Katherine M. Putnam, Ph.D.

C NIMH Severe Depression Trial: Background and C Emotional Processing of Psychosocial Stimuli in BPD Design Choices Jill M Hooley, D.Phil., Deborah A Yurgelun-Todd, Ph.D., Barnett S. Meyers, MD., Sibel Klimstra, MD., Catherine Staci A. Gruber, Ph.D. Peasley-MiHus, Ph.D., Michelle Gabriele, MS.W., Judith English, B.S.C, MoonSeong Heo, Ph.D., Melissa D Investigation of Pain Processing in BPD CarroU,Ph.D. Christian G. Schmahl, MD., Martin Bohus, M.D.

D Challenges in Conducting a Pharmacotherapy Study in E A PET Study of u-Opioid Neurotransmission and Psychotic Depression Affective Lability in BPD Alastair J. Flint, MB. Kenneth R. Silk, MD., Jon-Kar Zubieta, M.D., Robert Koeppe, Ph.D. E Real-Life Outcomes in Real-Life Patients: Discussion THIS SESSION WILL BE AUDIOTAPED. Barry D. Lebowitz, Ph.D. SYMPOSIUM 66 2:00 p.m.-5:00 p.m. Discussant: Barry D. Lebowitz, Ph.D. Room IE 16, Level 1, Javits Center THIS SESSION WILL BE AUDIOTAPED. DIAGNOSING AND MANAGING AGGRESSIVE MOOD- SYMPOSIUM 64 2:00 p.m.-5:00 p.m. DYSREGULATED YOUTH Room IE 13, Level 1, Javits Center Chp.: Joseph Biederman, M.D. SEPTEMBER 11TH: AFTER TWaAND-A-HALF YEARS A Parsing the Association Between Bipolar, Conduct, Chp.: Zebulon C Taintor, MD. and Substance Use Disorders Joseph Biederman, MD., Stephen V. Faraone, Ph.D., Janet A The First Two Weeks Onsite Wozniak, MD., Micheal Monuteaux, Sc.D. Antonio Abad, MD. B A Family Genetic Perspective on Childhood Mania B New York State Office of Mental Health Response Stephen V. Faraone, Ph.D. William M Tucker, MD. C Risperidone Treatment of Affective Symptoms in C New York City Health and Mental Health: First Mentally Retarded Youth With Conduct Disorder Responders Eric Mick, Sc.D., Joseph Biederman, MD., Georges Neal L. Cohen, M.D. Gharabawi, MD., Stephen V. Faraone, Ph.D., Gahan J. Pandina, Ph.D. D Disaster Psychiatry Outreach: Service and Training Craig L. Katz, MD. D Clinical Trials of a Mood Stabilizer for Aggressive, Mood-Dysregulated Youth E Medical and Psychiatric Organizations and Findings Janet Wozniak, MD. Zebulon C Taintor, MD. THIS SESSION WILL BE AUDIOTAPED. (Continued an next pug) 85 WEDNESDAY

E Collaborative Problem-Solving Therapy for Aggressive Discussant: Donna E. Stewart, M.D. Youth THIS SESSION WILL BE AUDIOTAPED. Ross W. Greene, Ph.D. SYMPOSIUM 69 2:00 p.m.-5:00 p.m. F Anticonvulsants in the Management of Aggression in Room 3D03/10, Level 3, Javits Center Youth Joseph M. Gonzalez-Heydrich, M.D. SUPPORTIVE PSYCHOTHERAPY: AN UPDATE THIS SESSION WILL BE AUDIOTAPED. Chp.: Roger Peele, MX). SYMPOSIUM 67 2:00 p.m.-5:00 p.m. Co-Clip.: Maryam Razavi, MX). Rooms 3D01/12, Level 3, Javits Center A History of Supportive Psychotherapy RESIDUAL SYMPTOMS IN DEPRESSION: Stephen Rojcewicz, Jr., MX). RECOGNITION AND TREATMENT B Role of Psychotherapy in the Management of Chp.: Matthew A. Menza, M.D. Depression Michael E. Thase, M.D. A An Overview of Residual Symptoms in Depression Andrew A. Nierenberg, MX). C Use of Supportive Psychotherapy With Bipolar Disorder B Sleep Disturbance as a Residual Symptom in Karen L. Swartz, MX). Depression Matthew A. Menza, MX). D Adapting Supportive Therapy for Treatment of BPD David J. Hellerstein, M.D., Ron B. Aviram, Ph.D., Jessica C Anxiety as a Residual Symptom in Depression Gerson, Ph.D., Kimberly Kotov, Ph.D., Barbara H. Alexander Bystritsky, MX). Stanley, Ph.D.

D Residual Sexual Dysfunction Associated With MDD E Development of Competencies in Supportive Therapy: and SSRI Treatment Process and Problems H. George Nurnberg, MX). Lisa A Mellman, MX).

E The Treatment of Residual Fatigue in Depression Discussants: Henry Pinsker, MX)., Julia B. Frank, MX). Humberto Marin, MX). THIS SESSION WILL BE AUDIOTAPED. THIS SESSION WILL BE AUDIOTAPED. SYMPOSIUM 70 2:00 p.m.-5:00 p.m. SYMPOSIUM 68 2:00 p.m.-5;00 p.m. Rooms 3D04/9, Level 3, Javits Center Room 3D02/11, Level 3, Javits Center ANXIETY DISORDERS IN YOUTH: CLINICAL AND WOMEN'S MENTAL HEALTH REVISITED: CURRENT RESEARCH UPDATES PERSPECTIVES, FUTURE TRENDS A ssodatian cf Women Psychiatrists Chp.: Marcia J. Slattery, MX).

Chp.: Sylvia W. Olarte, MX). A Evidence-Based Assessment Instruments With Children and Adolescents A Depression in the Reproductive Years Thomas H Ollendick, Ph.D. Nada L. Stotland, M.D. B Pharmacological Treatment of Anxiety Disorder in B Depression and Anxiety in Women in Late Life Youth Marion Z. Goldstein, MX). Marcia J. Slattery, MX).

C Domestic Violence: Its Impact Across the Life Cycle C Anxiety Disorders in Children and Adolescents: Are Leah J. Dickstein, MX). We Ready To Move Beyond The Study of Treatment Efficacy? D PTSD in Women: Current Concepts and Treatments Anne Marie Albano, Ph.D. Marian I. Butterfield, MX)., Mary Becker, M.S., Christine E. Marx, MX). D A Cognitive Neuroscience Perspective on Childhood Anxiety Disorders E Racism and Women's Mental Health: The Intersection AmyL. Krain, Ph.D. of Race and Gender THIS SESSION WILL BE AUDIOTAPED. Altha J. Stewart, M.D. 86 WEDNESDAY

SYMPOSIUM 71 2:00 p.m.-5:00 p.m. F Group Interventions for Psychological Trauma and Rooms 3D05/8, Level 3, Javits Center Terrorism Henry I. Spitz, M.D. DSM-V CLASSIFICATION OF PERSONALITY DISORDERS: THE WHITE PAPER AND BEYOND Discussant: Henry Grunebaum, MX). THIS SESSION WILL BE AUDIOTAPED. Chp.: Michael B. First, M.D. SYMPOSIUM 73 2:00 p.m.-5;00 p.m. A Dimensional Models of Personality Disorder Odets Room, Fourth Floor, Marriott Marquis Thomas A. Widiger, Ph.D. DISSOCIATIVE DISORDERS: ISSUES OF CULTURE B Relationship of Personality Traits and Disorders to AND ISSUES OF TRUST Axis I Disorders A ssodadonfor the A cknnoemznt (/Philosophy and Psychiatry M. Tracie Shea, Ph.D. Chp.: Deborah Spitz, M.D. C Axis I/Axis II Boundary: Spectrum Diseases and Molecular Neuroscience A Diversity in Presentation of Dissociative Disorders in John H. Krystal, M.D., Robert T. Malison, MD., Jaakko A. Turkey Lappalainen, M.D., Joel Gelernter, M.D. Vedat Sar, MD.

D Temperament, Personality, and Personality Disorder. B Differences Between Western and South African The Externalizing Spectrum Model Models of Dissociation Robert F. Krueger, Ph.D. Christa Kruger, M.D.

E The Neurobiology of Personality Traits: Focus on C Dissociation, Trances, and Transcendence: Cultural Aggression Values and Their Effects on Trust Emil F. Coccaro, M.D. Nancy L Potter, Ph.D. THIS SESSION WILL BE AUDIOTAPED. THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 72 2:00 p.m.-5:00 p.m. SYMPOSIUM 74 2:00 p.m.-5;00 p.m. Rooms 3D06/7, Level 3, Javits Center O'Neill Room, Fourth Floor, Marriott Marquis

GROUP THERAPY IN MEDICAL/PSYCHIATRIC CARE NEUROPSYCHIATRY OF TRAUMATIC BRAIN INJURY: CURRENT RESEARCH Chp.: David Spiegel, M.D. A rrerican Newopsychiatric A ssodation

A Group Therapy for Breast Cancer: Feeling and Chp.: Jonathan M Silver, M.D. Healing David Spiegel, M.D., Janine Giese-Davis, Ph.D., Lisa D. A The Cholinergic Hypothesis of Cognitive Impairment Butler, Ph.D., Catherine Classen, Ph.D., Cheryl Due to Traumatic Brain Injury Koopman, Ph.D. David B. Arciniegas, MD.

B Impact of Group Therapy on Anticancer Treatment B Catecholaminergic Dysfunction After Traumatic Brain Adherence Injury: Impact on Cognition David W. Kissane, M.D., David M Clarke, Ph.D., Thomas McAllister, MD., Laura Flashman, PhD., Brenna Graeme C. Smith, M.D., Brenda Grabsch, B.S.W. McDonald, PsyD., Heather Wishart, PhD., Richard B. Ferrell, MD., Andrew Saykin, PsyD. C Mindfulness-Based Stress-Reduction Groups Susan E. Abbey, MD. C Traumatic Brain Injury, Gene Expression, and Risk for Schizophrenia D Psychiatrist-Led Group Psychotherapy for the Dolores Malaspina, M.D., Cheryl M Corcoran, MD., Jill Chronically Mentally 111 Harkavy-Friedman, PhD., Raymond Goetz, PhD., David J. Leslie H. Gise, M.D., Annette Crisanti, Ph.D., Robert Printz, MD., Roberto Gil, MD. Randall, PhD., Dana Kiyabu, R.N., Travis Ho, B A

E Group Therapy for Substance Abuse David W. Brook, M.D. (Continued on next

87 WEDNESDAY

D Blast Injuries to the Brain: Armed Forces Injured B Strategies to Enhance Mental Health Care in the During Operation Iraqi Freedom Primary Care Sector: Working With Family Physicians Deborah Lee Warden, MD., Louis M French, Psy.D., Sagar V. Parikh, MD. Elisabeth Moy-Martin, R.N.G, Robert J. Labutta, MD., James M. Ecklund, M.D. C Evidence-Based Practice Leads to Improved Efficiency in the Work of a Specialized Mood- E Multicenter, Placebo-Controlled Trials in Traumatic Disorders Service Brain Injury: A Work in Progress Roumen V. Milev, MD., Gaby Abraham, MD., Fia Jonathan M. Silver, M.D. Voutsilakos, MD. THIS SESSION WILL BE AUDIOTAPED. D Translating Research Into Practice: The Application of SYMPOSIUM 75 2:00 p.m.-5:00 p.m. Clinical Guidelines in Mood Disorders Wilder Room, Fourth Floor, Marriott Marquis Valerie Taylor, MD., Glenda M MacQueen, MD.

PSYCHIATRY, ETHNICITY, AND CULTURE: AN E Developing a Community-Based Strategy for UPDATE ONETHNOPSYCHOPHARMACOLOGY, Depression: The British Columbia Experience MOOD, AND ANXIETY DISORDERS IN MINORITY Raymond W. Lam, MD., Elliot M Goldner, MD. POPULATIONS THIS SESSION WILL BE AUDIOTAPED. SYMPOSIUM 77 Chp.: Shamsah B. Sonawalla, M.D. 2:00 p.m.-5:00 p.m. Co-Chp.: Rajesh M. Parikh, M.D. Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis

A Ethnopsychopharmacology Update IMPACT OF TRAUMA AND LIFE STRESS IN BIPOLAR David C Henderson, MD. DISORDER

B Treatment of Anxiety and Depression Among Chinese Chp.: Joseph F. Goldberg, M.D. Americans Co-Chp.: David MiWowitz, Ph.D. Albert Yeung, M.D. A Psychosocial Stress and Vulnerability to Affective C Psychiatric Management of Hispanic Patients: Cross- Relapse Cultural Issues and Ethnopsychopharmacology Michael J.Gitlin,MD. David Mischoulon, MD. B Childhood Trauma and Outcome in Bipolar Patients D Depression and Anxiety in Women: An Update on Joseph F. Goldberg, MD., Jessica L. Garno, PhJD. Cross-Cultural Aspects and Pharmacologic Strategies Qaudio N. Soares, MD. C Bipolar Disorder and the Family Environment David Miklowitz, PhD. E Cultural Differences in the Diagnosis and Treatment of Mood and Anxiety Disorders: Considerations in the D Neurofunctional Correlates of Affective Stressors in Asian Indian Population Bipolar Patients Rajesh M. Parikh, M.D., Shamsah B. Sonawalla, M.D. Caleb M. Adler, MD., Stephen M Strakowski, MD., Scott Holland, Ph.D., Melissa P. DelBello, M.D. Discussant: Jerrold F. Rosenbaum, M.D. THIS SESSION WILL BE AUDIOTAPED. E Implications of the Kindling Model for Affective Relapse SYMPOSIUM 76 2:00 p.m.-5:00 p.m. Robert M Post, MD., Gabriele S. Leverich, L.CS.W., Ziegfeld Room, Fourth Floor, Marriott Marquis Andrew M Speer, MD. THIS SESSION WILL BE AUDIOTAPED. ADOPTING EVIDENCE-BASED PRACTICE IN THE TREATMENT OF MOOD DISORDERS: THE SYMPOSIUM 78 2:00 p.m.-5:00 p.m. CANADIAN EXPERIENCE Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis

Chp.: Sidney H Kennedy, M.D. GAY AND LESBIAN ORTHODOX JEWS: A PRIMER Co-Chp.: Roumen V. Milev, MD. FOR CLINICIANS

A Treating Depression Effectively: Applying Clinical Chp.: Jack Drescher, MD. Guidelines Sidney H. Kennedy, M.D. A Orthodox Jewish Gays and Lesbians: The Filmmaker's Perspective Sandi Dubowski

88 WEDNESDAY

B Failed Repaiative Therapy of Orthodox Jewish B Cognitive Effects in Adolescents Exposed Prenatally Homosexual Men and Women to Marijuana or Cigarettes Abba E. Borowich, M.D. Peter A Fried, Ph.D.

C Identities in Conflict: Treating Gay and Lesbian C Effects of Chronic Marijuana Use and THC on Brain Orthodox Jews Function in Humans: AfMRI Study Naomi Mark, M.S.W. Alan S. Bloom, Ph.D.

D Gayness and God: The Gay Orthodox Rabbi's D Behavioral and Treatment Research on Marijuana Perspective Withdrawal and Dependence Steven Greenberg AlanJ.Budney,Ph.D.

Discussant: Paul S. Appelbaum, MD. E The Endogenous Cannabinoids and the Control of THIS SESSION WILL BE AUDIOTAPED. Drug Craving Billy R Martin, Ph.D. SYMPOSIUM 79 2:00 p.m.-5:00 p.m. Booth/Edison Rooms, Fifth Floor, Marriott Marquis Discussant Billy R. Martin, Ph.D. THIS SESSION WILL BE AUDIOTAPED. PERSONALITY, THERAPEUTIC ALLIANCE, AND OUTCOME IN BRIEF PSYCHOTHERAPY SYMPOSIUM 81 2:00 p.m.-5:00 p.m. Majestic/Music Box/Winter Garden, Sixth Floor, Marriott Chp.: Arnold Winston, M.D. Marquis Co-Chp.: J. Christopher Muran, Ph.D. PERSONALITY DISORDERS: MULTIPLE A Personality, Therapeutic Alliance, and Outcome in PERSPECTIVES IN THE UNDERSTANDING AND Short-Term Dynamic and Cognitive-Behavioral TREATMENT OF RESISTANCE Psychotherapies Sarah L. Aderholt, M.D., Elena Bruck, M.D., J. Christopher Chp.: Joseph DiGiacomo, M.D. Muran, Ph.D., Arnold Winston, M.D. A Resistance in Personality Disorders From a B Personality, Therapeutic Alliance, and Overall Psychodynamic Perspective Outcome in Brief Relational Therapy R. Rao Gogineni, MD. Regina Biscoglio, M.A., J. Christopher Muran, Ph.D., Paul Watchel, PhD., Bernard S. Gorman, Ph.D. B Resistance in BPD: Cognitive-Behavioral Strategies That Facilitate Change C Patient-Rated Alliance and Overall Outcome in Brief Donna M. Sudak, MD. Psychotherapies Christopher Stevens, Ph.D., J. Christopher Muran, Ph.D., C Family Therapy With Pers onality Dis orders Jeremy D. Safran, Ph.D., Bernard S. Gorman, Ph.D. G. Pirooz Sholevar, M.D.

D Therapist-Rated Alliance and Overall Outcome in D Clinical Practices That Lead to Treatment Resistance Brief Psychotherapies William R. Dubin, MD. Kevin Gillett, J. Christopher Muran, Ph.D., Bernard S. Gorman, Ph.D., Karen Riggs-Skean, Ph.D. Discussant: Thomas S. Newmark, MD. THIS SESSION WILL BE AUDIOTAPED. THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 80 2:00 p.m.-5:00 p.m. SYMPOSIUM 82 2:00 p.m.-5:00 p.m. Imperial/Julliard Rooms, Fifth Floor, Marriott Marquis Plymouth/Uris/Shubert Rooms, Sixth Floor, Marriott Marquis CONSEQUENCES AND TREATMENT OF MARIJUANA CLINICAL CONTROVERSIES IN ECT ABUSE CoUaboradiE Session With the National Institute on Drug A buse Chp.: Conrad M Swartz, M.D. Chp.: Susan KB. Weiss, Ph.D. A Controversies in ECT: Electrode Placement Co-Chp.: Jag Khalsa, Ph.D. Conrad M Swartz, M.D. A Cognitive Toxicity of Cannabis: The Devil Is in the Confounding Variables B Controversies in ECT: Stimulus Dosing W. Vaughn McCalLMD. Harrison G. Pope, Jr., M.D., Deborah A (Continued an nextpag) Yurgelun-Todd, Ph.D. 89 WEDNESDAY

C Controversies in ECT: Physiological Monitoring SYMPOSIUM 85 2:00 p.m.-5:00 p.m. Charles H Kellner, M.D. Empire/Hudson Rooms, Seventh Floor, Marriott Marquis

D Denying Patients Treatments That Work DRUG ABUSE TREATMENT ISSUES IN WOMEN William H Reid, MD. Collaborative Session With the National Institute on Drug A buse Discussant: J. Stuart Lawson, Ph.D. Chp.: Cora Lee Wetherington, Ph.D. THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 83 2:00 p.m.-5:00 p.m. A Gender Differences in Treatment Needs, Services, Astor Ballroom, Seventh Floor, Marriott Marquis Utilization, and Outcomes Karol A Kaltenbach, PhD. TOXIC LOVE ON FILM: ROMANTIC LOVE, FROM NORMAL TO PATHOLOGIC B Treatment Issues in Drug-Dependent Women With Comorbid Depression Chp.: Anton C. Trinidad, M.D. Rajita Sinha, PhD. Co-Chp.: Robert]. Boland, M.D. C Trauma and PTSD: Issues in the Treatment of Drug- A Obsessive Love and the Loss of Self in Film Dependent Women Anton C. Trinidad, M.D. Denise Hien, Ph.D. B The Teaching of What is Normal and Abnormal in Romantic Love D Drug-Dependent Women With Partner Violence: Robert]. Boland, M.D. Treatment Issues Brenda A Miller, Ph.D., Linda P. King, Ph.D., Eugene C Femme Fatale and Its Allusions Maguin, PhD., Nancy]. Smyth, PhD. Harvey K Greenberg, MD. E Drug-Treatment Issues in Drug-Dependent, Pregnant D Love: What Is Normal? Anton C. Trinidad, MD. Women THIS SESSION WILL BE AUDIOTAPED. Hendree Jones, PhD.

SYMPOSIUM 84 2:00 p.m.-5:00 p.m. Discussant Kathleen T. Brady, MD. Columbia/Duffy Rooms, Seventh Floor, Marriott Marquis THIS SESSION WILL BE AUDIOTAPED.

MOVING THE TARGETS: THE NEUROBIOLOGY OF SYMPOSIUM 86 2:00 p.m.-5:00 p.m. ADDICTION Herald/Soho Rooms, Seventh Floor, Marriott Marquis Collaborative Session With the National Institute on Drug A buse MANAGING HIPAA-RELATED TENSIONS IN Chp.: Nancy Pilotte, Ph.D. CLINICAL PRACTICE

A Neuroadaptation in Addiction: The Extended Chp.: John O. Beahrs, MD. Amygdala and Brain-Reward System George F. Koob, Ph.D. A Intended and Actual Effects of HIPAA on Clinical Practice B Neural Circuitry of Relapse Qaudette H. Beahrs, M.S.W. Peter W. Kalivas, Ph.D. B The Impact of HIPAA on Psychiatric Hospital Care: C Drugs, Neuroplasticity, and Addiction The Good, the Bad, and the Ugly Terry E. Robinson, Ph.D. Steven S. Sharfstein, M.D., Robert P. Roca, MD., Angela Niparko, Erin Scally D How Do Drugs of Abuse Rewire the Motivational Circuitry? C Regulation, HIPAA, and the Quest for Optimum Marina E. Wolf, Ph.D. Constraint THIS SESSION WILL BE AUDIOTAPED. John O. Beahrs, MD.

D Complying With HIPAA Made Less Difficult JeffreyL. Metzner, MD.

Discussant: Harold I. Eist, MD. THIS SESSION WILL BE AUDIOTAPED.

90 WEDNESDAY

SYMPOSIUM 87 2:00 p.m.-5:00 p.m. C Unraveling Variations in Access to ADHD Care: Cantor/Jolson Rooms, Ninth Floor, Marriott Marquis Deductive Analysis Findings Regina Bussing, M.D., Mirka K. Ljungberg, Ph.D., Cynthia MEMORY IN THE U.S. AND FRANCE: VIVE LA Garvan, Ph.D., Dana Mason, B.S., Christine Leon, M.A DIFFERENCE D Quality Improvement of Mental Health Services for Children in Special Education Chp.: John A. Talbott, M.D. Sheryl H. Kataoka, M.D., Jeanne Miranda, Ph.D. Co-Chp.: Francois C Petitjean, M.D. Discussant: John M. Oldham, M.D. A What Can We Learn From the False-Memory Wars? THIS SESSION WILL BE AUDIOTAPED. Paul R. McHugh, M.D. SYMPOSIUM 89 2:00 p.m.-5:00 p.m. B PTSD: Too Much or Too Little Memory? Marquis Ballroom Salon C, Ninth Floor, Marriott Marquis Anne-Marie F. Pezous, M.D., Barbara Cochet, Eric Guillem, M.D., Saena Bouchez, M.D., Jean-Pierre Lepine, Ph.D. MEETING THE MENTAL HEALTH NEEDS OF LATINOS IN COMMUNITY AND PRIMARY CARE C The Nature of Traumatic Memory: Implications for Treatment Chp.: Myrna M. Weissman, Ph.D. Bessel A Van Der Kolk, MD. Co-Chp.: Amarendra Das, M.D.

D Depression and Dementia: Looking for Specific A PTSD in Latinos: Reactions in Primary Care to the Memory Impairments World Trade Center Attacks Eric Fakra, M.D., Bernard Michel, M.D., Jean-Michel Yuval Y. Neria, Ph.D., Amarendra Das, M.D., Rafael Azorin, M.D. Lantigua, M.D., Marc J. Gameroff, Ph.D., Mark Olfson, M.D., Adriana Feder, M.D., Myrna M. E Cognitive Impairment in Late-Life Depression Weissman, Ph.D. Charles F. Reynolds III, M.D., Meryl A Butters, Ph.D. B Depression and Diabetes in an Urban General F Depression: Remembering the Bad Things Medicine Clinic Natacha Fouilhoux, M.D., Francois C. Petitjean, M.D. Raz Gross, M.D., Mark Olfson, M.D., Marc J. Gameroff, Ph.D., Olveen Carrasquillo, M.D., Steven Discussant: Alexandra Malean, M.D. Shea, M.A, Rafael Lantigua, M.D., Myrna M. THIS SESSION WILL BE AUDIOTAPED. Weissman, Ph.D.

SYMPOSIUM 88 2:00 p.m.-5:00 p.m. C Bipolar Spectrum Disorder in Hispanic Primary Care Marquis Ballroom Salons A/B, Ninth Floor, Marriott Patients Marquis Amarendra Das, M.D., Marc J. Gameroff, Ph.D., Rafael Lantigua, M.D., Steven Shea, M.A, Mark Olfson, M.D., QUALITY OF CARE FOR CHILDREN: MULTIPLE Myrna M. Weissman, Ph.D. PERSPECTIVES D Disparities in Mental Health Treatment for Latinos in Chp.: Bonnie T. Zima, M.D. Community Care William Vega, Shula Minsky, Ed.D., Michael Gara, Ph.D., A Quality of Care From the Agency's Perspective: Are Theresa M. Miskimen, M.D. Medicaid Claims Data Valid? Penelope Knapp, M.D., Bonnie T. Zima, M.D., Michael Discussant: Roberto Lewis-Fernandez, M.D. Hulburt, Ph.D., Lingqi Tang, Ph.D., Heather Ladd, M.S., THIS SESSION WILL BE AUDIOTAPED. Naihua Duan, Ph.D., Kenneth B. Wells, M.D.

B Quality of Care for Children in Outpatient Mental Health Programs Bonnie T. Zima, M.D., Michael Hulburt, Ph.D., Penelope Knapp, M.D., Lingqi Tang, Ph.D., Heather Ladd, M.S., Naihua Duan, Ph.D., Kenneth B. Wells, M.D.

91 WEDNESDAY

B Symptoms and Biologic Correlates of PTSD: From 3:00 p.m. Sessions Early Adulthood to Old Age Rachel Yehuda, Ph.D. NEW RESEARCH POSTER SESSION 9 3:00 p.m.-5:00 p.m. C The Social Anxiety Spectrum Galleria, Level 4, Javits Center Michael R. Liebowitz, MD., Franklin R. Schneier, MD., Jonathan E. Shaywitz, MX). MOOD DISORDERS D The Repetitive Behavior Domain in Obsessive- For further information on New Research Sessions, please refer to Compulsive and Developmental Disorders NewResearch PragwnBook the included in your registration packet. Eric Hollander, MX)., Stacey Wasserman, MX).

E Mixed Anxiety and Depression: A Gordian Knot 7:00 p.m. Sessions Joseph Zohar, MX)., Yehuda Sasson, MX). INDUSTRY-SUPPORTED SYMPOSIUM 54 INDUSTRY-SUPPORTED SYMPOSIA 52-54 7:00 p.m.-10:00 p.m. Imperial Ballroom B, Second Floor, Sheraton New York INDUSTRY-SUPPORTED SYMPOSIUM 52 7:00 p.m.-10:00 p.m. BACK TO THE FUTURE: THE ROLE OF GAMMA- Grand Ballroom East, Third Floor, Hilton New York AMINOBUTYRIC ACID IN PSYCHIATRIC DISORDERS AND TREATMENT OPTIMIZING ANTIPSYCHOTIC TREATMENT IN Supported by Cephalon, Inc. PATIENTS WITH SCHIZOPHRENIA AND BIPOLAR DISORDER Chp.: Mark H Pollack, MD. Supported by Bristol-Myers Squibb Company

Chp.: Rajiv Tandon, MD. A Gamma- Aminobutyric Acid in the CNS Philip T. Ninan, MD. A Optimizing Pharmacotherapy for Maximized Outcomes B Neuroimaging and Anxiety Alan J. Mendelowitz, MD. Justine M. Kent, MD.

B Keeping Tolerability in Mind: Ensuring Adherence to C Gamma-Aminobutyric Acidergic Agents in Anxiety Maintain Recovery Treatment: A Look Back and Ahead Henry A Nasrallah, MD. Mark H Pollack, MD.

C Finding Effectiveness Across Patient Age Groups D Emerging Gamma-Aminobutyric Acidergic Targets Rajiv Tandon, MD. for Insomnia John W. Winkelman, MD. D Balancing the Efficacy and Tolerability for Pediatric Bipolar Disorder E Beyond Anxiety Disorders: The Role of Gamma- Melissa P. DelBello, MD. Aminobutyric Acid in Mood Disorders Naomi M. Simon, MD. E Treatment Considerations in Special Populations: Sex Differences Diana O. Perkins, MD.

INDUSTRY-SUPPORTED SYMPOSIUM 53 7:00 p.m.-10:00 p.m. Imperial Ballroom A, Second Floor, Sheraton New York

CORE SYMPTOM DOMAINS IN THE ANXIETY DISORDERS Supportedby WyethPharmaceuticals

Chp.: Michael R. Liebowitz, M.D. Co-Chp.: Eric Hollander, MD.

A Differential Diagnosis and Biology of Panic and GAD Jack M. Gorman, M.D. 92 THURSDAY, MAY 6, 2004

15.7TH ANNUAL MEETING

7:00 a.m. Sessions COURSE 98 8:00 a.m.-12 noon Concourse A, Concourse Level, Hilton New York

PART 2 OF INDUSTRY-SUPPORTED BREAKFAST INTRODUCTION TO TRANSCRANIAL MAGNETIC SYMPOSIA 50- 51 STIMULATION (TMS)

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 50, Co-Directors: Ziad H. Nahas, M.D., Leon J. Grunhaus, MX). PART 2 Faculty: Sarah H. Lisanby, M.D., Ehud M. Klein, M.D. 7:00 a.m.-8:30 a.m. Imperial Ballroom A, Second Floor, Sheraton New York COURSE 99 8:00 a.m.-12 noon Bryant Suite, Second Floor, Hilton New York PTSD: SEARCHING FOR ANSWERS IN TRAUMATIC TIMES ONLINE COMMUNICATION IN MENTAL HEALTH: Supported by Cqhcdon, Ire. DIFFERENT CONTEXTS, DIFFERENT ISSUES

Chp.: Jonathan R.T. Davidson, MX). Director: Robert C Hsiung, MX). Faculty: Ivan K. Goldberg, M.D., Alfred Herzog, MX)., A Treatment and Prevention of Chronic PTSD: Ronald W. Pies, MX)., Joel Yager, MX)., Psychosocial Approaches Elizabeth Zelvin, A.GS.W. Edna B.Foa, PhD. COURSE 100 8:00 a.m.-12 noon B Novel Drug Treatments for PTSD Beyond SSRIs Sutton North, Second Floor, Hilton New York Wei Zhang, M.D. NEUROPSYCHIATRY OF TRAUMATIC BRAIN INJURY INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 51, A rmriatn N&wjpsydriatricA ssodatian PART 2 7:00 a.m.-8:30 a.m. Director David B. Arciniegas, MD. Imperial Ballroom B, Second Floor, Sheraton New York Faculty: Thomas McAllister, MX)., Jonathan M. Silver, MX). BIPOLAR DISORDER IN WOMEN: REPRODUCTIVE IMPLICATIONS OF TREATMENT Supported by GktxoSnithKline 9:00 a.m. Sessions Chp.: Adele C Viguera, MX). CONTINUOUS CLINICAL CASE CONFERENCE 2: Co-Chp.: Lee S. Cohen, MX). PART 2 A Use of Antiepileptic Medications in Women 9:00 a.m.-12 noon Martha J. Morrell, MD. Rooms 3D01/12, Level 3, Javits Center

B Reproductive Endocrine Consequences of Treatment TWO HOSPITALIZED PATIENTS WITH REFRACTORY HadineJoffe,MX>. MOOD DISORDER AND COGNITIVE IMPAIRMENT Moderator. Stuart C Yudofsky, MX). Presenters: Richard L. Munich, MX)., Efram Bleiberg, MD., 8:00 a.m. Sessions Lauren B. Marangell, MX)., Alice Rogan, MX)., Florence Kim, MX). COURSES 98-ICC- Course descriptions are available in the CME THIS SESSION IS OPEN TO APAMEMBERS ONLY. Course Brochure included hi your registration BLUE REGISTRATION BADGE OR APA MEMBERSHIP packet. Admission by ticket only. CARD REQUIRED FOR ADMITTANCE.

93 THURSDAY

MASTER EDUCATOR CI.IN W-. j. LECTURE 25 CONSULTATION 12

9:00 a.m.-10:30 a.m. 9:00 a.m.-10:30 a.m. Rooms 1E07/8, Level 1, Javits Center This session is limited to 25 participants on a first-come, Godfrey D. Pearlson, M.D. first-served basis.

Through the Looking Glass: Uses of Simulation Iqbal Ahmed, M.D., on Psychiatric Disorders in the Elderly and Virtual Reality in Clinical Practice Room 1D04, Level 1, Javits Center and Brain Imaging Research THIS SESSION IS OPEN TO APA MEMBERS ONLY. Chp.: Mahmoud A Mohamed, MD. BLUE REGISTRATION BADGE OR APA MEMBERSHIP Co-Chp.: Maria A. Oquendo, MD. CARD REQUIRED FOR ADMITTANCE. The concept of virtual reality goes back almost 40 years, but only recently have advances in computing and associ- ated hardware allowed for clinical applicability. Godfrey WORKSHOPS D. Pearlson, MX)., reviews current achievements, caveats, and future prospects of virtual reality COMPONENT WORKSHOP 49 applications in psychiatry, including uses in the treatment 9:00 a.m.-10:30 a.m. of phobias and eating disorders, assessment and Rooms 1E01/2, Level 1, Javits Center rehabilitation, and as stimuli in brain imaging studies of complex behaviors such as driving, substance abuse, and THE BLAME AND SHAME GAME IN MEDICAL pathological gambling. Dr. Pearlson is Professor of ERRORS: DO YOU WANT TO PLAY IT? Psychiatry at Yale University School of Medicine in New APA CornnaeeonPatient Safety Haven, Connecticut, and Director of the Olin Neuropsychiatry Research Center at the Institute of Living in Hartf ord, Connecticut. His work in psychiatric Co-Chps.: Geetha Jayaram, MD., Benjamin G Grasso, M.D. neuroimaging has spanned the investigation of Participants: David M. McDowell, MD., Robert Michels, MD. Alzheimer's Disease, Huntington's Disease, schizophrenia, bipolar disorder, neurodevelopmental dis- orders, and normal aging. He is the author of over 200 iSSUKS 120-137 scientific papers and book chapters. Dr. Pearlson founded and formerly directed the Psychiatry ISSUE WORKSHOP 120 9:00 a.m.-10:30 a.m. Neuroimaging Laboratory at Johns Hopkins University Rooms 1E03/4/5, Level 1, Javits Center School of Medicine in Baltimore, Maryland. A Distinguished Fellow of the American Psychiatric Association, Dr. Pearlson has received the Ziskind- THE HORNS OF A DILEMMA: MYTHS AND Somerfeld Research Award of the Society of Biological REALITIES OF DRUG-INDUSTRY INTERACTION Psychiatry and the Distinguished Investigator Award of the National Alliance for Research on Schizophrenia and Chp.: John W. Burruss, M.D. Depression. He received his medical degree from the Participants: Woodie ML Zachry, Ph.D., Ali A Asghar-Ali, MD. Newcastle Upon Tyne University Medical School in Newcastle Upon Tyne, England. ISSUE WORKSHOP 121 9:00 a.m.-10:30 a.m. Frontiers of Science Lecture Series Room 1E09, Level 1, Javits Center THIS SESSION WILL BE AUDIOTAPED. GROUP PSYCHOTHERAPY WITH SUBSTANCE ABUSERS A rmwn Group Psychotherapy Association

Co-Chps.: David W. Brook, M.D., Henry I. Spitz, MD.

94 THURSDAY

ISSUE WORKSHOP 122 9:00 a.m.-10:30 a.m. ISSUE WORKSHOP 128 9:00 a.m.-10:30 a.m. Room IE 11, Level 1, Javits Center O'Neill Room, Fourth Floor, Marriott Marquis

MILIEU THERAPIES IN THE AGE OF MANAGED LEASH ON LIFE: HUMAN ATTACHMENT TO CARE, REVISITED ANIMALS

Chp.: C. Deborah Cross, M.D. Chp.: Debra A. Katz, M.D. Participants: Howard D. Kibel, M.D., Saul Scheidlinger, Ph.D., Participants: Jon Katz, Dehra A. Glueck, M.D., Tagalie Janet A. Bezmen, R.N. Heister, M.S.L.S.

ISSUE WORKSHOP 123 9:00 a.m.-10:30 a.m. ISSUE WORKSHOP 129 9:00 a.m.-10:30 a.m. Room IE 12, Level 1, Javits Center Wilder Room, Fourth Floor, Marriott Marquis

PSYCHIATRIC CONSULTATION REPORTS IN AVOIDING DUAL-AGENCY PITFALLS OF WORK- MINUTES: EXPLORING NEW TECHNOLOGIES RELATED NEUROPSYCHIATRIC IMPAIRMENTS

Chp.: Henry H Leung, M.D. Chp.: Harold J. Bursztajn, M.D. Participant Anna E. Rogers, M.D. Participants: Robindra K. Paul, M.D., David M. Reiss, M.D., Christine A, Martone, M.D. ISSUE WORKSHOP 124 9:00 a.m.-10:30 a.m. Room IE 14, Level 1, Javits Center ISSUE WORKSHOP 130 9:00 a.m.-10:30 a.m. Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis A COMPREHENSIVE APPROACH TO THE TREATMENT OF PAIN IN HIV ILLNESS TEACHING CORE COMPETENCIES: THE CHALLENGE FOR ACADEMIC PSYCHIATRY Chp.: David G. Krefetz, D.O. Participants: Richard T. Jermyn, D.O., David M. Kietrys, M.P.T., Co-Chps.: Mary S. Sciutto, M.D., MaryE. Bongiovi-Garcia, MX). Maryann Andrews, B.S.N. Participants: Kareem D. Ghalib, M.D., David A. Lowenthal, M.D. ISSUE WORKSHOP 125 9:00 a.m.-10:30 a.m. Room IE 16, Level 1, Javits Center ISSUE WORKSHOP 131 9:00 a.m.-10:30 a.m. Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis DETECTION OF MALINGERING KEEP IT REAL: PSYCHOLOGICAL PREPAREDNESS Chp.: Alan R. Hrsch, M.D. AND ACTIVE-COPING GROUP Participants: David E. Hartman, Ph.D., Paul Ekman, Ph.D., Carl M. Wahlstrom, Jr., M.D. Chp.: Paula G. Panzer, M.D. Participants: Robert H. Abramovitz, M.D., Susan E. Paula, Ph.D. ISSUE WORKSHOP 126 9:00 a.m.-10:30 a.m. Rooms 2D10/11, Level 2, Javits Center ISSUE WORKSHOP 132 9:00 a.m.-10:30 a.m. Booth/Edison Rooms, Fifth Floor, Marriott Marquis CAN SOCIAL THEORY BE INTEGRATED INTO THE LIBERATORY GOALS OF PSYCHIATRY? PSYCHIATRIC ASPECTS OF TREATING PRIMARY CAREGIVERS OF HOSPICE PATIENTS Co-Chps.: Carl I. Cohen, M.D., Kenneth S. Thompson, M.D. Participants: Astrid N. Rusquellas, M.D., Bradley E. Lewis, M.D., Co-Chps.: Jay L. Wung, M.D., Robert Taub, M.D. SamiTimimi Participant: Linda Gorman, R.N.

ISSUE WORKSHOP 127 9:00 a.m.-10:30 a.m. Rooms 2D14/15, Level 2, Javits Center

TREATMENT-RESISTANT PATIENTS WITH BULIMIA NERVOSA

Co-Chps.: Edi Cooke, Psy.D., Frampton Gwynette, M.D. Participants: Nettie Levine, RD., Waguih W. Ishak, M.D., Antonia Noble-Ludwig, M.F.T. 95 THURSDAY

ISSUE WORKSHOP 133 9:00 a.m.-10:30 a.m. MEDIA 7-8 Imperial/Julliard Rooms, Fifth Floor, Marriott Marquis MEDIA SESSION 7 9:00 a.m.-12 noon PSYCHIATRY TRAINING FOR PRIMARY-CARE Room IE 06, Level 1, Javits Center PHYSICIANS: WHAT, HOW, AND WHEN? Robot Stories: Emotional and Ethical Challenges of a Chp.: Hoyle Leigh, M.D. Technological Age Participants: Tana A. Grady-Weliky, M.D., Don R, Lipsitt, M.D., Seth M. Powsner, M.D., Deborah C Stewart, M.D. Co-Chps.: Ravi Chandra, M.D., John E. Beebe III, M.D. Participants: Paul S. Appelbaum, M.D., Arthur Caplan, Ph.D., Raj Reddy, Ph.D., Greg Pak, B.A. ISSUE WORKSHOP 134 9:00 a.m.-10:30 a.m. Majestic/Music Box/Winter Garden, Sixth Floor, Marriott MEDIA SESSION 8 9:00 a.m.-12 noon Marquis Ziegfeld Room, Fourth Floor, Marriott Marquis

WHOSE RESPONSIBILITY IS IT ANYWAY? THE Personality Disorders and the Film, NoirFemme Fatale TREATING PSYCHIATRIST'S? Chp.: Scott Snyder, M.D. Chp.: Bernard J. Arseneau, D.O.

ISSUE WORKSHOP 135 9:00a.m.-10:30a.m. jj.QQ a.m. SCSSIOHS Plymouth/Uris/Shubert Rooms, Sixth Floor, Marriott Marquis MEDICAL UPDATE 4 11:00 a.m.-12:30 p.m. SAD DAYS: A VIDEO OF PSYCHIATRIC PROBLEMS IN Room IE 13, Level 1, Javits Center AFGHANISTAN AND ITS REFUGEES HOW TO SHRINK OBESITY Chp.: Nigel M. Bark, MX). Participants: Khalid A. Mufti, M.D., Haroon R. Chaudhry, MX). Chp.: Evelyn Attia, MX). Presenter: Judith Korner, MX). ISSUE WORKSHOP 136 9:00 a.m.-10:30 a.m. THIS SESSION WILL BE AUDIOTAPED. Cantor/Jolson Rooms, Ninth Floor, Marriott Marquis

PROGRAM EVALUATION MADE SIMPLE SCIENTIFIC AND CLINICAL REPORT SESSIONS 28-35 Co-Chps.: Barbara A Johnson, M.D., James A Schuster, M.D. Participants: John G. Lovelace, M.S., Frank A Ghinassi, Ph.D., SCIENTIFIC AND CLINICAL REPORT SESSION 28 Mario Cruz, M.D. 11:00 a.m.-12:30 p.m. Rooms 1E01/2, Level 1, Javits Center ISSUE WORKSHOP 137 9:00 a.m.-10:30 a.m. EATING DISORDERS Marquis Ballroom Salons A/B, Ninth Floor, Marriott Marquis Chp.: Theodore E. Weltzin, MX). Co-Chp.: Andrew O. Skinner, MX). THE STALKING VICTIM: CAUSES, CONSEQUENCES, AND THERAPEUTIC CONSIDERATIONS 11:00 a.m. 83 "'Weight and Relapse to Cocaine and Alcohol Use in Chp.: Gail E. Robinson, M.D. Patients With Eating Disorders Participant: Karen M. Abrams, M.D. Olivera J. Bogunovic, MX)., David R. Gastfriend, MX).

11:30 a.m. 84 DSM-IV Comorbidity in Binge-Eating Disorder Carlos M. Grilo, Ph.D., Robin M. Masheb, Ph.D.

12 noon 85 Males at Risk: Hawaiian and Filipino Adolescents Alayne Yates, MX)., Jeanne Edman, Ph.D. THIS SESSION WILL BE AUDIOTAPED.

* Collaborative Session With the National Institute on Drug Abuse 96 THURSDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 29 SCIENTIFIC AND CLINICAL REPORT SESSION 31 11:00 a.m.-12:30 p.m. 11:00 a.m.-12:30 p.m. Room IE 12, Level 1, Javits Center Rooms 3D04/9, Level 3, Javits Center

ADDICTION PSYCHIATRY SLEEP AND SEASONALITY Collaborative Session With the National Institute onDrug Abuse Chp.: Karl Doghramji, MD. Chp.: Lisa M Goldfarb, M.D. Co-Chp.: Gerald F. Donovan, MD. Co-Chp.: Marketa M. Wills, MD.

11:00 a.m. 11:00 a.m. 86 PRISM-IV: Reliable Diagnosis in Alcohol and Drug 92 Modafinil Improves Patient Functioning in Shift Work Abusers Sleep Disorder Sharon Samet, MS.W., Edward V. Nunes, MD., Jakob Milton K. Erman, MD., Charles A. Gzeisler, Ph.D., David F. Meydan, Psy,D., Karen Matseoane, B.A., Deborah S. Dinges, Ph.D., James K. Walsh, Ph.D., Thomas Roth, Ph.D. Hasin, Ph.D. 11:30 a.m. 11:30 a.m. 93 Modafinil Treatment of Chronic Shift Work Sleep 87 Cognitive Functioning: Predictors of Outcome in Disorder Cocaine-Dependent Patients James K. Walsh, Ph.D., Charles A. Czeisler, Ph.D., David F. Efrat Aharonovich, Ph.D., Edward V. Nunes, M.D., Xinhua Dinges, Ph.D., Thomas Roth, PhD. Liu, Ph.D., Adam M. Bisaga, M.D., David M. McDowell, MD., Deborah S. Hasin, PhD. 12 noon 94 A Comparis on of Seas onality of Mood and Behavior in 12 noon African and African-American Students 88 Cocaine Expectancy Questionnaire: Psychometric and Samina M Yousufi, MD., Kelly J. Rohan, PhD., Courtney M Underlying Model Thrower, MA., Michael A Jackson, B.S., John J. Marie C Martin, Ph.D., Bruce J. Rounsaville, M.D., Adam J. Bartko, PhD., Charles O. Agumadu, MD., Teodor T. Jaffe, Ph.D., Charles H Wilber, MEd. Postolache, MD. THIS SESSION WILL BE AUDIOTAPED. THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 30 SCIENTIFIC AND CLINICAL REPORT SESSION 32 11:00 a.m.-12:30 p.m. 11:00 a.m.-12:30 p.m. Room 3D03/10, Level 3, Javits Center Rooms 3D06/7, Level 3, Javits Center

ISSUES IN ADDICTIONS ISSUES IN BPD

Chp.: David A. Casey, MD. Chp.: Anthony J. Rothschild, MD. Co-Chp.: Jesse H Wright, MD. Co-Chp.: John J. Schwab , MD.

11:00 a.m. 11:00 a.m. 89 *Psychosocial Therapies for Cocaine Dependence: A 95 The Frequency of DSM-IV Personality Disorders in Controlled Study Psychiatric Outpatients Adam J. Jaffe, Ph.D., Charles H Wilber, M.Ed., Bruce J. Rounsaville, MD. Mark Zimmerman, MD., Louis Rothschild, PhD. 11:30 a.m. 11:30 a.m. 90 Patient Treatment Matching With Ambulatory Cocaine 96 Inhibitory Functioning in BPD: A fMRI Study Abusers Sabine Herpertz, Knut Schnell, MD., Britta Winter, PhD., Charles H. Wilber, MEd., Adam J. Jaffe, PhD., Joshua J. Martina Ahrens, MD., Armin Thron, MD. Brandt, Psy.D., Marie C Martin, PhD., Richard A Rodriguez, B.S., Bruce J. Rounsaville, MD. 12 noon 12 noon 97 Life Changes, Social Adjustment, and Attempted Suicide 91 Virtual Reality Cue-Reactivity-Controlled Trial for in BPD and MDD Nicotine Dependence Thomas M Kelly, PhD., Paul H. Soloff, MD., J. John Patrick S. Bordnick, Ph.D., Ken Graap, MEd., Hilary Mann, MD. Copp, MS.W., Jeremy Brooks, Bobby Logue, B.S., THIS SESSION WILL BE AUDIOTAPED. Mirtna Ferrer, MS. THIS SESSION WILL BE AUDIOTAPED.

* Collaborative Session With the National Institute on Drug Abuse

97 THURSDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 33 SCIENTIFIC AND CLINICAL REPORT SESSION 35 11:00 a.m.-12:30 p.m. 11:00 a.m.-12:30 p.m. Wilder Room, Fourth Floor, Marriott Marquis Majestic/Music Box/Winter Garden, Sixth Floor, Marriott Marquis CONSULTATION LIAISON PSYCHIATRY ADULT ADHD Chp.: Anton C Trinidad, M.D. Co-Chp.: SermsakLolak, M.D. Chp.: Catherine C Crone, M.D. Co-Chp.: Robert Kelly, M.D. 11:00 a.m. 98 Depression and Nonlinear Heart Rate Dynamics in 11:00 a.m. Older Coronary Patients 104 Cognitive-Behavioral Therapy for Residual ADHD in Salvador M. Guinjoan, MD., Daniel E. Vigo, M.D., Adults Rodolfo D. Fahrer, M.D., M. Soledad Steven A Safren, Ph.D., Michael W. Otto, Ph.D., Timothy E. Laorondeguevara, B.S.G, Daniel Cardinali, M.D., Leonardo Wilens, M.D., Susan Sprich, Ph.D., Joseph Biederman, M.D., Nicola Siri, Ph.D., Eduardo Sampo, M.D. Carol Winette, Ph.D.

11:30 a.m. 11:30 a.m. 99 The Role of Dexmedetomidine in Reducing Delirium in 105 A Controlled Study of Functional Impairments in 500 Cardiotomy Patients ADHD Adults Jose R. Maldonado, M.D., Ashley Wysong, M.S., Thaddeus S. Stephen V. Faraone, Ph.D., Joseph Biederman, M.D. Block, M.D. 12 noon 12 noon 106 Long-Term Safety and Efficacy of Mixed Amphetamine 100 Psychiatry Training in Primary Care: Factors for a Salts Extended-Release for Adult ADHD Satisfactory Program Joseph Biederman, M.D., Thomas J. Spencer, M.D., Allan K. Hoyle Leigh, M.D., Deborah C. Stewart, M.D., Ronna Chrisman, M.D., Timothy E. Wilens, M.D., Simon J. Mallios, M.P.H Tulloch, M.D., Richard H Weisler, M.D. THIS SESSION WILL BE AUDIOTAPED. THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 34 11:00 a.m.-12:30 p.m. Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis WORKSHOPS

OCD ISSUES 138-146

Chp.: Carl I. Cohen, M.D. ISSUE WORKSHOP 138 11:00 a.m.-12:30 p.m. Co-Chp.: GeoffreyM. Hopkins, M.D. Rooms 1E03/4/5, Level 1, Javits Center

11:00 a.m. DIVERSE CULTURAL EXPRESSIONS AND 101 Self-Administered Versus Therapist-Administered INTERVENTIONS FOR ANXIETY AND DEPRESSIVE Cognitive-Behavior Therapy for Medication DISORDERS Nonresponders With OCD David Tolin, Ph.D., Scott Hannan, Ph.D., Gretchen Chp.: Nalini V. Juthani, M.D. Diefenbach, Ph.D., Nicholas Maltby, Ph.D., Patrick Participants: Virginia Contreras, M.D., Kingsley Nwokeji, M.D., Worhunsky, B.S. Akhtar Hossain, M.D.

11:30 a.m. ISSUE WORKSHOP 139 11:00 a.m.-12:30 p.m. 102 Effectiveness of Intensive Residential Treatment of Room 1E09, Level 1, Javits Center Severe Refractory OCD S. Evelyn Stewart, M.D., Colleen Farrell, B A, Denise Egan-Stack, M.A., Michael A. Jenike, MD. SPIRITUAL AND RELIGIOUS ASSESSMENT IN CLINICAL PRACTICE 12 noon 103 Hyperactive Error Processing in OCD Co-Chps.: Francis G. Lu, M.D., Christina M. Puchalski, M.D. Nicholas Maltby, Ph.D., Patrick Worhunsky, B.S., Kent A. Participant James L. Griffith, M.D. Kiehl, Ph.D., David Tolin, Ph.D. THIS SESSION WILL BE AUDIOTAPED.

98 THURSDAY

ISSUE WORKSHOP 140 11:00 a.m.-12:30 p.mp.m.. ISSUE WORKSHOP 141466 11:00 a.m.-12:30 p.m. Room IE 11, Level 1, Javits Center Marquis Ballroom Salon C, Ninth Floor, Marriott Marquis

LONG-TERM CARE INSURANCE DENIALS TO ONE- EVIDENCE-BASED TREATMENT FOR TIME PSYCHIATRIC PATIENTS SCHIZOPHRENIA IN A CORRECTIONAL SETTING

Co-Chps.: Rita R. Newman, M.D., Ruth B. Kantor, M.D. Chp.: Larry H. Dizmang, M.D. Participants: Lynn Lavendar, Esq., Brenda McElnea, Esq., Participants: John A. Chiles, MD., Karen Alexander, Ph.D., MarkWilensky,MBA David SUbaugh, Ph.D., Ira D. Click, M.D.

ISSUE WORKSHOP 141 11:00 a.m.-12:30 p.m. Room IE 14, Level 1, Javits Center • 2 noon Sessions AN EXTENSION OF THE ANALYSIS OF RESTORATIVE JUSTICE AND THERAPEUTIC ! I'- • V: (~ JURISPRUDENCE 12 noon-1:30 p.m. Room IE 16, Level 1, Javits Center Co-Chps.: Lawrence K. Richards, MX)., Abraham L. Halpern, M.D. APA AND THE PHARMACEUTICAL INDUSTRY: AN Participants: Michael L. Perlin, Bruce J. Winick, OPEN FORUM Marjorie A. Silver Chp.: Stephen M. Goldfinger, MX). ISSUE WORKSHOP 142 11:00 a.m.-12:30 p.m. Participants: Charles R. Goldman, MX)., Geetha Jayaram, MX)., David M. McDowell, M.D., Trevor R.P. Price, MX)., Nyapati R. Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis Rao, MX)., Anand Pandya, M.D., David B. Mallott, MX). CHALLENGING SLEEP PROBLEMS: LOOKING AT SLOW-WAVE SLEEP NEW RESEARCH POSTER SESSION 10 Chp.: Lois E. Krahn, M.D. 12 noon-2:00 p.m. Participants: Peter C Gleason, MX)., Martin B. Scharf, Ph.D. Galleria, Level 4, Javits Center

ISSUE WORKSHOP 143 11:00 a.m.-12:30 p.m. MEDICAL PSYCHIATRY AND GERIATRIC PSYCHIATRY Booth/Edison Rooms, Fifth Floor, Marriott Marquis For further information on New Research Sessions, please refer to WORKPLACE BURNOUT IN PSYCHIATRISTS: EVIDENCE FROM THE UNITED KINGDOM the NewResearth ProgramBook included in your registration packet.

Co-Chps.: Alex P. Mears, Ph.D., John Sharkey, M.D. 2;."0 p.ni. Sessions

ISSUE WORKSHOP 144 11:00 a.m.-12:30 p.m. SYMPOSIA 90-116 Plymouth/Uris/Shubert Rooms, Sixth Floor, Marriott Marquis SYMPOSIUM 90 2:00 p.m.-5;00 p.m. REACTIONS AFTER 9/11 IN A PRETRAUMATIZED Rooms 1E01/2, Level 1, Javits Center COMMUNITY IN THE SOUTH BRONX NEW CLINICAL INDICATIONS FOR LIGHT Co-Chps.: Jeffrey M. Levine, M.D., Andreas Evdokas, Ph.D. TREATMENT: STATUS REPORT Participants: Ibet Hernandez, C.S.W., Patrick J. Moynihan Chp.: Raymond W. Lam, M.D. ISSUE WORKSHOP 145 11:00 a.m.-12:30 p.m. Cantor/Jolson Rooms, Ninth Floor, Marriott Marquis A Treatment of Winter Depression: Light or Drugs? Raymond W. Lam, MX)., Anthony J. Levitt, MX)., TREATMENT OF RECENT-ONSET SCHIZOPHRENIA Robert D. Levitan, MX)., Murray W. Enns, M.D., Rachel L. IN COMMUNITY AND RESEARCH SETTINGS Morehouse, MX).

Chp.: Raman C Patel, MX). Participants: Gilbert Robinson, MX)., Rachel Miller, M.S.W., (Continued an nectpag) Jose M. Soto, M.D., Beth Lorell, CS.W. 99 THURSDAY

B Light Treatment for Antepartum Depression D Can You Ever Get Paid for Treating Patients in Long- Katharine L. WIsner, MD. Term Care Settings? Istvan J.E. Boksay, MD. C Bright Light and Negative Ion Treatment for Chronic Depression E Barriers to Psychiatric Care in Assisted-Living Facilities Namni Goel, PhJD., Jiuan Su Terman, PhD., Helen H Kyomen, MD. Michael Terman, Ph.D., Mela M Macchi, Ph.D., THIS SESSION WILL BE AUDIOTAPED. Jonathan W. Stewart, MX). SYMPOSIUM 93 2:00 p.m.-5:00 p.m. D A Meta- Analysis of Light Treatment for Nonseasonal Room 1E09, Level 1, Javits Center Depression Arja L. Tuunainen, M.D., Daniel F. Kripke, MD., DEVELOPMENTAL DISABILITIES FROM Takuro Endo, MD. CHILDHOOD TO ADULTHOOD

Discussant: Michael Terman, PhD. Chp.: Roxanne C Dryden-Edwards, MD. THIS SESSION WILL BE AUDIOTAPED. Co-Chp.: Paula J. Lockhart, MD.

SYMPOSIUM 91 2:00 p.m.-5:00 p.m. A Fetal Alcohol Spectrum Disorders for Mental Health Rooms 1E03/4/5, Level 1, Javits Center Professionals: A Brief Review Paula J. Lockhart, MD. MOOD DISORDERS IN WOMEN THROUGHOUT THE LIFE CYCLE B Behavioral Interventions for Autism and Developmental Disorders in Adults Chp.: Nina E. Cerfolio, MD. Joel D. Bregman, M.D., John Gertz, MD.

A Pregnant Addicts Do Not Use Drugs C Substance Use Disorders in Young Adults With and Leslie H. Gise, MD. Without Learning Disabilities Joseph H Beitchman, M.D., Lori Wilson, Arlene Young, B Postpartum Psychosis: Phenomenology, Treatment, and Edward Adlaf Prevention Margaret G. Spinelli, MD. D Psychopharmacology in Mental Retardation and Pervasive Developmental Disorders C Cyclic Moods and Acyclic Moods Bryan H King, M.D. Kimberly A, Yonkers, M.D.

D The Greatest Experiment Ever Performed on Women Discussants: Joseph H. Beitchman, MD., Bryan H. Barbara Seaman, Ph.D. King, MD., Joel D. Bregman, MD. THIS SESSION WILL BE AUDIOTAPED. THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 92 2:00 p.m.-5;00 p.m. SYMPOSIUM 94 2:00 p.m.-5:00 p.m. Room IE 06, Level 1, Javits Center Room IE 10, Level 1, Javits Center

OVERCOMING BARRIERS TO LONG-TERM CARE UPDATE ON TREATMENT OF STIMULANT ABUSE AND TREATMENT OF THE ELDERLY CoUaboratiieSession With theNatiomlInstitute onDrugAbuse APA QOTEspo^^G»wzS^o«Z,o^-Tey7nG»E^?r/ Treatment far the Elderly Chp.: David A Gorelick, MD.

Chp.: Helen H Kyomen, MD. A Recovery-Oriented Psychosocial Treatment Douglas M Ziedonis, MD. A An Inspirational Model of Care in Rural Long-Term-Care Facilities B Therapy and Placement Approaches for Cocaine Abuse David W. Hodo, MD. Treatments David R. Gastfriend, MD., Gurmit Shimi Kang, MD., B The PACE Model of Community-Based Care Robert K. Dolgoff, M.D. Sandrine Pirard, MD., Estee Sharon, Psy.D.

C An Ethno-Cultural Model of Care in Long-Term-Care C Pharmacological Treatment of Stimulant Abuse Facilities David A Gorelick, MD. Ronald Brenner, M.D. 100 THURSDAY

D Psychiatric Comotbidity in Stimulant Abusers C Low-Cost Contingency Management in Community Richard N. Rosenthal, M.D. Settings Nancy MPetry,Ph.D. £ Methamphetamine Abuse: 2004 Update Steven L. Batki, MD. D Cognitive-Behavioral Therapy and Naltrexone for THIS SESSION WILL BE AUDIOTAPED. Cocaine Dependence JoyM Schmitz, Ph.D., Angela L. Stotts, Ph.D., SYMPOSIUM 95 2;00 p.m.-5:00 p.m. John Grabowski, Ph.D. Room IE 11, Level 1, Javits Center E Behavioral Family Counseling and Naltrexone for Male, Opioid-Dependent Patients DEPRESSIVE PERSONALITY DISORDER VERSUS William S. Fals-Stewart, Ph.D., Timothy J. OFarrell, PhD. DYSTHYMIC DISORDER THIS SESSION WILL BE AUDIOTAPED. Chp.: John C Markowitz, MD. SYMPOSIUM 97 2:00 p.m.-5:00 p.m. Co-Chp.: Andrew E. Skodol II, MD. Room IE 14, Level 1, Javits Center A Conceptual Issues in the Overlap of Depressive Personality and Dysthymia ITALIAN PSYCHIATRY: 25 YEARS OF CHANGES Steven Huprich, Ph.D. Chp.: Mariano Bassi, MD. B Longitudinal Comparis on of Depres s ive Pers onality Co-Chp.: Allan Tasman, MD. Disorder and Dysthymic Disorder John C Markowitz, MD., Andrew E. Skodol II, MD., A Italian Psychiatrists and Italian Psychiatry: 25 Years of Eva Petkova, Ph.D., Hui Xie, Ph.D., David J. Changes Hellerstein, M.D. Mariano Bassi, M.D.

C Depressive Personality: Ten-Year Follow-Up B Intensive Community Care: Is It the Same in Italy and Daniel N. Klein, Ph.D. the Rest of the World? Angelo Fioritti, MD. D Impact of Comorbid Dysthymic Disorder on Outcome in Personality Disorders C Variations in Mental Health Service Provision in Italy David J. Hellerstein, MD., Andrew E. Skodol II, M.D., and Their Links With Socioeconomic Predictors John C Markowitz, MD., Eva Petkova, Ph.D., Giuseppe Tibaldi HuiXie,Ph.D. D Residential Care in Italy: A National Survey E Clinical Correlates of Chronicity in Depression: Results Giovanni De Girolamo, M.D., Angelo Picardi, MD., From the Rhode Island MIDAS Project Giovanni Santone, MD. Mark Zimmerman, MD., Iwona Chelminski, Ph.D. THIS SESSION WILL BE AUDIOTAPED. E Community Treatment of Schizophrenia in Italy Mirella Ruggeri, MD., Antonio Lasaluia, MD., Michele Tansella, MX). SYMPOSIUM 96 2:00 p.m.-5;00 p.m. THIS SESSION WILL BE AUDIOTAPED. Room IE 13, Level 1, Javits Center

BEHAVIORAL TREATMENTS FOR DRUG DEPENDENCE SYMPOSIUM 98 - WITHDRAWN Collaborative Session With the National Institute anDrugAbuse

Chp.: Lisa S. Onken, Ph.D. Co-Chp.: Bruce J. Rounsaville, MD.

A Durability of Cognitive-Behavioral Therapy Efficacy for Substance Abusers Bruce J. Rounsaville, MD.

B HIV Risk Reduction and Substance Abuse Treatment George E. Woody, MD.

101 THURSDAY

SYMPOSIUM 99 2:00 p.m.-5;00 p.m. B Meaning in Suicide From the Survivor's Perspective Rooms 3D01/12, Level 3, Javits Center CarlaFine,M.S.

MIND, BRAIN, AND INTERPERSONAL EXPERIENCE C Approaches to Engaging People of Color in Program IN PSYCHOTHERAPY Initiatives for Suicide Prevention and Intervention Donna H. Barnes, Ph.D. Chp.: Daniel J. Siegel, MX). Co-Chp.: Marcia Kraft Coin, MX). D Suicide: What Survivors Want From Mental Health Care Professionals A The Present Moment in Psychotherapy Frank R. Campbell, Ph.D. Daniel N. Stern, M.D. E The Clinician's Perspective: Why Is This Subject So Tough for Us? B The Central Role of Emotion in Psychotherapy Michael F. Myers, MX). Diana Fosha, Ph.D. Discussant: Morton Silverman, M.D. C Intersubjectivity, Narrative, and the Brain in THIS SESSION WILL BE AUDIOTAPED. Psychotherapy Daniel J. Siegel, MX). SYMPOSIUM 102 2:00 p.m.-5:00 p.m. THIS SESSION WILL BE AUDIOTAPED. Rooms 3D04/9, Level 3, Javits Center SYMPOSIUM 100 2:00 p.m.-5:00 p.m. INDIVIDUALIZING INTERPERSONAL Room 3D02/11, Level 3, Javits Center PSYCHOTHERAPY FOR MOOD DISORDERS

FROM RESEARCH TO CLINICAL PRACTICES IN Chp.: Ellen Frank, Ph.D. TREATING PATIENTS WITH BPD Co-Chp.: Nancy K. Grote, Ph.D.

(Hip.: John G. Gunderson, M.D. A Interpersonal and Social Rhythm Therapy for Bipolar I Disorder A Levels of Care: A Scientific and Clinical Overview Ellen Frank, Ph.D. John G. Gunderson, MX). B Individualizing Treatment for Depressed Patients With B Intensive Outpatient and Partial Hospital Care for BPD Co-Occuring Panic or Anxiety Anthony Bateman, MX). Jill M. Cryanowski, Ph.D., Ellen Frank, Ph.D., M, Katherine Shear, M.D. C Comparing Psychotherapies for Patients With BPD: C Motivational Interviewing and IPT: An Approach to A Progress Report Treatment Engagement Otto F. Kernberg, MX). Holly A Swartz, M.D., Nancy K. Grote, PhX>., Allan Zuckoff, M.D., Ellen Frank, Ph.D., M. Katherine D Effects of Psychotherapy on MDD in Patients With BPD Shear, MX). Janine L. Stevenson, MX)., Russell Meares, MX). D Group Psychotherapy for Infertile Women With E A Randomized Trial of Psychoeducation for Patients Depression With BPD Ellen F. Olshansky, D.Sc., Ellen Frank, Ph.D. Mary C Zanarini, Ed.D., Frances R. Frankenburg, M.D. THIS SESSION WILL BE AUDIOTAPED. THIS SESSION WILL BE AUDIOTAPED. SYMPOSIUM 103 2:00 p.m.-5:00 p.m. SYMPOSIUM 101 2:00 p.m.-5:00 p.m. Rooms 3D05/8, Level 3, Javits Center Room 3D03/10, Level 3, Javits Center BDD: IS IT A MIND, BODY, OR SOdOCULTURAL MEANING IN SUICIDE: OVERCOMING BARRIERS AND CONNECTING DIVERSE PERSPECTIVES PROBLEM AND HOW DO YOU TREAT IT?

Chp.: Michael F. Myers, MX). Chp.: Fugen Neziroglu, Ph.D.

A Existential Meaning: Unifying Diverse Perspectives to A BDD: Phenomenology, Etiology, and Sociocultural Understanding Suicide Influences James R. Rogers, Ph.D., Karen M. Soyka, M.S. SonyKhemlani-Patel, Ph.D. 102 THURSDAY

B How to Apply Cognitive and Behavior Therapy for BDD C Ocular Abnormalities in Community-Based Patients Fugen Neziroglu, Ph.D. With Schizophrenia Moira A Connolly, Roch Cantwell, MX)., Qara Kelly, MX)., C Update on Pharmacotherapy for BDD Michael Smith, Norman Button, John Nome Katharine A. Phillips, M.D. D Sexual Dysfunction in Schizophrenia D Cosmetic Surgery in BDD Shiona M. Macdonald, M.B., Jennifer Halliday, M.B., David Veale Susan Farrington, B.A, Thomas Macewan, M.B., Susan Wall, Valerie Sharkey, B.S.C, Robin G. McCreadie, D.Sc. E SNRI Treatment and Functional Imaging of BDD Eric Hollander, M.D., Andrea Allen, Ph.D., Lauren Priday, B.A E The Dental Health of People With Schizophrenia THIS SESSION WILL BE AUDIOTAPED. Robin G. McCreadie, D.Sc. THIS SESSION WILL BE AUDIOTAPED. SYMPOSIUM 104 2:00 p.m.-5:00 p.m. SYMPOSIUM 106 2:00 p.m.-5:00 p.m. Rooms 3D06/7, Level 3, Javits Center O'Neill Room, Fourth Floor, Marriott Marquis MODEL PSYCHIATRY RESIDENCY PROGRAMS ON DO NOT WAIT UNTIL YOU PRACTICE, KNOW IT RELIGION AND SPIRITUALITY NOW: WHAT RESIDENTS AND EARLY PSYCHIATRISTS NEED TO KNOW Chp.: Francis G. Lu, M.D. Co-Chp.: Christina M. Puchalski, M.D. Chp.: Consuelo G Cagande, M.D. Co-Chp.: Thomas S. Newmark, M.D. A Religion, Spirituality, and Culture in Psychiatric Practice at the University of Louisville A Professional Liability Insurance: A Primer for James Hyde, Ph.D. Psychiatrists Martin G. Tracy, J.D. B Enhancing Spirituality Teaching at the Medical University of South Carolina B Understanding Managed Care David W. Hiott, M.D., Dana King, M.D. Shivkumar Hatti, MX).

C University of Saskatchewan Curriculum on C Private Versus Administrative Versus Academic Practice Spirituality and Mental Health David A Baron, D.O. Marilyn D. Baetz, M.D. D Ethics for Psychiatry Residents and Early Career Discussants: John R, Peteet, M.D., Allan M. Josephson, MX). Psychiatrists THIS SESSION WILL BE AUDIOTAPED. Thomas S. Newmark, MX). THIS SESSION WILL BE AUDIOTAPED. SYMPOSIUM 105 2:00 p.m.-5:00 p.m. SYMPOSIUM 107 2:00 p.m.-5:00 p.m. Odets Room, Fourth Floor, Marriott Marquis Alvin/Carnegie Rooms, Fifth Floor, Marriott Marquis HEALTH AND LIFESTYLE OF PEOPLE WITH SCHIZOPHRENIA: THE VIEW FROM SCOTLAND PSYCHIATRY, ETHICS, AND END-OF-LIFE CARE: NEW INSIGHTS AND CHALLENGES Chp.: Robin G. McCreadie, D.Sc. Chp.: David W. Kissane, M.D. Co-Chp.: Ciara Kelly, M.D. Co-Chp.: Brian J. Kelly, M.B. A Smoking Habits of Scottish People With Schizophrenia A Impact of Demoralization on Decision Making in Ciara KeUy, M.D., Robin G. McGeadie, D.Sc., Physician-Assisted Suicide Roch CantweU, M.D., John Eagles, MX)., Paul Sclare, M.D., David W. Kissane, M.D., David M. Clarke, Ph.D., Simon Naji, M.D. Anthony Love, Ph.D., Simon Wein, MX).

B Diet and Cardiovascular Risk: Descriptive Study and B Spiritual Interpretation of the Demoralization Syndrome Randomized, Controlled Trial as Alienation From Self Robin G. McCreadie, D.Sc. Constance A. Jennings, MX)., David W. Kissane, MX).

(Cottinued an rtottpag)

103 THURSDAY

C Countertransference and Ethical Issues in End-of-Life D Cognitive Processes in Depersonalization Disorder Care Orna Guralnik, PsyD., Margaret Knutelska, M.P.H, Brian J. Kelly, M.B., Frances T. Varghese, M.B., Dan Daphne Simeon, M.D. Pelusi, BA, Paul Burnett, Ph.D., Marguerite Robertson, M.B., Shirlene Badger, B A E Neurochemistry and Pharmacological Treatment of Depersonalization Disorder D Competing Paradigms of Responding to Assisted- Daphne Simeon, M.D., Margaret Knutelska, MP.H, Suicide Requests in Oregon: Case Report Orna Guralnik, PsyD., Dorothy Nelson, B.S.C N. Gregory Hamilton, M.D., Catherine Hamilton, MA F A Cognitive-Behavioral Approach to Depersonalization Discussant: Herbert Hendin, M.D. Disorder THIS SESSION WILL BE AUDIOTAPED. AnthonyS. David, M.D., Dawn Baker, Ph.D., Elaine Hunter, Ph.D., Mauricio Sierra, M.D., MaryL. Phillips, M.D. SYMPOSIUM 108 2:00 p.m.-5:00 p.m. THIS SESSION WILL BE AUDIOTAPED. Belasco/Broadhurst Rooms, Fifth Floor, Marriott Marquis SYMPOSIUM 110 2:00 p.m.-5;00 p.m. AN INTEGRATION OF THE PATHOPHYSIOLOGY Majestic/Music Box/Winter Garden, Sixth Floor, Marriott AND PHARMACOTHERAPY FOR PTSD Marquis PSYCHOSOdAL IMPACT OF SARS ON PATIENTS, Chp.: Lori L. Davis, M.D. HOSPITALS, AND HEALTH CARE PROVIDERS

A Noradrenergic Function in the Pathophysiology and Chp.: Donna E. Stewart, M.D. Treatment of PTSD Steven M. Southwick, MJ3. A The Traumatic Impact of SARS on Nurses and Health Care Workers With Children B Hypothalamic Pituitary Adrenal Axis and Serotonergic Robert G. Maunder, M.D., William J. Lancee, Ph.D., Function in PTSD Jonathan). Hunter, M.D., Kenneth E. Balderson, M.D., J. Douglas Bremner, M.D. Sean B. Rourke, PhD., Patricia M. Petryshen, Ph.D., David S. Goldbloom, M.D., Donald A Wasylenki, M.D., C Amino Acid Neurotransmitter Modulation in PTSD Calvin Fones, M.D. Lori L. Davis, M.D., Frederick Petty, M.D. B Academic Physicians Coping During SARS Discussant: Charles R. Marmar, M.D. Donna E. Stewart, M.D., Sherry Grace, Ph.D., THIS SESSION WILL BE AUDIOTAPED. Karen Hershenfield, B.S.C, Emma K. Robertson, Ph.D.

SYMPOSIUM 109 2:00 p.m.-5:00 p.m. C Consultation-Liaison Psychiatry During the SARS Booth/Edison Rooms, Fifth Floor, Marriott Marquis Outbreak: Response to Patients and Administration Jonathan J. Hunter, M.D. FEELING UNREAL: A CONTEMPORARY OVERVIEW OF DEPERSONALIZATION DISORDER D Psychosocial Effects of Quarantine Due to SARS in Health Care Workers Emma K. Robertson, Ph.D., Karen Hershenfield, B.S.C, Chp.: Daphne Simeon, M.D. Sherry Grace, Ph.D., Donna E. Stewart, M.D.

A The Phenomenology of Depersonalization Disorder E Group Psychological Perspectives on the SARS Daphne Simeon, M.D., Margaret Knutelska, MP.H, Epidemic in Toronto Dorothy Nelson, B.S.C, Orna Guralnik, PsyD. Molyn Leszcz, M.D. THIS SESSION WILL BE AUDIOTAPED. B The Neurophysiological Basis of Depersonalization Disorder SYMPOSIUM 111 2:00 p.m.-5:00 p.m. AnthonyS. David, M.D., MaryL. Phillips, M.D., Plymouth/Uris/Snubert Rooms, Sixth Floor, Marriott Nicholas Medford, M.D., Mauricio Sierra, M.D. Marquis

C Neurobiology of the Dissociative States Produced by TRAUMATIC STRESS: THE BRIDGE BETWEEN Ketamine NEUROSdENCE AND PSYCHODYNAMIC John H Krystal, M.D., J. Douglas Bremner, M.D., PSYCHIATRY Amit Anand, M.D., Dennis S. Charney, M.D., Cyril Dsouza, M.D. Chp.: Andrei Novae, M.D. 104 THURSDAY

A Disorganized Attachment Alters the Cortisol Stress B The Health Impact of Sexual and Physical Abuse and Response in Human Infants PTSD Among Women With Pelvic Pain Robert D. Levitan, MX)., Eman Leung, M.A., Susan Samantha Meltzer-Brody, MX)., Jane Leserman, Ph.D., Goldberg, Ph.D., Stephen Matthews, Ph.D., Leslie Wilma I. Castilla-Puentes, MX)., Marian I. Butterfield, MX). Atkinson, Ph.D. C Does Having a Disability Increase Women's Risk of B Biological Aspects of Intergenerational Responses to Sexual and Physical Assault' Traumatic Stress Kathryn E. Moracco, Ph.D., Neepa Ray, M.S.G, Rachel Yehuda, Ph.D. Daniela Sotres-Alvarez, M.S.C., Lawrence L. Kupper, Pamela A. Dickens, M.P.H., Donna Scandlin, M.Ed., C The Neurobiology of Cognitive Bias Sandra L. Martin, Ph.D. Andrei Novae, MX). D Treating PTSD Related to Sexual Trauma in Women D Psychodynamic Neurobiology Marian I. Butterfield, M.D. Barton J. Blinder, M.D. E Sexual Abuse in the Context of Psychiatric Disorders Discussant: Roger K. Pitman, M.D. Anita L.H. Clayton, MX). THIS SESSION WILL BE AUDIOTAPED. Discussants: Ruby G Castilla-Puentes, MX)., SYMPOSIUM 112 2:00 p.m.-5:00 p.m. Wilma I. Castilla-Puentes, MX). Columbia/Duffy Rooms, Seventh Floor, Marriott Marquis THIS SESSION WILL BE AUDIOTAPED.

INSTITUTIONAL ETHICS IN PSYCHIATRY: A SYMPOSIUM 114 2:00 p.m.-5:00 p.m. MULTIDISdPLINARY PERSPECTIVE Cantor/Jolson Rooms, Ninth Floor, Marriott Marquis

Chp.: David H. Brendel, MX). PROVIDING PSYCHIATRIC SERVICES AROUND THE WORLD WITH A SHORTAGE OF PSYCHIATRISTS A Ethical and Legal Aspects of Confidentiality in The Royal College cfPsychiatrists Psychiatric Institutions Rebecca W. Brendel, M.D. Chp.: Nigel M. Bark, MX). Co-Chp.: A Hamid Ghodse, Ph.D. B Institutional Obligation to Balance Science With Ethics in Research: Role of the IRB A Peer-Specialists, Self-Help Groups, and Psychiatrists: Scott E. Lukas, Ph.D. An Opportunity to Expand Resources and Horizons Peter Stastny, MX). C Some Functions of a Psychiatric Hospital Ethics Committee B The New U.K. Graduate Mental Health Worker J. Alexander Bodkin, M.D. Andrew Kent, M.D.

D Ethical Roles, Identity, and Bureaucratic Health Care C Setting Up a Psychiatric Service for a Group of Afghan Jennifer Radden, Ph.D. Refugees Living in Pakistan Khalid A Mufti, M.D., Farooq Naeem, M.R.C Discussant Alan A. Stone, M.D. THIS SESSION WILL BE AUDIOTAPED. D Management of Mental Health Services With Scarce Resources: The Kenyan Experience SYMPOSIUM 113 2:00 p.m.-5:00 p.m. Marx O. Okonji, MA Empire/Hudson Rooms, Seventh Floor, Marriott Marquis E The Marriage of Modern and Traditional Methods in THE EFFECTS OF SEXUAL AND PHYSICAL ABUSE Mental Health Care in Egypt ON WOMEN'S HEALTH Nasser F. Loza, M.B., Sherif F. Atallah, M.R.C

Chp.: Jane Leserman, Ph.D. Discussant Martin Gittelman, MX). Co-Chp.: Samantha Meltzer-Brody, M.D. THIS SESSION WILL BE AUDIOTAPED.

A The Lasting Effects of Sexual Abuse on Health: What Is the Evidence? Jane Leserman, Ph.D.

105 THURSDAY

SYMPOSIUM 115 2;00 p.m.-5;00 p.m. SYMPOSIUM 116 2:00 p.m.-5;00 p.m. Marquis Ballroom Salons A/B, Ninth Floor, Marriott Marquis Ballroom Salon C, Ninth Floor, Marriott Marquis Marquis HOW TO PRACTICE EVIDENCE-BASED MEDICINE MEETING THE CHALLENGE OF ADOLESCENT ADHD Chp.: Donna M. Sudak, M.D.

Chp.: Timothy E. Wilens, M.D. A Introduction to Evidence-Based Medicine Bryce Templeton, M.D. A Functional Outcomes in Adolescents With ADHD Eric Mick, Sc.D. B Review of Basic Statistical Concepts Maju Mathews, M.D. B Diagnostic Issues: The Challenge of Adolescent ADHD Laurence L. Greenhill, M.D. C Critical Appraisal of Randomized Controlled Trials Adedapo B. Williams, M.D. C Comorbidities in Adolescents With ADHD Joseph Biederman, M.D. D Critical Appraisal of Systematic Reviews and Meta-Analysis D Safety and Efficacy of OROS Methylphenidate in Babatunde A. Adetunji, M.D. Adolescents With ADHD THIS SESSION WILL BE AUDIOTAPED. Timothy E. Wilens, M.D.

E Improvements in Adolescents' Driving Performance With OROS Methylphenidate Daniel J. Cox, Ph.D. THIS SESSION WILL BE AUDIOTAPED.

106 2004 ANNUAL MEETING TOPIC AREAS FOR THE SCIENTIFIC PROGRAM

DISORDERS 34. Social and Community Psychiatry 35. Stress 1. AIDS and HIV-Related Disorders 36. Suicide 2. Alcohol and Drug-Related Disorders 37. Violence, Trauma, and Victimization 3. Anxiety Disorders 4. Attention Spectrum Disorders TREATMENTS 5. Cognitive Disorders (Delirium, Dementia, Amnestic, etc.) 6. Dissociative Disorders 38. Behavior and Cognitive Therapies 7. Eating Disorders 39. Combined Pharmacotherapy and Psychotherapy 8. Mental Retardation (Child/Adolescent/Adult) 40. Couple and Family Therapies 9. Mood Disorders 41. Group Therapy 10. Personality Disorders 42. Individual Psychotherapies 11. Schizophrenia and Other Psychotic Disorders 43. Psychopharmacology 12. Sexual and Gender Identity Disorders 44. Other Somatic Therapies 13. Sleep Disorders 45. Treatment Techniques and Outcome Studies 14. Somatoform Disorders OTHER ISSUES PRACTICE AREAS/SETTINGS 46. Computers 15. Psychiatric Administration and Services: Public, 47. Creativity and the Arts Private, and University 48. Gender Issues 49. Health Services Research SUBSPEdALTY AREAS OR SPECIAL INTERESTS 50. Historical Questions 51. Information Technology 16. Addiction Psychiatry 52. Internet 17. Biological Psychiatry and Neuroscience 53. Lesbian/Gay/Bisexual/Transgender Issues 18. Brain Imaging 54. Managed Care and Health Care Funding 19. Child and Adolescent Psychiatry and Disorders 55. Men's Health Issues 20. Consultation-Liaison and Emergency Psychiatry 56. National Institute on Drug Abuse 21. Cross-Cultural and Minority Issues 57. Personal Digital Assistants (PDAs) 22. Diagnostic Issues 58. Political Questions 23. Epidemiology 59. Presidential Theme: Psychotherapy and 24. Ethics and Human Right Psychopharmacology: Dissolving the Mind-Brain 25. Forensic Psychiatry Barrier 26. Genetics 60. Professional and Personal Issues 27. Geriatric Psychiatry 61. Religion, Spirituality, and Psychiatry 28. Neuropsychiatry 62. Resident and Medical Student Concerns 29. Psychiatric Education 63. Stigma/Advocacy 30. Psychiatric Rehabilitation 64. Telepsychiatry 31. Psychoanalysis 65. Virtual Reality 32. Psychoimmunology 66. Women's Health Issues 33. Research Issues

GUIDE TO USING THE TOPIC INDEX

Use this index to find sessions of interest to you. There are five overall topics: Disorders, Practice Areas/Settings, Subspecialty Areas or Special Interests, Treatments, and Other Issues. Under each overall topic, you will find subtopics listed in alphabetical order with the formats (type of session) listed alphabetically underneath. Within each format, you will find the title of the individual session listed by number. The listing will also show the page number the session appears on. You should refer to the page number in this PmgramBook to obtain further details about the session.

107 TOPIC INDEX

DISORDERS Page# Page# 16 Broadening Horizons: Advances in Understanding the Etiology, Effects, and Treatment of Anxiety Disorders 6 TOPIC 1: AIDS AND HIV-RELATED DISORDERS 17 The Hidden Faces of Anxiety 6 43 Emotion Regulation and Plasicity of Underlying Circuitry: Implications for Depression, Anxiety, and Long-Term CLINICAL CASE CONFERENCE Brain Function 66 3 Psychiatric Issues in the Management of Patients With HIV 46 Panic Anxiety: Understanding Its Nature and Nurturing Infection 70 Recovery 66 50 PTSD: Searching for Answers in Traumatic Times, Part 1 69 50 PTSD: Searching for Answers in Traumatic Times, Part 2 93 DISCUSSION GROUP 53 Core Symptom Domains in the Anxiety Disorders 92 (For Residents Only) 9 HIV 20 54 Back to the Future: The Role of Gamma-Aminobutyric Acid in Psychiatric Disorders and Treatment 92 MASTER EDUCATOR CLINICAL CONSULTATION 5 Neuropsychiatric Complications of HTV-I Infection 44 SCIENTIFIC AND CLINICAL REPORTS 5 Carbon Dioxide Test in Respiratory Panic Disorder A SCIENTIFIC AND CLINICAL REPORT Qonazepam Trial 23 50 Evaluation of an HIV Intervention for Psychiatric Care 6 Child Abuse and the Development of PTSD in a Canadian Providers in South Africa 52 Epidemiological Sample 23 29 Early Detection of Relapse in Patients with Panic Disorder With Agoraphobia 50 SYMPOSIA 30 Three-Year Prophylaxis in Panic Disorder: To Continue or 47 What Every Psychiatrist Needs to Know About HI V/AIDS 63 Discontinue? 50 59 What You Need to Know About Treatment of HIV-Related 31 Discontinuation of Medications in Panic Patients 50 Disorders 84 102 Effectiveness of Intensive Residential Treatment of Severe Refractory OCD 98 COMPONENT WORKSHOP 31 Sex, Drugs, and HIV: Synergistic Epidemics 53 SYMPOSIA 18 Evolutionary and Ethological Perspectives on Social Anxiety ISSUE WORKSHOPS Disorder 34 14 Early Trauma, PTSD, and HIV: Association With 108 An Integration of the Pathophysiology and Pharmacotherapy Transmission and Nonadherence 19 for PTSD 104 124 A Comprehensive Approach to the Treatment of Pain in HIV Illness 95 COMPONENT WORKSHOP 15 Update on Practice Guidelines: PTSD and Acute Stress TOPIC 2: ALCOHOL AND DRUG-RELATED Disorder 25 DISORDERS ISSUE WORKSHOPS 111 What Love Has to Do With It: Exploring the Role of Love COURSE in Mental Illness 81 12 Systemic Therapies for Substance Abuse Disorders 3 138 Diverse Cultural Expressions and Interventions for Anxiety and Depressive Disorders 98 SCIENTIFIC AND CLINICAL REPORTS 56 The Effects of State Income Inequality and Alcohol Tax on TOPIC 4: ATTENTION SPECTRUM DISORDERS Alcohol Dependence 77 57 Effect of Age on Long-Term Outcomes of Inpatient Alcoholism Treatment 77 COURSES 58 Topiramate Treatment of Alcohol Dependence: Effects on 2 ADD in Children and Adolescents 1 Psychosocial Functioning and Its Relationship With Heavy 14 ADDinAduks 5 Drinking 77 38 Advanced Assessment and Treatment of ADD 14

SYMPOSIUM DISCUSSION GROUP 54 Anticonvulsants for Treating Multiple Components of 20 Clinical Management of ADHD With Children, Alcohol-Dependence Syndrome 64 Adolescents, and Adults (Meet the Authors) 76

ISSUE WORKSHOP INDUSTRY-SUPPORTED SYMPOSIA 25 Drug Abuse and Mental Health Treatment in Lieu of 4 Adult ADHD: Clinical Utility and Validity 2 Imprisonment 26 18 Targeting Executive Dysfunctions for Treatment 7 38 Conceptualizing and Treating ADHD Adults 39 TOPIC 3: ANXIETY DISORDERS 47 Adult ADHD Diagnosis and Treatment 67

FOCUS LIVE SESSION SCIENTIFIC AND CLINICAL REPORTS 2 PTSD and Anxiety Disorders: Test Your Knowledge 21 35 ADHD Comorbidity in Preschool Children 51 36 Atomoxetine for Comorbid ADHD and Affective Symptoms 51 37 Abuse Liability Assessment of Atomoxetine in a INDUSTRY-SUPPORTED SYMPOSIA Drug-Abusing Population 51 7 Impulsivity: Emerging Clinical Perspectives 3 104 Cognitive-Behavioral Therapy for Residual ADHD in Adults 98 9 GAD: Evidence-Based Considerations From Pathophysiology 105 A Controlled Study of Functional Impairments in 500 to Long-Term Management 4 ADHD Adults 98 14 The Many Faces of Anxiety. Origins, Pathogenesis, and 106 Long-Term Safety and Efficacy of Mixed Amphetamine Salts Management 6 Extended-Release for Aduk ADHD 98

108 TOPIC INDEX

SYMPOSIUM Page # SYMPOSIA Page # 115 Meeting The ChaEenge of Adolescent ADHD 106 36 Eating Disorders 2004: From PETs to Psyche 60 46 Translational Research on Eating Disorders 62 ISSUE WORKSHOP 47 New Technologies for the Assessment of ADHD 47 ISSUE WORKSHOP 127 Treatment-Resistant Patients With Bulimia Nervosa 95 TOPIC 5: COGNITIVE DISORDERS (DELIRIUM, DEMENTIA, AMNESTIC, ETC.) TOPIC 8: MENTAL RETARDATION (CHILD/ADOLESCENT/ADULT) COURSES 74 The Evaluation and Identification of the Major Dementias 55 5 94 Delirium in the General Hospital 82 67 SYMPOSIUM INDUSTRY-SUPPORTED SYMPOSIA 93 Developmental Disabilities From Childhood to Adulthood 100 15 From Pathology to Practice: Evolving Therapeutic Strategies for Alzheimer's Disease 6 25 Novel Intervention Strategies Across the Spectrum of COMPONENT WORKSHOP Dementia: Real Patients and Real Outcomes 11 9 Mission Possible: The Science of Psychiatry and the Art of 32 Current Alzheimer's Disease Treatments and Beyond: Advocacy 18 Advances Impacting Clinical Practice, Part 1 13 32 Current Alzheimer's Disease Treatments and Beyond: TOPIC 9: MOOD DISORDERS Advances Impacting Clinical Practice, Part 2 41 42 Reaching Beyond Alzheimer's Disease With Cholinergic Therapy 40 CONTINUOUS CLINICAL CASE CONFERENCE 2 Two Hospitalized Patients With Refractory Mood Disorder REVIEW OF PSYCHIATRY: SECTION 2 and Cognitive Impairment, Part 1 70 Cognitive-Behavior Therapy 57 2 Two Hospitalized Patients With Refractory Mood Disorder and Cognitive Impairment, Part 2 93 SCIENTIFIC AND CLINICAL REPORT 99 The Role of Dexmedetomidine in Reducing Delirium in COURSE Cardiotomy Patients 98 87 The Neuroendocrinology of Mood Disorders 70

COMPONENT WORKSHOP DISCUSSION GROUPS 46 Is There a Standard of Care for the Treatment of Dementia? 80 4 Dementia and Delirium 15 8 Depression in Alzheimer's and Other Neurologic ISSUE WORKSHOP Conditions: Evaluation and Treatment 20 87 Vascular Dementia: Assessment, Imaging, and Treatment 74 INDUSTRY-SUPPORTED SYMPOSIA 2 Preventive Psychiatry in Mood Disorders: A New Frontier 1 TOPIC 6: DISSOCIATIVE DISORDERS 3 Bipolar Disorder and Alcoholism: Diagnostic Challenges and Therapeutic Interventions 2 SYMPOSIA 5 Towards DSM-V: Phenomenology, Neurobiology, and 73 Dissociative Disorders: Issues of Culture and Issues of Trust 87 Treatment Response in Depression 2 109 Feeling Unreal: A Contemporary Overview of 8 Bipolar Disorder: Improving Outcomes When Theory, Depersonalization Disorder 104 Science, and Clinical Practice Converge 4 11 Interface Between Depression and Medical Illness 4 TOPIC 7: EATING DISORDERS 12 Antidepressant Treatments You May Not Know About, But Should... 5 COURSES 19 The Treacherous Triad for Depression 8 20 Beyond 5HT: New Treatments for Depression 9 22 Therapeutic Interventions in Eating Disorders: Basic Principles 7 23 Unmasking Bipolar Disorder: Overcoming the Barriers to 28 Current Concepts in Child and Adolescent Eating Disorders 8 Treatment Success 9 27 Moderators and Mediators of Antidepressant Response 11 DISCUSSION GROUP 33 Recognizing the Many Faces of Bipolar Disorder, Part 1 13 15 Psychiatric Comorbidity in the Eating Disorders: 33 Recognizing the Many Faces of Bipolar Disorder, Part 2 41 Diagnosis, Treatment, and Research 48 39 Plotting a Course to Remission: Navigating the Intersection of Mind, Brain, and Body 39 INDUSTRY-SUPPORTED SYMPOSIUM 44 Challenges in Treating Bipolar Illness and Comorbid Disorders 66 48 Binge-Eating Disorder: Genes, Treatments, and Consequences 67 45 Does the Pharmacology of Antidepressant Drugs Matter? 66

MASTER EDUCATOR CLINICAL CONSULTATION LECTURE 2 Evaluation and Treatment of Eating Disorders 17 6 The Search for Genes of Bipolar Disorder: From Classical Genetics to Novel Molecular Targets 21 MEDICAL UPDATE 4 How to Shrink Obesity 96 SCIENTIFIC AND CLINICAL REPORTS 20 Duloxetine Versus Placebo in the Prevention of Relapse SCIENTIFIC AND CLINICAL REPORTS of MDD 24 84 DSM-IV Comorbidity in Binge-Eating Disorder 96 21 Response to Antidepressants Is Independent of Gender 24 85 Males at Risk: Hawaiian and Filipino Adolescents 96 22 Depression and BPD During the Immediate Prepartum Period 24 (Continued en nextpag) 109 TOPIC INDEX

Page* SYMPOSIA Page # 32 Brain Bioenergetics and Thyroid Hormone Treatment in 2 Treatment of Maladaptive Personality Traits 30 MOD 50 48 Personality Disorders in the Workplace 63 33 Depressed Outpatients From Primary Care Versus Specialty 53 The Boundaries of BPD 64 Care Settings 50 65 Neuroimaging and Emotional Deregulation in BPD 85 34 Limits to the Treatment of Major Depression 51 71 DSM-V Classification of Personality Disorders: The White 59 Prevalence of Maternal Depression in Honduras 77 Paper and Beyond 87 65 Characteristics of Patients Treated With Gabapentin 81 Personality Disorders: Multiple Perspectives in the Referred to a Bipolar Specialty Clinic 78 Understanding and Treatment of Resistance 89 66 Olanzapine/Fluoxetine Combination: Rapid Onset With 95 Depressive Personality Disorder Versus Dysthymic Disorder 101 Low Risk of Mania 78 100 From Research to Clinical Practices in Treating Patients 67 Psychotic Features in MDD Are Associated With Mania 78 With BPD 102 76 Predictors of Outcome in 52 Cases of Psychotic Nonaffective Disorders 79 ISSUE WORKSHOP 43 Values-Based Treatment of Relational Disorders 47 SYMPOSIA 8 From Response to Recovery: The Consumer and Clinician MEDIA WORKSHOP Collaboration in Depression and Psychosis 31 8 Personality Disorders and the Film, Noir Femme Fatale 96 21 Do Children Benefit When Their Parents With Depression Are Treated Successfully? 35 40 Perinatal Depression: Burden, Neurobiology, and Treatment 61 TOPIC 11: SCHIZOPHRENIA AND OTHER 50 Genetic Correlates in Bipolar Disorders 63 PSYCHOTIC DISORDER 58 Unipolar MDD: International Update 65 62 Treatment-Resistant Depression 84 66 Diagnosing and Managing Aggressive Mood-Dysregulated ADVANCES IN RESEARCH Youth 85 Evidence-Based Treatment in Schizophrenia 20 67 Residual Symptoms in Depression: Recognition and Treatment 86 COURSES 76 Adopting Evidence-Based Practice in the Treatment of 64 Integrated Dual Disorder Treatment: Evidence-Based Practice 43 Mood Disorders: The Canadian Experience 88 77 Assessing Positive and Negative Symptoms in Psychosis 77 Impact of Trauma and Life Stress in Bipolar Disorder With the PANSS 69 90 New Clinical Indications for Light Treatment: Status Report 99 DISCUSSION GROUP ISSUE WORKSHOP 3 What Is the Best Medication for People Suffering From 93 Practical Management of Mood Disorders 74 Schizophrenia? 15 132 Psychiatric Aspects of Treating Primary Caregivers of Hospice Patients 95 FOCUS LIVE SESSION 3 Schizophrenia and Other Psychotic Disorders 28 TOPIC 10: PERSONLITY DISORDERS INDUSTRY-SUPPORTED SYMPOSIA ADVANCES IN RESEARCH 21 Are All Atypical Antipsjchotics Equal for Treatment of Epidemiology and Treatment Implications of Personality Disorders 20 Cognitive and Affective Symptoms in Schizophrenia? 9 24 Recovering From Schizophrenia: How Treatment Can COURSES Improve Outcomes and Prevent Chrorucity 10 19 Personality Disorders: Combining Relational Therapy and 26 Effective Long-Term Management of Schizophrenia: Psychopharmacology 5 Reat World Considerations 11 62 Treating the Self and Interpersonal Problems of Personality 31 New Advances in the Treatment of Psychosis, Part 1 13 Disorder 43 31 New Advances in the Treatment of Psychosis, Part 2 41 86 Psychotherapy of Borderline Personality 70 35 Transcending Efficacy: Effective Treatment of Psychosis Across Disorders, Part 1 13 35 Transcending Efficacy: Effective Treatment of Psychosis DISCUSSION GROUPS Across Disorders, Part 2 41 7 Untying the Gordian Knot: Comorbid Bipolar II Illness 52 Optimizing Antipsychotic Treatment in Patients With and Personality Disorders 20 Schizophrenia and Bipolar Disorder 92 14 Personality Disorders Over Time (Meet the Authors) 48 LECTURE INDUSTRY-SUPPORTED SYMPOSIUM 19 The Rok of Glutamate in the Pathophysiology of 36 BPD: Regulation of Affect and Impulse Control 38 Schizophrenia 71

LECTURE MASTER EDUCATOR CLINICAL CONSULTATIONS 7 Mind, Brain, and Personality Disorders 22 7 Combining and Integrating Medication and Psychotherapy for Schizophrenia and Other Axis 1 Disorders 50 MASTER EDUCATOR CLINICAL CONSULTATION 9 Can the Ordinary Mind Empathize With Psychotic 6 Personality Disorders 49 Experiences? 72

SCIENTIFIC AND CLINICAL REPORTS RESEARCH CONSULTATION 8 Childhood Prevalence of BPD 23 2 Brain Imaging Studies in Schizophrenia 50 9 Apparent Versus Reported Sadness: Correlation With Personality Traits 23 95 The Frequency of DSM-IV Personality Disorders in Psychiatric Outpatients 97 96 Inhibitory Functioning in BPD: An fMRI Study 97 110 TOPIC INDEX

SCIENTIFIC AND CLINICAL REPORTS Page# ISSUE WORKSHOP Page # 11 Do Patients With Schizophrenia Show Periods of Complete 142 Challenging Sleep Problems: Looking at Slow-Wave Sleep 99 Recovery? A 20-Year Follow-Up 23 12 Twenty-Year Outcome in Schizophrenia: What's Sex Got to Do With It? 23 TOPIC 14: SOMATOFORM DISORDERS 13 Recovery From Schizophrenic Psychoses Until Age 35 23 74 ICSOHQ Intercontinental Schizophrenia Outpatient Health CLINICAL CASE CONFERENCE Outcomes Study 79 1 Boundary Issues and the Challenge of the Somatizing Patient 15 75 Male Patients With Schizophrenia Have Impairment in the Processing of Spatial Information From Dissociated Spatial COURSES Reference 79 61 Pain Management for Psychiatrists: An Overview of Frames Treatment Approaches 42 76 The Complexities of Chronic Pain: Psychiatric Issues and SYMPOSIA Treatments 56 13 Neurodevelopment and Schizophrenia: Clinical and Bask Science Perspectives 33 45 Delusional Disorder: A Reconsideration of the Scientific and SYMPOSIUM Conceptual Basis for the DSM Reformulation of Paranoia 62 103 BDD: Is It a Mind, Body, or Sociocukural Problem and 105 Health and Lifestyle of Peopk With Schizophrenia: The How Do You Treat It? 102 View From Scotland 103 ISSUE WORKSHOPS ISSUE WORKSHOPS 21 Chronic Fatigue Syndrome: Disease or Abnormal Illness 10 Can Early Intervention Prevent Psychosis? Management Behavior? 25 of the Prodromal Phase 19 50 Fibromyalagia: Current Understanding and Future Directions 47 40 My Name is Walter James Cross 46 71 Psychogenic Seizures: A Prototype of Somatoform Disorder 54 64 Management of Difficult Schizophrenia 53 70 The Out-of-the-Shadow Project 54 145 Treatment of Recent-Onset Schizophrenia in Community PRACTICE AREAS/SETTINGS and Research Settings 99 TOPIC 15: PSYCHIATRIC ADMINISTRATION AND MEDIA WORKSHOP SERVICES: PUBLIC, PRIVATE, AND 1 DrwmerBoy 20 UNIVERSITY

TOPIC 12: SEXUAL AND GENDERIDENTITY LECTURES DISORDERS 3 The Changing Face of Mental Health Services 16 16 How Many Psychiatrists Do We Need? 56 INDUSTRY-SUPPORTED SYMPOSIUM 22 Public Academic Liaison: Pursuit of Best Practices in a 10 Sex, Sexuality, and 5HT 4 Time of Economic Entrenchment 76

MEDICAL UPDATE SCIENTIFIC AND CLINICAL REPORT 3 Better Sex: Naturally 77 52 Inter-European Countries Comparison on Treatment Use for Mental Health Disorders 52 SYMPOSIA 34 Women's Sexuality Update: Overcoming Obstacles to Pleasure 60 SYMPOSIA 51 Critical Perspectives on Gender Identity Disorder in 38 How to Launch a Successful Private Practice, Part 3 60 Children and Adolescents 64 86 Managing HIPAA-Related Tensions in Clinical Practice 90

ISSUE WORKSHOPS COMPONENT WORKSHOPS 89 The Sissy Duckling: The Perils of Childhood Gender Variance 74 7 State Hospital Psychiatry: Been Down so Long It Looks 98 Understanding and Treating Compulsive Sexual Behavior 75 Like up to Me 18 100 Sexual Satisfaction and Mental Health in Orthodox Jewish 29 Helping District Branches Relate to APA and to Their Women 75 Members 53

TOPIC 13: SLEEP DISORDERS ISSUE WORKSHOPS 19 Psychiatry in the Primary Care Setting: Making It Work for the Psychiatrist 25 COURSES 39 How to Launch a Successful Private Practice, Part 1 46 24 Melatonin and Light Treatment of SAD, Skep, and Other 61 How to Launch a Successful Private Practice, Part 2 53 2 Body Clock Disorders 102 Implementing Psychosocial Treatments in Real-World Settings 75 32 Irresistible Sleep: Narcolepsy Update 14 71 Overview and Update of Sleep Disorders Medicine 55 SUBSPECIALTY AREAS OR SPECIAL INTERESTS INDUSTRY-SUPPORTED SYMPOSIA 28 Beyond Sleep Onset: New Perspectives on the Treatment of Insomnia 11 TOPIC 16: ADDICTION PSYCHIATRY 49 Exploring the True Morbidity of Insomnia 67 COURSES SCIENTIFIC AND CLINICAL REPORTS 85 Office-Based Buprenorphine Treatment of 92 Modafinil Improves Patient Functioning in Shift Work Sleep Opioid-Dependent Patients 70 Disorder 97 96 Street Drugs and Mental Disorders: Overview and Treatment 82 93 Modafinil Treatment of Chronic Shift Work Skep Disorder 97 98 Introduction to Transcranial Magnetic Stimulation (TMS) 93 111 TOPIC INDEX

FORUM Page # SCIENTIFIC AND CLINICAL REPORTS Page # 10 Buprenorphine: What the Clinician Should Know 81 47 Externalizing Behaviors in Preadolescent Children: A National Panel Study 52 INDUSTRY-SUPPORTED SYMPOSIUM 48 Gender and the Prediction of Drug and Alcohol Abuse in 40 Pharmacotherapy of Addictions: From Clinics Into Adolescent Inpatients 52 Office Practice 39 SYMPOSIUM LECTURE 70 Anxiety Disorders in Youth: Clinical and Research Updates 86 23 The Brain In Love 82 COMPONENT WORKSHOPS SYMPOSIUM 19 Approaches to Assessment and Diagnosis of Infants and 56 Alcoholics Anonymous and Spiritually Oriented Recovery 65 Small Children 25 35 The Psychiatrist in the Schools: Medication, Boundaries, and COMPONENT WORKSHOP Transference Issues 72 48 Buprenorphine in the Trenches: What the General 40 New Classification of Psychopathology of Infants and Psychiatrist Needs to Know 80 Young Children 73

ISSUE WORKSHOP ISSUE WORKSHOP 97 Addiction Psychiatry: Science, Craft, and Spirituality 75 58 Cutting-Edge Management of Tourette's Syndrome and Its Comorbidities 48 MEDIA WORKSHOP 2 The Movie Traffic. Hollywood, Teen Substance Abuse, TOPIC 20: CONSULTATION-LIAISON AND and U.S. Drug Poky 20 EMERGENCY PSYCHIATRY

TOPIC 17: BIOLOGICAL PSYCHIATRY AND DISCUSSION GROUPS NEUROSCIENCE 1 The Medical Care for the Chronically Mentally 111: The Role of the Psychiatrist (Meet the A uthors) 15 18 Psychological Engagement During the Consultation Process REVIEW OF PSYCHIATRY: SECTION 3 (Meet the Authors) 71 Developmental Psychobiology 72 LECTURE SCIENTIFIC AND CLINICAL REPORT 17 Feeling and Healing: Biopsychosocial Treatments and Their 103 Hyperactive Error Processing in OCD 98 Effects on Medical Illness 56

SYMPOSIUM MEDICAL UPDATES 14 Current Concepts of the Neurobiology of the Self 33 1 Irritable Bowel Syndrome 22 2 Hepatitis B and G What's New? 50 TOPIC 18: BRAIN IMAGING SCIENTIFIC AND CLINICAL REPORT LECTURE 98 Depression and Nonlinear Heart Rate Dynamics in Older 25 Through the Looking Glass: Uses of Simulation and Virtual Coronary Patients 98 Reality in Clinical Practice and Brain Imaging Research 94 SYMPOSIA REVIEW OF PSYCHIATRY: SECTION 4 32 The Scars of SARS: Its Impacts on Patients, Health Care Brain Stimulation in Psychiatric Treatment 83 Workers, and the Community 59 43 Tragic Events in the Emergency Department: The Role of SCIENTIFIC AND CLINICAL REPORTS Psychiatry and the Institutional Impact 62 68 fMRI of Spatial Working Memory in Schizotypal 107 Psychiatry, Ethics, and End-of-Life Care: New Insights and Personality Disorder 78 Challenges 103 69 Hypof rontality in Patients With Schizophrenia and Bipolar 110 Psychosocial Impact of SARS on Patients, Hospitals, and Disorders: An fMRI Study 78 Health Care Providers 104

SYMPOSIUM COMPONENT WORKSHOP 41 Neuroimaging Seminar 61 22 Blood on the Floor Responding to Catastrophic Events and High Risks 45 ISSUE WORKSHOPS 4 Functional Imaging in Court: Uses and Controversies 19 ISSUE WORKSHOPS 114 Evaluating Treatment With Functional Brain Imaging 81 49 Update on Hepatitis C and Psychiatric Issues 47 96 Innovations in Academic Emergency Psychiatry 75 TOPIC 19: CHILD AND ADOLESCENT PSYCHIATRY AND DISORDERS TOPIC 21: CROSS-CULTURAL AND MINORITY ISSUES ADVANCES IN RESEARCH Treatment of Child Adolescent Anxiety and Depression: CLINICAL CASE CONFERENCE What Have We Learned? 20 2 Assessing and Treating Psychiatric Symptoms in Individuals With Cardiovascular Disease 42 RESEARCH ADVANCES IN MEDICINE Comorbidity of Ps>chiatric and Addictive Disorders in Children 45

112 TOPIC INDEX

COURSES Page # SCIENTIFIC AND CLINICAL REPORTS Page # 16 DSM-IV-TR Cuhural Formuktions: Diagnosis and Therapy 5 38 Effects of 9/11 and Chronic Stress on Female Drinking 92 The Clinical Application of Cultural Psychiatry 82 and Anxiety 51 49 Prevalence and Outcomes of Childhood Adversity in an LECTURE Australian Population 52 20 Latino Youth in the U.S.: Developmental and Mental Health 81 Psychotropic Drug Utilization in Six European Countries 79 Challenges 71 82 Onset of DSM-IV Alcohol Abuse and Dependence: A 10-Year Prospective Study 79 SCIENTIFIC AND CLINICAL REPORTS 94 A Comparison of Seasonality of Mood and Behavior in African and African-American Students 97 24 Ethnic-Matched, Culturally-Competent, Model-Based ACT Team: E arly Outcome Report 24 : 60 Screening for Depression Among Chinese Americans in u M *r n. f-.'TMlCh AND } IVM \N KK,HT> Primary Care Using Two Items 77 61 Suicidal Thinking in Colombian Youth With a History of COURSE Attempted Suicide 77 78 Bioethics Update 2004 69 80 Ethnicity, Diagnosis, and Health Care Utilization in Incarcerated Women 79 DISCUSSION GROUP 16 Ethics in Psychiatric Practice 48 SYMPOSIA 75 Psychiatry, Ethnicity, and Culture: An Update on FOCUS LIVE SESSION Ethnopsychopharmacology, Mood, and Anxiety Disorders in 1 Forensic and Ethical Issues in Psychiatry 16 Minority 88 87 Memory in the U.S. and France: Vive La Difference 91 89 Meeting the Mental Health Needs of Latinos in Community FORUMS and Primary Care 91 2 Ethical Dilemmas in Practice and Research 27 8 Should Sex Be Prevented in Psychiatric Units? Arguments and New Directions 55 COMPONENT WORKSHOPS 12 APA and the Pharmaceutical Industry. An Open Forum 99 1 How to Teach and Leam Cultural Competence in Geriatric Psychiatry 17 MASTER EDUCATOR CLINICAL CONSULTATION 6 Facilitating Research on Minority Populations by Minority 8 Psychiatric Issues and Interventions at the End of Life 72 Researchers 18 10 Bridging Across Culture and Generations: An Asian-American Perspective 18 ROUND TABLE DISCUSSION 23 The Ties That Bind: Considerations of Culture and Family in Coercion and Treatment: Medical, Legal, and Ethical Issues 45 Mental Health Treatment 45 39 Reducing Disparities in Access to Psychiatric Care: APA SCIENTIFIC AND CLINICAL REPORT Perspectives 73 45 How Do Psychiatric Patients Perceive Research Participation? 51 43 Response to the Simon Bolivar Award Lecture on Latino Youth in the U.S.: Developmental and Mental Health SYMPOSIA Challenges 79 16 The Death Penalty: Law and Medical Ethics in the Face of New Court Opinions 34 ISSUE WORKSHOPS 112 Institutional Ethics in Psychiatry: A Multidisciplinary 31 Treating African-American Patients With Psychotherapy. Perspective 105 A Training Dilemma 26 57 It Doesn't Happen to Us: Exploring Trauma and Resiliency COMPONENT WORKSHOPS in Minorities 48 25 Revision of the APA Ethics Annotations: Fostering Dialogue 46 86 Migration and Professional Identity Experience of Organizing 37 APA Ethics Procedures 73 Russian-American Psychiatry 74 44 Psychiatric Ethics in the US. and Throughout the World 80 91 Premarital Counseling: The Facts of Life and More 74 92 Psychotherapy Issues Throughout the Life C)cle in Asian Women 74 ISSUE WORKSHOPS 8 Are There Limits to Boundary Limits? 19 29 Boundary Violation: History, Typology, and Prevention 26 MEDIA WORKSHOP 59 Approaching Moral Issues in Mental Health Treatment 53 3 Cultural Assessment in Clinical Psychiatry: Two Training 95 Guideline Development for the Assessment of Competency 75 Videotapes 48 TOPIC 25: FORENSIC PSYCHIATRY TOPIC 22: DIAGNOSTICISSUES COURSES SYMPOSIUM 35 The Psychiatrist as Expert Witness 14 12 Behavioral Dimensions of Psychiatric Disorders 33 58 The Detection of Malingered Mental Illness 42 80 Insanity Defense Evaluations 69 TOPIC 23: EPIDEMIOLOGY 81 Contemporary Malpractice Liability: A Practical Guide 69 84 Infanticide: A Dialogue Between the Psychiatrist and the Attorney 70 RESEARCH ADVANCES IN MEDICINE Epidemiology of Comorbid Psychiatric and Addictive Disorders 45 FORUMS Depression in Hepatitis C Patients and Interferon Treatment 45 4 Jails or Treatment? Alternatives to Incarceration 27 Research Advances in HIV Care 45 6 Reversing the Criminalization of the Seriously Mentally 111 55

LECTURE 1 Infanticide: The Hope of Prevention and the Promise of Saved Lives 10 113 TOPIC INDEX

SYMPOSIUM Page # TOPIC 28: NEUROPSYCHIATRY 17 The Scientific Basis of Expert Testimony: Its Application to Page# Matrimonial Disputes 34 COURSES 20 Advances in Neuropsychiatry 7 COMPONENT WORKSHOPS 26 Determining Medical Fitness to Drive: Relevant Issues for 13 What's New in Psychiatry and the Law at APA? 24 Psychiatrists 8 17 Fitness to Practice Medicine: The Roles of the Evaluating 42 Traumatic Brain Injury: Neuropsychiatric Assessment 15 Psychiatrist 25 51 Temporal Lobe and Limbic System Anatomy and the 26 The Juvenile Justice System: Assessment, Services, Relation to Psychiatric Illness 28 and Data Use 46 57 The Missing Piece of the Puzzle: Tic Disorders in Adults With OCD or ADD 42 ISSUE WORKSHOPS 66 Updates in Neuropsychiatry: Delirium, Traumatic Brain 9 Brooklyn Mental Health Court: Felony Offenders With Injury, and Post-Stroke Depression 43 Mental Illness 19 100 Neuropsychiatry of Traumatic Brain Injury 93 35 The Clinical Impact of Treating Civil and Qirninally-Mandated Psychiatric Patients 46 INDUSTRY-SUPPORTED SYMPOSIUM 69 Rehabilitating Traumatized Girls in Residential 37 Interferon-Induced Depression: Consequences of Treating Juvenile- Justice Settings 54 Chronic Hepatitis C 38 99 Kendra's Law Becomes Reality: Assisted Outpatient Treatment in Manhattan 75 LECTURE 113 Fitness-for-Duty Evaluations for Law-Enforcement Officers 81 8 Social Neuroscience: A New Basic Science for Psychiatry 28 118 Juvenile-Justice Success Series, Chapter 1: Musicianship, Jazz, and Blues 81 119 Politics and Pregnancy: The Regina McKnight Case 81 MASTER EDUCATOR CLINICAL CONSULTATION 125 Detection of Malingering 95 3 Neuropsychiatry of Stroke: Recent Advances 22 129 Avoiding Dual- Agency Pitfalls of Work-Related Neuropsychiatric Impairments 95 REVIEW OF PSYCHIATRY: SECTION 1 134 Whose Responsibility Is It Anyway? The Treating Neuropsychiatric Assessment 45 Psychiatrist's? 96 141 An Extension of the Analysis of Restorative Justice and SYMPOSIA Therapeutic Jurisprudence 99 57 An Update on Parkinson's Disease and Its Psychiatric Complications 65 TOPIC 26: GENETICS 74 Neuropsychiatry of Traumatic Brain Injury: Current Research 87 111 Traumatic Stress: The Bridge Between Neuroscience and COURSE Psychodynamic Psychiatry 104 9 Psychiatric Genomics: Applications for Clinical Practice 3 COMPONENT WORKSHOPS SCIENTIFIC AND CLINICAL REPORT 21 The Neurobiology of Self-Awareness: Learning From Autism and BPD About How We Know Ourselves 45 71 Prevalence of MTHFR C677T and Mehionine Synthase A2756G Polymorphisms in Major Depression and Impact on Response to Fluoxetine Treatment 78 ISSUE WORKSHOP 65 The Application of Bedside Executive-Function Measures 53 TOPIC 27: GERIATRIC PSYCHIATRY TOPIC 29: PSYCHIATRIC EDUCATION COURSES 45 Depression in Later Life: An Interdisciplinary Approach 27 79 Psychiatric Consultation in Long-Term Care 69 COURSES 5 The Biopsychosocial Formulation: An Approach to Oral Board Presentations 1 MASTER EDUCATOR CLINICAL CONSULTATION 18 Teaching Psychiatry? Let Hollywood Help! 5 12 Psychiatric Disorders in the Elderly 94 21 Evidence-Based Medicine: An Introduction for Psychiatrists 7 47 Dimensions of Psychotherapy Supervision: A Case-Based SCIENTIFIC AND CLINICAL REPORT Approach 27 17 Interpersonal Psychotherapy for Depressed Elders 68 How to Pass the Boards! The Part II Oral Exam 43 With Cognitive Dysfunction 24 97 I Found It at the Movies: Using Film Clips to Understand and Teach Psychiatry 82 SYMPOSIUM 92 Overcoming Barriers to Long-Term Care and Treatment DISCUSSION GROUP of the Elderly 100 6 The Future Structure of Psychiatric Classification and Its Role in Enhancing Therapy, Teaching, and Research 20 COMPONENT WORKSHOP 20 Helping Older Persons With Schizophrenia: Treatment, FORUM Research, and Policy 25 3 ABPN Update: Requirements for ABPN Examination 27

ISSUE WORKSHOPS LECTURE 13 The After-Death Telephone Call to Family Members: Clinical 24 Striking Accord: Tales of Teaching and the Heart 83 Perspectives 19 28 The Transitional Object in Dementia 26 SCIENTIFIC AND CLINICAL REPORT 90 Geriatric Psychiatry Around the Globe: Present and Future 74 100 Psychiatry Training in Primary Care: Factors for a Satisfactory Program 98

114 TOPIC INDEX

SYMPOSIUM Page # RESEARCH CONSULTATION Page # 116 How to Practice Evidence-Based Medicine 106 1 Evaluating Evidence in Clinical Trials and Research Papers 22

COMPONENT WORKSHOPS ISSUE WORKSHOP 27 Wherefore Neuroscience: How Much Does the 18 Psychiatric Research Perspectives in Latin America 20 Psychiatrist Need to Know? 52 49 The Blame and Shame Game in Medical Errors: Do You Want to Play It? 94 TOPIC 34: SOCIAL AND COMMUNITY PSYCHATRY ISSUE WORKSHOPS 66 The Psychiatry Resident as Educator A Proposal for Curriculum and Supervision 54 CONTINUOUS CLINICAL CASE CONFERENCE 73 Problems in the Psychiatric Education of International 1 Helping Patients Counter Demoralization While Living Medical Graduates 54 With a Chronic or Recurrent Psychiatric Illness, Part 1 15 77 Mirror, Mirror on the Wall: Ambition and the Teaching 1 Helping Patients Counter Demoralization While Living Psychiatrist 73 With a Chronic or Recurrent Psychiatric Illness, Part 2 43 88 Medical Training for Psychiatrists: What Do We Need to Know? 74 COURSES 130 Teaching Core Competencies: The Challenge for Academic 60 Disaster Psychiatry: Terrorism, Trauma, and Things to Do 42 Psychiatry 95 82 Psychiatry in Jail 70 133 Psychiatry Training for Primary-Care Physicians: What, How, and When? 96 DISCUSSION GROUPS TOPIC 30: PSYCHIATRIC REHABILITATION 12 Cross-Cultural Psychotherapy 43 13 Public Psychiatry: Leading the Way in Transforming Service Delivery in the 21st Century 43 COURSE 33 Recovery From Mental Illness and Stigma: Integrating FORUM Medicine and Rehabilitation 14 11 9/11 Research: A Review and Reviews 82 SYMPOSIUM 25 Psychiatric Rehabilitation: Integrating Mind and Body Globally 36 LECTURE 10 Language, Psychosis, and the Speciation Event 29 ISSUE WORKSHOP 63 Psychiatric Rehabilitation and Psychodynamics 53 PRESIDENTIAL SYMPOSIUM 3 Reconstructing Postwar Mental Health Services 83 TOPIC 31: PSYCHOANALYSIS SCIENTIFIC AND CLINICAL REPORTS DISCUSSION GROUP 14 A Program for Treating Weight Gain Induced by Atypical 2 Who Should Be Psychoanalyzed? 15 Antipsychotics 23 51 Developing Capacity Within CBOs for Health Education ISSUE WORKSHOP and Outreach 52 38 Initial Psychiatric Interview: A Psychodynamic Approach to 90801 46 SYMPOSIA TOPIC 32: PSCHOIMMUNOLOGY 15 The Development of ADAP: The Adolescent Depression Awareness Program 33 SCIENTIFIC AND CLINICAL REPORT 39 Use of Mandates and Leverage in Community-Based Treatment 61 70 Low Levels of Antibodies to Cardiolipin in First-Episode 114 Providing Psychiatric Services Around the World With a and Chronic Schizophrenia 78 Shortage of Psychiatrists 105 TOPIC 33: RESEARCH ISSUES COMPONENT WORKSHOP COURSES 16 Public Psychiatry: Leading the Way in Transforming Service 1 Assessment and Treatment of Drug-Induced Movement Delivery in the 21st Century 25 Disorders 1 53 Doing Research on a Shoestring Budget 42 ISSUE WORKSHOPS 46 Engaging the Homeless in Treatment Strategies and Results 47 LECTURE 54 A Shared-Ore Model for Treating the Homeless Mentally 111 48 12 Adventures in Psychiatric Research: Neurobiology to 103 Criminal Justice System and Serious Mental Illness, Problems, and Solutions 75 Public Policy 44 108 Sometimes It Is About You: The Use of Self in Engaging and Treating Homeless Individuals 80 NEW RESEARCLw ±JA~lJ. U.XX_AlH. M. h^JMSESSIONi kSf •& ^XJ. ^S WJ 126 Can Social Theory Be Integrated Into the Liberatory Young Investigators' Poster Session 17 Goals of Psychiatry? 95 Young Investigators' Oral/Slide Session 28 j Young Investigators' Oral/Slide Session 28 4 Youngo Investigatorst ' Oral/Slide Session 28 TOPIC 35: STRESS 5 Poster Session 37 6 Poster Session 55 COURSE Poster Session 7 66 52 Child Murder by Parents 28 8 Poster Session 82 9 Poster Session 92 10 Poster Session 99 SYMPOSIA 10 Mental Health Teams: Health Promotion and Preservation in War and Peace 32 64 September 11th: After Two-and-a-Half Years 85 115 TOPIC INDEX

COMPONENT WORKSHOP Page # COMPONENT WORKSHOPS Page# 33 Terrorism in America: The Distant Victims and the Role 3 Public Health and Mental Health Partnership in Terrorism of IMG Psychiatrists 72 and Disasters 17 4 Child Soldiers: Child Victims of War and Terrorism: ISSUE WORKSHOPS Psychosocial and Spiritual Needs 17 42 Infertility: A Chronic Illness With Chronic Challenges 47 11 VA Mental Health's Response to Terrorism 18 18 Terror at Home: Addressing Domestic Violence in Your 131 Keep It Real: Psychological Preparedness and Active-Coping Group 95 Practice 25 41 Consultation and Legal Clarification in Sexual Harassment 73 TOPIC 36: SUCIDE ISSUE WORKSHOPS 1 Disruptive Employees: Feedback-Assisted Counseling and DISCUSSION GROUP Treatment 18 10 Assessing and Managing Suicide Risk Clinically-Based 33 Mental Health Needs of Our Soldiers and Their Families 46 Guidelines for Risk Management (Meet the A uthors) 43 72 Clinical Effects of Sexual Abuse by Catholic Priests: A Forensic Perspective 54 SCIENTIFIC AND CLINICAL REPORTS 76 Children and Families Facing Terrorism, Disasters, and 10 High-Lethality Suicide Attempts in BPD 23 Complex Emergencies 54 62 Suicidality and Second-Generation Antipsychotics in 84 PTSD in the New York Fire Department: Bodies and Minds 74 Patients With Schizophrenia 77 112 Psychiatry and Homeland Security: An Exercise in Weapons 63 Melancholia and Suicide Attempt Probability and Lethality 78 of Mass Destruction Response Planning 81 64 Nonviolent Suicides in Women Are Increased During and 117 Developing a Community Mental Health Response to After High Exposure to Tree Pollen 78 Disasters and Terrorism 81 97 Life Changes, Social Adjustment, and Attempted Suicide 135 Sad Days: A Video of Psychiatric Problems in Afghanistan in BPD and MOD 97 and Its Refugees 96 137 The Stalking Victim: Causes, Consequences, and Therapeutic SYMPOSIA Considerations 96 144 Reactions After 9/11 in a Pretraumatized Community in the 97 Italian Psychiatry: 25 Years of Changes 101 South Bronx 99 101 Meaning in Suicide: Overcoming Barriers and Connecting Diverse Perspectives 102 MEDIA WORKSHOP ISSUE WORKSHOPS 5 Postgenocide Psychological Trauma in Film, The Swrrrer cfA-uya. 75 12 Death by Suicide: The Words of Those Left Behind 19 15 Responding to the Impact of Suicide on Clinicians 19 TREATMENTS 20 No-Suicide Decisions, Contracts, and Assessment of Risk: Values and Cautions 25 115 Suicide and Schizophrenia: A Family Interview 81 TOPIC 38: BEHAVIOR AND COGNITIVE TOPIC 37: VIOLENCE, TRAUMA, AND THERAPIES VICTIMIZATION ADVANCES IN RESEARCH Hippocampal Volume in Major Depression: Effect of Antidepressant COURSES Treatment 20 11 Assessing the Risk of Violence in Both Forensic and Sex Offender Settings 3 COURSES 13 Risk Assessment for Vioknce 5 8 Behavioral Neuroanatomy: An Introduction 3 30 Psychiatric Interventions in Disasters: Lessons From 10 Cognitive Therapy for Severe Mental Disorders 3 Experience 8 15 Engaging Resistant and Hostile Patients Into 93 Men Sexually Abused as Boys: Meanings, Consequences, Participatory Treatment 5 and Treatment 82 23 Basic Hypnosis: Principles and Applications 7 25 Cognitive Therapy for Schizophrenia 8 SCIENTIFIC AND CLINICAL REPORTS 40 Cognitive-Behavior Therapy for Adult and Pediatric OCD: 39 Psychosocial Predictors of Long-Term Resilience Following The Basics 14 the 9/11 Attacks 51 44 Advanced Hypnosis: Applications in Psychiatry 15 40 The Terrorist as a Nonpatient Subject of Psychiatric 89 Introduction to Cognitive-Behavioral Therapy 71 Investigation 51 53 Evaluation of a Therapeutic Interagency Preschool for SCIENTIFIC AND CLINICAL REPORT Traumatized Children 52 101 Self-Administered Versus Therapist-Administered 54 Mental Health in Postwar Afghanistan 52 Cognitive-Behavior Therapy for Medication Nonresponders 55 A Three-Dimensional Model of Violence in Schizophrenia 52 With OCD 98

SYMPOSIA ISSUE WORKSHOP 5 Child Soldiers, Child and Adolescent Victims of War and 36 Using Cognitive Therapy for Psychosis in Psychiatric Practice 46 Terrorism: Biopsychosocial Treatment for Reintegration Into Family and Society 31 TOPIC 39: COMBINED PHARACOOTHERAPY 6 New Directions in Terrorism and Political Violence: Causes AND PSYCHOTHERAPY and Responses 31 11 PTSD in Persons With Serious Mental Illness 32 28 New Perspectives in the Treatment of Complex PTSD 58 COURSES 35 Contemporary Issues in Sport Psychiatry 60 65 A Psychodynamic Approach to Treatment-Refractory 37 Psychiatric Interventions With Medically-Evacuated Soldiers 60 Mood Disorders 43 113 The Effects of Sexual and Physical Abuse on Women's 95 Integrating Psychotherapy and Pharmacotherapy 82 Health 105 116 TOPIC INDEX

SCIENTIFIC AND CLINICAL REPORT Page # Page# 18 Integrating Psychotherapy With Medication to Improve 79 Personality, Therapeutic Alliance, and Outcome in Brief Outcome 24 Psychotherapy 89 102 Individualizing Interpersonal Psychotherapy for SYMPOSIA Mood Disorders 102 9 Recent Advances in the Treatment of Psychiatric Disorders in Primary Care: A U.S./U.K. Perspective 32 COMPONENT WORKSHOP 29 Bipolar Patients: Treatments and Cultural Issues in Latin 2 Can't Work, Shouldn't Work, Mustn't Work: Assessing America 58 Function and Mental Impairment in Psychiatric Illness 17 30 Psychotherapy and Pharmacotherapy Dissolving the Mind-Brain Barrier 58 ISSUE WORKSHOPS 49 Obsessive-Compulsive Spectrum Disorders: Update on 80 Psychodynamic Treatment of Depression 73 Clinical Management 63 128 Leash on life: Human Attachment to Animals 95

ISSUE WORKSHOPS TOPIC 43: PSYCHOPHARMACOLOGY 30 Cognitive Therapy and Pharmacotherapy Teaching Residents Integrated Treatment Methods 26 101 Treatment of Adult ADHD: Combining Cognitive and ADVANCES IN PSYCHOPHARMACOLOGY Medical Approaches 75 An Update for Clinicians 28

TOPIC 40: COUPLE AND FAMILY THERAPIES COURSES 34 Drug Treatment of Schizophrenia 14 63 Psychiatry Update: In Spanish 43 COURSES 90 Med-Psych Drug-Drug Interactions 71 37 Families Coping With Medical Illness: An Integrative Treatment Approach 14 INDUSTRY-SUPPORTED SYMPOSIA 70 Basic Family Skills for an Inpatient Psychiatrist 55 22 Combination Therapy: New Strategies in the Management of Severe Mental Disorders 9 MEDIA WORKSHOP 29 Psychopharmacologyand Reproductive Transitions: Impact 6 The Beginning Stages of Couples'Therapy Video Case Studies 75 of Psychotropic Medications and Sex Hormones on Brain 12 Functioning, Weight, and Reproductive Safety TOPIC 41: GROUP THERAPY 30 Choosing the Right Dose of Atypical Antipsychotics: Art or Science? 12 SYMPOSIUM RESEARCH CONSULTATION 72 Group Therapy in Medical/Psychiatric Care 87 3 Designing and Implementing Studies Contrasting Psycnopharmacology and Psychotherapy 77 ISSUE WORKSHOPS 55 Group Interventions With Adolescents in Outpatient, SCIENTIFIC AND CLINICAL REPORTS Inpatient, and School Settings 48 2 Rivastigmine and Glantamine Treatment of Schizophrenic 121 Group Psychotherapy With Substance Abusers 94 Cognitive Impairment 22 122 Milieu Therapies in the Age of Managed Care, Revisited 95 3 Dosing of Second-Generation Antipsychotics in a Large State Hospital System 22 TOPIC 42: INDIVIDUAL PSCHYTHERAPIES 7 Tiagabine Treatment of Social Anxiety Disorder 23 15 Increased Lipid Levels and Antipsychotic Medication 23 COURSES 16 QTc Prolongation Associated With Ziprasidone 23 4 Interpersonal Psychotherapy 1 28 Buprenorphine: An Effective Treatment for Heroin Addicts 50 17 Interpersonal Psychotherapy 5 41 Antipsychotic Treatment and Sexual Adverse Events: 29 Using Boundary Crossings as Creative Therapy Instead The Role of Prolactin 51 of Slippery Slopes 8 42 Three-Bead Extended-Release Carbamazepine Capsule 43 Davanloo's Intensive Short-Term Dynamic Psychotherapy (SPD417) Continuation: Maintenance Therapy in Bipolar in Clinical Practice 15 Disorder 51 46 Dream Translation: One Empirically-Based Approach 27 43 Parkinsonism in a Nursing Home: Underrecognition 51 49 The Advanced Practice of Psychotherapy 27 44 Concurrent Use of Multiple Antipsychotics in Psychiatric 69 Brief Psychodynamic Psychotherapy The Core Conflictual Inpatients 51 Relationship Theme Method 55 46 Polypharmacy and Its Ramifications in a Chronic Psychiatric Hospital 51 72 Oral S-Adensoyl Methionine (SAMe) for Antidepressant FORUM Augmentation: An Open-Label Trial 78 1 Evidence-Based Psychotherapy 27 73 Somatic Symptoms as Predictors of Time to Onset of Response to Fluoxetine in MDD 78 MASTER EDUCATOR CLINICAL CONSULTATION 4 Finding the Hidden Self: Engaging Difficult Patients SYMPOSIA in Exploratory Psychotherapy 22 19 Beyond B12: An Update on Nutrition and Psychiatry 34 44 Culture, Ethnicity, Race, and Psychopharmacology New SCIENTIFIC AND CLINICAL REPORT Research Perspectives 62 19 Review of Psychotherapy Research Involving a Pill-Placebo 63 Psychotic Depression in 2004: The NIMH Collaborative Control 24 Severe Depression Study 85

SYMPOSIA 33 Interpersonal Psychotherapy. Research Update 59 52 The Art and Science of Brief Therapies 64 69 Supportive Psychotherapy An Update 86 117 TOPIC INDEX

ISSUE WORKSHOPS Page # Page 7 The Benzodiazepine Controversy Revisited 19 # 81 When Usual Treatments Fail: Antipsychotk Strategies for Refractory OTHER ISSUES Schizophrenia 73 104 Innovative Methods of Promoting Use of Evidence-Based Psychopharmacology 80 TOPIC 46: COMPUTERS 107 Negative-Symptom Spectrum Disorders: Response to Pharmacotherapy of Asperger's Disorder 80 ISSUE WORKSHOPS TOPIC 44: OTHER SOMATIC THERAPIES 2 The Office of the Future: Technology in Psychiatry 18 123 Psychiatric Consultation Reports in Minutes: Exploring New Technologies 95 COURSES 3 Using Neurofeedback in Your Practice: Introduction With Hands-On Experience 1 TOPIC 47: CREATIVITY AND THE ARTS 39 ECT Practice Update 14 55 The Way of Yoga and Herbs in the Treatment of Stress, Depression, COURSE and Aggression 42 73 Writing About Clinical Experiences 55

SYMPOSIA FORUM 1 Brain Stimulation: New Treatments for Mood Disorders 30 5 Musk and the Mind: Beethoven 27 82 Clinical Controversies in ECT 89 LECTURE ISSUE WORKSHOP 11 Body and Soul 38 83 Kundalini Yoga Meditation Techniques for Psychiatric Disorders 74 SYMPOSIA 20 Telling Stories: The Psychiatrist as Novelist 35 TOPIC 45: TREATMENT TECHNIQUES AND 83 Toxk Love on Film: Romantic Love, From Normal OUTCOME STUDIES to Pathologk 90

COURSE ISSUE WORKSHOPS 50 Rating Scales: A Bask Overview 27 37 The Theater of Emotions 46 51 The Art of the Unconscious: Shakespeare, Poetry, Film, DISCUSSION GROUP and Psychiatry 47 5 Evidence-Based Psychiatry (Meet the Ambon) 20 60 The Portrayal of Psychiatry in Recent American Film 53 62 Using Art and Poetry: From Medkation Management to Countertransference 53 INDUSTRY-SUPPORTED SYMPOSIA 79 The Portrayal of ECT on Television, Film, and the Internet 73 1 Treatment Resistance: Concepts and Management in Mood and Anxiety Disorders 1 13 Broadening the Horizon of Atypical Antipsychotic MEDIA WORKSHOP Applications 5 7 Robot Stories: Emotional and Ethical Challenges of a 34 Evidence-Based Medicine: The Next Generation, Part 1 13 Technological Age 96 34 Evidence-Based Medicine: The Next Generation, Part 2 41 TOPIC 48: GENDER ISSUES MASTER EDUCATOR CLINICAL CONSULTATION 11 Establishing Relationships, Enhancing Adherence, and COMPONENT WORKSHOPS Improving Outcomes 77 14 Novel Careers in Psychiatry: Women Who Have Made Their Own Way 25 SCIENTIFIC AND CLINICAL REPORTS 47 Bend It Like Beckham Asian Women, Achievements, 4 The Meaning of Response in Acute Schizophrenia 22 and Cultural Conflicts 80 90 Patient Treatment Matching With Ambulatory Cocaine Abusers 97 ISSUE WORKSHOP 22 Career Development for Minority Women Psychiatrists 26 SYMPOSIA 27 Behavioral Activation, Cognitive Therapy, and Medication TOPIC 49: HEALTH SERVICES RESEARCH for Major Depression 57 31 Practice Guidelines, Quality Indicators, and a Practice Research Network: An International View 59 SCIENTIFIC AND CLINICAL REPORTS 23 Treatment Effectiveness and Functional Recovery in ISSUE WORKSHOPS Schizophrenia 24 25 Work Disability and Treatment Access in Psychiatry 24 11 Detoxification of the Opioid-Dependent Chronic-Pain Patient 19 106 Will Outcomes Evaluation and Research Initiatives Save the Therapeutic Community? 80 SYMPOSIUM 146 Evidence-Based Treatment for Schizophrenia in a Correctional 88 Quality of Care for Children: Multiple Perspectives 91 Setting 99 COMPONENT WORKSHOP 28 What Do Employers Want? Employee Mental Hsakh Benefits 52

118 TOPIC INDEX

ISSUE WORKSHOPS Page # Page 116 Ethical and Practkal Challenges in Emergency # Psychiatric Research 81 TOPIC 56: NATIONAL INSTITUTE ON DRUG 136 Program Evaluation Made Simple 96 143 Workplace Burnout in Psychiatrists: Evidence From the ABUSE SPECIAL TRACK United Kingdom 99 LECTURES TOPIC 50: HISTORICAL QUESTIONS 2 Signal Integration in the Brain 16 13 Why Does the Human Brain Become Addicted? 44 15 Anticraving Medication: A New Class of Psychoactive COMPONENT WORKSHOP Medication? 49 12 Whither Our Own History? Debating the Value of the 18 Conceptual and Methodological Flaws in the Evaluation of Study of Psychiatry's Past 24 Addiction Treatment 57 21 Stress and Relapse to Substance Use Disorders 76 TOPIC 51: INFORMATION TECHNOLOGY SCIENTIFIC AND CLINICAL REPORTS LECTURE 26 Challenges in Increasing Access to Buprenorphine Treatment 50 9 I Am a Fact, Not a Fiction 29 27 A Double-Blind, Double-Dummy, Randomized, Prospective, Efficacy Study of the Partial Mu Opiate Agonist Acute Detoxification of Heroin Addicts 77 TOPIC 52: INTERNET 78 Cannabis Use Reduces the Likelihood of Sustained Remission From Other Drugs 79 COURSE 79 Substance-Induced Risk for Depression in a 91 Psychiatry and the Internet 82 Substance-Dependent Population 79 99 Online Communication in Mental Heakh: Different 83 Weight and Relapse to Cocaine and Alcohol Use in Patients Contexts, Different Issues 93 With Eating Disorders 96 86 PRISM-IV: Reliable Diagnosis in Alcohol and Drug Abusers 97 COMPONENT WORKSHOP 87 Cognitive Functioning: Predictors of Outcome in Cocaine- 42 Online Interaction Between APA, Members, and the Public 79 Dependent Patients 97 88 Cocaine Expectancy Questionnaire: Psychometric and ISSUE WORKSHOP Underlying Model 97 89 Psychosocial Therapies for Cocaine Dependence: A 41 Online Video Games: Psychopathological or Psychotherapeutic? 46 Controlled Study 97

SYMPOSIA TOPIC 53: LESSBIAN/GAY/BISEXUAL/ 3 Functional Brain Imaging of Addiction 30 TRANSGENDER ISSUES 4 Treatment of Chronic Pain in Recovering Addicts 30 22 Obesity: Lessons Learned From Addiction 35 COURSE 23 Alcohol, Drug, and Psychiatric Disorders in the U.S.: 48 Gay Men and the Problem of Romantic Love 27 Current Status and Trends 36 24 Genetic and Environmental Factors Contributing to COMPONENT WORKSHOP Vulnerability to Addiction 36 30 The Teaching of Gay, Lesbian, Bisexual, and Transgender 42 Smoking and Comorbid Mental Disorders 61 Issues 53 55 ADHD Subtypes and Subgroups at Risk for Substance Use Disorders 65 MEDIA WORKSHOP 60 Choosing the Best Treatment for Substance Abuse 84 61 Practical Techniques in the Assessment and Treatment 4 When Bays Fly. Club Drugs in the Gay Male Community 48 of Tobacco Dependence 84 80 Consequences and Treatment of Marijuana Abuse 89 TOPIC 54: MANAGED CARE AND HEALTH CARE 84 Moving the Targets: The Neurobiology of Addiction 90 FUNDING 85 Drug Abuse Treatment Issues in Women 90 94 Update on Treatment of Stimulant Abuse 100 COURSE 96 Behavioral Treatments for Drug Dependence 101 36 Current CPT Coding and Documentation Requirements 14 ISSUE WORKSHOPS PRESIDENTIAL SYMPOSIUM 3 E, K, and GHB: The New ABQ of Substance Abuse 18 6 Drug Abuse and Suicidal Behavior 19 2 Wither Go the States: The Impact of Budget Cuts 57 16 Cocaine and Tobacco Use During Pregnancy: Adverse Outcomes in Offspring 20 COMPONENT WORKSHOPS 26 Obtaining Research Funding From NIH: Keys to 24 Universal Health Care and Other Models 45 , Successful Grant Writing 26 34 CPT Coding and Documentation Update 72 27 To Smoke or Not to Smoke: The Dilemmas of Tobacco-Free 45 The 2004 Medicare Update and Making the Most of Addiction Treatments 26 the Carrier Advisory Committee 80 34 The Impact of Migration on Addictive Disorders: A Challenge for the Americas 46 TOPIC 55: MEN'S HEALTH ISSUES 45 Steroid Abuse: Growing Problem for Adolescents and a Hidden Problem for Aduks 47 LECTURE 48 Emerging Pharmacotherapies for Treatment of Stimulant Dependence 47 5 Surviving Jock Culture 21 56 Addiction Research as a Career Choice in Psychiatry 48 74 Drugs and Other Addictions: Does One Size Fit All? 54 75 Stress, Trauma, and Drug Abuse 54 82 Treatment of Patients With Drug Dependence and Psychiatric Illness 73

119 TOPIC INDEX

Page# Page# ' : >-: ••<<..' ,= - !'!• ESONAL DIGITAL ASSISTANTS (PDA; I'C'"'I' .K ''.. i: Kt;. 1 iGION. *•• P H* i T'..;AL11"V.. AND PSYCHIATRY COURSES 56 How to Use Your Palm OS PDA in Psychiatric Practice: Basic 42 COURSE 75 How to Use Your Palm OS PDA in Psychiatric Practice: 72 Meditation for Psychotherapists and the Paradigm of Health 55 Advanced 56 LECTURES 4 Psychiatry and Spirituality. A Holistic Perspective 17 i Tk., ?K; POLITICAL QUESTIONS 14 Dialogue From the Rims of the Grand Canyon: On Bridging the Post-Freudian Chasm Between Religion and COURSE Psychiatry 49 67 Personality and Political Behavior 43 MASTER EDUCATOR CLINICAL CONSULTATION ! 10 Engaging Patients' Spiritual Resources in Building ' •; vr>iC 5 > PRESIDENTIAL THEME: PSYCHO Resilience to Relapse of Major Psychiatric Disorders 76 THERAPY AND PSYCHOPHARMA- COLOGY: DISSOLVING THE MIND- SYMPOSIA BRAIN BARRIER 78 Gay and Lesbian Orthodox Jews: A Primer for Clinicians 104 Model Psychiatry Residency Programs on Religion COURSE and Spirituality 103 83 Helping Parents From the Inside Out: Attachment, Mindsight, and the Brain 70 ISSUE WORKSHOPS 17 Controversies at the Interface Between Religion and DISCUSSION GROUP Psychiatric Practice 20 11 What Can Brain Diseases Teach Us About the 94 Dissolving Therapeutic Barriers: Spirituality Group Mind-Brain Interface? 43 Work With Psychiatric Staff 74 110 The Day I Died: A Near-Death Documentary and the FORUM Mind-Brain Barrier 81 7 Unconscious Prediction, Conscious Monitoring, and 139 Spiritual and Religious Assessment in Clinical Practice 98 Therapeutic Change: Is There a Mind-Brain Barrier? 55 TOPIC 62: RESIDENT AND MEDICAL STUDENT PRESIDENTIAL SYMPOSIUM 1 The Biopsychosocial Model: Myth or Reality? 29 CONCERNS

SYMPOSIA DEBATE 26 Effective Treatment of PTSD: What Works Best for Whom? 37 Resolved: The RRC Should Continue to Require That Psychiatric 99 Mind, Brain, and Interpersonal Experience in Psychotherapy 102 Residency Programs Must Demonstrate That the Residents Have Achieved Competency in Psychodynamic Psychotherapy 15 ISSUE WORKSHOP 109 Multiple Perspectives on the Pathological Fear Response: Integration DISCUSSION GROUPS of Psychotherapeutic and Psychopharmacologk Therapies 81 17 Publishing and Grant Writing (Far Residents Only) 48 19 Patient Safety (Far Residents Only) 71 TOPIC 60: PROFESSIONAL AND PERSONAL ISSUES RESIDENT'S SESSION COURSES Meet the Experts: Sunny-Side Up 14 6 The Conceptual Basis of Psychiatry 31 Improving Your Presentation Skills: A Coaching Approach 41 Money Matters I: Using Theory in Clinical Practice 15 SYMPOSIUM 106 Do Not Wait Until You Practice, Know It Now: What 59 Treating Medical Students and Physicians 42 Residents and Early Psychiatrists Need to Know 88 Money Matters II: Advanced Clinical Practice 70 103

MASTER EDUCATOR CLINICAL CONSULTATION COMPONENT WORKSHOPS 1 Treating One's Students and Colleagues: The Eternal 5 Career Choices in Psychiatry: Exploring Fellowship Training 18 Challenge of Boundaries 17 36 Taking the First Step: What Are My Options in the Transition to Practice? 72 COMPONENT WORKSHOP 38 Dollars: The Pharmaceutical Industry in Psychiatric Training 73 32 Looking Back, Looking Forward: Pathways for Blacks in Psychiatry 53 ISSUE WORKSHOPS 23 What Psychiatry Residents Can Expect From ISSUE WORKSHOPS NIMH-Sponsored Research Training 26 5 Reinventing Careers: Transitions and Later-Life Strategies 44 Oral Boards Boot Camp 47 for Psychiatrists 19 52 The Impact of 9/11 on Psychiatric Residents and Training 24 Treating Physicians: Issues in Diversity 26 Programs 47 32 Risk-Management Issues in Psychiatric Practice 26 53 Implementing the Institute of Medicine Report: Fostering 68 Closing a Psychiatric Practice: Clinical and Risk-Management Research Careers via Residencies 47 Issues 54 78 The Trauma of Medical Mistakes: An Experiential Workshop 73 120 The Horns of a Dilemma: Myths and Realities of Drug-Industry Interaction 94

120 TOPIC INDEX

Page# Page# TOPIC 63: STIGMA/ADVOCAY TOPIC 66: WOMEN'S HEALTH ISSUES

SYMPOSIUM COURSE 7 IRestMyCase 31 7 Management of Psychiatric Disorders in Pregnant and Postpartum Mothers: Overview 5

COMPONENT WORKSHOP INDUSTRY-SUPPORTED SYMPOSIA 8 Leadership Skills for Public Advocacy 18 41 Hormones, Mood, and Cognition: Treatment Considerations in Older Women 39 ISSUE WORKSHOP 51 Bipolar Disorder in Women: Reproductive Implications of 105 When Psychiatrists Have Suffered a Mental Illness: ' Treatment, Part 1 69 Their Stories and Insights 80 51 Bipolar Disorder in Women: Reproductive Implications of Treatment, Part 2 93 TOPIC 64: TELEPSYCHATRY SYMPOSIA 68 Women's Mental Health Revisited: Current Perspectives, COURSE Future Trends 86 54 Expanding Health Care Delivery? Let Telepsychiatry Help! 42 91 Mood Disorders in Women Throughout the Life Cycle 100

TOPIC 65: VITRUAL REALITY ISSUE WORKSHOPS 67 Interface Between Psychiatry and Obstetrics: Comprehensive SCIENTIFIC AND CLINICAL REPORT Perinatal Care 54 91 Virtual Reality Cue-Reactivity-Controlkd Trial for Nicotine 85 Women's Mental Heahh in Times of Turmoil: An International Dependence 97 Perspective 74

ISSUE WORKSHOP 140 Long-Term Care Insurance Denials to One-Time Psychiatric Patients 99

121 P ARTTCTP 4'NfT TNDF X

1 1 A T1 A -I r* T 1 |~T A "\ T;K TT TAT 1. /f T" Y"* ^"TT" 'X T"/"^ 2\JLA \ Ji Al LJ/IS / ' iA 1.. X1 NX i NI \JA £\JLJ I \/iVXJLLJl H H U1 11. liNvj!\j( -,- j

5 Anders, Thomas F 73 Baron, David A 21,49,103 Andersen, Arnold E 60 Barr.A. 30 Abad, Antonio 85 Anderson, Allan A 80 Barr, Heather 45 Abbey, Susan E 87 Anderson, Berry 30 Barratt, Ernest S 3 Abelskov, Kirsten 74 Anderson, Carl M. 47 Barrett, James E 19 Abelson, James L 34 Anderson, Mam 52 Bartels, Stephen J 25 Abi-Dargham, Anissa 11 Anderson, Mary Beth 19 BartkoJohnJ 97 Abidi, Safia C. 60 Anderson, Tanya R 26 Bartlik, Barbara D 60 Ablow.KeithR 35 Andrade, Ana CF 58 Barwell, Michelle M 19 Abou-Allaban, Yousef 20 Andreasen, Nancy G 48,62 fiasco, Monica A. 3, 57 Abraham, Gaby 88 Andrews, Maryann 95 Baskys, Andrius 13 Abraham, Melissa E 77, 81 Anfang, Stuart A. 25 Bass, Judith 59 Abram, Karen M. 32 Angelino, Andrew F 47,56,70 Bassi, Mariano 101 Abramovitz, Robert H. 95 Angermeyer, Mathias C 52 Bateman, Anthony 102 Abramowitz, Jonathan 14,63 Ansari, Rubaba 51 Batki, Steven L 101 Abrams, Karen M. 96 Anscombe, Roderick J 35 Bauer, Michael 18,70 Adamides, Jr., Odysseus 47 Anton, Jr., Raymond F 64 Baxter, Elizabeth A. 80 Adams, MargoS 53 Appelbaum, PaulS 16, 34,48,61, 89,96 Beahrs, Qaudette H. 90 Addis, Michael 58 Apter-Danon, Gisele 24 Beahrs, John 0 90 Adelson, Stewart L 53 Araghiniknam, M 33 Beardslee, William R 35 Aderholt, Sarah L 89 Arambula, Michael R. 46 Beaubrun, Gabrielle F 7 Adetunji, Babatunde A. 106 Arciniegas, David B 87,93 Beck, JudithS 26,64 Adityanjee, A. 6 Armstrong, Scott C 71 Becker, Daniel F 52 Adiutori, Gritstiano 46 Arnow, Bruce A. 39 Becker, Judith V 3 Adlaf, Edward 100 Aronne, Louis J 67 Becker, Mary 86 Adler, Caleb M 88 Arroyo, William 73 Beebe III, John E 96 Adler, Lenard A. 2, 67 Arseneau, Bernard J 96 Beeber, AlanR 15 Agras, W. Stewart 60 Asghar-Ali, Ali A. 94 Begg, Melissa D 33 Agumadu, Charles 0 97 Ashkenazy, Yaacov 23 Beitchman, Joseph H. 100 Aharonovich, Efrat 79, 97 Ashley, Kenneth B 53 Beitman, Bernard D 45, 58, 82 Ahmed, Iqbal 17,94 Asms, Gregory M. 38 Belger, Aysenil 10 Ahrens, Martina 97 Atallah,SherifF 105 Bell, CarlC 46,53,73 Ait-Daoud, Nassima 64,77 Atkinson, Leslie 105 Bell, Michael A. 85 Akerele, Evaristo 0 23 Atkinson, Jr., J. H. 82 Bell, Robinette N. 54 Akhtar, Fatema Z 77 Attia, Evelyn 96 Bellack,AlanS 73 Akhtar, Salman 18, 43 Auchincloss, Elizabeth 22 Benbadis, Selim 54 Akiskal, Hagop S 65 August, Gerald 65 Benca,RuthM 67 Akman, Jeffreys 15,43 Avena, Nicole N 62 Benedek, David M. 25,71 Alarcon, Renato D 18, 47, 79 Aviram, Ron B 86 Benedek, Elissa P 19 Albano, Anne Marie 57, 86 Azarow,Jay. 51 Benson, Timothy G 45 Albert, David B 32 Azorin, Jean-Michel 91 Beresin, Eugene V 17,83 Alda, Martin 63 Bergmans, Yvonne 30 Alexander, Karen 99 5 Bernstein, Carol A 5, 7, 55 Alexander, Mary-Jane 32 Bernstein, David P 30, 63 Alexopoulos, George S 7 Baciu, Monica 78 Berry, Janet 75 Alger.IanE 19,37,46,75 Bacon, Bryan 32 Bezmen, Janet A. 95 Al-Jadiry, Abdul M 83 Badger, Shirlene 104 Bhat,ShyamK 14 Allen, Albert J 51 Baetz, Marilyn D 103 Bialer, Philip A. 84 Allen, Andrea 103 Bailer, Ursula 60 Biederman, Joseph 2,45,85,98,106 Allen, David M. 30 Baker, Dawn 104 Bierut, Laura J 36 Allen, TrinaB 72 Baldassano, Claudia F 12 Biluuma, Oleg 52 Almagor, Gila 75 Balderson, Kenneth E 104 Binder, Renee L 24 Alonsojordi 52,79 Baldessarini, Ross J 79 Birndorf, Catherine A. 60 Alpert, Jonathan E 34, 35,78 Balon, Richard 83 Bisaga, AdamM. 84,97 Altchuler, Steven 1 14,45 Barak, Yoram 71,77 Biscoglio, Regina 89 Alva, Gustavo 40 Barchas, JackD 44 Bishop, Leigh C 53 Alves-Bradford, Jean-Marie E 48 Bardey, A. Sasha 45 Bitzer, Johannes 54 Alzenberg, Dov 77 Bark, Nigel M. 96,105 Black, Donald W. 64 Amen, Daniel G 19,81 Barkin, Evelyn 31 Black, Jed E 11 Amiri, Shahrad Rod 84 Barkley, Russell A. 39 BlackJohnL 3 Anand, Amit 104 Barlow, David 27 Bland, Walter P 17 Ananth, Jambur V 51 Barnes, Donna H 102 Blaustein, Margaret 37

122 PARTICIPANT INDEX

Blehar.Mary 12 Bryson, Susan 60 Casey, David A. 24,50,78,97 Bleiberg, Efram 70,93 Bub, Barry 73 Cash, Charles D 26 Blinder, Barton] 28,48, 58, 81, 82,105 Buchsbaum, Bradley. 78 Cassano, Giovanni B 65 Block, Susan D 72 Buchsbaum, Monte S 78,85 Cassem, Edwin H. 82 Block, Thaddeus S 98 Buckley, Peter F 12,76 Castellanos, F. Xavier 47,65 Blom,MarcB.J.... 59 Budettijan 70 Castellanos, Francisco 39 Bloom, Alan S 89 Budman, Cathy L 48 Castilla-Puentes.RubyC 58,77,105 Bloom, Sandra L 25 Budney, Alan] 89 Castilla-Puentes, Sandra R 77 Blume,SheilaB 37,75,76 Bunt, GregoryC 36,43, 80 Castilk-Puentes, Wilmal 77,105 Blumenfield, Michael 42 Burgoyne, Karl S 19 Celenza, Andrea 26 Boddam, D. Randall 63 Burk, Isabel 20 Cerda, Gabrielle M 35 Bodkin, J. Alexander 105 Burke, AinsleyK 78 Cerfolio, Nina E 100 Bogdanov, Irene 78 Burks, Ginny 35 Chacko, ChowallurD 72 Bogunovic, Olivera J 96 Burmester, Bill 82 Chaitin, Barry F 45 Bonus, Martin 38, 85 Burnett, Paul 104 Chakos, Miranda H. 79 Boksay.IstvanJ.E 100 Burns, AlanaM 78 Chan, Carlyk H. 42 Boland, Robert] 42,90 Burns, Gretchen 26 Chandler, Paula C 62 Bob, Nicholas R 50 BurrussJohnW. 81,94 Chandra, Ravi 96 Bob, Peter M 75 Bursztajn, Harold J 19,75,95 Chang, Jacquelyn B 80 Bolton,Paul 59 Burt, VivienK 8, 39 Chang, KikiD 66 Bongiovi-Garcia, Mary E 95 Busch, Fredric N 73 Chang, Linda 30 Bonnie, Richard 34 Bussing, Regina 91 Chapman, Daniel P 26,79 Bonovitz, Jennifer M 81 Butler, Lisa D 51,87 Chapman, Joab 78 Book, Howard E 8,55 Buttenwieser, Paul A. 35 ChappelJohnN , 70 Boomsma, Dorett 65 Butterfield, Marian 1 34, 35, 55,74, 86,105 Charney, Dennis S 4,6,104 Bordnick, Patricks 97 Butters, Meryl A. 91 Chatoor, Irene 73 Borowich, Abba E 89 Button, Norman 103 Chaudhry, Haroon R. 96 Bottiglieri, Teodoro 78 Butts, Hugh 53 Chaudhry, Zubaida A. 22 Bouchez, Saena 91 Buxton, Martin 32 Chelminski, Iwona 101 Bougerol, Thierry 78 Buysse, Daniel J 67 Chen,Xin-Hua 51 Boutros, Nashaat N 3, 45 Bystritsky, Alexander 32, 86 Chengappa, K.N. Roy 12 Bowden, Charles L 77 Cheong, Josepha A. 28,73 Bowman, Elizabeth S 49 C Chester, Adam R. 72 Boyle, Michael 23 Chester, Janis G 31 Bozzo, Jose R. 58 Cabrejos, Qaudio 0 77 Chew.N. 59 Brady, Kathleen T. 48, 65,76,90 Cagande, Consuelo C 103 Chia, S.E 59 Brandt, Joshua J 97 Caine,EricD 19 Chider, Liisa 52 Bregman, JoelD 100 Cairney.John 52 Chiles, Catherine 1 Breitbart, William 82 Calabrese, Joseph R. 26,75 Chiles, John A 99 Breiter, Hans C. 30, 36 Caldas de Almeida, Jose M 20 Choujames C.Y 43 Bremner, J. Douglas 104 Caley, Charles F 23 Chou, S. Patricia 36 Brendel, David H. 1,105 Caligor, Eve 70 Chow, Wendy 24 Brendel, Rebecca W. 51, 81,105 Calkins, Colby 85 Choy.Yujuan 18,50 Brenner, Ronald 100 Callahan, Jr., William E 46,53,60,61 Chrisman, Allan K 98 Breslau, Naomi 61 Camacho, Alvaro 74 Christensen, Daniel D 11 Bresnahan, Michaeline 33 Cammarata, Claire 74 Christodoulou, George 59 Briggs, Susan D 78 Campbell, Frank R. 102 Chujames A. 58 Brod, Thomas M. 1 CampbellJanL 77 Chung, Christopher K 19 Broitmand, Marina 35 Campbell, William H 1 Ciccone.J. Richard 37 Brook, David W. 76, 87, 94 Campo, Ana E 71, 74, 79 Qechanowski, Paul 32 Brooks, Jeremy 97 Cancro, Robert 36,56 Chrome, Leslie L 22,73 Brown, Alan S 33 Candilis, Philip 46 Claes, Stephan 2 Brown, E. Sherwood 5 Canino.Ian A. 79 Clark, David L 3 Brown, Gregory 19 Canive, Jose M 72 dark, H. Westley 39 Brown, Richard 30 Cannavo Antognini, Francesca 27 Clark, Michael R 56 Brown, Richard A. 62 Cantwell, Roch 103 Clark, Michelle 0 29,53 Brown, Richard P 17,42,73,77 Caplan, Arthur 96 Clarke, David M 87,103 Brown, Jr., Robert S 50 Capuron, Lucile 38 OarkinJohnF 70 Brown, Steven 51 Cardinali, Daniel 98 Classen, Catherine 87 Brown, Thomas E 1, 5,14 Carlezon, William 41 Clayton, Anita L.H. 4,66,105 Brown, Walter A. 13 Carlson, Gabrielle 13 Clemens, Norman A 52 Bruce, William 79 Carpenter, Linda L 6,9 Qoitre, Marylene 37 Bruck, Elena 89 Carrasquillo, Olveen 91 Qoninger, C Robert 62 Brugha, Tery 52 Carroll, Melissa 85 Qougherty, Kathleen 59 Brunette, Mary F 43 Carter, Diana 3 Coccaro.EmilF 33,38,87 Bryant, Karl E 64 Carty, Patricia 32 Cochet, Barbara 91 Bryskin, Lawrence 74 Case, Michael 78 Coello, Miguel 77 Bryson, Heather 79 Casey, BJ 72 Coffey, C Edward 7

123 PARTICIPANT INDEX

Coffman, Jennifer K 57 D Dube, Sanjay. 78 Cohen, Amy. 80 Dubin, William R 75,89 Cohen, Bruce ML 13,41,61 Dargani, Narender. 79 Dubois, Michel 56 Cohen, Carl 1 25,95,98 Das, Amarendra 91 Dubowski, Sandi 88 Cohen, Lee S 39,69,93 Datta, Moitri N. 46 Duckworth, Sarah 31 Cohen, Mary Ann 19,53 David, Anthony S 104 Duffy, FariftehF 24,59 Cohen, Michael 1 David, Panakkal 32 Dufour.MaryC 36 Cohen, Neal L 85 Davidoff, Donald A. 27 Dunayevich, Eduardo 43 Cohen, Patricia R 35 Davidson, Jonathan RT. 21,35,67,69,93 Dunlop, Boadie W. 2 Coiro, Maryjo 35 Davis, Jack 28 Dunner, David L 58 Colantuoni, Carlo 62 Davis, Lori L 66,104 Duque, Luis 31 Coleman,Eli 75 Davis, Mary H. 18 Durfee, Sandra 33 Collins, Eric D 49 Davis, Robert M. 77 Duros, Christopher C 74 Collins, Gary R 75 Dawson, David L 20,46 Dvorak, Ramona 27 Collins, Pamela Y. 52 Dawson, Deborah A. 36 Dwyer, R Gregg 46 Colliver, James 36 DeBattista, Charles 2,7,70 Colosimo, Lisa 46 De Chiara, Margherita 50 E Combrinck-Graham, Lee 18 de Contreras, GilmaP 77 Combrinck- Hertz, Mark 18 De Crisce, Dean M. 19 Eagles, John 103 Comptonlll, Wilson 36,73 De Girolamo, Giovanni 79,101 Ebert, Michael H 27 Conley, Robert R 15,73 Deitch, David 26 Ecklund, James M. 88 Connolly, Moira A. 103 de Kloet, Ronald 30 Edenberg, Howard 36 Connor, Kathryn M. 34 DelBello, Melissa P 5,88,92 Edman, Jeanne 96 Contreras, Virginia 98 DeLeon, George 80 Egan- Stack, Denise 98 Cooke.Edi 95 Delgado, Pedro L 39,43 EisenJaneL 63 Copans, Stuart A. 53 D'Emic, Matthew 19,27 Eisner, Lori R 78 Coplan, Jeremy D 6 DePaulo, Jr., J.Raymond 34,63 Eist, Harold 1 31,90 Copp, Hilary 97 Desai,AbhilashK 69 Ekman,Paul 95 Corcoran, Cheryl M 87 Desai, Prakash N. 7 Elbogen, Eric B 61 Cordes, Jeffrey A. 53 Desjardins, Juliette C 51 Elferink, Andre JA 24 Cornelius, Tlior J 18 DeSouza, Cherilyn 78 Elhaj, Omar 26,75 Corrado, Filomena 50 Detke, Michael J 24 Elliot, Diane L 47 Corral, Maria R 3 Deutschman, Daniel A. 18 Ellisjames W. 34 Correak, Jennifer 75 DeVane, C Lindsay 28 Ellis, Meiling K 50 Corya,SaraA 78 Devins, Gerald 59 Ellison, James M. 27 Cott, Jerry M 34 Devlin, Charles 80 Elmouchtari, Abdelouahed 3 Cottier, Linda 54 Devlin, Michael J 62,63 Endo, Takuro 100 Cournos, Francine 23, 52, 63, 80 Devouche, Emmanuel 24 Engeriser, Jason L 32 Courtois, Christine 58 Dewan, MantoshJ 18,42,64 England, Mary Jane 24 Cowan, Ronald L 48 Dewey, Stephen L 47 English, Judith 85 Cowley, DeborahS 29 deZwaan, Martina 60 Engstrom, Frederick W. 82 Cox, Daniel J 106 Diamond, Dickson S 81 Enns, Murray W. 99 Cox,ToddS .'....33,34 Diamond, Guy 35 Epstein, Steven A 24 Coyle, Jr., Joseph T. 71 Dickens, Pamela A 105 Erman, Milton K 97 Cozza, Kelly L 71 Dickstein, Leah J 42,73,80,86 Ernst, Carrie L 45,52 Cozza, Stephen J 60 Didemente, Carlo C 77 Escobar, Franklin 58 Cozzolino, Edoardo 50 di Cori, Ferruccio A. 46 Escobar, Javier 1 20,43 Crady.Meg 81 Diefenbach, Gretchen 98 Eth, Spencer 73,80 Craske, Michelle G 32 DiezRoux, Ana 77 Euler, Dillon C 80 Crisanti, Annette 87 DiGiacomo, Joseph 89 Evans, Dwight L. 4 Qone, Catherine C 15, 56,98 Dimidjian, Sona A. 58 Evans, Suzette M. 84 Crosby, Ross D 60 Dinges, David F 97 Evdokas, Andreas 99 Cross, C Deborah 95 Ditkowsky, Keith 57 Everett, Anka S 45 Crossett, Judith H. W. 69 Dizmang, Larry H. 99 Crow, Scott J 60 Dobson, KeithS 58 F Crow, Timothy J 29 Doghramji, Karl 55,69,97 Crowe, Raymond R 36 Dolgoff, Robert K 100 Faber, Raymond A 55 Cruz, Mario 96 Donovan, Gerald F 97 Fabio, Anthony 23 CryanowskiJillM. 102 Doraiswamy, P. Murali 11,41 Faedda, Gianni L 47 Csernansky, John G 33 Dossenbach, Martin 79 Fahrer, Rodolfo D 20,98 Cummings, Jeffrey L 7,13,65 Douaihy, Antoine B 84 Faison, Warachal E 6,17,62 Cutler, Winnifred B 60 Drake, Robert E 10,43 Fakra,Eric 91 Cyranowski, Jill M. 59 Drescherjack. 88 Fals-Stewart, WilliamS 101 Czeisler, Charles A. 97 Drury, Laura 55 Faraone, Stephen V 36,39, 85,98 Czobor.Pal 52 Dryden-Edwards, Roxanne C 47,100 Paries, Douglas E 51 Drye, Robert C 25 Farlow, Martin K 40 Dsouza, Cyril 104 Farrell, Colleen 98 Duan, Naihua 91 Farrington, Susan 103

124 PARTICIPANT INDEX

Fatemi, S. Hossein 33 Friend, Jeffrey M. 51 Glatt, Stephen 36 Faulkner, Larry R 27 Frierson, Richard L 46 Gleason, Peter C 99 Faull, Robert 23 Fromson, John A. 25 Click, Ira D 24,50,63,99 Fava, Maurizio 2,34, 50,66,77,78 Frye.MarkA 2,66,70 Glueck,DehraA 95 Fawcettjan 58 Fullerton, Carol 31 Gnagy, Elizabeth M 65 Feder, Adriana 91 Goate, Alison 36 Feijo, Marcelo 58 G Goekoop, Jaap G 30 Feinberg, Todd E 33 GoelNamni 100 Fendrich, Michael 51 Gabbard, Glen O. 22,29, 38,45 Goethe, John W. 23,51 Fenton, Andre 79 Gabriele, Michelle 85 Goetz, Raymond 33, 87 Fenton, Wayne S 23,47 Gaby, Lynne M 15,43 Gogineni, R. Rao 89 Ferguson, Yvonne B 7 Gaebel, Wolfgang 59 Coin, Marcia Kraft 7,10,14,22,29, Fernandez, Francisco 44,54 Gaiser, Georgia 74 37,55,67,83,102 Fernandez, Hubert H 51 Galanter, Marc 3,65,75,80 Gois man, Robert M. 71 Ferrando, Stephen] 63 Galchen, Rivka R. 79 Gold,LizaH 7 Ferrell, Richard B 87 Galea,Sandro 59,82 Gold, Philip W. 4 Ferrer, Mirtha 97 Galeno, Roxana 58 Gold, Wayne L 59 Fichtner, Christopher G 23 Galfalvy, Hanga G 78 Goldberg, David A 73 Findling, Robert L 13,26 Gallant, Joel 45 Goldberg, Ivan K 93 Fine,Carla 19,102 Gallardo.KathyA 72 Goldberg, Jeffrey. 54 Fioritti, Angelo 101 Gameroff, Marc J 91 Goldberg, Joseph F 2,4,23,63,88 Fireman, Marian 80 Gara, Michael 91 Goldberg, Linn 47 First, Michael B 5,87 Garber, Judy 35 Goldberg, Pablo 38 Fischbein, Ellen R 26 Garland, David W. 73 Goldberg, Susan 105 Fisher, HelenE 4,82 Garno, Jessica L 88 Goldbloom, David S 104 Fisler, Carol 19,45 Garrett, Michael D 29,72 Golden, Robert N. 4,50 Fhzpatrick, Thomas M 60 Garvan, Cynthia 91 Goldfarb,LisaM 97 Flaherty, Joseph A. 51 Garver, David L 22 Goldfinger, Stephen M. 27,54,77,99 Flashman, Laura 87 Gasic, Gregory P 30, 36 Goldman, Charles R. 99 Fleming, Candace M 5 Gasquet, Isabella 79 Goldman, Morris B 14 Flint, Alastair J 85 Gastfriend, David R. 96,100 Goldman-Rakic, Patricia S 33 Flynn, Cynthia 35 Gaviria, F. Moises 74 Goldner, Elliot M 88 Flynn, Heather A 61 Gaw, Albert C 18,26,74 Goldstein, Marion 2 86 Foa,EdnaB 1,64,93 Gaynes, Bradley N 50 Goldstein, Mark A 78 Folsom, David P 53 Gaytan, Jr., Osvaldo 45 Goldston, David B 19 Fones, Calvin 59,104 Gazely, Sharon 48 Gomez, Ivan S 77 Ford, Elizabeth B 55 Geary, Nori 62 Gonzales, Lizza G 33,34 Foroud, Tatiana 36 Geldmacher, David 11 Gonzalez, Gerado 39 Forstein, Marshall 55,63, 84 Gelernterjoel 67,87 Gonzalez-Heydrich, Joseph M. 86 Forsten, Robert D 32 Gelfand, Yevgeny. 79 Good, Candace R. 78 Fosha, Diana 102 Gelinas.DeniseJ 58 Goodhue, Angelique D 72 Fouilhoux, Natacha 91 GellerJeffreyL 18,25 Goodwin, Ericka L 18 Foulds, Jonathan 84 Gellerman, David M. 18 Gopal,Murali 72 Foulks, Edward F 54,73 GendeL Michael H 25,65 Gordon, Edward 72, 80 Fouwels, Annemarie 24 George, MarkS 7,30 Gordy, TracyR 14,46,53,72 Fowler, Joanna S 35 Gerard, Adriel 60 Goreiick, David A 100 Fox, Lindy 43 Gerbarg, Patricia L 42 Gorman, Bernard S 89 Fox, Michelle 32 Gerson, Jessica 86 Gorman, Jack M. 9,19,77,92 Fradkin, Howard 82 Gertzjohn 100 Gorman, Linda 95 Frances, Richard J 75 Getter, Elizabeth V 53 Gottlieb, Diane B 54 Frank, Ellen 1,59,102 Getz, Glen 45 Gotway-Crawford, Carol 52 Frank, Guido K.W. 60 Ghaemi, S. Nassir 1,9, 46, 66 Gou, Shenyang 50 FrankJuliaB 15,43,86 Ghafoori, Bita 81 Gould, Elizabeth 66 Frankenburg, Frances R. 64, 102 Ghalib.KareemD 95 Graap, Ken 97 Frankle, W. Gordon 85 Gharabawi, Georges 85 Grabowski, John 101 Frascella, Joseph 35 Ghinassi, Frank A- 96 Grabsch, Brenda 87 Frazier, Jean A. 61 Ghodse, A Hamid 105 Grace, Sherry 104 Frazier, Shervert H 31 Gianoli-Valente, Marina 24 Gracious, Barbara L 12 Frederick, Struve 45 Giese-Davis, Janine 87 Grady-Weliky, Tana A 18,96 Freedman, Alfred M 34 Gil, Roberto 87 Graignic-Phillippe, Rozenn 24 Freemantle, Nick 13 Gilaberte, Inmaculada 24 Granacher, Jr., Robert P 15 French, Louis M 88 Gillespie.IanA 8 Grant, Bridget F 36 Freyd, Jennifer J 58 Gillett, Kevin 89 Grant, Jon E 63 Fried, Peter A. 89 Ginter, Waker 39 Grant, Steven J 54 Friedman, Edward S 26 Gise, Leslie H 87,100 Grasso, Benjamin C 94 Friedman, Joseph 51 Gissinger, Rabbi Shlomo 74 Gravenstein, Stefan 33 Friedman, Matthew J 18,25,60 Gitlin, Michael J 88 Gray, GregoryE 7,20 Friedman, Michelle E 75 Gittelman, Martin 105 Gray, Kevin F 55

125 PARTICIPANT INDEX

Greden, JohnF 8,20,47, 61 Hanin, Edward 19 Ho, Travis 87 Green, Melval 25 Haning III, William F 32 HobfolL Stevan 31 Greenberg, Benjamin D 83 Harm, Delia M. 26 Hodge, Andrew 79 Greenberg, Harvey R 90 Hannan, Scott 98 Hodo, David W. 26,100 Greenberg, Roger P 64 Hansen, MarkR 14 HoebeLBartleyG 62 Greenberg, Steven 89 Hanson, Graeme 25 Hoen, Cynthia N... 75 Greene, Ross W. 86 Harding, Richard K 73 Hoencamp, Erik 59 Greenfield, Shelly F 57 Harding IV, George T. 49 Hofecker-Fallahp, Maria F 54 Greengard, Paul 16 Harkavy- Friedman, Jill 87 Hofer, Myron 72 Greenhill, Laurence L 106 Harlan, William 12 Hoffer, Axel 26 Greenleaf, Marcia 7,15 Harlap, Susan 33 Hoffman, Ralph E 83 GreistJohnH. 4 Harmon, Larry 18 Hoffman, Rosalind G 19 Griffith, Ezra E.H. 34 Harper, Thomasetta 45 Hoffman-Rieken, Kristina 8 Griffith, James L 15,43,76,98 Harrison-Ross, Phyllis 29 Hogan, Michael F 18,57 Grilo, Carlos M 52,96 Harrow, Martin 23 Holland, Scott 88 Grimaldi, Jr., John AR. 53 Hartman, David E 95 Hollander, Annette J 73 Gross, Raz 91 Harty.Seth 65 Hollander, Eric 3,63,75,92,103 Grossberg, George T. 69 Harvey, Philip D 25 Hollon, Steven D 57,58 Grossman, Linda S 23, 51 Hasin, Deborah S 36,77,79,97 Holmes, William 82 Grote, NancyK 102 Hassoun, Youssef 63 Hooky, JillM 85 Gruber, Staci A 85 Hatti, Shivkumar 103 Hopkins, GeoffreyM 73,98 Grunebaum, Henry 87 Hawryluck, Laura 59 Hopper, Elise 37 Grunebaum, Michael F 78 Hayes, Rosalind 17,31 Hopper, James 37 Grunhaus, Leon J 93 Heck, Jeffrey 77 Horton, Leslie A. 77 Guardino, MaryT. 50 Heckers, Stephan H. 13,41,61 Horton, Richard 70 Guerin, Denette 85 Heimberg, Rkhard G 34 Horwood, Jeremy 23 Guerrero, Angela L 17 Heinze, Gerardo 20 Hossain, Akhtar 98 Guglielmino, Livia 50 Heister, Tagalie 95 Howe, Edmund G 69 Guillem,Eric 91 Hellerstein, David J 27,35,86,101 Howland, Robert H. 85 Guinjoan, Salvador M. 98 Henderson, Claire 77 Hsiung, Robert C 18,42,79,93 Gulick, RoyM 63 Henderson, David C 88 Hu,Rona 7 Gunatilake , Sarath 51 Henderson, Shanta P 45 Huang, William 46 Gunderson, Erik W. 81 Hendin, Herbert 104 Hudson, James 1 67 Gunderson, John G 64,102 Hendrie, HughC 74 Hudziak, James J 65 Gupta, Dipak 31 Hennenjohn 64,79 Hughes, Carrol 35 Guralnik, Orna 104 Henry, Michael E 61 Hughes, JohnR 61 Guschwan, Marianne T. 16, 80 Heo, MoonSeong 85 Hughes, Maryfran 62 Gutheil, Thomas G .....26 Herbener, Ellen S 23 Hulburt, Michael 91 Gutman, David A. 51 Herbert, Sarah E 64 Hunter, Edward N 78 Guyker, Wendy M 77 Herman, John B 62,73 Hunter, Elaine 104 Gwynette, Frampton 95 Herman, Judith 32,58 Hunter, Jonathan J 104 Hermann, Richard C 80 Huprich, Steven 101 H Hernandez, Ibet 99 Hurwitz, Thomas D 55 Herpertz, Sabine 97 Hussain, Mohammad Z 22 Habeych, Miguel 77 Herrell, Richard 78 Hutton,HeidiE 19,70 Haffmans, Judith 59 Herrick, Jason P 79 Hwang, Michael Y. 53 Hafliger, Silvia 39, 50 Hersh, Richard G 69 Hyde, James 103 Hagan, MaryM 62 Hershberger, Jason E 52 Hyler, Steven E 5,20,42 HajaLFady 48 Hershenfield, Karen 104 Hymowitz, Paul 34 Hales, Deborah J 16,21,28 Hershko, Ruth 78 Hynes, Charles J 27 Hales, Robert E 13,41 Heru, Alison M 55 Hall, Heather M. 74 Herzog, Alfred 93 I Hall, Lacresha L 48 Herzog, David B 60 Hall, Laura Lee 57 Hess, SaUyG 33, 34 Inderbitzin, Lawrence B 19 Hall, Sandra B 77 Hicklin, Thomas A. 32 Insel, Thomas R 28 Halliday, Jennifer 103 Hicks, Daniel W. 50,78 losifescu, Dan V 50,66,78 Halmi, Katherine A. 7,60 Hicks, MadelynH. 80 Irigoyen-Rascon, Fructuoso R 72 Halper, James P 47 Heble, J. Paul 42 Isay, Richard A. 27 Halperin, Jeffrey 65 Hen, Denise 90 Ishak,WaguihW. 1,95 Halpern, Abraham L 99 Herholzer, Robert W. 81 Isohanni, MattiK 23 Hamblen, Jessica 32 Hgginsjr., NapoleonB 48,72 Hameedi, Faiq 53 Hll,DarrylB 64 J Hamid, Hamada 28 Hinrichs, Anthony 36 Hamilton, Catherine 104 Hiott, David W. 103 Jabbarpour, Yad M 18 Hamilton, N. Gregory 104 Hire, Richard 0 53 Jackson, Lucille 19 Hamilton, Tom 55 Hirsch,AlanR 95 Jackson, Michael A. 97 Hamner, Mark B 5 Hrschfeld, Robert MA. 9 Jackson-Siegel, Jeanne 41 Hanford, Russ 35 Hrshberg, Laurence 1 Jacobs, Douglas G 77

126 PARTICIPANT INDEX

Jaffe, Adam J 97 Katsnelson, Nelly 74 Klein, Diane A 63 Jaffe, AriB 22 Katz, Craig L 82,85 Klein, EhudM 93 Jaffe, Ellen 80 Katz, Debra A 95 Klein, Rachel G 65 Jaffe, Richard L 14 Katz, Jon 95 Klevins.LF 31 Jain, Vivek 14 Katzav, Aviva 78 Klibanski, Anne 60 James, Regina S 47 KaurKhalsa,HariM 79 Klimstra, Sibel 85 James, William A. 52 Kayjerald 82 Klinkman, Michael 50 Jamison, Kay R 80 Kaye.WalterH 6,60 Kloss, Raymond J 56 Janicak, Philip G 14 Keairns, Yvonne 31 Knapp, Penelope 91 Jankowski, Kay 32 Keck, Jr., Paul E 4,31,78 Knegtering, Rikus 51 Jasinsky, Donald R. 51 Keefe, Frank 4 Knight-Richardson, Norwood 83 Javors, Martin A , 77 Keefe, Richard S.E 10 Knobler, Haim 77 Jayaram, Geetha ....6,10,17,20,45,71, 80,94,99 Keenan, Julian P 33 Knox, Patricia C 50 Jenike, Michael A. 98 Kehayan, V. Alex 42 Knutelska, Margaret 104 Jennings, Constance A. 103 Keisling, Robert W. 15,43 Ko.S.M. 59 Jensen, John E 50 Keitner, Gabor 1 51 Kocsis, James H 60 Jermyn, Richard T. 95 Keller, Martin B 6, 84 Koen, Lisa 26 Jeste, Dilip V 13,74 Keller, Richard T 81 Koenigsberg, Harold W. 78, 85 Jibson, Michael D 73 Kelley,AnnE 35 Koeppe, Robert 85 Jimerson, David C 7, 63 Kellner, Charles H 14,90 Kogan, Richard 27 Jobe, Thomas H 23 Kelly, Bernice 81 Koh, David 59 Jobson, Kenneth 0 80 Kelly, Brian J 103,104 Kohlenberg, Robert J 58 Joffe.Hadine 39,40,93 Kelly, Ciara 103 Kohn-Trattner, Amira 75 Johnson, Bankole A. 2, 64, 77 Kelly, David 19 Kolodner, George F 80 Johnson, Barbara A 96 Kelly, Kevin V 74 Kolzet, Julie 60 Johnson, Bradley R 3 Kelly, Robert 23, 51, 77,98 Komarow, Hirsh 78 Johnson, Brian 19 Kelly, Thomas M 23,97 Koob, George F 61,90 Jones, Billy E 26 Kendrick, Anthony 32 Koopman, Cheryl 51, 87 Jones, Hendree 90 Kenna, George 64 Kopala, Lili 9 Jones, Kristina L.N 53, 74 Kennedy, Robert S 82 Koplin, Brett A 3 Jones, Peter B 23 Kennedy, Sidney H 59,88 Koponen, Hannu J 23 Jones, Ronald A 28 Kent, Andrew 105 Korczyn, Amos 40 Jonker, Kosse 59 Kent, Justine M 34,92 Komer, Judith 96 Jorgenson, Linda M 8,19 Kernberg, Otto F 70,102 Kornstein, Susan G 11 Josephson, Allan M 20,103 Keshavan, Matched S 50 Korts.Russel 13 Joshi, Kaustubh G 53 Kesskr, Ronald C 2,4 Kosel,Markus 83 Joshi, Paramjit 34 Kestenbaum, Clarice J 19,42 Koskinen, Johanna 23 Joy, Charles R. 47, 53 Ketter, Terence A 51 Koskoff, Harriett 48 Judd, Lewis L 21, 65 Kettl,PaulA 81 Kossoy, Amy 60 Judge, Rajinder A. 5 Khadivi, Ali 46 Kosten, Thomas R 19, 39, 50,70 Judge, Sheik 15 Khalsajag 30,89 Kosza, Ida 36 Jurchak, Martha 53 Khan, Arifulla 13 Kotov, Kimberly 86 Juthani, Nalini V 20, 26, 37, 54, 74, 98 Khan, Mahrukh S 75 Kotwal, Renu 3 Khan, Neelofar 77 Koutsemok, Igor 26 Khan, ShirinRF 13 Kovasznay, Beatrice M 18 K Khandehval, Madhulika S 80 Kovess, Viviane 52 Kahn, Jeffrey P 52 Khemlani-Patel, Sony 102 Koyanagi, Chris 57 Kalali,AmirH 51 Kibel, Howard D 95 Kozel, Andrew F 30 Kalin,NedH 66 Kiehl,KentA 98 Kraemer, Helena C 51, 60 Kalivas, Peter W. 90 Kietrys, David M 95 Krahn,LoisE 14,99 Kaltenbach, Karol A 90 Kilpatrick, Dean 54 Krain, AmyL 57, 86 Kalunian, Douglas A 80 Kim, Edward 53,75 Krakowski, Menahem 1 52 Kamara, Taafoi S 85 Kim, Florence 45,70,93 Kramer, Laura Kean 78 Kamm, Ronald L 21,60 Kim, Kathleen M 26 Kramer, Milton 27,47, 54 Kampman, Kyle M 47 Kim, Scott Y 46 Kramer, Peter D 35 Kane, John M 11 King, Bryan H. 18,100 Kramer, Thomas AM 82 Kang, Gurmit Shimi 100 King, Cheryl 35 Krefetz, David G 95 Kantor.RuthB 99 King, Dana 103 Krejci, Jonathan 84 Kaplan, Ana 43 King, LindaP 90 Kremen, William 36 Kaplan, Gabriel 43 Kingdon, David G 8,46, 57 Kriger.PaulF 42 Kaplan, Sandra J 54 Kinzie, J.David 82 Kring, Brunhild 54 Kapral,Moira 59 Kirwin,PaulD ..1 Kripke, Daniel F 100 Kapur, Shitij 3,12 Kissane, David W. 87,103 Krishnan, K. Ranga R 9,13,28,41 Karasu, T. Byram 27 Kiyabu, Dana 87 Kroenke, Kurt 8 Kastelic, Elizabeth A 33,34 Klagsbrun, Samuel C 27 Krueger, Lynnette 42 Kataoka, Sheryl H 91 Kleber, Herbert D 48, 81, 84 Krueger, Robert F 87 Kathol, Roger G 74 Kleiman, Andrew M. 75 Kruger, Christa 87 Katon, Wayne J 32 Klein, Daniel N 101 Krystal, AndrewD 11

127 PARTICIPANT INDEX

KrystalJohnH. 87,104 Leung, Henry H. 95 Lowe, Chet 17 Kudler, Harold S 18 Levendusky, Philip G 71 Lowenkopf, Eugene M. 69 Kunwar, Arun R. 52 Levenson, Alan 1 26 Lowenthal, David A. 27,95 Kuojack 46 Levenson, James L 15,74 Loza, Nasser F 105 Kupfer, David J 11,59 Leventhal, Eric 53 Lu, Francis G 5,48,59,73,98,103 Kupper, Lawrence L 105 Leverich, Gabriele S 88 LubyJoanL 25 Kushner, Mara 18 Levin, Barry 35 Lucak, Susan 22 Kweder, Sandra L 12 Levin, Frances R. 47,51,84 Ludman, Evette 32 Kyomen, Helen H. 100 LevineJeffreyM 99 Luff, Jamie A 50 Le vine, Jerome 22 Lukas, Scott E 105 L Levine, Nettie 95 LuoJohnS 18,42,56 Levitan, Robert D 99,105 Lutterman, Theodore C 57 Labutta, Robert J 88 Levitt, Anthony J... 99 Lyketsos, Constantine 20,65 Ladd, Heather 91 Levounis, Petros 18,26,48 Lymberis, Maria T. 73 Lafayette, Jennifer M. 62 Levy, Bruce R. 74 Lynch, Thomas 41 Lafer.Beny 58 Lewis, BradleyE 95 Lyons, Michael 36 Laje, Gonzalo 50 Lewis, Catherine F 79 5 Lalonde, Justine K 67 Lewis , Lydia J 4 Lam, Raymond W. 88,99 Lewis, Roya 54 Lamb, H Richard 55 Lewis-Fernandez, Roberto 5,91 Ma, Jennie Z 77 Lamdan, Ruth M. 54 Lewy, Alfred J 8 Macchi, Mela M. 100 Lamon-Fava, Stefania 78 U Eric C 18 Macdonald, ShionaM. 103 Lancee, William J 104 Li, Xingbao 30 Macewan, Thomas 103 Lane, Tom 57 Liang, Warren M 84 Mack,AvramH 16,24,75 Langsley, Donald G 53,73 Lieberman, Jeffrey A. 10,28,38 MacKenzie, K. Roy 21 Lantigua, Rafael 91 Liebowitz, Michael R. 34,92 MacLurg, B. Jason 81 Laorondeguevara, M. Soledad 98 Lieff, Susan J 73 MacQueen, Glenda M. 88 Lappalainen, Jaakko A. 87 Lim, M K 59 Maguin, Eugene 90 Laruelk, Marc 34, 85 Lim,RussellF 5 Maguire, Marcella 75 Lasaluia, Antonio 101 Limoges, Richard F 25 Mah, Kenneth 59 Lathlean, Judith 32 Lin, Elizabeth 32 Malaspina, Dolores 33,87 Laurence, Jessica 33 Lin,Keh-Ming 62,82 Malcolm, Jr., Robert J 64 Lauriello, John 28 Lindegger, Graham 52 MaldonadoJoseR. 7,15,43,98 Lauronen, Erika 23 Lindeman, Sari 23 Malean, Alexandra 91 Lauterbach, Edward C 3 Lindenmayer, Jean-Pierre 73 Malhotra,AnilK 63 Lautin, Andrew L. 28 Linehan, Marsha M. 19,27,58 Malison, Robert T. 87 Lavendar, Lynn 99 Ling, Walter 30,39,70 Mallios, Ronna 98 Lavori, Philip 11 Link, Bruce G 77 Mallott, David B 99 Lavretsky, Helen 11 Links, PaulS 30,63 Malloy, ErinM 35 Law.Roslyn 59 Linn, Kenneth 27 Malmquist, Carl P 19 Law, Samuel F 24 Lipsitt, DonR. 96 Malone, Kevin M 23 Lawson, J. Stuart 90 Lipsyte, Robert 21 Maltby, Nicholas 98 Lawson, William B 62 Usanby, Sarah H. 30, 83,93 Make, Carol A. 50 Lebovits, Allen 56 Liskow, Barry 1 77 Mancini, Catherine L 23 Lebowitz, Barry D 85 List, James F 67 Manevitz, Alan Z.A. 47 Leckman, James F 72 Liu, Xinhua 77,79,97 Manji, HusseiniK 28 LeDoux, Joseph 33 Livesleyjohn 30,43 Mann, Henry B 1 Lee, Karen L 14 Ljungberg, Mirka K 91 Mann, J.John 23,63,78,97 Lee, Steven J 48 Loboprabhu, Sheik M. 19,26 Mannuzza, Sal 65 Lee, Susanne 33 Lockhart, Paula J 100 Manos, Peter J 82 Lee, Thomas C 24 Loebel, J.Pierre 29 Manschreck, Theo C 62 Lefley, Harriet P 25 Logsdon, Linda 25 Manu, Peter 25,74 Legault, Qaudine 12,40 Logue, Bobby 97 Manzo, MaryP 60 Lehman, Anthony F 20,27 Lolak, Sermsak 98 MarangelL Lauren B 30,70,93 Lehmann, Laurent S 18 Lomax II, James W. 19,26 Marano, Anthony 34 Leigh, Hoyk 96,98 Londino, Donna L 80 March, John S 20 LeMelle, Stephanie 61 Lonesome, Ronald B 26 Marcus, Eric R. 19,20 Le Nestour, Annick 24 Loonen, Anton J.M. 1 Marcus, Sheila 61 Leo, Raphael J 42 Lopes, Fabiana L 23 Marder, Stephen R 11,14 Leon, Christine 91 Lopes-Cardozo, Barbara 52 Marin, Humberto 43, 86 Leon-Andrade, Carlos 58 Lopez, Juan F 61 Mark, Margery 65 Lepine, Jean-Pierre 91 Lopez-IborJr.JuanJ 65,80 Mark, Naomi 89 LeQuesne, Elizabeth 53 Lorell, Beth 99 Markou, Athina 61 Leroi, Iracema 65 Lotufo-Neto, Francisco 58 MarkowitzJohnC 5,59,101 Leserman, Jane 105 Lounsbury, David 52 Marmar, Charles R. 104 Lester, Barry M. 20 Love, Anthony 103 Marotti, Ferruccio 46 Leszcz, Molyn 104 Lovelace, John G 96 Marrocco, MaryK 7 Leung, Eman 105 Lovell, Mark 45 Marsh, Laura 65

128 PARTICIPANT INDEX

Marshall, Chris E 51 Melamed, Michael L 74 Morgenstern, Jon 75 Marshall, Geraldine 36 Mellman, Lisa A. 15,27, 86 Morin, David P 85 Marshall, Randall D 37,51,69 Melonas, Jacqueline M 26,46,69 Morrell, Martha J 93 Martin, Billy R 89 Meltzer, Carolyn 60 Morris, John C 6 Martin, Marie C 97 Meltzer, Herbert Y 9 Morrison, Jason M 52 Martin, Sandra L 105 Meltzer-Brody, Samantha 105 Morse, Eric D 60 Martinez, Humberto 36 Mendelowitz, Alan J 92 Moszynski, Peter 17 Martone, Christine A. 95 Mendlewicz, Julien 21,65 MoultonJohnL 65 Marx, Christine E 86 Mendoza, Ricardo P 62 Mourilhe, Patrica 46 Marzorati, Paolo 50 Menvielle, EdgardoJ 64,74 Moussaoui, Driss 80 Masand, Prakash S 6,9 Menza, Matthew A, 65,86 Moy-Martin, Elisabeth 88 Maser, Jack 63 Merideth, Philip T 80 Moynihan, Patrick J 99 Masheb, Robin M. 96 Merikangas, Kathleen 45 Mrazek, David A 3,27 Mason, Dana 91 Merlock, Megan 57 Mucha, Theodore F 51 Massie, Mary Jane 52 Mesci, Aruz 51 Muehlbach, Britta 80 Mathews, Maju 106 Mestry, Kezziah 52 Muench, Frederick 75 Mathis, Chet 60 Metzger, EranD 63 Muenzenmaier, Kristina H. 32 Matorin, Ami A, 26 MetznerJeffreyL 24,90 Mueser.KimT 32,43 Matseoane, Karen 97 Meydan, Jakob 79,97 Mufti, Khalid A. 96,105 Matthews, Stephen 105 Meyer, Jonathan M 9,15 Mullen, Jamie 22 Mattos, Paulo E 55 Meyers, Barnett S 85 Mulsant, Benoit H. 85 Mattson, Marlin RA 45 Michel, Bernard 91 Munich, Richard L 70,93 Maullin, Nathalie 48 Michels, Robert 15,27,94 Munoz, Rodrigo A. 20,26,45, 59, 83 Maunder, Robert G 104 Mick, Eric 85,106 Murakami, Jessica L 77 Mavissakalian, MatigR. 50 Miettunenjouko 23 Muran, J. Christopher 89 May, Matthew 7,15 Mikalac, Cecilia M 15,70 Musacchio de Zan, Amelia 46 Mayberg, Helen S 2 Miklowitz, David 88 Muskin, Philip R. 4,22,73,77, 82 Mayers, Harold A 34 Milev, Roumen V 88 Musselman, Dominique L 4 Mayes, Linda C 20 Milgram, Rabbi Goldie 73 Myers, Michael F 19,26,42,73, 80,102 Mazer, Neal 46 Miller, Alexander L 12 Myers, Nicholas 18 Mazzasalma, Marco A. 23 Miller, AndrewH 28 Myers, Wade C. 73, 80 McAllister, Thomas 87,93 Miller, Brenda A. 90 Mynors-Wallis, Lawrence 32 McCall, W. Vaughn 14, 89 Miller, Dinah 35 Myrick, Hugh 2,64 McCauley, Elizabeth 35 Miller, GaryE 74 Mcdelland,GaryM 32 Miller, Karen K 60 N McCrady, Barbara S 65 Miller, MarkD 24 McCreadie, Robin G 103 Miller, Rachel 99 Nace, Edgar 65,75 McCurtis, Henry L 26 Miller, SheldonI 75 Nadelson, Carol C 19 McDermott, Stephen P 67 Millman, Robert B 75 Nader, Michael 36 McDonald, Brenna 87 Milone, Richard D 46,73 Naeem,Farooq 105 McDonald, NoeUe 57 Minehart, Margaret A. 75 Nahas, Ziad H 30,93 McDonald, William M 4 Miner, Lucinda L 26 Nair.Jyotsna 45 McDonough, Susan C 61 Mink, Sale 33,34 Najavits, Lisa M 54 McDowell, David J 81 Minsky, Shula 91 Naji, Simon 103 McDowell, David M...27,44, 50, 81, 84,94,97,99 Mintz, David L 43 Nam, Theodore S 60 McElnea, Brenda 99 Mintzer, Jacobo E 6,43 Nand, Surinder S 18,26 McElroy, Susan L 2, 9 Miotto, Karen A. 82 Napoli, Joseph C 42 McEwen, Bruce S 8 Miranda, Jeanne 91 Nardi, Antonio E 23 McGeer, Allison 59 Mirecki, Ilona 77 Narrow, William E 24,50,59 McGlashan, Thomas H. 64 Mischoulon, David 34,78, 88 Nascimento, Isabella 23 McGreal, Bryan J 53 Mishory, Alexander 30 Naser, Jeffrey A. 23,72 McGuire, Marsden H. 80 Miskimen, Theresa M 91 Nasrallah, Henry A. 9,24,92 McHugh, Paul R. 20,91 Misra, Madhu 60 NdlelaJ. Charles 5 Mclntyre, JohnS 25,27,47,59 Misri, Shaila 3 Needell, Nancy J 19 Mclntyre, Kevin 47 Mitchell, James E 7, 60 Nehama,Yael 23 Mclntyre, Roger S 9 Mohamed, Mahmoud A. 94 Nelson, Charleston 72 McKeith,IanG 40 Mohatt, Dennis 57 Nelson, Dorothy 104 McLellan, A. Thomas 57 Molina, Brooke S.G 65 Nelson,J. Craig 66 McLoughlin, Kris A, 18 Mollica, Richard F 54 Nelson, Jessie 67 McNicholas, Laura F 39,70 Monahan, John 61 Nemeroff, Charles B 1,2,4,29,58,84 McQueryJoyD 25 Montgomery, Richard A. 18,42,56 Nene, Sudhandshu 26 McShea.MaryC 85 Montoya, IvanD 48 Neria,YuvalY 91 Meares, Russell 102 Monuteaux, Micheal 85 Nesse, Randolph M. 34 Mears.AlexP 99 Moracco, Kathryn E 105 Nestadt, Gerald 20 Mechanic, David 16 Mordecai, Donald J 18 Neuberger, Peshy 74 Medford, Nicholas 104 Morehouse, Rachel L 99 Neuberger, Rabbi Yaakov 74 Medoza, Richardo 19 Morgan, Linda 47 Neugebauer, Richard 59 Mee-Lee, David 5 Morgan-Minott, Melodic 72 New, Antonia S 78, 85

129 PARTICIPANT INDEX

Newcomer, John W. 13,41 Opler, Lewis A. 19,32,69 Peselow, Eric D 22,23, 47, 50 Newcom, Jeffrey H. 51, 65 Oquendo, Maria A. 38,47,63,78,94 PeteetJohnR 20,53,103 Newman, Michelle G ...4 Ordorica, Patricia 1 18,26,44,46,73,81 Petersen, Timothy J 5,34, 50,78 Newman, Rita R 73,99 Oreskovkh, Michael R. 50 Petersen-Crair, Pamela J 26 Newmark, Thomas S 60,89,103 Orzack, Maressa H. 46 Petitjean, Francois C 91 Newport, D.Jeffrey 70 Osinowo, Thomas 0 14 Petkova, Eva 101 Newton, Thomas 82 Osofsky, Howard J 46,54 Petry.NancyM 54,101 Neziroglu, Fugen 102,103 Osser, David N. 80 Petryshen, Patricia M 104 Ng, Anthony T. 8 Ostacher, Michael J 78 Petty, Frederick 104 Ng, David 51 Oswald, KimberlyD 62 Pevalin, David J 52 Niaz, Unaiza 74 Othmer, Ekkehard 78 Peveler, Robert C 32 Nickel, Elizabeth J 77,78. Othmer, Sieglinde C 78 Peyser, Herbert S 79 Nicola Siri, Leonardo 98 Otto, Grace 53 Pezous, Anne-Marie F 91 Nicolo, Alessandro 46 Otto, Michael W. 6,9,98 Pfeffer, Cynthia R 25,52 Nierenberg, Andrew A. 5, 34, 50, 78, 86 Oulvey, Eugene A. 14 Pfefferbaum, Betty. 8 Nierenberg, Marvin A. 80 Pflanz, Steven E 17,47,53 Nihalani,NikhilD 51,79 P Phillips, Katharine A. 63,103 Nman, Philip T. 2,23,92 Phillips, Mary L 104 Nineberg, Allan S 54 Packer, Samuel 48 Pi, Edmond H.T. 62 Ning, Autumn 54 Page, Everet 31 Piasecki, Melissa P 70 Nininger, James E 7 Painter, Albert F 27 Picardi, Angelo 101 Niparko, Angela 90 Paizis, Maty. 50 Pickering, Roger P 36 Nir, Yehuda 75 Pak,Greg 96 Pickering, Ruth 32 Njenga, Frank G 31 Pally, Regina 55 Pies, Ronald W. 93 Noble-Ludwig, Antonia 95 Palmer, Christopher M 32 Piez, Deborah A. 23 Noel, Richard L 74 Palmer, Orrin 42 Pilotte, Nancy 54,90 Noji,Eric 54 Paltrow, Lynn M 81 Pilowsky, Daniel J 35 Noll, Elizabeth 64 Panadero, Charles V 18 Finals, Debra A. 81 Nonacs, Ruta M. 39 Panahon, Norma C 74 Pincus, Simon H 32 Noordsy, Douglas ,43 Pandina, GahanJ 85 Pine, Daniel 20 Nordahl, Thomas E 45 Pandurangi, Ananda K 29 Pinsker, Henry 86 Norko, Michael A 10 Pandya, Anand 23, 53, 82,99 Pinson, Letitia A. 7 Norman, Matthew W. 72 Panzer, Paula G 52,95 Pipe, Beth 23 Norrie.John 103 Papakostas, George I 34,78 Pirard, Sandrine 100 Norris, Donna M. 26 Papirio, Stefania 46 Pitman, Roger K 105 North, CarolS 8,17,82 Papp, Laszlo A. 23 Pittman, Mary 47 Notman, Malkah T 19 Parameswaran, Sharat 51 Placidi, Rachel J 62 Novae, Andrei 104, 105 Pardes, Herbert 20 Plakun,EricM 19,43 Nunes, Edward V 26, 73,79, 84,97 Parikh, Rajesh M 88 Pleak, Richard R. 64 Nurnberg, H. George 86 Parikh, Sagar V 88 Pliskin,NeilH 74 Nutt, David J 69 Paris, Joel F 48,64 Plotsky.Paul 54 Nwokeji, Kingsley 98 Park, Lawrence T. 62,81 Podniesinksi, Elizabeth 57 Nzama, Thobile 52 Parnham, George 70 Polidori, Gabriella 79 Parsons, Jeffrey 75 Pollack, David A. 57 * ~) Passik, Steve 30 Pollack, MarkH 6,92 Pastor, Larry H. 81 Pollack, William S 31 Oakman, Jonathan 23 PateJenniferE 19,81 Pollock, Jonathan D 36 O'Brien, Charles P 48,49 PatelJayendraK 85 Polosan, Mircea C 78 O'Brien, Robert 75 Patel, Raman C 99 Pope, Jr., Harrison G 47,89 O'Connell, Anne 47 Pato, Michele T. 42,73 Popoiu, Veronica 53 Oepen, Godehard 72 Patterson, Robert D 80 Portenoy, Russ 30 Oesterheld, Jessica R. 71 Paul, Robindra K 95 PostJerroldM 31,43 OParrell, Timothy J 101 Paula, Susan E 95 Post, Robert M 78, 88 Offsay, Julian 80 Pearlson, GodfreyD 94 Postolache.TeodorT. 78,97 O'Halloran.RuthA. 79 Peasley-Miklus, Catherine 85 Potenza, Marc N. 54 Ohayon, Maurice M 39 PeeL Deborah C 31 Potkin, Steven G 40 Okasha, Ahmed 80, 83 Peele, Roger 31,86 Potter, Nancy L 87 Okasha, TarekA. 62 Pelchat, Marcia L 35 Powell, Barbara J 77,78 OKeefe, Kelly 19 Pelham, Jr., William E 65 Powsner.SethM 18,96 Okereke, N. Kalaya 53 Pelusi,Dan 104 Prasad, Konasale M.R. 52 Okonji,MarxO 105 Penick, Elizabeth C 77,78 Pressman, Mary Anne 22,50 Olarte, Sylvia W. 74,86 Penzel, Fred 48 Preter, Maurice 75 OldhamJohnM 23,38,59,91 Perahia, David G 24 Price, Julie 60 Olfson,Mark 91 Perel, James M 58 Price, Marilyn 81 Ollendick, Thomas H 86 Perkins, Diana 0 41,92 Price, Trevor RP 99 Olshansky, Ellen F 102 Perlin, Michael L 99 Friday, Lauren 103 OMalley.MaryB 67 Perlis, RoyH. 4,78 Prince, Jefferson B 1,5,14, 39 Onken,LisaS 101 Person, Ethel S 4 Printz, David J 87

130 PARTICIPANT INDEX

Prohovnik, Isak 85 Rice, John 36 Rubenstein, Michael N. 42 Puchalski, Christina M 98,103 Richards, Lawrence K 99 Rubin, Eugene H. 15 Puddester, Derek 7 Richardson, Denise M 45 Rudden, Marie G 73 Pugliese, Maria A. 42 Richardson, Jarrett W. 14 RudisillJohnR. 27 Pullen,IanM 25 Richman, Judith A 51 Ruditis, Ilze 24 Pumariega, Andres J 71,79 Ries, Richard K 19,65 Rudolph, Mark N. 79 Purselle, David C 67 Rifkin, Arthur 24 Rudolph, Steven E 19 Putnam, Katherine M 85 Riggs-Skean, Karen 89 Rueda-Lara, Maria A 42 Putnam, Jr., Frank W. 52 Riley, Anne 35 Ruggeri, Mirella 101 Pyles, Robert L 31 Rinaldi, Paul J 26 Ruiz, Pedro 20,26,46,62,73,79 Qian,F 59 Rinne, Thomas 30 Ruiz, Robert T. 32 Ritchie, ElspethC 51,83 Ruiz-Mellot, Katherine G 78 Q Rhvo.EvaC 18 Rush, A John 5,27,30,50, 57, 84 Rizvi, Shireen 58 Rusquellas, Astrid N. 95 Quanbeck, Cameron D 2 RoacheJohnD 77 Russo, Leo 77,79 Quesada, Gonzalo F 18 Roberts, Laura W. 16,46,73 Ryan, Deirdre M. 3 Robertson, EmmaK 104 Ryan, J. Michael 13,41 R Robertson, Judith 35 Ryan, Julie L 50 Robertson, Marguerite 104 Rychik,AbeM 69 Rabins, Peter V 43 Robinowitz, Carolyn B 19 Ryk,RoelH 30 Racy, John C 17 Robinson, Gail E 8,96 Rada, Pedro 62 Robinson, Gilbert 99 S Radden, Jennifer 46,105 Robinson, Robert G 22 Rae, DonaldS 50 Robinson, Susan 59 Saari, Kaisa 23 Rainey, Charles J 56 Robinson, TerryE 90 Sacamano, James T. 55 Raison, Charles 39 Roca, Catherine A. 70 Sachs, GaryS 9 Rajouria, Namita 42 Roca, Robert P 90 Sackeim, Harold A 11, 30, 83 Rakic.Pasko 33 Rodenhauser, Paul 27 Sadavoyjoel 24 Rambaldini, Gloria 59 Rodgers, Bryan 52 Saf ran, Jeremy D 89 Ramirez, C 31 Rodriguez, Denny 54 Safren, Steven A 98 Ramirez, Luis F 8,27 Rodriguez, Richard A 97 Said, Tewfik 15 Ramirez, Paul M 69 Roffman, Joshua L 52 Sajatovic, Martha 27 Ramsay, J. Russell 75 Rogan, Alice 70,93 Sakauye, Kenneth M. 17 Randall, Robert 87 Rogan, Gerald 80 Salaam, Karriem L 54 Rao, ArunaS 48 Rogers, Anna E 95 Sales, Roberta 81 Rao.NyapatiR. 47,54,99 Rogers, James K 102 Salloway, Stephen P 11 Rapaport,MarkH 1,16,21,28 Rogge, Scott D 46 Salo,RuthE 45 Rapkin, Bruce 52 Rohan, Kelly J 97 Salvatore, Paola 79 Rapp, Stephen R. 12 Rohrbaugh, Robert M 1 Salzman,Carl 4 Rasgon, Natalie L 66,70 Rojcewicz, Jr., Stephen 86 Samet, Sharon 97 Rath, Darlyne 59 Rolland, JohnS 14 Sampo, Eduardo 98 Rathod, Shanaya 46 Rondon, MartaB 74 Sandson,NeilB 71 Rausch, Jeffrey! 80 Ronningstam, Elsa F 63 Sano, Mary 6 Ravitz, Paula 1 Roose, Steven P 5,11 Santone, Giovanni 101 Ray.Neepa 105 Rosen, Cherise 23,51 Sar.Vedat 87 Razavi, Maryam 86 RosenbaumJerroldF 5,30,88 Saitorius, Norman 36,65, 83 Realmuto, George M. 65 Rosenbaum, Talli 75 Sasson, Yehuda 92 Reddy.Raj 96 Rosenberg, Stanley 32 Savage, Seddon R. 30 Regier, Darrel A 24,27, 44, 59 Rosenberger, John W. 73 Savolainen, Markku J 23 Reich, D. Bradford 64 Rosenfeld, Alvin A 35 Saxon, Andrew J 50 Reich, James H 30, 63 Rosenman, Stephen J 52 Saykin, Andrew 87 Reid, William H 90 Rosenthal, Norman 77 Scally.Erin 90 Reifler, Burton V 27 Rosenthal, Richard N 18,101 Scandlin, Donna 105 Reinblatt, Shauna P 18,25 Roskes, ErikJ 55 Schacht, Lucille 57 Reinus, John F 38 Rospenda, Kathleen M 51 Schaefer, Catherine A 33 Reiss, David M. 95 Rostain, Anthony L 48,75 Schaepper, Mary Ann 72 Reissman, DoriB 17 Roth, Thomas 11,97 Schane, Murray D 82 RennerJr.JohnA 80 Rothe, Eugenio M 72 Scharf, Martin B 99 Renshaw, PerryF 41, 50, 61 Rothenberg, Jami 84 Schatzberg, Alan F 28,39,44,56,66 Reoux, Joseph P 50 Rothschild, Anthony J 85,97 Scheiber, Stephen C 27 Resnick, Patricia 32 Rothschild, Louis 97 Scheidlinger, Saul 48,95 Resnick, Phillip J 5,14,28,42,69 Rothstein, David 31,51 Schetky, Diane H. 34 Resnikoff.RoyO 5 Rotter, Merrill R, 46 Schiffer, Randolphs 55 Ressler, Kerry J 2 Rounsaville, Bruce J 97,101 Schillerstrom, Jason E 53 Reus, Victor 1 27 Rourke, SeanB 104 Schlaepfer, Thomas E 83, 84 Reyes, Raymond M. 80 Royalle, Candida 60 Schloredt, Kelly 35 Reynolds III, Charles F 91 Roy-Byrne, Peter P 32,67 Schloss, Heather 78 Riba, Michelle B 10,14, 37, 58, 80 Rozenberg, Marina 60 Schmahl, Christian G 38, 85

131 PARTICIPANT INDEX

Schmaling, Karen B 58 Shulman, Kenneth 1 13 Speer, Andrew M. 88 Schmidt, Jr., Chester W. 14,46,53,72 Shumaker, Sally A. 12,40 Spencer, Donald 50 SchmitzJoyM 73,101 Sidwell, Robert 33 Spencer, Thomas J 2,67,98 Schneiderman, Jason 78 Siegel, Carole 36 Spiegel, David 4,7,15,51,56,87 Schneier, Franklin R 34,92 Siegel, Daniel J 67,70,73,102 Spiegel, Herbert 7,15 Schnell, Knut 97 Siegel, Glenn N. 47 Spinazzola, Joseph F 37, 58 Schoener, GaryR. 8 Sierra, Manuel 77 Spinelli, Margaret G 10,70,100 Schore, Allan N. 33 Sierra, Mauricio 104 Spinhovem, Philip 59 Schreibersdorf, Lisa 19,27 Siever, LarryJ 78, 85 Spitz, Deborah 87 Schubmehl, James Q 15 Silbaugh, David 99 Spitz, Henryl 87,94 Schultz, Susan K 25 Silberman, Edward K 42 Sprich, Susan 98 Schulz, S. Charles 5,6 Silenzio, Rosella 50 Squire, Kurt 46 Schuster, James A 96 Silk,KennethR 85 Srinivasaraghavan, Jagannathan 18 Schwab , JohnJ 97 Silver, Jonathan M. 87,88,93 Stabinsky, Harvey 77 Schwartz, Bruce J 45 Silver, Larry B 76 Stabinsky, Susan 52,78 Schwartz, GaryJ 62 Silver, Marjorie A. 99 Stahl, Stephen M 7,9 Schwartz, Joseph M 25,72 Silver, Stuart B 76 Stangler, Ronnie S 18 Schwartz, Michael 51 Silver-man, Joel J 47 Stanley, Barbara H 38, 86 Schwartz, Thomas L 24 Silverman, Morton 102 Staryjoel 33 Sciutto, MaryS 95 Silverman, Samuel M 80 Stastny, Peter 105 Sclare, Paul 103 Simantov, Sophia 74 Staudenmeier, Jr., James J 32 Scott, Jan L 57 Simeon, Daphne 104 Steadman, Henry J 61 Scott, John 59 Simon, AsherB 52 Stebbins, Glenn T. 74 Scott, Lisa 72 Simon, Gregory 32 Steenbarger, Brett 64 Scott, Marcia A. 17 Simon, Naomi M. 6,92 Stefanis, Costas 65 Scully, Jr., James H 7,27, 56 Simon, Robert 1 25,43 Steiker, Carol 34 Seaman, Barbara 100 Simons, Lucy 32 Stein, Dan J 3,63 Secin, Ricardo 58 Simpson, George M 10 Stein, Elliot A. 30 Seeman, Mary V 19 Simpson, William 37 Stein, Murray B 6,32,34,66,67 Segal, Gerald 42 Singer, Kenneth 82 Stein, SethP 80 Segebarth, Christoph 78 Sinha, Rajita 90 Steinberg, Marc L 84 Seidman, Larry J 39 Siris, Samuel G. 53 Steinberg, Rosalie 24 Seidman, Stuart N. 12 Sirota, Elizabeth 80 Steiner, Meir 39,61 Selemon, Lynn D 33 Sirota, Pinkhas 78 Steinglass, Peter J 3 Selhub, Jacob 78 Sit, Dorothy 85 Steinkuehler, Constance 46 Sensky, Thomas 57 Sites, Jane 52 Steinman, David 81 Serrano, Alberto 58 Sivrioglu, Yusuf 27 Stern, Daniel N. 102 Servis, MarkE 49 Skinner, Andrew 0 24,50,96 Stern, Harriet C 73 Shafii, Mohammad 17 Sklarsky, Katherine 78 Stevens, Christopher 89 Shah,ManojR 45 Skodol II, Andrew E 38,101 Stevenson, Janine L 102 Shah, Vital N. 23,79 Skotzko, Christine E 42 Stewart, Akha J 25,43,73, 86 Shalev.AriehY 54 Slattery, Marcia J 86 Stewart, Deborah C 96,98 Shanfield, Stephen B 33 Small, Dana 35 Stewart, Donna E 86,104 Shankar, Sri Sri Ravi 17 Small, GaryW. 11 Stewart, Jonathan W. 100 Shannahoff-Khalsa, David 74 Smeriglio, Vincent L 20 Stewart, S. Evelyn 98 Shapira, Nathan A. 54 Smiley, Susan E 54 Stewart, Stephanie M 46 Shapiro, Edward R, 19,43 Smith, Felicia A. 62 Stiller, John W. 78 Shapiro, Theodore 73 Smith, Graeme C. 87 Stinson, Fredericks 36 Sharfstein, Steven S 90 Smith, Matthew B 56 Stoddard, Jr., Frederick J 45 Sharkeyjohn 99 Smith, Michael 103 Stolar, Andrea G 17,81 Sharkey, Valerie 103 Smith, Michael W. 5 Stoll, Andrew L 41 Sharma, Tonmoy 74 Smyth, Nancy J 90 Stone, Alan A. 24,34,62,105 Sharon, Estee 100 Snyder, Scott 96 Storosum, Jitschak G 24 Shaw, Jon A 17 Scares, Oaudio N. 12,39,88 Stotland, Nada L 7,53,73, 86 Shaywitz, Jonathan E 92 Sokol, Mae S 8 Stotts, Angela L 101 Shea, M Trade 87 Solhkhah, Ramon 18 Stowe, ZacharyN. 2 Shea, Steven 91 Solloway, Scott 22 Strain, Eric C 70 Shear, M Katherine 59,102 Soloif.PaulH. 23,97 Strakowski, Stephen M 88 Sheehan, David V 6,22 Solursh, Lionel P 75 Straus, Sharon 59 Sheline, Yvette 1 20 Sommers, Denise 14 Strauss, John S 55 Shelley, Anne-Marie 32 Somoza, Eugene G 77 StreltzerJonM 19,82 Shen, Hong 72 Sonawalla, ShamsahB 88 Strokoff, Harris 75 Sherboume, Cathy D 32 Sood, Bella 35 Stroup, T. Scott 10 Shinfuku, Naotaka 36 Sorrentino, Renee M 57 Stuart, ScottP 1 Sholevar, G. Pirooz 89 Sotq, Jose M 99 Stunkard, Albert J 4 Shoptaw, Steven 47 Sotres-Alvarez, Daniela 105 Styra, Rima 59 Shrager, Daniel 31 Southwick, Steven M 104 Suarez, Raymond E 74 Shreeram, SrirangamS 78 Soyka, KarenM 102 Sudak,DonnaM 26,89,106

132 PARTICIPANT INDEX

Sullivan, Ann Marie T. 53 Toto, Anna Marie 75 Vigo, Daniel E 98 Sullivan, Carl R 19 Tracy, Martin G 26,46,103 Viguera, Adele C 4,69,93 Sullivan, Gregory B 23 Tran, Pierre V 24 Vilagut, Gemma 79 Sullivan,]. Greer 32 Treisman, Glenn J 19,20,47, 50,70 Viswanathan, Ramaswamy 80 Sunderland, Trey 13,41 Trieschmann, Martha 51 Vocci, Francis J 47 Suomi, Stephen J 34 Triffleman, Elisa G 50 Vogel-Scibilia, Suzanne E 25,54, 80 Susser, Ezra S 33, 82 Trimble, Michael R 7 Volkman, Edward A. 54 Svikis, Dace 50 Trinidad, Anton C 23,90,98 Volkov, Marina 26 Swain, James E 72 Trippitelli, Carol L 79 Volkow, Nora D 3,20,35,44 Swann, AlanC 3, 33 Trivedi, Madhukar H. 50 Volpp, Serena Y. 4 Swanson, James M 7 Trosch, Richard N. 13 Von Korff, Michael 32 Swanson, Jeffrey W. 61 Trujillo, Manuel 53 Voutsilakos, Fia 88 Swartz, Conrad M 33,89 Truman, Christine J 50 Vreeland, Elizabeth 75 Swartz, Holly A. 59,102 Tschan, Werner 54 Wachtler,Sol 75 Swartz, Karen L 33,34,86 Tseng, Wen-Shing 82 Wade, Terrance J 52 Swartz, Marvin S 61 Tso, Alice C 74 Swern, AnneJ 27 Tsodikov, Faina 23 W Swift, Robert M 64 TsuangJohnW. 19,82 Szabo, Boglarka 33, 34 Tsuang, Ming T. 36 Wadler.Garyl 47 Szarek, Bonnie L 23, 51 Tucker, Phebe M 8 Wagner, H Ryan 61 Szigethy, Eva M 45 Tucker, William M 42,85 Wagner, KarenD 9 Szor, Henry 23 Tuerk, Catherine 64,74 WahlstromJr.,CarlM 95 Tulloch, Simon J 98 Wain, Harold J 60 T Tune, LarryE 15,71 Wainberg, Milton L 52,55,75 Turgay, Atilla 51 Wakschlag, Lauren S 20 Taintor, Zebulon C 36, 85 Turkington, Douglas 8,46, 57 Waldrep, Douglas A, 60 TalbottJohnA 91 Tuunainen, Aria L 100 Walker, Edward A 32 Tandon, Rajiv 3,14,92 Walker, Roger D 18,73 Tang, Cheuk 78 U WalkupJohnT. 48 Tang, Lingqi 91 Wall, Susan 103 Tansella, Michele 101 Uhl, George 36 WallackJoelJ 45 Tanzi, Rudolph 13 Ulmer, Carolyn 75 Walsh, B. Timothy 62,63,67 Taranto, Richard G 24,62 Umbrell, Laura J 42 Walsh, James K 97 Tariot, Pierre N. 13,41 Upadhya, Gopalakrishna K 46 Wang, Fujun 24 Tasman, Allan 10,15,101 Upshur, Carole C 80 Wang, Gene-Jack 35 Taub, Robert 95 UrbaitisJohnC 25 Wang, Lei 33 Taylor, Brent 64 Ursano, Robert J 17,25,31,46,60 Wapenyi,KhakasaH 53 Taylor, Valerie 88 Ustun, T. Bedirhan 2 Warden, Deborah Lee 88 Taylor, WarrenD 6, 41 Warshaw, Carole L 25 Teicher, Martin H. 47, 54 V Wasserman, Stacey 92 Teitelbaum, Son 74 Wasylenki, Donald A 104 Templeton, Bryce 106 Vaglum,Per 30,63 Watchel,Paul 89 Teplin, Linda A 32 Vaidya, Nutan A- 26 Wauford, Pamela K 62 Terman, Jiuan Su 100 Valenca, Alexandre M 23 Waxmonsky, James G 67 Terman, Michael 8, 100 Van Ameringen, Michael A 23 Waylen, Andrea 23 Thakur, MugdhaE 11 Van Cauter, Eve 67 Wehr.AllisonM 45,57 Thase, Michael E 3, 9,13,58, 59, Van Den Brink, Wim 24,30 Weiden, Peter J 3,11,79 66, 73, 78, 85, 86 VanDerKolk,BesselA 37,58,91 Weimann, Gabriel 31 Thielke, Stephen M 25 Vanderpool, Donna 46, 54 Wein, Simon 103 Thienhaus.OleJ 70 Van Dyck, Richard 59 Weinberg, Naimah Z 65 Thomas, Christopher R 42 VanPraag, Herman M 1 Weine, Stevan M 31 Thomas, Jean M 25, 73 van Zwieten, Barbara J 24 Weiner, Elyse D 47 Thompson, Christopher 32 Varghese, Frances T. 104 Weiner, Richard D 14 Thompson, Kenneth S 25, 95 Varma, SatishC 16 Weinmann,S 59 Thompson, Leonti H. 75 Varma, Sudeepta 80 Weinstein, Henry C 55 Thompson, Michael J 52 Vazquez, Delia M 61 Weintrob, Alex 34 Thomson, CaptaneP 45 Veale, David 103 Weisberg, Risa B 6 Thorn, Nicole 65 Veenstra-VanderWeele, Jeremy 18 Weisler, Richard H 51,98 Thron, Arrnin 97 Vega, William 91 Weisman, Henry W. 75 Thrower, Courtney M 78,97 Veijola, Juha M 23 Weiss, Francine 73 Thuluvath, Paul 45 Verdeli, Helena 59 Weiss, Jeffrey 19 Tibaldi, Giuseppe 101 Vereen, Jr., Donald R 47 Weiss, Margaret D 2 Tillman, Jane G 19 Verma, Sumer 32 Weiss, Roger D 73 Timimi, Sami 95 Vernikov, Rozaliya 74 Weiss, Susan RB 89 Todd, Richard D 65 Viamontes, George 1 45, 58 Weissman, Myrna M. 27, 35,59,91 Tohen, Mauricio F 78, 79 Viana, Jason B 62 Weller, ElizabethB 27 Tolin, David 98 Viederman, Milton 71 Wells, Kenneth B 91 Ton, Hendry 56, 74 Vigezzi, Pierluig 50 Weltzin, Theodore E 96

133 PARTICIPANT INDEX

Wenk, GaryL 6 X Wessells, Michael 31 West, Joyce C 24,50,59 Xie,Hui 101 Westermeyer, Joseph J 82 Wetherington, Cora Lee 90 Y Whalen,Paul 66 Whiteside, Stephen 14 Yager, Joel 7,15,47,60,93 Whitman, Anne 31 Yang, C Paul 74 Wick, Paul H. 45 Yangjian 24 Wickramaratne, Priya 59 Yates, Alayne 96 Widiger, Thomas A. 87 Yehuda, Rachel 75,92,105 Wiesner, Irving S 20 Yeomans, Frank E 70 Wilber, Charles H 97 Yeung, Albert 77,88 Wilens, TimothyE 39,65,67,98,106 Ying, Patrick 73 Wilensky, Mark 99 Yonkers, KimberlyA. 6,61,100 Wilk, Joshua E 27,50,59 Young, Arlene 100 WilHns, Jeffrey N. 46 Young, Judy 74 Williams, Adedapo B 106 Young, Keith W. 46,53,60,61 Williams, Eric R. 48 Young, KimberlyS 46 Williams, Jill 84 Yousufi, Samina M 97 Williamson, Johnny L 46 Yu, Van 80 Wills, CherylD 54, 81 Yudofsky, Stuart C 13,41,45,70,93 Wills, Marketa M 24,45,53,97 Yurgelun-Todd, Deborah A. 4,41,61,85,89 Wilson, G. Terrence 60 Wilson, Kumanan 59 Z Wilson, Lori 100 Winette, Carol 98 Zachry, Woodie M 94 Winick, Bruce J 99 Zanarini, MaryC 23,38,64,102 WinkelmanJohnW. 55,67,92 Zarate,Jr.,CarlosA. 79 Winstead, Daniel K 27 Zatzick, Douglas F 25 Winston, Arnold 89 Zaubler, Thomas S 75 Winter, Britta 97 Zdanowicz, Mary 45 Winters, Ken C. 65 Zelvin, Elizabeth 93 Wise, Brian K 25 Zhang, Wei 4,93 Wise, Robert A. 45 Ziedonis, Douglas M 48,62, 84,100 Wishart, Heather 87 Zima, Bonnie T 91 Wislar, Josephs 51 Zimmerman, Mark 97,101 Wisner, Katherine L 70,100 Zin, Walter A. 23 Wohlfarth,TamarD 24 Zitek,BrookE 75 Wohlreich, Madelaine M 25 Zohar, Joseph 92 Wolf, Marina E 90 Zonana, Howard V 24,34 Wolfe, Barbara E 7,63 Zoulalian, Carol 48 Wolfe, Tom 38 Zubieta, Jon-Kar 8,30, 85 Wolke, Dieter 23 Zuckoff, Allan 102 Wolkin, Adam 28 Wonderlich, Stephen A. 60 Wong, Marleen 46 Wood,WilliamC 25,73 Woody, George E 101 Worhunsky, Patrick 98 Worley, Linda L.M 56 WorthingtonmjohnJ 34,78 Wozniak, Janet 69, 85 Wright, Harry H. 25 Wright, Jesse H 3, 8,26, 57,97 Wright, MarkS 79 WuJosephC 19,81 Wulsin, LawsonR. 77 WungJayL 95 Wyatt, Richard J 33 WynnJohnD 29 Wysong, Ashley. 98

134 AMERICAN PSYCHIATRIC ASSOCIATION - 158TH ANNUAL MEETING

MAY 21-26,2005 Atlanta, Georgia \I

\T Psychosomatic Medicine: Integrating Psychiatry & Medicine

Michelle Riba, M.D. President Marian I. Butterfield, M.D., Chairperson Scientific Program Committee

THE SUBMISSION SCHEDULE

Format Deadline

Industry-Supported Symposium June 1,2004 Course September 7, 2004 Reports September 7, 2004 Symposium September 7, 2004 Workshops Issue: September 7, 2004 Component: September 20, 2004 New Research December 3, 2004

Incomplete and/or Incorrect Forms Will Not Be Considered. For complete submission forms, you may download the forms at www.psych.org, click on the Annual Meeting logo, then click on submission forms. You may also contact the APA toll free at 1-888-357-7924, and speak directly with an Answer Center Coordinator. If you want to volunteer to chair a session, please send a letter to the attention of Dr. Butterfield at the American Psychiatric Association. Please indicate your name, address, area of expertise, and the type of session you would like to chair. Please be aware that we receive more requests than available slots. If you are selected as a chairperson, you will be notified by the end of November.

135 American Psychiatric AssocMH Audiotapes Recorded Live!

High Quality Continues for the 2004 Annual Meeting...

Live recordings will be available for most of the following: • Lectures • Advances in Research • Advances in Psychopharmacology Presidential Symposia • Medical Updates Scientific and Clinical Reports • Symposia • Debate • Roundtable Discussion • Research Advances in Medicine

Tapes may be purchased on site at Mobiltape's booth at the Javits Convention Center.

Mobiltape Company, Incorporated 24730 Avenue Tibbitts, Suite 170 Valencia, CA 91355 Phone: (661) 295-0504 4 (800) 369-5718 Fax: (661)295-8474 Website: www.mobiltape.com 136 5 Mental Health Disparities in the Community

t • Psychiatrists in community practice or public sector including state, community, and Veterans Affairs hospitals, community clinics, and jails • Psychiatric administrators • Persons interested in social issues that have an impact on patients • Minority psychiatrists and International Medical Graduates • Psychiatric Residents • Medical Students

Why Should You Attend? • Earn up to 48 hours of category 1 credit • Receive a 40% discount on APA member registration fees • Industry-Supported Lunch and Dinner Symposia are presented each day

How Will You Benefit? • Learn the latest knowledge and skills in clinical psychiatry, which can be utilized to 56th Institute improve patient care • Acquire a deeper understanding of how the current health care system affects patient care • Gain new knowledge and skills useful in clinical and public psychiatry settings on Psychiatric • Recognize and improve mental health disparities in the community Services IPS is your comprehensive educational and networking event with a clinical focus on topics including: October 6-10,2004 • Cross-cultural and minority issues • AIDS • Social and community psychiatry • Psychiatric administration Hilton Atlanta Hotel • Psychopharmacology and services • Resident and medical student concerns • Treatment techniques and • Substance abuse outcome studies Atlanta, GA • Child and adolescent issues • And much more Registration starts June 1,2004. Visit www.psych.org for detailed program information and to register.

Questions? Call: 1-888-357-7924 (Toll Free) or 703-907-7300 Fax: 703-907-1090 Email: [email protected] Visit: www.psych.org

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 48 credits toward the AMA Physician's Recognition Award and for the CMS requirement of the APA. Each physician should claim only those credits that he/she actually spent in the activity.

137 The First and Last Word AT YOUR ANNUAL MEETING BOOKSTORE

Treatment Companion to APPI Bookstore at the 2004 the DSM-IV®-TR Casebook Edited by Robert L Spitzer, M.D., APA Annual Meeting Michael B. First, M.D., Miriam Gibbon, M.S.W., and Janet B. W. Williams, D.S.W. Psychiatry's premiere publisher brings the cutting- edge titles you've been waiting for directly to you! 2004 • 360 pages • ISBN 1-58562-139-0 paperback • $39.00 « Item #62139 Come check out APPI's latest groundbreaking selec- 2004 • 360 pages • ISBN 1-58562-194-3 tion, from the newest textbooks, review series, and hardcover • $54.00 • Item #62194 journals, to electronic products for your handheld or online. The APPI Bookstore is the one place you can The American Psychiatric Publishing go to gather all the resources you'll need in the next Textbook of Child and Adolescent year. Update subscriptions, complete your series col- Psychiatry, Third Edition Edited by Jerry M. Wiener, M.D., and lections, browse through hard to find titles, and even Mina K. Dulcan, M.D. develop your course adoptions—all in one stop. 2004 • 1,140 pages • ISBN 1-58562-057-2 Don't miss the Author Book Signings or the Sunrise hardcover • $165.00 • Item #62057 Special, with discounts of 25% for APA Members-in- Training—see you there! The American Psychiatric Publishing Textbook of Psychopharmacology, Third Edition Edited by Alan F. Schatzberg, M.D., and APPI Bookstore Hours Charles B. Nemeroff, M.D., Ph.D. ;;;.,$|$ufday, May 1 10:00am - 5:00pm 2004 • 1296 pages • ISBN 1-58562-060-2 :};'f^^;JVtey 2...... 10:00am - 4:30pm hardcover • $178.00 • Item #62060 .;• -;;'i^©p|jay,"Hay 3 10:00am - 5:30pm .-;',ly

138 in Psychiatry

Concise Guide to Ethics in Mental Health Care Review of Psychiatry, ; aura Wei-,;, Roberts, M.I) ,,ind New Core Competencies! Volume 23 Alien K.ihcT.M D.. Ph R Cert CoMpetMcta for Series Editors: |ohn M. (Jldhain, M L), M.S., 2004 • 384 pages • ISSN 0-88048-944-8 Psychiatric Edwatiei and Michelle B.Riba.M.D., M.S. paperback • $29 95 • Item #8944 Defining, Teochincj, ar>d Asseising Brain StMwktta in Psychiatric Treatment Resicient Competence APRIL Linda Boerger Andrews, M.P., and Edited by Sarah H. Lisanby, M.D. John William Burruss, M.D. 2004 • 160 pages • ISBN 5-58562-175-7 2005 Appointment Book 2004 • 176 poges • ISBN ! -58562-1 30-7 paperback • $34 95 • Item #62175 Anirrk'.ui iVvvhi.iinc A.s.v:aatH>n poperbock • $32,50 • Item #62130 CogirftivtHWwvJor TWopy 2004 • 192 pages • ISBN 089042-331-8 Th« Art and Sda.ce of Brief Rditcd by Jesse H, Wright, M.D., Ph.D. spiralbcxjnd • $32 95 • item #2331 PsydMlberapl»s 2004 • 160 poges • ISBN 1-58542-178-1 A Proctitioner'i Go»ae paparbock • $34.95 • Item 062178 American Psychiatric Association Practice Guidelines for the Treatment (Core Competencies in Psychotherapy) N**r*pif&atrk Ass^ssmirt of Psychiatric Disorders Edited by Mantash J. Dewan, M.D., Edited by Stuart C. Yudofsky, M.D., and H. Compendium 2004 Brett N. Steenbarger, Ph.D., and Roger P. Greenberg, Ph.D. Florence Kim, M.D. AiikTiL.in rNvvhm'r^' As>u^;a!vn 2004 • 176 poges • ISBN 1-585*2-177-3 2004 • 336 pog«s • (S&N V58562-067-X 2004 • 896 pages • ISBN 0-89042-375-X paperback • $34 95 • Item #62177 poperbock • $38.50 • Item #62067 harocovef • $83.50 • Item #2375 DtvdofHMfttal Psydwbiology 2004 • 896 pages • ISBN 0-89042-376-8 Img-Tern PsyrJiodywiaic Psychotbsropy paperback • $64.00 • Item #2376 A Basic Text Edited by B. |.Casey, Ph.D. ICore Competencies in Ptychotberopy) 2004 • 176 pages • ISBN 1-58562-176-5 Quick Reference to th« American Psychiatric poperbock • $34,95 • Ham #62176 Glen O.Gabbard, M.D. Association Practice Guidelines for the Treatment SET of Review of Psychiatry, Volume 23 of Psychiatric Disorders 2004 • 224 pages • ISBN 1-58562-144-7 paperback • $33.95 • Item #62144 2004 • S10900 • Hem #5082 C_o<*ii_>e'X!ium 7004

2 Introduction to S«pporti»e Psydwttarapy 2004 * 208 pages • ISBN 0-89042-377-6 (Core Competencies in Psychotherapy] JANUARY paperback • $32 00 • item #2377 Arnold Winston, M.D., Essentials of Clinical Psychiatry, Second Edition Richard N. Kosenlhal, M. 11.,and Psychodynamic Treatment of Depression Ld:tedbv Kcbett I. !i,i;ci> M 1'.. M.fl A ,,ind Henry Pmsker, M D. rH-,:riL X. Huxh M ; >., Mint KuddiT. M.n.,,in.i Suiarl ',' iLdut4vM !' 2004 • 192pooe5 • ISBN 1-58562-147-1 2 2004 • 1032 pages • ISBN 1-58562-033-5 poperbock • $32.50 • Item #62147 2004 • 320 poges • ISBN 1 58562 084-X paperback • $72.00 • item #62033 paperback • $32.95 • Item #62084 Doing the Right Thing APRIL Ar^ Apf->riXi«.h tc Mc!ol Ksues p. Cotatonja Mental Health ^eotmer! -rc.,n P^ychofxitholocjy to Neurob>o!ogy Facr and Anxiety 1 The Benefits of "^anski'ionai Research ii.lni K i'L-lre'.,M.|i I d.lcd In Sunitv N. l\l'^!t, M.: , Vephan i MJM:I, M 1" .Andrew 1-i.iiK'is, M [\, hdited bv j.uk M.doiman, M.I), 2004 • 144 poges • ISBN 1-58562-083-1 I'll :>...ind(,ri'i;ory I Fr;,chi,MK\ M.P. paperback • $24.95 • Item #62083 2004 • 336 pages • ISBN 1-58562-149-8 2004 • 256 poges • ISBN 1 -58562-085-8 paperback • $39.95 • Mem #62149 popcrbock • $38 00 • Item #62085 FEBRUARY CPT Handbook for Psychiatrists, Third Edition Clinical Manual of Anxiety Disorders DSM-IV-TR Guidebook ('.hrstcr \V Sihmuli, jr., M.iX. Rebecca V'wtfll, hJhedbv Pan | stein, M.D., Ph.D Mich.iel H. iiivt.M li.AHt-ii ! ut\-e\ M.II, and and hllen lalle H.ui.ld Ai.in l'iri-,i*,M I! 2004 • 200 pages • IS6N 1 58562-076-9 2004 • 160 poges • ISBN 1-58562-157-9 paperback • $32,00 • Item #62076 2004 -512 pages • ISBN 1 -58562-1 88-9 spiroltxxmd • $39.00 • Item #62157 hardcover « $69.50 • Item #62188 2004 -512 pages • ISBN 1 -58542-068-8 Trance and Treatment MARCH paperback • $59.50 « Item #62068 Conical Uses of Hypnosis, Second Edition Essentials of Neuroiirwging for Qinical Practice Herbert Spiegel, M.D..and David Spiegel. M i'. Klitcd bv Darin H Pi'i;i;herlv. M I'.. M V.. 2004 • 448 pogei • ISBN 1-58562-190-0 Su'tt I Rauih M D.and jeiruld :- Kwnkium.M ! popcrbock • $52.00 • Item #62!90 2004 • 176pagei • ISBN 1-58562-079-3 hardcover • $42 00 • Item *62079 Mew It without not i ce.

139 INDUSTRY-SUPPORTED SYMPOSIUM 1 Saturday, May 1,12:30 p.m. - 3:30 p.m. Special Events Hall ID, Level 1, Javits Center

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity. Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served basis. For more information about the meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1 -888-357-7924 (within the U.S. or Canada! or at 703-907-7300. Supported by an unrestricted educational grant from JANSSEN Sponsored by the American Psychiatric Association RS-U52

INDUSTRY-SUPPORTED SYMPOSIUM 2 Saturday, May 1,12:30 p.m. - 3:30 p.m. Empire Ballroom B/C/D, Ballroom Level, Grand Hyatt

Preventive PROGRAM OBJECTIVES AGENDA After attending this continuing medical education 12:00 PM Lunch Psychiatry in symposium, the psychiatrist should be able to: 10.30 Welcome and Introduction Mood Disorders: • Understand the effects of early-life trauma on CHARLES B. NEMEROFF, MD, PhD neurobiology and the subsequent development SYMPOSIUM CHAIR The New of psychiatric illness Emory University School of Medicine • Provide psychiatrists and psychologists with 12-35 PM Identification of Risk Frontier available information on medication use Factors for Development during pregnancy and lactation of Depression: Focus on • Discuss the emerging role of neuroimaging Early-Life Trauma Symposium to be held at the as it affects psychiatry CHARLES B. NEMEROFF, MD, PhD American Psychiatric • Become familiar with data suggesting various i;05 PM Achieving the Optimal Balance Between Association 157th Annual genetic changes may be associated with Treatment of Maternal Depression and Meeting psychiatric disease. Infant Medication Exposure ZACHARY N. STOWE, MD SATURDAY, MAY 1, 2004 Emory University School of Medicine The American Psychiatric Association (APA) 12:30 PM - 3:30 PM is accredited by the Accreditation Council 1:35 PM Functional Brain Imaging: f '* or Continuing Medical Education to provide Subtyplng Depression Grand Hyatt New York •ontinuing medical education for physicians. HELEN S. MAYBERG, MD Park Avenue at Grand Central The APA designates this educational activity for a Emory University School of Medicine Empire State Ballroom B/C/D maximum of 3 category 1 credits toward the AMA Physician Recognition Award and for the CME requirement 2:05 PM Genetic Research In Psychiatry: New York, New York of the APA. Each physician should claim only those Diagnostic and Therapeutic Implications credits that he/she actually spent in the activity. STEPHAN CLAES, MD, PhD Sponsored by the American Attendees must be registered for the APA Annual Meeting to University of Antwerp (UA) Psychiatric Association attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the 2:35 PM Panel Discussion With Questions and Supported by an unrestricted meeting, please visit the APA website at www.psych.org or Answers educational grant from contact the APA toll free at 1-888-357-7924 (within the GlaxoSmithKline US or Canada) or 703-907-7300. 3:30 PM Closing Remarks, Adjournment CHARLES B. NEMEROFF, MD, PhD

140 INDUSTRY-SUPPORTED SYMPOSIUM 3 Saturday, May 1, 12:30 p.m. - 3:30 p.m. Grand Ballroom East, Third Floor, Hilton New York

INDUSTRY-SUPPORTED SYMPOSIUM 4 Saturday, May 1, 12:30 p.m. - 3:30 p.m. Broadway Ballroom, Sixth Floor, Marriott Marquis

141 INDUSTRY-SUPPORTED SYMPOSIUM 5 Saturday, May 1, 12:30 p.m. - 3:30 p.m. Imperial Ballroom A, Second Floor, Sheraton New York

INDUSTRY-SUPPORTED SYMPOSIUM 6 Saturday, May 1, 6:00 p.m. - 9:00 p.m. Empire Ballroom B/C/D. Ballroom Level, Grand Hyatt INDUS'IKY-SLTPORTED SYMPOSIUM 7 Saturday, May 1, 6:00 p.m.. - 9:00 p.m. jtYnki Ballroom East, Third Floor, Hilton New York

1VDi :(qUY~S'UPPORlED SYMPOSIlJIvf 8 SaHii\lAy: May L 6:00 p.m. - 9:00 p.m. Bro.u.tvv-.u- Ballroom, Sixth Floor, Manioit Marqius

143 INDUSTRY-SUPPORTED SYMPOSIUM 9 Saturday, May 1, 6:00 p.m. - 9:00 p.m. Grand Ballroom, Mezzanine Level, Roosevelt

INDUSTRY-SUPPORTED SYMPOSIUM 10 Saturday, May 1, 6:00 p.m. - 9:00 p.m. Imperial Ballroom A, Second Floor, Sheraton New York

144 INDUSITIY-SUPPORTED SYMPOSIUM 11 Saturday, May 1, 6:00 p.m. - 9:00 p.m. imperial Ballroom B, Second Floor, Sheraton New York

industry supported symposium 12 Sunday, May 2, 8:OC a.m. - 11:00 a.m. Speew! Event? Hall ID. Level 1, Javits Center

145 INDUSTRY-SUPPORTED SYMPOSIUM 13 Sunday, May 2, 8:00 a.m. - 11:00 a.m. Empire Ballroom B/C/D, Ballroom Level, Grand Hyatt

INDUSTRY-SUPPORTED SYMPOSIUM 14 Sunday, May 2, 8:00 a.m. - 11:00 a.m. Grand Ballroom East, Third Floor, Hilton New York

146 INDUSTRY-SUPPORTED SYMPOSIUM 15 Sunday, May 2, 8:00 a.m. - 11:00 a.m. Broad way Ballroom, Sixth Floor, Marriott Marquis

From Pathology to Practice: Evolving Therapeutic Strategies for Alzheimer's Disease Sunday, May 2,2004 | Breakfast 7:30 AM - 8:00 AM, Scientific Program 8:00 AM - 11:00 AM | Marriott Marquis, Broadway Ballroom

INDUSTRY-SUPPORTED SYMPOSIUM 16 Sunday, May 2, 8:00 a.m. - 11:00 a.m. Grand Ballroom, Mezzanine Level, Roosevelt

147 INDUSTRY-SUPPORTED SYMPOSIUM 17 Sunday, May 2, 8:00 a.m. - 11:00 a.m. imperial Ballroom A, Second Floor, Sheraton New York

The PROGRAM OBJECTIVES AGENDA After attending this continuing medical education 7:30 AM Breakfast symposium, the psychiatrist should be able to: Hidden Faces 8:00 AM Welcome and Program Introduction • Become familiar with the physical comorbidi- PRAKASH S. MASAND, MD of Anxiety ties associated with anxiety disorders and their SYMPOSIUM CHAIR bidirectional relationship Duke University Medical Center • Identify gender differences associated with Symposium to be held at the 8:05 AM The Somatic Face of Anxiety anxiety disorders with respect to presentation, American Psychiatric Association progression of disease, and response to PRAKASH S. MASAND, MD 157th Annual Meeting treatment 8:35 AM Anxiety In Men and Women: • Appreciate the wide variation in presentation, Two Faces of the Same Coin SUNDAY, MAY 2, 2004 prevalence, and treatment response of anxiety KIMBERLY A. YONKERS, MD 8:00 AM - 11:00 AM disorders in different cultures and ethnic groups Yale University • Increase awareness of the difficulties in School of Medicine Sheraton New York recognizing and treating anxiety in the elderly. Hotel and Towers 9:05 AM The Many Faces of Anxiety: Understanding Cultural and Ethnic Imperial Ballroom A The American Psychiatric Association (APA) Variation in Psychiatric Illness New York, New York is accredited by the Accreditation Council for GEETHA JAYARAM, MD Continuing Medical Education to provide The Johns Hopkins Hospital continuing medical education for physicians. The APA designates this educational activity for a maximum 9:35 AM Facets of Anxiety of 3 category 1 credits toward the AMA Physician In the Elderly Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that WARREN D. TAYLOR, MD Sponsored by the American he/she actually spent in the activity. Duke University Medical Center Psychiatric Association Attendees must be registered for the APA Annual Meeting to 10:05 AM Panel Discussion With Supported by an unrestricted attend this symposium. Seating is limited and will be based Questions and Answers on first-come, first-served. For more information about the educational grant from meeting, please visit the APA website at www.psych.org or 11:00 AM Closing Remarks, GlaxoSmithKline contact the APA toll free at 1-888-357-7924 (within the Adjournment US or Canada) or 703-907-7300. PRAKASH S. MASAND, MD

INDUSTRY-SUPPORTED SYMPOSIUM 18 Sunday, May 2, 8:00 a.m. - 11:00 a.m. Imperial Ballroom B, Second Floor, Sheraton New York

148 INDUSTRY-SUPPORTED SYMPOSIUM 19 Sunday, May 2, 1:30 p.m. - 4:30 p.ni Special Events Hall ID, Level 1, Javits Center-

1NDUS1KY-SUPPORTCD SYMPOSIUM 20 Sunday, May 2, 1:30 p.m. - 4:30 p.m. Empire Ballroom B/C/D, Ballroom Level, Grand Hvau

149 INDUSTRY-SUPPORTED SYMPOSIUM 21 Sunday, May2, 1:30 p.m. - 4:30 p.m. Grand Ballroom East, Third Floor, Hilton New York

INDUSTRY-SUPPORTED SYMPOSIUM 22 Sunday, May 2,1:30 p.m. - 4:30 p.m. Broadway Ballroom, Sixth Floor, Marriott Marquis

150 INDUSTRY-SUPPORlliD SYMPOSIUM 23 Sunday, May 2, 1:30 p.m. - 4:30 p.m. imperial Ballroom A, Second Floor, Sheraton New York

The American Psychiatric Association [APAI is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that he/she actually spent in the educational activity. Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be based on first-come, first-served. For more information about the meeting, please visit the APA website atwww.psych.org or contact the APA toll free at 1-888-357-7924 (within the U S or Canada) or at 703-907-7300. Supported by an unrestricted educational grant from JANSSEN H "SSSSK? Sponsored by the American Psychiatric Association RS-1451

INDUSTRY-SUPPORTED SYMPOSIUM 24 Sunday, May 2, 7:00 p.m. - 10:00 p.m. Special Events Hail ID, Level 1, javits Center

151 INDUSTRY-SUPPORTED SYMPOSIUM 25 Sunday, May 2, 7:00 p.m. - 10:00 p.m. Empire Ballroom B/C/D, Ballroom Level, Grand Hyatt

INDUSTRY-SUPPORTED SYMPOSIUM 26 Sunday, May 2, 7:00 p.m. - 10:00 p.m. Grand Ballroom East, Third Floor, Hilton New York

152 INDUSTRY-SUPPORTED SYMPOSIUM 27 Sunday, May 2, 7:00 p.m. - 10:00 p.m. Broadway Ballroom, Sixth Floor, Marriott Marquis

INDUSTRY SUPPORTED SYMPOSIUM 28 Sunday, May 2, 7:00 p.m.-10:00 p.m. Grand Ballroom, Mezzanine Level, Roosevelt

Beyond Sleep Onset New Perspectives on the Treatment of InsomniaA

Sunday, May 2,2004 Scientific Program Agenda Accreditation Statement 7:00 PM-10:00 PM 6:30 PM - 7:00 PM The American Psychiatric Association (APA) Grand Ballroom, Mezzanine Level Dinner is accredited by the Accreditation Council The Roosevelt Hotel 7:00 PM - 7:10 PM for Continuing Medical Education to provide New York City, New York Introduction and Welcome continuing medical education for physicians. Chair: Andrew Krystal, MD Faculty Credit Designation 7:10 PM - 7:40 PM Andrew Krystal, MD (Program Chair) The APA designates this educational activity Prevalence and Impact of Insomnia: for a maximum of 3 category 1 credits toward Director, Sleep Research Laboratory Treating the Entire Insomnia Syndrome and Insomnia Program the AMA Physician Recognition Award and Associate Professor of Psychiatry Mugdha Thakur, MD for the CME requirement of the APA. Each and Behavioral Sciences 7:40 PM - 8:10 PM physician should claim only those credits Duke University Medical Center Differential Diagnosis of Insomnia that he/she actually spent in the activity. Durham, North Carolina and Co-morbid Conditions: Importance Registration Mugdha Thakur, MD of Sleep History Clinical Associate, Psychiatry and Jed Black, MD Attendees must be registered for the APA Behavioral Sciences Annual Meeting to attend this symposium. 8:10 PM - 8:40 PM Duke University Medical Center Seating is limited and will be based on first Measures of Treatment Efficacy Durham, North Carolina come, first served. For more information Thomas Roth, PhD Jed Black. MD about the meeting, please visit the APA Director, Stanford Sleep Disorders Clinic 8:40 PM - 9:10 PM Web site at www.psych.org or contact the Stanford University Overview of the Treatment of Insomnia APA toll free at 1-888-357-7924 (within US Stanford, California Andrew Krystal, MD or Canada) or 703/907-7300. Thomas Roth, PhD 9:10 PM -10:00 PM Sponsored by the American Psychiatric Chief, Division Head, Sleep Disorders and Association. Research Center Question-and-Answer Session Henry Ford Hospital Chair: Andrew Krystal, MD Supported by an unrestricted educational Detroit, Michigan 10:00 PM Adjournment time grant from Sepracor.

153 INDUSTRY-SUPPORTED SYMPOSIUM 29 Sunday, May 2, 7:00 p.m. - 10:00 p.m. Imperial Ballroom A, Second Floor, Sheraton New York

Psychopharmacology and PROGRAM OBJECTIVES AGENDA Reproductive Transitions: After attending this continuing medical education sym- 6:30 PM Dinner posium, the psychiatrist should be able to: 7:00 PM Introduction The Impact of Psychotroplc • Understand some of the complex interactions CLAUDIO N. SCARES, MD, PhD, SYMPOSIUM CHAIR between gender-based characteristics, psychophar- Massachusetts General Hospital Medications and Sex macologic interventions, and reproductive biology AND MARY C. BLEHAR, PhD, COCHAIR Hormones on Brain • Recognize the challenges of labeling products for use National Institute of Mental Health in pregnancy and lactation, and to better understand Functioning, Weight, different sources available to assist physicians in 7:05 PM Labeling Products for Use In Pregnancy: Moving Forward and Reproductive Safety assessing toxicities from drug exposures SANDRA KWEDER, MD • Identify gender-related characteristics associated with U.S. Food & Drug Administration weight gain while using psychotropic 7:30 PM Questions and Answers medications, and to learn about novel strategies to manage this problem 7:35 PM Weight Gain, Psychotroplc Medications, and Gender: Potential Pharmacologlc Strategies Symposium to be held at • Understand the concept of a male menopause the American Psychiatric or andropause and its clinical implications, with par- BARBARA GRACIOUS, MD ticular emphasis on the role of testosterone as University of Rochester Medical Center Association 157th Annual a potential hormonal intervention for depression 8:00 PM Questions and Answers Meeting • Examine the association between menopausal transi- 8:05 PM Testosterone Decline In the Aging Male: tion and the occurrence of mood disturbances, and to Does "Andropause" Exist? understand the extent to which symptomatic women may benefit from hormonal and non- STUART SEIDMAN, MD SUNDAY, MAY 2, 2004 hormonal interventions Columbia University College of Physicians & Surgeons 7:00 PM - 10:00 PM • Understand the impact of hormone therapy on the 8:30 PM Questions and Answers incidence of dementia and cognitive impairment in 8:35 PM Perimenopause-Related Mood Disturbance: Sheraton New York postmenopausal women, and how these findings An Update on Risk Factors and Novel Treatment Strategies should be interpreted Available Hotel and Towers The American Psychiatric Association (APA) CLAUDIO N. SCARES, MD, PhD is accredited by the Accreditation Council for Imperial Ballroom A 15 9:00 PM Questions and Answers I Continuing Medical Education to provide New York, New York continuing medical education for physicians. 9:05 PM Estrogen Plus Progestln and the Incidence of Dementia and MIM Cognitive Impairment In Postmenopausal Women: The Women's The APA designates this educational activity for a maximum of Health Initiative Memory Study — Updates 3 category 1 credits toward the AMA Physician Recognition Sponsored by the American Award and for the CME requirement of the APA. Each physi- SALLY SHUMAKER, PhD Psychiatric Association cian should claim only those credits that he/she actually Wake Forest University spent in the activity. 9:30 PM Panel Discussion with Questions and Answers Supported by an unrestricted Attendees must be registered for the APA Annual Meeting to CLAUDIO N. SCARES, MD, PhD, educational grant from attend this symposium. Seating is limited and will be based MARY C. BLEHAR, PhD, AND WILLIAM HARLAN, MD on first-come, first-served. For more information about the National Institute of Mental Health GlaxoSmithKHne meeting, please visit the APA website at www.psych.org or contact the APA toll free at 1-888-357-7924 (within the 10:00 PM Adjournment US or Canada) or 703-907-7300.

INDUSTRY-SUPPORTED SYMPOSIUM 30 Sunday, May 2, 7:00 p.m. - 10:00 p.m. Imperial Ballroom B, Second Floor, Sheraton New York

154 INDUSTRY-SUPPORTED SYMPOSIUM 31 Monday, May3, and Tuesday, May4, 7:00 a.m.-8:30 a.m. Grand Ballroom East, Third Floor, Hilton New York

INDUSTRY-SUPPORTED SYMPOSIUM 32 Monday, May3, and Tuesday, May4, 7:00 a.m.-8:30 a.m. westside Ballroom 3-4, Fifth Floor, Marriott Marquis

155 INDUSTRY-SUPPORTED SYMPOSIUM 33 Monday, May 3, and Tuesday, May 4, 7:00 a.m. - 8:30 a.m Broadway Ballroom, Sixth Floor, Marriott Marquis

INDUSTRY-SUPPORTED SYMPOSIUM 34 Monday, May 3, and Tuesday, May 4, 7:00 am - 8:30 a.m. Imperial Ballroom A, Second Floor, Sheraton New York

156 IN1;H.;> TRY-SUPPORTED SYMPOSIUM 35 I ;thlav, Mav \ and Tuesday, May 4, 7:00 a.m. - 8:30 a.m. mp:Tui Ballroom B, Second Floor, Sheraton New York

> i.'STRY- SUPPORTED SYMPOSIUM 36 Monday, May 3, 7:CC p.m. - 10:00 p.m. Baihoorn liast, 'Ihi.r.1 Floor, Hill on New York

157 INDUSTRY SUPPORTED SYMPOSIUM 37 Monday, May 3, 7:00 p.m. - 10:00 p.m. Westside Ballroom 1-2, Fifth Floor, Marriott Marquis

INDUSTRY SUPPORTED SYMPOSIUM 38 Monday, May 3, 7:00 p.m. - 10:00 p.m. Westside Ballroom 3-4, Fifth Floor, Marriott Marquis

158 INDl.'S'l'RY-SUPPORTED SYMPOSIUM 39 Monday, May 3, 7:00 p.m. - 10:00 p.m. 8roadw,-iv Ballroom, Sixth Floor, Mamon Marquis

1 \DLViKY-SIMPORTED SYMPOSIUM 4C Mf.sn.iay, May 3. 7:00 p.m. - 10:00 p.m. Grand Ballroom, Mexzanmc Level, Roosevelt

159 1 \DLViKY-SIMPORTED SYMPOSIUM 41 Mf.sn.iay, May 3. 7:00 p.m. - 10:00 p.m. Grand Ballroom, Mexzanmc Level, Roosevelt

1 \DLViKY-SIMPORTED SYMPOSIUM 42 Mf.sn.iay, May 3. 7:00 p.m. - 10:00 p.m. Grand Ballroom, Mexzanmc Level, Roosevelt

160 INDUSTRY-SUPPORTED SYMPOSIUM 43 Tuesday, May 4, 7;CO p.m. - 10:00 p.m. Grand Ballroom Easu Third Floor, Hilton New York

INDUSTRY-SUPPORTED SYMPOSIUM 44 Tuesday, May 4, 7:CC p.m.- iO^C p.m. Westside Ballroom 1-2, Fifth Floor, Marriott Marquis

161 INDUSTRY-SUPPORTED SYMPOSIUM 45 Tuesday, May 4, 7:00 p.m. - 10:00 p.m. Westside Ballroom 3-4, Fifth Floor, Marriott Marquis

INDUSTRY-SUPPORTED SYMPOSIUM 46 Tuesday, May 4, 7:00 p.m. - 10:00 p.m. Broadway Ballroom, Sixth Floor, Marriott Marquis

162 iN.! >t.:SYRY--SLPPOTOT.D SYMPOSIUM -P j.ivsdav, Miy 4, YOG p m. - Ko.CC p.m. •'..romo Ballroom, Mc/^anme Level, Roosevelt

IU':; o 'sYRY-SUPPORiYD SYMPOSIUM 48 • n. •',;<:), :^,.,\\ 4, •• Uv. p.;>;. - j.^'.vu P.m. j '.;'.ii.v. r1.u L'Oin'orr: A, SevorY .Floor., biicnu o; New York

163 INDUSmV-SUPPORTED SYMPOSIUM 49 'Tuesday, May 4, 7:00 p.m. - 10:00 p.m. Imperial. Ballroom B, Second Floor, Sheraton New York

INDUSTRY-SUPPORTED SYMPOSIUM 50 Wednesday, May 5, and Thursday; May 6, 7:00 a.ra - 8:30 a.m. imperial Ballroom A, Second Floor, Sheraton New York

An educational symposium to be presented rl Aj/J.* Searching for Answers in Traumatic Times at the 2004 APA Annual Meeting

Wednesday and Thursday, May 5 & 6, 2004 Sponsored by the American Psychiatric Association Breakfast 6:30am-7:00am Symposium 7:00am-8:30am This program is supported by an unrestricted f£ educationaP • li grant frof m i^epnalon/"• u i , incT . K^ Cepholon Sheraton New York Hotel & Towers Imperial Ballroom A, Second Floor Educational Objectives At the conclusion of this symposium, the participant should be able to: Educational Council Understand the overall consequences of PTSD. Pmgmm Chair Describe the impact of terrorist actions on mental health. Jonathan Davidson, MD Randall Marshall, MD Understand the neurobiology of PTSD, including the rales of GABA and glutamate. Duke University Medical Center New York State Psychiatric Institute Recognize the nature of sleep disturbance and its treatment. Durham, North Carolina New York, New York Discuss Effective and ineffective forms of psychotherapy and pharmacotherapy. «***x Wei Zhang, MD, PhD Agenda Karl Doghramji, MD Duke yniversity Meta| Center Wednesday, May 5, 2004 Thomas Jefferson University Hospital Durtiani] North Caro|ina Philadelphia, Pennsylvania 6:30am-7:00am Breakfast David Nutt, MD, PhD 7:00am-7:05am Welcome & Introduction • Jonathan Davidson, MD (Program Chair) Edna Foa, PhD University of Bristo| 7:05am-7:30am PTSD: Its Burden and the Toll From Terrorism • Randall Marshall, MD University of Pennsylvania Bristol [ng|and] United Kingdom 7:30am-7:55am Treatment and Prevention of Chronic PTSD: Psychosocial Approaches • Philadelphia, Pennsylvania Edna Foa, PhD 7:55am-8:30am Discussion Q&A The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 8:30am Program Adjourns 'fliundoy, May 6, 2004 The APA designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician 6:30am-7:00am Breakfast Recognition Award and for the CME requirement of the APA. Each physician should claim only those credits that 7:00am-7:05am Introduction 81 Review • Jonathan Davidson, MD (Program Chair) he/she actually spent in the activity, 7:05am-7:30am Brain Imaging in PTSD: Going Beyond Serotonin • David Nutt, MD, Phi Participation 7:30am-7:55am Sleep in PTSD and Other Anxiety Disorders • Karl Doghramil, MD Attendees must be registered for the APA Annual Meeting to attend this symposium. Seating is limited and will be 7:55am-8:20am Novel Drug Treatments for PTSD Beyond SSRIs • Wei Zhang, MD, PhD based on first-come, first-served. For more information about the meeting, please visit the APA website at 8:20am-8:30am Q&A Panel Discussion www.psych.org or contact the APA toll free at 1-888-357-7924 (within the U.S. or Canada) or 703-907-7300. 8:30am Program Adjorurns

164 INDUSTRY-SUPPORTED> SYMPOSIUMSYMPOSIUM 51S Wednesday, May5, and Thursday, May6, 7:00 a.m.-8:30 a.m. Imperial Ballroom B, Second Floor, Sheraton New York

INDUSTRY-SUPPORTED SYMPOSIUM 52 Wednesday, May5, and Thursday, May6, 7:00 a.m.-8:30 a.m. Grand Ballroom Fast, Thud Moor Hilton Jx^ York

165 INDUSTRY-SUPPORTED SYMPOSIUM 53 Wednesday, May 5, 7:00 p.m. - !0:CO p.m. Imperial Ballroom A, Second Floor, Sheraton New York

INDUSTRY-SUPPORTED SYMPOSIUM 54 Wednesday, May 5, 7:00 p.m. - 10-00 p.m. Imperial Ballroom B, Second Floor, Sheraton New York

166 merican Psychiatric Association Exhibit

Look for us right next door to the APPI Bookstore in the Exhibit Hall.

Presenting...... all the benefits of membership in the nation's oldest medical specialty society. APA's mission is to promote the highest quality care tor individuals with mental disorders and their families, promote psychiatric education and research advances, represent the profession of psychiatry, and serve the professional needs of its members. Whether you're a prospective, new, long-time, or international member, visit the APA exhibit and find out how APA can help you in your professional life. At the exhibit you can: • Pick up your APA membership information and resource handbook • Leam about new APA programs and initiatives SHOW TIMES • Participate in APA advocacy efforts • Search the Job Bank for the latest Saturday, May I 10:00 am - 5:00 pm employment opportunities Sunday, May 2 8:00 am - 4:30 pm • Activate your online subscriptions to APA journals Monday, May 3 10:00 am- 5:30 pm • Submit your new member application and enter to win Tuesday, May 4 10:00 am -6:00 pm an APPI gift certificate Wednesday, May 5 10:00 am -3:00 pm • And more!

While af the exhibit, take a moment to learn about the key roles of these APA subsidiary organizations

AMERICAN PSrCHIAfRIC INSTITUTE ^•feAmerican Psychiatric Foundation APIRE IrV Advancing public undemanding of menu! illnesses to, RESEARCH ant) EDUCATION Our mission is to contribute to psychiatry's science The charitable and educational subsidiary, our base and to improve the Quality of psychiatric care mission is to advance public understanding that through research, education, health policy analysis mental illnesses are real and can be effectively and dissemination. treated.